Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Behavioral & Substance Use Disorder Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
go back to main search page
Accession:CHEBI:79091 term browser browse the term
Definition:An EC 2.7.11.* (protein-serine/threonine kinase) inhibitor that interferes with the action of mitogen-activated protein kinase (EC 2.7.11.24).
Synonyms:related_synonym: ATP:protein phosphotransferase (MAPKK-activated) inhibitor;   ATP:protein phosphotransferase (MAPKK-activated) inhibitors;   Dp38 inhibitor;   Dp38 inhibitors;   EC 2.7.11.24 inhibitor;   EC 2.7.11.24 inhibitors;   ERK inhibitor;   ERK inhibitors;   ERK1 inhibitor;   ERK1 inhibitors;   ERK2 inhibitor;   ERK2 inhibitors;   JNK inhibitor;   JNK inhibitors;   JNK3alpha1 inhibitor;   JNK3alpha1 inhibitors;   LeMPK3 inhibitor;   LeMPK3 inhibitors;   MAP kinase inhibitor;   MAP kinase inhibitors;   MAP-2 kinase inhibitor;   MAP-2 kinase inhibitors;   MAPK inhibitor;   MAPK inhibitors;   MBP kinase I inhibitor;   MBP kinase I inhibitors;   MBP kinase II inhibitor;   MBP kinase II inhibitors;   MEK inhibitor;   MEK inhibitors;   PMK-1 inhibitor;   PMK-1 inhibitors;   PMK-2 inhibitor;   PMK-2 inhibitors;   PMK-3 inhibitor;   PMK-3 inhibitors;   SAPK inhibitor;   SAPK inhibitors;   STK26 inhibitor;   STK26 inhibitors;   c-Jun N-terminal kinase inhibitor;   c-Jun N-terminal kinase inhibitors;   extracellular signal-regulated kinase inhibitor;   extracellular signal-regulated kinase inhibitors;   microtubule-associated protein 2 kinase inhibitor;   microtubule-associated protein 2 kinase inhibitors;   microtubule-associated protein kinase inhibitor;   microtubule-associated protein kinase inhibitors;   mitogen-activated protein kinase (EC 2.7.11.24) inhibitors;   mitogen-activated protein kinase inhibitor;   mitogen-activated protein kinase inhibitors;   myelin basic protein kinase inhibitor;   myelin basic protein kinase inhibitors;   p38-2 inhibitor;   p38-2 inhibitors;   p38delta inhibitor;   p38delta inhibitors;   p42 mitogen-activated protein kinase inhibitor;   p42 mitogen-activated protein kinase inhibitors;   p42(mapk) inhibitor;   p42(mapk) inhibitors;   p44mpk inhibitor;   p44mpk inhibitors;   pp42 inhibitor;   pp42 inhibitors;   pp44(mapk) inhibitor;   pp44(mapk) inhibitors;   stress-activated protein kinase inhibitor;   stress-activated protein kinase inhibitors
 alt_id: CHEBI:75997
 xref: wikipedia.en:MEK_inhibitor;   wikipedia.en:Mitogen-activated_protein_kinase


show annotations for term's descendants           Sort by:
anthra[1,9-cd]pyrazol-6(2H)-one term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb1a ATP binding cassette subfamily B member 1A multiple interactions ISO
EXP 		pyrazolanthrone inhibits the reaction [MAP3K1 protein results in increased expression of ABCB1 mRNA]; pyrazolanthrone inhibits the reaction [Oxygen deficiency results in increased expression of ABCB1 mRNA]
pyrazolanthrone inhibits the reaction [Particulate Matter results in increased expression of and results in increased activity of ABCB1 protein]; pyrazolanthrone inhibits the reaction [Vehicle Emissions results in increased expression of and results in increased activity of ABCB1 protein] 		CTD PMID:15604272 PMID:18474546 NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135 		JBrowse link
G Ace2 angiotensin converting enzyme 2 multiple interactions EXP pyrazolanthrone inhibits the reaction [2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [ACE2 protein inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]]; pyrazolanthrone inhibits the reaction [2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [ACE2 protein inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]]; pyrazolanthrone inhibits the reaction [7-Ala-angiotensin (1-7) inhibits the reaction [ACE2 protein inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]]; pyrazolanthrone inhibits the reaction [7-Ala-angiotensin (1-7) inhibits the reaction [ACE2 protein inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]] CTD PMID:27302421 NCBI chr  X:33,925,458...33,972,851
Ensembl chr  X:33,925,458...33,971,596 		JBrowse link
G Ache acetylcholinesterase multiple interactions EXP pyrazolanthrone inhibits the reaction [Streptozocin results in increased activity of ACHE protein] CTD PMID:20600246 NCBI chr12:25,042,882...25,050,608
Ensembl chr12:25,043,461...25,050,410 		JBrowse link
G Acp5 acid phosphatase 5, tartrate resistant multiple interactions ISO crocin promotes the reaction [pyrazolanthrone inhibits the reaction [TNFSF11 protein results in increased activity of ACP5 protein]]; pyrazolanthrone inhibits the reaction [TNFSF11 protein results in increased activity of ACP5 protein] CTD PMID:30580027 NCBI chr 8:28,939,984...28,946,639
Ensembl chr 8:28,939,985...28,943,929 		JBrowse link
G Acta2 actin alpha 2, smooth muscle multiple interactions ISO 6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride promotes the reaction [pyrazolanthrone inhibits the reaction [Folic Acid results in increased expression of ACTA2 protein]]; pyrazolanthrone inhibits the reaction [Folic Acid results in increased expression of ACTA2 protein]; pyrazolanthrone promotes the reaction [6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride inhibits the reaction [Folic Acid results in increased expression of ACTA2 protein]] CTD PMID:31447676 NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503 		JBrowse link
G Adam17 ADAM metallopeptidase domain 17 multiple interactions ISO pyrazolanthrone inhibits the reaction [hydroquinone results in increased expression of ADAM17 protein]; pyrazolanthrone inhibits the reaction [hydroquinone results in increased expression of and results in increased stability of ADAM17 mRNA] CTD PMID:23791922 NCBI chr 6:46,601,583...46,663,690
Ensembl chr 6:46,601,583...46,649,344 		JBrowse link
G Adipoq adiponectin, C1Q and collagen domain containing multiple interactions ISO pyrazolanthrone inhibits the reaction [TNF protein results in decreased expression of ADIPOQ mRNA] CTD PMID:18577375 NCBI chr11:91,226,524...91,240,244
Ensembl chr11:91,226,180...91,240,169 		JBrowse link
G Ager advanced glycosylation end product-specific receptor multiple interactions ISO pyrazolanthrone inhibits the reaction [Toluene 2,4-Diisocyanate results in increased expression of AGER protein] CTD PMID:33075463 NCBI chr20:4,152,758...4,155,956
Ensembl chr20:4,151,965...4,155,685 		JBrowse link
G Agtr1a angiotensin II receptor, type 1a multiple interactions ISO pyrazolanthrone inhibits the reaction [sodium arsenite results in increased expression of AGTR1 mRNA] CTD PMID:23603059 NCBI chr17:34,383,397...34,435,523
Ensembl chr17:34,381,467...34,435,660 		JBrowse link
G Ahr aryl hydrocarbon receptor multiple interactions ISO pyrazolanthrone binds to and results in increased activity of AHR protein CTD PMID:17959153 NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901 		JBrowse link
G Aifm1 apoptosis inducing factor, mitochondria associated 1 multiple interactions ISO
EXP 		pyrazolanthrone inhibits the reaction [arsenic trioxide affects the localization of AIFM1 protein]
pyrazolanthrone inhibits the reaction [cadmium acetate affects the localization of AIFM1 protein]; pyrazolanthrone inhibits the reaction [Isoflurane results in increased cleavage of and affects the localization of AIFM1 protein]
pyrazolanthrone inhibits the reaction [Acetaminophen affects the localization of AIFM1 protein] 		CTD PMID:18412143 PMID:20423716 PMID:24577723 PMID:25043952 PMID:29289695 NCBI chr  X:132,528,107...132,567,237
Ensembl chr  X:132,528,107...132,567,237 		JBrowse link
G Akr1b1 aldo-keto reductase family 1 member B1 multiple interactions EXP pyrazolanthrone inhibits the reaction [Curcumin results in increased expression of AKR1B1 mRNA] CTD PMID:17640564 NCBI chr 4:63,899,222...63,913,315
Ensembl chr 4:63,899,222...63,913,315 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions
decreases expression 		ISO
EXP 		pyrazolanthrone inhibits the reaction [arsenic trichloride results in increased activity of AKT1 protein]; pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in decreased phosphorylation of and results in decreased activity of AKT1 protein]; pyrazolanthrone inhibits the reaction [cholix toxin, Vibrio cholerae results in increased phosphorylation of AKT1 protein]; pyrazolanthrone inhibits the reaction [diallyl trisulfide results in decreased phosphorylation of AKT1 protein]; pyrazolanthrone inhibits the reaction [Fingolimod Hydrochloride results in decreased phosphorylation of AKT1 protein]; pyrazolanthrone inhibits the reaction [Indomethacin results in increased phosphorylation of AKT1 protein]; pyrazolanthrone inhibits the reaction [rhoifolin results in decreased phosphorylation of AKT1 protein]
pyrazolanthrone inhibits the reaction [etoxazole results in increased phosphorylation of AKT1 protein]; pyrazolanthrone inhibits the reaction [flufenoxuron results in increased phosphorylation of AKT1 protein]
pyrazolanthrone results in decreased expression of AKT1 protein 		CTD PMID:16046226 PMID:17341418 PMID:20534739 PMID:22020565 PMID:22696236 More... NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610 		JBrowse link
G Akt2 AKT serine/threonine kinase 2 multiple interactions ISO [TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of AKT2 mRNA; crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of AKT2 mRNA] CTD PMID:30580027 NCBI chr 1:92,004,705...92,061,420
Ensembl chr 1:92,014,859...92,061,420 		JBrowse link
G Alox5 arachidonate 5-lipoxygenase decreases expression ISO pyrazolanthrone results in decreased expression of ALOX5 protein CTD PMID:23539630 NCBI chr 4:151,203,948...151,251,126
Ensembl chr 4:151,203,949...151,251,126 		JBrowse link
G Ampd3 adenosine monophosphate deaminase 3 multiple interactions ISO pyrazolanthrone inhibits the reaction [Ozone results in increased expression of AMPD3 mRNA] CTD PMID:17460151 NCBI chr 1:174,319,526...174,364,605
Ensembl chr 1:174,294,867...174,364,608 		JBrowse link
G Apoa1 apolipoprotein A1 multiple interactions ISO pyrazolanthrone inhibits the reaction [Phosphatidylinositols results in increased expression of APOA1 protein] CTD PMID:19013290 NCBI chr 8:55,423,945...55,425,729
Ensembl chr 8:55,423,825...55,425,729 		JBrowse link
G Apod apolipoprotein D multiple interactions ISO pyrazolanthrone inhibits the reaction [Paraquat results in increased expression of APOD mRNA]; pyrazolanthrone inhibits the reaction [Paraquat results in increased expression of APOD protein] CTD PMID:21688324 NCBI chr11:82,936,216...82,957,264
Ensembl chr11:82,936,038...82,957,263 		JBrowse link
G App amyloid beta precursor protein multiple interactions ISO pyrazolanthrone inhibits the reaction [[Clioquinol co-treated with Copper] results in decreased expression of APP protein alternative form]; pyrazolanthrone inhibits the reaction [APP protein results in increased expression of and results in increased cleavage of CASP1 protein]; pyrazolanthrone inhibits the reaction [APP protein results in increased expression of and results in increased cleavage of IL1B protein]; pyrazolanthrone inhibits the reaction [APP protein results in increased expression of NLRP3 protein] CTD PMID:16648635 PMID:28004443 NCBI chr11:37,506,207...37,724,351
Ensembl chr11:37,506,408...37,722,971 		JBrowse link
G Aqp1 aquaporin 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of AQP1 protein] CTD PMID:21647617 NCBI chr 4:85,812,784...85,824,964
Ensembl chr 4:85,812,784...85,830,504 		JBrowse link
G Ar androgen receptor multiple interactions ISO pyrazolanthrone affects the reaction [Quercetin inhibits the reaction [mibolerone results in increased expression of AR protein]] CTD PMID:20148354 NCBI chr  X:67,135,317...67,304,476
Ensembl chr  X:67,135,317...67,304,467 		JBrowse link
G Atf2 activating transcription factor 2 multiple interactions ISO pyrazolanthrone inhibits the reaction [2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester results in increased phosphorylation of ATF2 protein]; pyrazolanthrone inhibits the reaction [2-aminodiphenyl results in increased expression of and results in increased phosphorylation of ATF2 protein]; pyrazolanthrone inhibits the reaction [ATF2 protein results in decreased susceptibility to Cisplatin]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased phosphorylation of ATF2 protein]; pyrazolanthrone inhibits the reaction [Cisplatin results in increased activity of ATF2 protein]; pyrazolanthrone inhibits the reaction [Cisplatin results in increased phosphorylation of and results in increased activity of ATF2 protein]; pyrazolanthrone inhibits the reaction [hydroquinone results in increased phosphorylation of ATF2 protein]; pyrazolanthrone inhibits the reaction [O(2)-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate results in increased phosphorylation of ATF2 protein]; pyrazolanthrone inhibits the reaction [sodium arsenite results in increased expression of ATF2 mRNA]; pyrazolanthrone inhibits the reaction [sodium arsenite results in increased expression of ATF2 protein modified form]; pyrazolanthrone inhibits the reaction [sodium arsenite results in increased expression of ATF2 protein]; pyrazolanthrone inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of ATF2 protein]
pyrazolanthrone inhibits the reaction [[[cupric chloride results in increased abundance of Copper] co-treated with [zinc chloride results in increased abundance of Zinc]] results in increased phosphorylation of ATF2 protein]; pyrazolanthrone inhibits the reaction [Anisomycin results in increased phosphorylation of ATF2 protein]; pyrazolanthrone inhibits the reaction [trovafloxacin results in increased phosphorylation of ATF2 protein] 		CTD PMID:12393500 PMID:12663670 PMID:22003962 PMID:23591579 PMID:23791922 More... NCBI chr 3:79,125,814...79,202,896
Ensembl chr 3:79,126,705...79,202,745 		JBrowse link
G Atf3 activating transcription factor 3 multiple interactions ISO pyrazolanthrone inhibits the reaction [Acrylamide results in increased expression of ATF3 protein]
pyrazolanthrone inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of ATF3 protein]; pyrazolanthrone inhibits the reaction [O(2)-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate results in increased phosphorylation of ATF3 protein] 		CTD PMID:22003962 PMID:25531190 PMID:33921748 NCBI chr13:105,274,103...105,331,653
Ensembl chr13:105,282,440...105,295,750 		JBrowse link
G Atf4 activating transcription factor 4 multiple interactions EXP
ISO 		pyrazolanthrone inhibits the reaction [[cupric chloride binds to pyrrolidine dithiocarbamic acid] which results in increased expression of ATF4 mRNA]
pyrazolanthrone inhibits the reaction [honokiol results in increased expression of ATF4 protein] 		CTD PMID:20920558 PMID:33550458 NCBI chr 7:113,684,681...113,686,739
Ensembl chr 7:113,684,681...113,686,739 		JBrowse link
G Bad BCL2-associated agonist of cell death multiple interactions ISO pyrazolanthrone inhibits the reaction [naphtho(1,2-b)furan-4,5-dione results in increased expression of BAD protein] CTD PMID:19747539 NCBI chr 1:213,562,719...213,572,034
Ensembl chr 1:213,562,187...213,572,034 		JBrowse link
G Bag3 BAG cochaperone 3 multiple interactions ISO pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of BAG3 mRNA]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of BAG3 protein] CTD PMID:22020323 NCBI chr 1:192,533,460...192,557,281
Ensembl chr 1:192,475,828...192,557,280 		JBrowse link
G Bak1 BCL2-antagonist/killer 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [docetaxel results in increased activity of BAK1 protein] CTD PMID:17317842 NCBI chr20:5,102,334...5,111,615
Ensembl chr20:5,102,335...5,110,974 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions
increases expression 		ISO
EXP 		[U 0126 co-treated with pyrazolanthrone] inhibits the reaction [fisetin results in increased expression of BAX protein]; [XMU-MP-1 co-treated with U 0126 co-treated with pyrazolanthrone] inhibits the reaction [fisetin results in increased expression of BAX protein]; MYC affects the reaction [pyrazolanthrone results in increased expression of BAX protein]; pyrazolanthrone affects the reaction [Methylmercury Compounds affects the localization of BAX protein]; pyrazolanthrone inhibits the reaction [3-oxo-29-noroleana-1,9(11),12-trien-2,20-dicarbonitrile results in increased expression of BAX protein]; pyrazolanthrone inhibits the reaction [4-vinyl-2,6-dimethoxyphenol results in increased expression of BAX protein]; pyrazolanthrone inhibits the reaction [Acetaminophen results in increased expression of BAX protein]; pyrazolanthrone inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; pyrazolanthrone inhibits the reaction [Docetaxel results in increased activity of BAX protein]; pyrazolanthrone inhibits the reaction [fisetin results in increased expression of BAX protein]; pyrazolanthrone inhibits the reaction [Methylmercury Compounds inhibits the reaction [BAX protein binds to YWHAZ protein]]; pyrazolanthrone inhibits the reaction [nickel sulfate results in increased expression of BAX protein]; pyrazolanthrone inhibits the reaction [Pt(O,O'-acac)(gamma-acac)(DMS) affects the localization of BAX protein]; pyrazolanthrone inhibits the reaction [sodium arsenite results in increased cleavage of BAX protein]; pyrazolanthrone inhibits the reaction [surfactin peptide results in increased expression of BAX protein]; pyrazolanthrone promotes the reaction [Arsenic Trioxide results in increased activity of and results in increased localization of BAX protein]
pyrazolanthrone inhibits the reaction [bakuchiol affects the localization of BAX protein]; pyrazolanthrone inhibits the reaction [cadmium acetate results in increased expression of BAX protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of BAX protein]; pyrazolanthrone inhibits the reaction [Isoflurane results in increased expression of BAX protein]; pyrazolanthrone inhibits the reaction [sodium arsenite results in increased expression of BAX protein]
pyrazolanthrone inhibits the reaction [Acetaminophen affects the localization of BAX protein]; pyrazolanthrone inhibits the reaction [triethylene glycol dimethacrylate results in increased expression of BAX protein] 		CTD PMID:14514659 PMID:15034932 PMID:16046226 PMID:16972261 PMID:17292878 More... NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429 		JBrowse link
G Bbc3 Bcl-2 binding component 3 multiple interactions ISO pyrazolanthrone inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased expression of BBC3 protein]; pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased expression of BBC3 protein] CTD PMID:30472098 PMID:32540572 NCBI chr 1:86,141,450...86,150,666
Ensembl chr 1:86,141,603...86,150,666 		JBrowse link
G Bcas2 BCAS2, pre-mRNA processing factor multiple interactions ISO pyrazolanthrone inhibits the reaction [Ozone results in increased expression of BCAS2 mRNA] CTD PMID:17460151 NCBI chr 2:193,381,000...193,388,881
Ensembl chr 2:193,380,982...193,388,878 		JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
decreases phosphorylation 		ISO
EXP 		pyrazolanthrone inhibits the reaction [1,4-naphthoquinone analog results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [3-oxo-29-noroleana-1,9(11),12-trien-2,20-dicarbonitrile results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [4-vinyl-2,6-dimethoxyphenol results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [6-(N,N-dimethylamino)-2-(naphthalene-1-yl)-4-quinazolinone results in increased phosphorylation of BCL2 protein]; pyrazolanthrone inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of BCL2 protein]; pyrazolanthrone inhibits the reaction [Docetaxel results in increased phosphorylation of BCL2 protein]; pyrazolanthrone inhibits the reaction [fosbretabulin results in increased phosphorylation of BCL2 protein]; pyrazolanthrone inhibits the reaction [naphtho(1,2-b)furan-4,5-dione results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [Oxidopamine results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [pachastrissamine analog inhibits the reaction [BCL2 protein binds to BECN1 protein]]; pyrazolanthrone inhibits the reaction [Pt(O,O'-acac)(gamma-acac)(DMS) results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [surfactin peptide results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [trimethyltin chloride results in decreased expression of BCL2 protein]
pyrazolanthrone results in decreased phosphorylation of BCL2 protein
pyrazolanthrone inhibits the reaction [[cupric chloride binds to pyrrolidine dithiocarbamic acid] which results in decreased expression of BCL2 mRNA]; pyrazolanthrone inhibits the reaction [[cupric chloride binds to pyrrolidine dithiocarbamic acid] which results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [Acetaminophen results in increased expression of BCL2 protein modified form]; pyrazolanthrone inhibits the reaction [cadmium acetate results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in decreased expression of BCL2 protein]; pyrazolanthrone results in increased phosphorylation of and results in decreased activity of BCL2 protein
pyrazolanthrone inhibits the reaction [Cardiotoxins results in increased phosphorylation of BCL2 protein] 		CTD PMID:14724571 PMID:17317842 PMID:17786558 PMID:18412143 PMID:19428505 More... NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900 		JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions ISO
EXP 		[pyrazolanthrone co-treated with U 0126] inhibits the reaction [fisetin results in decreased expression of BCL2L1 protein]; [XMU-MP-1 co-treated with pyrazolanthrone co-treated with U 0126] inhibits the reaction [fisetin results in decreased expression of BCL2L1 protein]; pyrazolanthrone inhibits the reaction [[Sulindac co-treated with Arsenic Trioxide] results in increased phosphorylation of BCL2L1 protein]; pyrazolanthrone inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]; pyrazolanthrone inhibits the reaction [fisetin results in decreased expression of BCL2L1 protein]; pyrazolanthrone inhibits the reaction [naphtho(1,2-b)furan-4,5-dione results in decreased expression of BCL2L1 protein]; pyrazolanthrone inhibits the reaction [nickel sulfate results in decreased expression of BCL2L1 protein]; pyrazolanthrone inhibits the reaction [pachastrissamine analog inhibits the reaction [BCL2L1 protein binds to BECN1 protein]]
pyrazolanthrone inhibits the reaction [Acetaminophen results in increased expression of BCL2L1 protein modified form] 		CTD PMID:18281123 PMID:19540902 PMID:19747539 PMID:20166895 PMID:31044527 More... NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907
Ensembl chr 1:161,745,540...161,764,907 		JBrowse link
G Bcl2l11 Bcl2-like 11 multiple interactions ISO pyrazolanthrone inhibits the reaction [sodium arsenite results in increased expression of BCL2L11 protein]
pyrazolanthrone inhibits the reaction [docetaxel results in increased degradation of BCL2L11 protein]; pyrazolanthrone inhibits the reaction [Lovastatin results in increased expression of BCL2L11 protein]; pyrazolanthrone inhibits the reaction [Nimustine results in increased expression of BCL2L11 mRNA]; pyrazolanthrone inhibits the reaction [temozolomide results in increased expression of BCL2L11 mRNA] 		CTD PMID:16166651 PMID:17317842 PMID:18766339 PMID:26418950 NCBI chr 3:135,820,042...135,857,330
Ensembl chr 3:135,817,562...135,960,695 		JBrowse link
G Bdnf brain-derived neurotrophic factor multiple interactions ISO pyrazolanthrone inhibits the reaction [BDNF protein results in increased expression of SOD2 protein] CTD PMID:22261313 NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:116,619,633...116,670,657 		JBrowse link
G Becn1 beclin 1 multiple interactions
decreases expression 		EXP
ISO 		pyrazolanthrone inhibits the reaction [Colistin results in increased expression of BECN1 protein]; pyrazolanthrone inhibits the reaction [decamethrin results in increased expression of BECN1 protein]
SP600125 decreases expression of protein in oxygen-glucose deprived rat neuronal PC12 cells
pyrazolanthrone inhibits the reaction [pachastrissamine analog inhibits the reaction [BCL2 protein binds to BECN1 protein]]; pyrazolanthrone inhibits the reaction [pachastrissamine analog inhibits the reaction [BCL2L1 protein binds to BECN1 protein]]; pyrazolanthrone promotes the reaction [polyphyllin I results in increased expression of BECN1 protein] 		CTD
RGD		 PMID:26588882 PMID:28842171 PMID:31421117 PMID:35123989 PMID:27769861 RGD:329853763 NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,731,650...86,747,002 		JBrowse link
G Bglap bone gamma-carboxyglutamate protein multiple interactions EXP [pyrazolanthrone co-treated with SB 203580 co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] inhibits the reaction [Quercetin results in increased expression of BGLAP protein]; pyrazolanthrone inhibits the reaction [Quercetin results in increased expression of BGLAP protein] CTD PMID:26136938 NCBI chr 2:176,136,341...176,137,318
Ensembl chr 2:176,136,341...176,137,318 		JBrowse link
G Bid BH3 interacting domain death agonist multiple interactions ISO pyrazolanthrone promotes the reaction [arsenic trioxide results in increased cleavage of BID protein] CTD PMID:16972261 NCBI chr 4:155,785,366...155,808,775
Ensembl chr 4:155,785,377...155,808,275 		JBrowse link
G Birc2 baculoviral IAP repeat-containing 2 multiple interactions ISO pyrazolanthrone promotes the reaction [IL1A protein results in increased expression of BIRC2 mRNA] CTD PMID:12832416 NCBI chr 8:13,253,697...13,273,672
Ensembl chr 8:13,253,706...13,271,911 		JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 multiple interactions ISO pyrazolanthrone inhibits the reaction [arsenic trioxide results in decreased expression of BIRC5 protein]; pyrazolanthrone inhibits the reaction [naphtho(1,2-b)furan-4,5-dione results in decreased expression of BIRC5 protein]; pyrazolanthrone inhibits the reaction [sodium arsenite results in decreased expression of BIRC5 mRNA]; pyrazolanthrone inhibits the reaction [sodium arsenite results in decreased expression of BIRC5 protein] CTD PMID:16328441 PMID:19747539 PMID:21594580 PMID:22706169 NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,572,080...103,582,155 		JBrowse link
G Bnip3 BCL2 interacting protein 3 multiple interactions ISO pyrazolanthrone inhibits the reaction [Cadmium results in increased expression of BNIP3 protein] CTD PMID:24824807 NCBI chr 1:203,137,778...203,154,962
Ensembl chr 1:203,137,778...203,154,962 		JBrowse link
G Bnip3l BCL2 interacting protein 3 like multiple interactions ISO pyrazolanthrone inhibits the reaction [sodium arsenite results in increased expression of BNIP3L protein] CTD PMID:34861471 NCBI chr15:45,350,081...45,373,213
Ensembl chr15:45,334,537...45,373,282 		JBrowse link
G Camk2a calcium/calmodulin-dependent protein kinase II alpha multiple interactions EXP pyrazolanthrone inhibits the reaction [Cadmium Chloride results in increased phosphorylation of CAMK2A protein] CTD PMID:21933187 NCBI chr18:56,648,779...56,711,505
Ensembl chr18:56,649,025...56,711,504 		JBrowse link
G Capn1 calpain 1 multiple interactions EXP pyrazolanthrone inhibits the reaction [Isoflurane results in increased expression of CAPN1 protein] CTD PMID:29289695 NCBI chr 1:212,705,219...212,736,134
Ensembl chr 1:212,705,222...212,729,445 		JBrowse link
G Capn2 calpain 2 multiple interactions EXP pyrazolanthrone inhibits the reaction [Isoflurane results in increased expression of CAPN2 protein] CTD PMID:29289695 NCBI chr13:96,681,902...96,732,625
Ensembl chr13:96,681,848...96,732,625 		JBrowse link
G Casp1 caspase 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [irinotecan results in increased cleavage of CASP1 protein]
pyrazolanthrone inhibits the reaction [APP protein results in increased expression of and results in increased cleavage of CASP1 protein] 		CTD PMID:26431797 PMID:28004443 NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:10,746,333...10,882,275 		JBrowse link
G Casp12 caspase 12 multiple interactions EXP pyrazolanthrone inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased cleavage of CASP12 protein] CTD PMID:24140863 NCBI chr 8:10,927,188...10,954,442
Ensembl chr 8:10,926,994...10,954,442 		JBrowse link
G Casp2 caspase 2 decreases activity ISO pyrazolanthrone results in decreased activity of CASP2 protein CTD PMID:17317842 NCBI chr 4:72,116,265...72,134,023
Ensembl chr 4:72,116,246...72,134,022 		JBrowse link
G Casp3 caspase 3 multiple interactions
increases expression
decreases activity
increases activity 		ISO
EXP 		[U 0126 co-treated with pyrazolanthrone] inhibits the reaction [fisetin results in increased cleavage of CASP3 protein]; [XMU-MP-1 co-treated with U 0126 co-treated with pyrazolanthrone] inhibits the reaction [fisetin results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [1,4-naphthoquinone analog results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone analog results in decreased expression of CASP3 protein]; pyrazolanthrone inhibits the reaction [2-aminodiphenyl results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [3-oxo-29-noroleana-1,9(11),12-trien-2,20-dicarbonitrile results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [5-((4-methylphenyl)methylene)-2-(phenylamino)-4(5H)-thiazolone results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [6-(N,N-dimethylamino)-2-(naphthalene-1-yl)-4-quinazolinone results in increased expression of CASP3 protein]; pyrazolanthrone inhibits the reaction [8-bromo-7-methoxychrysin results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [[Arsenic Trioxide co-treated with Ethacrynic Acid] results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [[fludarabine co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [[Sulindac co-treated with Arsenic Trioxide] results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Acetaminophen results in increased expression of CASP3 protein]; pyrazolanthrone inhibits the reaction [Biological Products results in increased expression of CASP3 mRNA]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [Chlorpyrifos results in increased expression of CASP3 protein modified form]; pyrazolanthrone inhibits the reaction [Citrinin results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [coronarin D results in increased expression of CASP3 protein modified form]; pyrazolanthrone inhibits the reaction [dehydroxymethylepoxyquinomicin results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [ellipticine results in increased cleavage of and results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [fisetin results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [flubendazole results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [Indomethacin results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Ketoconazole results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [morusin results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [Oxygen deficiency promotes the reaction [HBEGF protein mutant form results in increased activity of CASP3 protein]]; pyrazolanthrone inhibits the reaction [Paraquat results in increased expression of CASP3 protein modified form]; pyrazolanthrone inhibits the reaction [Phytochemicals results in increased expression of CASP3 protein modified form]; pyrazolanthrone inhibits the reaction [polyphyllin I results in increased expression of CASP3 protein modified form]; pyrazolanthrone inhibits the reaction [Pulsatilla saponin D results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [Quercetin results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [rhoifolin results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [sodium arsenite results in increased cleavage of CASP3 protein]; pyrazolanthrone promotes the reaction [dihydromyricetin results in increased cleavage of CASP3 protein]; pyrazolanthrone promotes the reaction [FAS protein results in increased cleavage of and results in increased activity of CASP3 protein]; pyrazolanthrone promotes the reaction [pachastrissamine analog results in increased cleavage of CASP3 protein]; pyrazolanthrone promotes the reaction [picrasidine I results in increased expression of CASP3 protein modified form]; pyrazolanthrone promotes the reaction [usnic acid results in increased activity of CASP3 protein]
pyrazolanthrone results in increased expression of CASP3 protein modified form
pyrazolanthrone inhibits the reaction [4-methyl-2,4-bis(4-hydroxyphenyl)pent-1-ene results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [[cupric chloride binds to pyrrolidine dithiocarbamic acid] which results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased expression of CASP3 protein]; pyrazolanthrone inhibits the reaction [bakuchiol results in increased activity of and results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [cadmium acetate results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [Cadmium Chloride results in increased cleavage of and results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Cadmium Chloride results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [Carmustine results in increased activity of and results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [decamethrin results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [Doxorubicin results in increased expression of CASP3 protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [Isoflurane results in increased expression of CASP3 protein modified form]; pyrazolanthrone inhibits the reaction [manganese chloride results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [manganese chloride results in increased expression of CASP3 protein]; pyrazolanthrone inhibits the reaction [Manganese results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [Manganese results in increased expression of CASP3 protein]; pyrazolanthrone inhibits the reaction [nickel chloride results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Palmitic Acid results in increased expression of CASP3 mRNA]; pyrazolanthrone inhibits the reaction [Palmitic Acid results in increased expression of CASP3 protein]; pyrazolanthrone inhibits the reaction [satratoxin H results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [Thrombin results in increased expression of and results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Vitamin K 3 results in increased cleavage of CASP3 protein]; pyrazolanthrone promotes the reaction [celastrol inhibits the reaction [Cadmium Chloride results in increased cleavage of CASP3 protein]]
6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride promotes the reaction [pyrazolanthrone inhibits the reaction [Folic Acid results in increased activity of CASP3 protein]]; pyrazolanthrone inhibits the reaction [4-hydroxy-2-nonenal results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Cadmium results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Folic Acid results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [pseudolaric acid B results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [Pulsatilla saponin D results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [Sodium Fluoride results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [TEMPO results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Tretinoin results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [triethylene glycol dimethacrylate results in increased cleavage of CASP3 protein]; pyrazolanthrone promotes the reaction [6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride inhibits the reaction [Folic Acid results in increased activity of CASP3 protein]]
pyrazolanthrone results in decreased activity of CASP3 protein
pyrazolanthrone results in increased activity of CASP3 protein 		CTD PMID:12393500 PMID:15034932 PMID:15095415 PMID:15254339 PMID:15501958 More... NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732 		JBrowse link
G Casp4 caspase 4 multiple interactions ISO pyrazolanthrone inhibits the reaction [Bortezomib results in increased cleavage of CASP4 protein] CTD PMID:16357177 NCBI chr 8:10,883,817...10,919,978
Ensembl chr 8:10,883,769...10,920,727 		JBrowse link
G Casp6 caspase 6 multiple interactions EXP
ISO 		pyrazolanthrone inhibits the reaction [Vitamin K 3 results in increased activity of CASP6 protein]; pyrazolanthrone inhibits the reaction [Vitamin K 3 results in increased cleavage of CASP6 protein]
pyrazolanthrone inhibits the reaction [dehydroxymethylepoxyquinomicin results in increased cleavage of CASP6 protein]; pyrazolanthrone inhibits the reaction [Indomethacin results in increased activity of CASP6 protein]; pyrazolanthrone inhibits the reaction [surfactin peptide results in increased cleavage of and results in increased activity of CASP6 protein] 		CTD PMID:15501958 PMID:16310883 PMID:17341418 PMID:19954742 NCBI chr 2:221,140,287...221,152,727
Ensembl chr 2:221,140,256...221,152,726 		JBrowse link
G Casp7 caspase 7 multiple interactions ISO
EXP 		pyrazolanthrone inhibits the reaction [ellipticine results in increased cleavage of and results in increased activity of CASP7 protein]; pyrazolanthrone promotes the reaction [dihydromyricetin results in increased cleavage of CASP7 protein]; pyrazolanthrone promotes the reaction [usnic acid results in increased activity of CASP7 protein]
pyrazolanthrone inhibits the reaction [4-methyl-2,4-bis(4-hydroxyphenyl)pent-1-ene results in increased cleavage of CASP7 protein]; pyrazolanthrone inhibits the reaction [[cupric chloride binds to pyrrolidine dithiocarbamic acid] which results in increased cleavage of CASP7 protein]; pyrazolanthrone inhibits the reaction [Cadmium Chloride results in increased cleavage of CASP7 protein]; pyrazolanthrone inhibits the reaction [nickel chloride results in increased activity of CASP7 protein]
pyrazolanthrone inhibits the reaction [arsenic trioxide results in increased activity of CASP7 protein]; pyrazolanthrone inhibits the reaction [TEMPO results in increased activity of CASP7 protein] 		CTD PMID:20920558 PMID:21843585 PMID:21843586 PMID:23405080 PMID:24157283 More... NCBI chr 1:265,442,647...265,481,938
Ensembl chr 1:265,442,676...265,482,512 		JBrowse link
G Casp8 caspase 8 multiple interactions ISO pyrazolanthrone inhibits the reaction [6-(N,N-dimethylamino)-2-(naphthalene-1-yl)-4-quinazolinone results in increased expression of CASP8 protein]; pyrazolanthrone inhibits the reaction [[Buthionine Sulfoximine co-treated with Arsenic Trioxide] results in increased cleavage of CASP8 protein]; pyrazolanthrone inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] results in increased cleavage of CASP8 protein]; pyrazolanthrone inhibits the reaction [Aminolevulinic Acid analog results in increased activity of CASP8 protein]; pyrazolanthrone inhibits the reaction [coronarin D results in increased expression of CASP8 protein modified form]; pyrazolanthrone inhibits the reaction [dehydroxymethylepoxyquinomicin results in increased cleavage of CASP8 protein]; pyrazolanthrone inhibits the reaction [Quercetin results in increased cleavage of CASP8 protein]; pyrazolanthrone promotes the reaction [Arsenic Trioxide results in increased activity of CASP8 protein]; pyrazolanthrone promotes the reaction [FAS protein results in increased cleavage of and results in increased activity of CASP8 protein] CTD PMID:15501958 PMID:15767555 PMID:16061660 PMID:16972261 PMID:17145888 More... NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699 		JBrowse link
G Casp9 caspase 9 multiple interactions
increases activity 		ISO
EXP 		pyrazolanthrone inhibits the reaction [5-((4-methylphenyl)methylene)-2-(phenylamino)-4(5H)-thiazolone results in increased cleavage of CASP9 protein]; pyrazolanthrone inhibits the reaction [6-(N,N-dimethylamino)-2-(naphthalene-1-yl)-4-quinazolinone results in increased expression of CASP9 protein]; pyrazolanthrone inhibits the reaction [Aminolevulinic Acid analog results in increased activity of CASP9 protein]; pyrazolanthrone inhibits the reaction [coronarin D results in increased expression of CASP9 protein modified form]; pyrazolanthrone inhibits the reaction [dehydroxymethylepoxyquinomicin results in increased cleavage of CASP9 protein]; pyrazolanthrone inhibits the reaction [Indomethacin results in increased activity of CASP9 protein]; pyrazolanthrone inhibits the reaction [morusin results in increased cleavage of CASP9 protein]; pyrazolanthrone inhibits the reaction [Pt(O,O'-acac)(gamma-acac)(DMS) results in increased activity of CASP9 protein]; pyrazolanthrone inhibits the reaction [Quercetin results in increased cleavage of CASP9 protein]; pyrazolanthrone promotes the reaction [dihydromyricetin results in increased cleavage of CASP9 protein]
pyrazolanthrone inhibits the reaction [[cupric chloride binds to pyrrolidine dithiocarbamic acid] which results in increased cleavage of CASP9 protein]; pyrazolanthrone inhibits the reaction [nickel chloride results in increased activity of CASP9 protein]; pyrazolanthrone inhibits the reaction [Vitamin K 3 results in increased cleavage of CASP9 protein]
pyrazolanthrone inhibits the reaction [4-hydroxy-2-nonenal results in increased activity of CASP9 protein]; pyrazolanthrone inhibits the reaction [Cardiotoxins results in increased cleavage of CASP9 protein]
pyrazolanthrone results in increased activity of CASP9 protein 		CTD PMID:15034932 PMID:15501958 PMID:15831436 PMID:16310883 PMID:16322078 More... Ensembl chr 5:159,391,188...159,409,648 JBrowse link
G Cat catalase multiple interactions ISO pyrazolanthrone inhibits the reaction [rhoifolin results in increased activity of CAT protein]; pyrazolanthrone promotes the reaction [Pyrogallol results in decreased expression of CAT protein] CTD PMID:20191265 PMID:35383226 NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526 		JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions ISO
EXP 		pyrazolanthrone inhibits the reaction [Cocaine results in increased expression of CCL2 protein]; pyrazolanthrone inhibits the reaction [Cyclosporine results in increased expression of CCL2 mRNA]; pyrazolanthrone inhibits the reaction [Cyclosporine results in increased expression of CCL2 protein]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; pyrazolanthrone inhibits the reaction [NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased expression of CCL2 mRNA]]; pyrazolanthrone inhibits the reaction [Palmitates results in increased secretion of CCL2 protein]; pyrazolanthrone inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]; pyrazolanthrone inhibits the reaction [Tacrolimus results in increased expression of CCL2 protein]; pyrazolanthrone promotes the reaction [Ozone results in increased expression of CCL2 mRNA]
pyrazolanthrone inhibits the reaction [Allopurinol results in increased expression of CCL2 mRNA]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]
pyrazolanthrone inhibits the reaction [diphenylarsinic acid results in increased secretion of CCL2 protein] 		CTD PMID:17460151 PMID:18303122 PMID:20354174 PMID:20712904 PMID:23958496 More... NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875 		JBrowse link
G Ccl5 C-C motif chemokine ligand 5 multiple interactions ISO pyrazolanthrone inhibits the reaction [Cyclosporine results in increased expression of CCL5 mRNA]; pyrazolanthrone inhibits the reaction [Tacrolimus results in increased expression of CCL5 mRNA] CTD PMID:23958496 NCBI chr10:68,820,330...68,824,906
Ensembl chr10:68,738,651...68,824,884 		JBrowse link
G Ccn2 cellular communication network factor 2 multiple interactions ISO [pyrazolanthrone co-treated with U 0126] inhibits the reaction [fisetin results in decreased expression of CCN2 protein]; [XMU-MP-1 co-treated with pyrazolanthrone co-treated with U 0126] inhibits the reaction [fisetin results in decreased expression of CCN2 protein]; pyrazolanthrone inhibits the reaction [fisetin results in decreased expression of CCN2 protein] CTD PMID:31044527 NCBI chr 1:22,621,498...22,624,614
Ensembl chr 1:22,621,501...22,624,976 		JBrowse link
G Ccnb1 cyclin B1 multiple interactions ISO pyrazolanthrone inhibits the reaction [6-(N,N-dimethylamino)-2-(naphthalene-1-yl)-4-quinazolinone results in increased expression of CCNB1 protein] CTD PMID:23212307 NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:33,646,252...33,655,225 		JBrowse link
G Ccnd1 cyclin D1 multiple interactions
decreases expression 		ISO pyrazolanthrone inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of CCND1 mRNA]; pyrazolanthrone inhibits the reaction [kahweol results in decreased expression of CCND1 protein]; pyrazolanthrone inhibits the reaction [kahweol results in increased phosphorylation of CCND1 protein]
pyrazolanthrone results in decreased expression of CCND1 protein 		CTD PMID:18593901 PMID:19801633 PMID:27424123 NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810 		JBrowse link
G Ccr2 C-C motif chemokine receptor 2 multiple interactions ISO pyrazolanthrone inhibits the reaction [Silicon Dioxide results in increased expression of CCR2 protein] CTD PMID:26163174 NCBI chr 8:132,611,883...132,619,106
Ensembl chr 8:132,611,410...132,620,059 		JBrowse link
G Cd14 CD14 molecule multiple interactions ISO pyrazolanthrone inhibits the reaction [Calcitriol results in increased expression of CD14 protein]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of CD14 protein] CTD PMID:14729647 PMID:18180316 NCBI chr18:28,609,558...28,611,409
Ensembl chr18:28,608,883...28,611,292 		JBrowse link
G Cd207 CD207 molecule multiple interactions
decreases expression 		ISO pyrazolanthrone promotes the reaction [nickel sulfate results in decreased expression of CD207 protein]
pyrazolanthrone results in decreased expression of CD207 protein 		CTD PMID:15588916 NCBI chr 4:117,712,879...117,719,191
Ensembl chr 4:117,712,879...117,719,191 		JBrowse link
G Cd36 CD36 molecule multiple interactions ISO pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in decreased expression of CD36 mRNA] CTD PMID:21873422 NCBI chr 4:18,209,088...18,302,142 JBrowse link
G Cd80 Cd80 molecule multiple interactions ISO pyrazolanthrone inhibits the reaction [Fungal Polysaccharides results in increased expression of CD80 protein] CTD PMID:28235615 NCBI chr11:75,760,073...75,798,978
Ensembl chr11:75,760,147...75,797,540 		JBrowse link
G Cd86 CD86 molecule multiple interactions ISO pyrazolanthrone inhibits the reaction [Fungal Polysaccharides results in increased expression of CD86 protein] CTD PMID:28235615 NCBI chr11:77,647,565...77,706,178
Ensembl chr11:77,647,600...77,725,361 		JBrowse link
G Cdc25c cell division cycle 25C multiple interactions ISO pyrazolanthrone inhibits the reaction [5-(2,4-dihydroxybenzylidene)-2-(phenylimino)-1,3-thiazolidin affects the expression of CDC25C protein] CTD PMID:16179969 NCBI chr18:26,608,483...26,630,292
Ensembl chr18:26,609,959...26,630,292 		JBrowse link
G Cdh1 cadherin 1 decreases expression
multiple interactions 		ISO pyrazolanthrone results in decreased expression of CDH1 protein
6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride promotes the reaction [pyrazolanthrone inhibits the reaction [Folic Acid results in decreased expression of CDH1 protein]]; pyrazolanthrone inhibits the reaction [Folic Acid results in decreased expression of CDH1 protein]; pyrazolanthrone promotes the reaction [6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride inhibits the reaction [Folic Acid results in decreased expression of CDH1 protein]]
pyrazolanthrone inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 protein]; pyrazolanthrone promotes the reaction [nickel sulfate results in decreased expression of CDH1 protein] 		CTD PMID:15588916 PMID:31447676 PMID:33396024 NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565 		JBrowse link
G Cdh5 cadherin 5 multiple interactions ISO pyrazolanthrone inhibits the reaction [Varenicline results in decreased expression of CDH5] CTD PMID:28842382 NCBI chr19:821,875...860,931
Ensembl chr19:822,464...860,822 		JBrowse link
G Cdk1 cyclin-dependent kinase 1 multiple interactions
decreases expression 		ISO pyrazolanthrone inhibits the reaction [6-(N,N-dimethylamino)-2-(naphthalene-1-yl)-4-quinazolinone results in increased expression of CDK1 protein]
pyrazolanthrone results in decreased expression of CDK1 protein 		CTD PMID:18593901 PMID:23212307 NCBI chr20:19,265,252...19,280,456
Ensembl chr20:19,265,289...19,280,455 		JBrowse link
G Cdk2 cyclin dependent kinase 2 multiple interactions
decreases activity 		ISO pyrazolanthrone inhibits the reaction [naphtho(1,2-b)furan-4,5-dione results in decreased expression of CDK2 protein]
pyrazolanthrone results in decreased activity of CDK2 protein 		CTD PMID:12534346 PMID:19747539 NCBI chr 7:1,714,392...1,721,964
Ensembl chr 7:1,714,392...1,721,878 		JBrowse link
G Cdk5 cyclin-dependent kinase 5 multiple interactions EXP pyrazolanthrone inhibits the reaction [[sodium arsenite co-treated with lead acetate co-treated with Cadmium Chloride] results in increased phosphorylation of CDK5 protein]; pyrazolanthrone inhibits the reaction [troglitazone results in increased phosphorylation of CDK5 protein] CTD PMID:24481447 NCBI chr 4:11,647,098...11,651,606
Ensembl chr 4:11,647,141...11,652,777 		JBrowse link
G Cdk5r1 cyclin-dependent kinase 5 regulatory subunit 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [resveratrol results in decreased expression of CDK5R1 mRNA] CTD PMID:21736731 NCBI chr10:65,981,692...65,985,831
Ensembl chr10:65,978,911...65,989,272 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions
increases expression 		ISO
EXP 		pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased expression of CDKN1A protein]; pyrazolanthrone inhibits the reaction [tributyltin results in increased expression of CDKN1A protein]; pyrazolanthrone promotes the reaction [Arsenic Trioxide results in increased expression of CDKN1A mRNA]; pyrazolanthrone promotes the reaction [Arsenic Trioxide results in increased expression of CDKN1A protein]; pyrazolanthrone promotes the reaction [EGF protein results in increased expression of CDKN1A mRNA]
pyrazolanthrone promotes the reaction [Diethylnitrosamine results in increased expression of CDKN1A protein]
pyrazolanthrone results in increased expression of CDKN1A protein 		CTD PMID:15961274 PMID:16061660 PMID:16283431 PMID:19418558 PMID:31734849 More... NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969 		JBrowse link
G Cdkn2a cyclin-dependent kinase inhibitor 2A multiple interactions ISO pyrazolanthrone inhibits the reaction [Particulate Matter results in increased methylation of CDKN2A promoter] CTD PMID:22355787 NCBI chr 5:109,100,763...109,114,448
Ensembl chr 5:109,100,772...109,119,248 		JBrowse link
G Cebpa CCAAT/enhancer binding protein alpha multiple interactions ISO pyrazolanthrone inhibits the reaction [Glucose results in increased localization of and results in increased activity of CEBPA protein] CTD PMID:24376792 NCBI chr 1:96,896,584...96,899,256
Ensembl chr 1:96,896,171...96,899,309 		JBrowse link
G Cebpb CCAAT/enhancer binding protein beta multiple interactions ISO pyrazolanthrone inhibits the reaction [Calcitriol results in increased expression of CEBPB mRNA]; pyrazolanthrone inhibits the reaction [Calcitriol results in increased expression of CEBPB protein]; pyrazolanthrone inhibits the reaction [Glucose results in increased localization of and results in increased activity of CEBPB protein] CTD PMID:14729647 PMID:24376792 NCBI chr 3:176,817,005...176,818,436
Ensembl chr 3:176,816,859...176,838,072 		JBrowse link
G Cebpd CCAAT/enhancer binding protein delta multiple interactions ISO pyrazolanthrone inhibits the reaction [Glucose results in increased localization of and results in increased activity of CEBPD protein] CTD PMID:24376792 NCBI chr11:98,268,856...98,269,994
Ensembl chr11:98,265,651...98,280,824 		JBrowse link
G Ces3a carboxylesterase 3a multiple interactions ISO pyrazolanthrone inhibits the reaction [Ozone results in increased expression of CES3 mRNA] CTD PMID:17460151 NCBI chr19:49,902,312...49,910,484 JBrowse link
G Chuk component of inhibitor of nuclear factor kappa B kinase complex multiple interactions EXP pyrazolanthrone inhibits the reaction [sodium arsenite results in increased phosphorylation of CHUK protein] CTD PMID:19616567 NCBI chr 1:252,908,748...252,944,273
Ensembl chr 1:252,908,749...252,944,273 		JBrowse link
G Cldn4 claudin 4 multiple interactions EXP pyrazolanthrone inhibits the reaction [Sodium Chloride results in increased expression of CLDN4 mRNA]; pyrazolanthrone inhibits the reaction [Sodium Chloride results in increased expression of CLDN4 protein] CTD PMID:23816505 NCBI chr12:27,388,160...27,389,958
Ensembl chr12:27,387,981...27,389,958 		JBrowse link
G Cpeb1 cytoplasmic polyadenylation element binding protein 1 multiple interactions EXP pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased phosphorylation of CPEB1 protein]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of CPEB1 mRNA] CTD PMID:21620800 NCBI chr 1:144,709,278...144,817,388
Ensembl chr 1:144,709,691...144,815,880 		JBrowse link
G Cpeb4 cytoplasmic polyadenylation element binding protein 4 multiple interactions ISO pyrazolanthrone inhibits the reaction [sodium arsenite promotes the reaction [CPEB4 protein binds to SORBS3 protein]] CTD PMID:25237887 NCBI chr10:16,222,271...16,284,248
Ensembl chr10:16,225,672...16,283,787 		JBrowse link
G Cpt1b carnitine palmitoyltransferase 1B increases expression
multiple interactions 		ISO pyrazolanthrone results in increased expression of CPT1B mRNA
pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in decreased expression of CPT1B mRNA] 		CTD PMID:21873422 NCBI chr 7:122,370,974...122,380,473
Ensembl chr 7:122,370,444...122,380,036 		JBrowse link
G Creb1 cAMP responsive element binding protein 1 decreases phosphorylation
multiple interactions 		ISO
EXP 		pyrazolanthrone results in decreased phosphorylation of CREB1 protein
pyrazolanthrone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of CREB1 protein]; pyrazolanthrone inhibits the reaction [diphenylarsinic acid results in increased phosphorylation of CREB1 protein] 		CTD PMID:25605016 PMID:28087833 PMID:32920012 NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:73,397,306...73,466,339 		JBrowse link
G Crh corticotropin releasing hormone multiple interactions ISO pyrazolanthrone inhibits the reaction [2,2',4,4'-tetrabromodiphenyl ether results in increased expression of CRH mRNA] CTD PMID:28189027 NCBI chr 2:104,059,184...104,061,048
Ensembl chr 2:104,058,770...104,061,386 		JBrowse link
G Cs citrate synthase multiple interactions ISO pyrazolanthrone affects the reaction [triethylene glycol dimethacrylate affects the activity of CS protein] CTD PMID:33684387 NCBI chr 7:1,348,389...1,374,624
Ensembl chr 7:1,342,942...1,375,938 		JBrowse link
G Csf2 colony stimulating factor 2 multiple interactions ISO pyrazolanthrone inhibits the reaction [Particulate Matter results in increased secretion of CSF2 protein] CTD PMID:19460412 NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,887,692...38,890,031 		JBrowse link
G Csnk1d casein kinase 1, delta decreases activity ISO pyrazolanthrone results in decreased activity of CSNK1D protein CTD PMID:12534346 NCBI chr10:106,713,497...106,754,953
Ensembl chr10:106,694,279...106,754,953 		JBrowse link
G Cst3 cystatin C multiple interactions ISO 6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride promotes the reaction [pyrazolanthrone inhibits the reaction [Folic Acid results in increased expression of CST3 protein]]; pyrazolanthrone inhibits the reaction [Folic Acid results in increased expression of CST3 protein]; pyrazolanthrone promotes the reaction [6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride inhibits the reaction [Folic Acid results in increased expression of CST3 protein]] CTD PMID:31447676 NCBI chr 3:156,790,061...156,794,116
Ensembl chr 3:156,790,079...156,793,937 		JBrowse link
G Ctf1 cardiotrophin 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [cobaltous chloride results in increased expression of CTF1 protein]; pyrazolanthrone inhibits the reaction [Vitamin K 3 results in increased expression of CTF1 protein] CTD PMID:16507596 NCBI chr 1:191,758,512...191,771,259
Ensembl chr 1:191,757,477...191,776,395 		JBrowse link
G Cxcl1 C-X-C motif chemokine ligand 1 multiple interactions EXP pyrazolanthrone inhibits the reaction [diphenylarsinic acid results in increased secretion of CXCL1 protein] CTD PMID:28087833 NCBI chr14:17,477,542...17,479,321
Ensembl chr14:17,477,549...17,479,811 		JBrowse link
G Cxcl10 C-X-C motif chemokine ligand 10 multiple interactions ISO pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of CXCL10 mRNA] CTD PMID:12832416 NCBI chr14:15,989,066...15,991,263
Ensembl chr14:15,989,018...15,991,261 		JBrowse link
G Cxcl16 C-X-C motif chemokine ligand 16 multiple interactions EXP pyrazolanthrone inhibits the reaction [cypermethrin results in increased expression of CXCL16 protein] CTD PMID:35512476 NCBI chr10:55,665,355...55,669,950
Ensembl chr10:55,664,742...55,670,226 		JBrowse link
G Cxcl2 C-X-C motif chemokine ligand 2 multiple interactions ISO pyrazolanthrone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of CXCL2 protein] CTD PMID:21507677 NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,465,242...17,467,255 		JBrowse link
G Cyba cytochrome b-245 alpha chain multiple interactions EXP pyrazolanthrone inhibits the reaction [Glucose results in increased expression of CYBA protein] CTD PMID:22245600 NCBI chr19:67,396,143...67,404,214
Ensembl chr19:67,396,143...67,404,214 		JBrowse link
G Cycs cytochrome c, somatic multiple interactions ISO pyrazolanthrone inhibits the reaction [4-vinyl-2,6-dimethoxyphenol results in increased expression of CYCS protein]; pyrazolanthrone inhibits the reaction [surfactin peptide affects the localization of CYCS protein]; pyrazolanthrone promotes the reaction [Arsenic Trioxide affects the localization of CYCS protein]
pyrazolanthrone inhibits the reaction [4-hydroxy-2-nonenal affects the localization of CYCS protein] 		CTD PMID:16322078 PMID:16972261 PMID:19954742 PMID:30653946 NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816
Ensembl chr18:80,982,668...80,984,816 		JBrowse link
G Cygb cytoglobin multiple interactions ISO pyrazolanthrone inhibits the reaction [2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole results in increased expression of CYGB mRNA] CTD PMID:25781201 NCBI chr10:102,376,506...102,386,272
Ensembl chr10:102,376,507...102,386,272 		JBrowse link
G Cyp11a1 cytochrome P450, family 11, subfamily a, polypeptide 1 multiple interactions ISO
EXP 		pyrazolanthrone inhibits the reaction [bisphenol A results in increased expression of CYP11A1 mRNA]; pyrazolanthrone inhibits the reaction [bisphenol A results in increased expression of CYP11A1 protein]
pyrazolanthrone inhibits the reaction [nickel sulfate results in decreased expression of CYP11A1 mRNA]; pyrazolanthrone inhibits the reaction [nickel sulfate results in decreased expression of CYP11A1 protein] 		CTD PMID:26209791 PMID:28697429 PMID:29567110 NCBI chr 8:67,318,665...67,330,196
Ensembl chr 8:67,270,556...67,330,196 		JBrowse link
G Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 increases expression
multiple interactions 		ISO
EXP 		pyrazolanthrone results in increased expression of CYP17A1 mRNA
pyrazolanthrone inhibits the reaction [nickel sulfate results in decreased expression of CYP17A1 mRNA]; pyrazolanthrone inhibits the reaction [nickel sulfate results in decreased expression of CYP17A1 protein]
pyrazolanthrone inhibits the reaction [FGF19 protein results in decreased expression of CYP17A1 mRNA] 		CTD PMID:16269825 PMID:29567110 NCBI chr 1:255,476,861...255,484,547
Ensembl chr 1:255,476,861...255,482,974 		JBrowse link
G Cyp19a1 cytochrome P450, family 19, subfamily a, polypeptide 1 multiple interactions ISO
EXP 		pyrazolanthrone inhibits the reaction [LEP protein results in increased expression of CYP19A1 mRNA]; pyrazolanthrone inhibits the reaction [LEP protein results in increased expression of CYP19A1 protein]; pyrazolanthrone inhibits the reaction [o,p'-DDT results in increased expression of CYP19A1 protein]
pyrazolanthrone inhibits the reaction [bisphenol A results in increased expression of CYP19A1 mRNA]; pyrazolanthrone inhibits the reaction [bisphenol A results in increased expression of CYP19A1 protein]
pyrazolanthrone inhibits the reaction [bisphenol A results in increased expression of and results in increased activity of CYP19A1 protein] 		CTD PMID:20096755 PMID:20678559 PMID:28571770 PMID:28697429 NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:63,449,148...63,476,917 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions
decreases expression
increases expression 		ISO pyrazolanthrone inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; resveratrol inhibits the reaction [pyrazolanthrone results in increased expression of CYP1A1 mRNA]
pyrazolanthrone results in decreased expression of CYP1A1 mRNA
pyrazolanthrone inhibits the reaction [Copper results in increased expression of CYP1A1 mRNA]; pyrazolanthrone inhibits the reaction [Lead results in increased expression of CYP1A1 mRNA]; pyrazolanthrone inhibits the reaction [Mercury results in increased expression of CYP1A1 mRNA]; pyrazolanthrone inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; pyrazolanthrone inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]; pyrazolanthrone promotes the reaction [Copper inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]]; pyrazolanthrone promotes the reaction [Lead inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]]; pyrazolanthrone promotes the reaction [Mercury inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]] 		CTD PMID:17959153 PMID:18078826 NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012 		JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 increases expression
multiple interactions 		ISO pyrazolanthrone results in increased expression of CYP1A2 mRNA
pyrazolanthrone inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A2 mRNA]; resveratrol inhibits the reaction [pyrazolanthrone results in increased expression of CYP1A2 mRNA] 		CTD PMID:17959153 NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149 		JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; pyrazolanthrone inhibits the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA] CTD PMID:22486562 NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions ISO pyrazolanthrone inhibits the reaction [Calcitriol results in increased expression of CYP3A4 mRNA] CTD PMID:17965521 NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857 		JBrowse link
G Cyp4f40 cytochrome P450, family 4, subfamily f, polypeptide 40 multiple interactions
decreases expression 		ISO pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of CYP4F11 mRNA]; pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of CYP4F11 mRNA]
pyrazolanthrone results in decreased expression of CYP4F11 mRNA 		CTD PMID:19812349 NCBI chr 7:12,342,121...12,357,974
Ensembl chr 7:12,342,590...12,356,733 		JBrowse link
G Cyp7a1 cytochrome P450 family 7 subfamily A member 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [Tretinoin results in decreased expression of CYP7A1 mRNA]; pyrazolanthrone inhibits the reaction [Tretinoin results in decreased expression of CYP7A1 protein] CTD PMID:30709899 NCBI chr 5:24,174,505...24,184,202
Ensembl chr 5:24,174,505...24,184,202 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions ISO
EXP 		pyrazolanthrone inhibits the reaction [dihydrocapsaicin results in increased expression of DDIT3 protein]; pyrazolanthrone inhibits the reaction [honokiol results in increased expression of DDIT3 protein]; pyrazolanthrone inhibits the reaction [Indomethacin results in increased expression of DDIT3 protein]; pyrazolanthrone inhibits the reaction [Leflunomide results in increased expression of DDIT3 protein]; pyrazolanthrone inhibits the reaction [Quercetin results in increased expression of DDIT3 protein]; pyrazolanthrone inhibits the reaction [Resveratrol results in increased expression of DDIT3 mRNA]; pyrazolanthrone inhibits the reaction [Resveratrol results in increased expression of DDIT3 protein]; pyrazolanthrone inhibits the reaction [tanshinone results in increased expression of DDIT3 protein]
pyrazolanthrone inhibits the reaction [alpha-naphthoflavone results in increased expression of DDIT3 protein]
pyrazolanthrone inhibits the reaction [4-methyl-2,4-bis(4-hydroxyphenyl)pent-1-ene results in increased expression of DDIT3 protein]; pyrazolanthrone inhibits the reaction [[cupric chloride binds to pyrrolidine dithiocarbamic acid] which results in increased expression of DDIT3 mRNA]; pyrazolanthrone inhibits the reaction [Cadmium Chloride results in increased expression of DDIT3 protein] 		CTD PMID:17049495 PMID:17341418 PMID:19139269 PMID:20920558 PMID:24612139 More... NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509 		JBrowse link
G Dio1 iodothyronine deiodinase 1 multiple interactions ISO [Sulfasalazine co-treated with pyrazolanthrone] inhibits the reaction [IL1B protein results in decreased expression of DIO1 mRNA] CTD PMID:16614379 NCBI chr 5:127,303,089...127,319,784
Ensembl chr 5:127,303,083...127,319,771 		JBrowse link
G Dnmt1 DNA methyltransferase 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [Particulate Matter results in increased expression of DNMT1 protein] CTD PMID:22355787 NCBI chr 8:27,716,797...27,763,405
Ensembl chr 8:27,716,797...27,763,119 		JBrowse link
G Dnmt3a DNA methyltransferase 3 alpha multiple interactions EXP [pyrazolanthrone co-treated with cypermethrin] results in decreased expression of DNMT3A protein CTD PMID:34794910 NCBI chr 6:32,507,316...32,621,678
Ensembl chr 6:32,512,070...32,614,970 		JBrowse link
G Dnmt3b DNA methyltransferase 3 beta multiple interactions EXP [pyrazolanthrone co-treated with cypermethrin] results in decreased expression of DNMT3B protein CTD PMID:34794910 NCBI chr 3:162,590,777...162,629,313
Ensembl chr 3:162,604,037...162,629,313 		JBrowse link
G Doc2b double C2 domain beta multiple interactions ISO pyrazolanthrone inhibits the reaction [Ozone results in increased expression of DOC2B mRNA] CTD PMID:17460151 NCBI chr10:61,126,295...61,151,533
Ensembl chr10:61,126,295...61,151,533 		JBrowse link
G Dyrk1a dual specificity tyrosine phosphorylation regulated kinase 1A decreases activity ISO pyrazolanthrone results in decreased activity of DYRK1A protein CTD PMID:12534346 NCBI chr11:47,360,824...47,479,033
Ensembl chr11:47,360,850...47,479,033 		JBrowse link
G Edn1 endothelin 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [Glucose results in increased expression of EDN1 mRNA] CTD PMID:24376792 NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687 		JBrowse link
G Ednra endothelin receptor type A multiple interactions EXP pyrazolanthrone inhibits the reaction [Particulate Matter results in increased expression of EDNRA mRNA]; pyrazolanthrone inhibits the reaction [Particulate Matter results in increased expression of EDNRA protein] CTD PMID:20561571 NCBI chr19:47,137,360...47,207,961
Ensembl chr19:47,137,771...47,201,284 		JBrowse link
G Ednrb endothelin receptor type B multiple interactions EXP pyrazolanthrone inhibits the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB mRNA]; pyrazolanthrone inhibits the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB protein]; pyrazolanthrone inhibits the reaction [Particulate Matter results in increased expression of EDNRB mRNA]; pyrazolanthrone inhibits the reaction [Particulate Matter results in increased expression of EDNRB protein]; pyrazolanthrone inhibits the reaction [Smoke analog results in increased expression of EDNRB protein] CTD PMID:20561571 PMID:20716444 PMID:26496744 NCBI chr15:87,055,490...87,086,765
Ensembl chr15:87,057,691...87,086,765 		JBrowse link
G Egf epidermal growth factor multiple interactions ISO pyrazolanthrone inhibits the reaction [arsenite results in increased expression of and results in increased secretion of EGF protein]; pyrazolanthrone inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Cisplatin]]; pyrazolanthrone inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]]; pyrazolanthrone inhibits the reaction [EGF protein results in increased secretion of MUC5AC protein]; pyrazolanthrone promotes the reaction [EGF protein results in increased expression of CDKN1A mRNA] CTD PMID:15961274 PMID:21613822 PMID:22766066 PMID:36343453 NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:220,893,660...220,976,297 		JBrowse link
G Egfr epidermal growth factor receptor decreases expression ISO
EXP 		pyrazolanthrone results in decreased expression of EGFR mRNA; pyrazolanthrone results in decreased expression of EGFR protein CTD PMID:15923621 PMID:18332871 NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358 		JBrowse link
G Egr1 early growth response 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [Curcumin results in increased expression of EGR1 protein]
pyrazolanthrone inhibits the reaction [arsenic trioxide results in increased expression of EGR1 mRNA] 		CTD PMID:15688020 PMID:18316600 NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,736,838...26,740,843 		JBrowse link
G Eif2ak2 eukaryotic translation initiation factor 2-alpha kinase 2 multiple interactions EXP pyrazolanthrone inhibits the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased cleavage of EIF2AK2 protein] CTD PMID:32574669 NCBI chr 6:21,941,147...21,977,115
Ensembl chr 6:21,952,631...21,977,116 		JBrowse link
G Elk1 ETS transcription factor ELK1 multiple interactions ISO pyrazolanthrone inhibits the reaction [Anisomycin results in increased phosphorylation of ELK1 protein]; pyrazolanthrone inhibits the reaction [Curcumin results in increased phosphorylation of ELK1 protein]; pyrazolanthrone inhibits the reaction [sodium arsenite results in increased phosphorylation of ELK1 protein] CTD PMID:12660819 PMID:18316600 PMID:21642427 NCBI chr  X:3,692,367...3,709,252
Ensembl chr  X:3,693,293...3,709,249 		JBrowse link
G Endog endonuclease G multiple interactions EXP pyrazolanthrone inhibits the reaction [cadmium acetate affects the localization of ENDOG protein] CTD PMID:24577723 NCBI chr 3:33,846,935...33,849,531
Ensembl chr 3:33,846,885...33,849,573 		JBrowse link
G Epor erythropoietin receptor multiple interactions ISO pyrazolanthrone inhibits the reaction [testosterone-3-carboxymethyloxime-bovine serum albumin conjugate results in increased expression of EPOR mRNA] CTD PMID:20189893 NCBI chr 8:28,765,738...28,770,371
Ensembl chr 8:28,765,746...28,770,322 		JBrowse link
G Erbb2 erb-b2 receptor tyrosine kinase 2 multiple interactions ISO pyrazolanthrone inhibits the reaction [ERBB2 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of CXCL8 mRNA]]; pyrazolanthrone inhibits the reaction [ERBB2 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased secretion of CXCL8 protein]] CTD PMID:33396024 NCBI chr10:83,907,491...83,931,365
Ensembl chr10:83,907,460...83,931,481 		JBrowse link
G Ern1 endoplasmic reticulum to nucleus signaling 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [dihydrocapsaicin results in increased expression of ERN1 protein] CTD PMID:19139269 NCBI chr10:91,826,663...91,920,976
Ensembl chr10:91,830,428...91,920,791 		JBrowse link
G Esr2 estrogen receptor 2 multiple interactions ISO pyrazolanthrone inhibits the reaction [bisphenol S results in increased phosphorylation of ESR2 protein] CTD PMID:38301581 NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:100,545,206...100,644,709 		JBrowse link
G Etfa electron transfer flavoprotein subunit alpha multiple interactions ISO pyrazolanthrone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ETFA protein] CTD PMID:24394546 NCBI chr 8:64,731,192...64,787,965
Ensembl chr 8:64,731,193...64,788,080 		JBrowse link
G Ezh2 enhancer of zeste 2 polycomb repressive complex 2 subunit multiple interactions ISO pyrazolanthrone inhibits the reaction [Arsenicals results in increased phosphorylation of EZH2 protein] CTD PMID:23255093 NCBI chr 4:77,624,223...77,698,598
Ensembl chr 4:77,624,223...77,687,183 		JBrowse link
G F2 coagulation factor II, thrombin multiple interactions ISO pyrazolanthrone inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased expression of F3 protein] CTD PMID:19944065 NCBI chr 3:98,051,958...98,065,246
Ensembl chr 3:98,051,960...98,065,246 		JBrowse link
G F3 coagulation factor III, tissue factor multiple interactions ISO pyrazolanthrone inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased expression of F3 protein]; pyrazolanthrone inhibits the reaction [Histamine results in increased expression of F3]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of F3 protein]; pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of F3 mRNA] CTD PMID:16009787 PMID:19944065 PMID:20118172 PMID:27556861 NCBI chr 2:212,511,675...212,523,375
Ensembl chr 2:212,511,680...212,523,369 		JBrowse link
G Fadd Fas associated via death domain multiple interactions
decreases phosphorylation 		ISO pyrazolanthrone inhibits the reaction [Aminolevulinic Acid analog results in increased phosphorylation of FADD protein]; pyrazolanthrone inhibits the reaction [Paclitaxel results in increased phosphorylation of FADD protein]; pyrazolanthrone inhibits the reaction [polyphenon E results in increased phosphorylation of FADD protein]
pyrazolanthrone results in decreased phosphorylation of FADD protein 		CTD PMID:16450001 PMID:21138480 PMID:23285096 NCBI chr 1:209,169,245...209,175,423
Ensembl chr 1:209,169,318...209,174,976 		JBrowse link
G Fas Fas cell surface death receptor multiple interactions
increases activity
increases expression 		ISO pyrazolanthrone inhibits the reaction [FGF7 protein results in increased expression of FAS protein]; pyrazolanthrone promotes the reaction [FAS protein results in increased cleavage of and results in increased activity of CASP3 protein]; pyrazolanthrone promotes the reaction [FAS protein results in increased cleavage of and results in increased activity of CASP8 protein]
pyrazolanthrone results in increased activity of FAS protein
pyrazolanthrone results in increased expression of FAS protein 		CTD PMID:16061660 PMID:16162944 NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:241,205,935...241,246,104 		JBrowse link
G Faslg Fas ligand multiple interactions ISO pyrazolanthrone affects the reaction [temozolomide results in increased expression of FASLG mRNA]; pyrazolanthrone inhibits the reaction [[sorafenib co-treated with Vitamin K 1] results in increased expression of FASLG protein]; pyrazolanthrone inhibits the reaction [Nimustine results in increased expression of FASLG mRNA]; pyrazolanthrone inhibits the reaction [Quercetin results in increased expression of FASLG protein] CTD PMID:20301194 PMID:21165570 PMID:26418950 NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503 		JBrowse link
G Fbxo32 F-box protein 32 multiple interactions ISO pyrazolanthrone inhibits the reaction [Indican results in increased expression of FBXO32 protein] CTD PMID:30849338 NCBI chr 7:91,620,925...91,654,491
Ensembl chr 7:91,620,925...91,654,491 		JBrowse link
G Fem1b fem-1 homolog B multiple interactions ISO pyrazolanthrone promotes the reaction [Ozone results in increased expression of FEM1B mRNA] CTD PMID:17460151 NCBI chr 8:72,160,722...72,173,996
Ensembl chr 8:72,160,722...72,173,996 		JBrowse link
G Fgf1 fibroblast growth factor 1 multiple interactions EXP pyrazolanthrone inhibits the reaction [FGF1 protein results in increased expression of SPP1 mRNA] CTD PMID:15121739 NCBI chr18:30,937,670...31,023,786
Ensembl chr18:30,939,870...30,961,393 		JBrowse link
G Fgf19 fibroblast growth factor 19 multiple interactions ISO pyrazolanthrone inhibits the reaction [FGF19 protein results in decreased expression of CYP17A1 mRNA]; pyrazolanthrone inhibits the reaction [FGF19 protein results in decreased expression of PON1 mRNA] CTD PMID:16269825 NCBI chr 1:209,485,813...209,490,267
Ensembl chr 1:209,485,813...209,490,267 		JBrowse link
G Fgf2 fibroblast growth factor 2 multiple interactions ISO
EXP 		pyrazolanthrone inhibits the reaction [hydroxyethyl methacrylate results in increased secretion of FGF2 protein]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of FGF2 mRNA]; pyrazolanthrone inhibits the reaction [Sodium Chloride results in increased expression of FGF2 mRNA]
pyrazolanthrone inhibits the reaction [diphenylarsinic acid results in increased secretion of FGF2 protein]
pyrazolanthrone inhibits the reaction [FGF2 protein results in increased secretion of TNFRSF11B protein] 		CTD PMID:12832416 PMID:19176594 PMID:25290095 PMID:26800359 PMID:28087833 NCBI chr 2:122,164,454...122,218,796
Ensembl chr 2:122,164,454...122,224,493 		JBrowse link
G Fgf7 fibroblast growth factor 7 multiple interactions ISO pyrazolanthrone inhibits the reaction [FGF7 protein results in increased expression of FAS protein]; pyrazolanthrone inhibits the reaction [FGF7 protein results in increased expression of SCD protein]; pyrazolanthrone inhibits the reaction [FGF7 protein results in increased expression of SREBF1 protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased secretion of FGF7 protein] CTD PMID:15677771 PMID:16162944 NCBI chr 3:133,734,557...133,786,678
Ensembl chr 3:133,734,673...133,786,328 		JBrowse link
G Fn1 fibronectin 1 multiple interactions ISO 6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride promotes the reaction [pyrazolanthrone inhibits the reaction [Folic Acid results in increased expression of FN1 protein]]; pyrazolanthrone inhibits the reaction [Folic Acid results in increased expression of FN1 protein] CTD PMID:31447676 NCBI chr 9:80,645,507...80,714,200
Ensembl chr 9:80,645,507...80,714,137 		JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO
EXP 		[2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one co-treated with 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole co-treated with pyrazolanthrone] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 affects the localization of FOS protein]; pyrazolanthrone inhibits the reaction [2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester results in increased phosphorylation of FOS protein]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of FOS protein]; pyrazolanthrone inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of FOS protein]
pyrazolanthrone inhibits the reaction [diphenylarsinic acid results in increased expression of and results in increased phosphorylation of FOS protein]; pyrazolanthrone inhibits the reaction [Patulin results in increased expression of FOS protein] 		CTD PMID:22020770 PMID:24469321 PMID:24967690 PMID:28087833 PMID:34896196 NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598 		JBrowse link
G Fosl1 FOS like 1, AP-1 transcription factor subunit multiple interactions ISO pyrazolanthrone inhibits the reaction [Particulate Matter results in increased expression of FOSL1 mRNA]; pyrazolanthrone inhibits the reaction [Vehicle Emissions results in increased expression of FOSL1 mRNA] CTD PMID:14565943 NCBI chr 1:212,183,885...212,192,391
Ensembl chr 1:212,183,833...212,192,391 		JBrowse link
G Foxo1 forkhead box O1 multiple interactions ISO pyrazolanthrone inhibits the reaction [mevastatin results in increased phosphorylation of FOXO1 protein]; pyrazolanthrone inhibits the reaction [tricarbonyldichlororuthenium (II) dimer results in increased phosphorylation of FOXO1 protein] CTD PMID:26385185 PMID:39431643 NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:138,462,697...138,541,419 		JBrowse link
G Foxo3 forkhead box O3 multiple interactions ISO pyrazolanthrone inhibits the reaction [cordycepin results in decreased phosphorylation of and affects the localization of FOXO3 protein]; pyrazolanthrone inhibits the reaction [deoxynivalenol affects the localization of FOXO3A protein]; pyrazolanthrone inhibits the reaction [Ethanol results in increased phosphorylation of FOXO3 protein]; pyrazolanthrone inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased phosphorylation of FOXO3 protein] CTD PMID:26470730 PMID:28099944 PMID:30169763 NCBI chr20:47,251,968...47,348,254
Ensembl chr20:47,255,878...47,346,845 		JBrowse link
G Fshb follicle stimulating hormone subunit beta multiple interactions EXP pyrazolanthrone inhibits the reaction [FSHB protein results in increased abundance of Estradiol]; pyrazolanthrone inhibits the reaction [FSHB protein results in increased abundance of Progesterone] CTD PMID:22067323 NCBI chr 3:114,003,262...114,007,072
Ensembl chr 3:114,003,262...114,007,072 		JBrowse link
G Gabpa GA binding protein transcription factor subunit alpha multiple interactions ISO pyrazolanthrone inhibits the reaction [Gallic Acid results in increased expression of GABPA protein] CTD PMID:16308312 NCBI chr11:37,375,040...37,404,060
Ensembl chr11:37,375,084...37,404,059 		JBrowse link
G Gadd45a growth arrest and DNA-damage-inducible, alpha multiple interactions ISO pyrazolanthrone inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of GADD45A protein]; troglitazone inhibits the reaction [pyrazolanthrone results in increased expression of GADD45A mRNA]; troglitazone inhibits the reaction [pyrazolanthrone results in increased expression of GADD45A protein]
pyrazolanthrone inhibits the reaction [Excitatory Amino Acid Agents results in increased expression of GADD45A mRNA] 		CTD PMID:15064713 PMID:20955365 PMID:25469469 NCBI chr 4:97,484,497...97,486,799
Ensembl chr 4:97,484,502...97,486,807 		JBrowse link
G Gadd45b growth arrest and DNA-damage-inducible, beta multiple interactions ISO pyrazolanthrone inhibits the reaction [sorafenib results in increased expression of GADD45B mRNA]; pyrazolanthrone inhibits the reaction [sorafenib results in increased expression of GADD45B protein] CTD PMID:21062976 NCBI chr 7:9,428,689...9,430,991
Ensembl chr 7:9,428,689...9,430,718 		JBrowse link
G Galnt3 polypeptide N-acetylgalactosaminyltransferase 3 multiple interactions ISO pyrazolanthrone inhibits the reaction [Cadmium results in increased expression of GALNT3 mRNA] CTD PMID:24614234 NCBI chr 3:71,150,559...71,187,321
Ensembl chr 3:71,150,571...71,174,323 		JBrowse link
G Gata2 GATA binding protein 2 multiple interactions ISO pyrazolanthrone inhibits the reaction [Lipopolysaccharides affects the localization of and results in increased activity of GATA2 protein] CTD PMID:23940812 NCBI chr 4:122,211,501...122,225,058
Ensembl chr 4:122,211,829...122,225,055 		JBrowse link
G Gch1 GTP cyclohydrolase 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of GCH1 mRNA] CTD PMID:12832416 NCBI chr15:22,884,006...22,917,412
Ensembl chr15:22,884,006...22,917,412 		JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit multiple interactions ISO pyrazolanthrone inhibits the reaction [[clivorine co-treated with Quercetin] results in increased expression of GCLC mRNA]; pyrazolanthrone inhibits the reaction [cinnamaldehyde results in increased expression of GCLC protein]; pyrazolanthrone inhibits the reaction [Quercetin promotes the reaction [Acetaminophen results in increased expression of GCLC mRNA]]; pyrazolanthrone inhibits the reaction [Quercetin results in increased expression of GCLC mRNA]; pyrazolanthrone inhibits the reaction [Quercetin results in increased expression of GCLC protein]
pyrazolanthrone inhibits the reaction [Ozone results in increased expression of GCLC mRNA]; pyrazolanthrone promotes the reaction [arsenite results in increased expression of GCLC mRNA] 		CTD PMID:17460151 PMID:19328227 PMID:21469739 PMID:25881548 NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893 		JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit multiple interactions
decreases activity 		ISO pyrazolanthrone inhibits the reaction [[Acetaminophen co-treated with Quercetin] results in increased expression of GCLM mRNA]; pyrazolanthrone inhibits the reaction [Quercetin inhibits the reaction [clivorine results in decreased expression of GCLM mRNA]]; pyrazolanthrone inhibits the reaction [Quercetin results in increased expression of GCLM mRNA]; pyrazolanthrone inhibits the reaction [Quercetin results in increased expression of GCLM protein]
pyrazolanthrone results in decreased activity of GCLM protein 		CTD PMID:16972261 PMID:25881548 NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:213,031,838...213,055,003 		JBrowse link
G Gdf15 growth differentiation factor 15 multiple interactions ISO pyrazolanthrone promotes the reaction [silybin results in increased expression of GDF15 protein] CTD PMID:24440808 NCBI chr16:18,838,436...18,842,022
Ensembl chr16:18,838,436...18,842,022 		JBrowse link
G Gh1 growth hormone 1 multiple interactions EXP pyrazolanthrone inhibits the reaction [deoxynivalenol results in decreased expression of GH1 mRNA]; pyrazolanthrone inhibits the reaction [deoxynivalenol results in decreased expression of GH1 protein] CTD PMID:26141394 NCBI chr10:91,727,883...91,729,860
Ensembl chr10:91,727,884...91,729,859 		JBrowse link
G Gja1 gap junction protein, alpha 1 multiple interactions EXP
ISO 		pyrazolanthrone inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of GJA1 protein]; pyrazolanthrone inhibits the reaction [Amphetamine results in increased expression of GJA1 protein]; pyrazolanthrone inhibits the reaction [Indican results in decreased expression of and affects the localization of GJA1 protein]; pyrazolanthrone inhibits the reaction [Indican results in decreased expression of GJA1 mRNA]
pyrazolanthrone inhibits the reaction [resveratrol results in increased expression of GJA1 protein] 		CTD PMID:15194466 PMID:24449132 PMID:32045570 PMID:36863560 NCBI chr20:36,302,490...36,315,010
Ensembl chr20:36,302,352...36,319,689 		JBrowse link
G Glb1 galactosidase, beta 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased activity of GLB1 protein]; pyrazolanthrone promotes the reaction [SB 203580 inhibits the reaction [Arsenic Trioxide results in increased activity of GLB1 protein]]; SB 203580 promotes the reaction [pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased activity of GLB1 protein]] CTD PMID:31734849 NCBI chr 8:122,963,718...123,036,326
Ensembl chr 8:122,963,718...123,036,326 		JBrowse link
G Got1 glutamic-oxaloacetic transaminase 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [Acetaminophen results in increased activity of GOT1 protein] CTD PMID:33959992 NCBI chr 1:252,306,541...252,337,622
Ensembl chr 1:252,284,434...252,329,871 		JBrowse link
G Gp1ba glycoprotein Ib platelet subunit alpha multiple interactions ISO pyrazolanthrone promotes the reaction [THPO protein results in increased expression of GP1BA protein] CTD PMID:20523355 NCBI chr10:55,831,901...55,856,729
Ensembl chr10:55,829,832...55,854,560 		JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions ISO
EXP 		pyrazolanthrone inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein]
pyrazolanthrone inhibits the reaction [Acetaminophen results in increased activity of GPT protein]
pyrazolanthrone inhibits the reaction [Acetaminophen results in increased expression of GPT protein] 		CTD PMID:20166895 PMID:26218279 PMID:33959992 NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160 		JBrowse link
G Gpx3 glutathione peroxidase 3 multiple interactions ISO pyrazolanthrone inhibits the reaction [Acetaminophen results in decreased activity of GPX3 protein] CTD PMID:33959992 NCBI chr10:39,529,335...39,537,406
Ensembl chr10:39,529,448...39,537,405 		JBrowse link
G Gsta1 glutathione S-transferase alpha 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [Acetaminophen results in decreased expression of GSTA1 mRNA]; pyrazolanthrone inhibits the reaction [Acetaminophen results in decreased expression of GSTA1 protein] CTD PMID:33959992 NCBI chr 9:31,199,887...31,216,606
Ensembl chr 9:31,199,888...31,211,528 		JBrowse link
G Gsta4 glutathione S-transferase alpha 4 multiple interactions ISO pyrazolanthrone inhibits the reaction [GSTA4 gene mutant form results in increased susceptibility to 1,1,4-tris(acetyloxy)-2-nonene] CTD PMID:24353929 NCBI chr 8:87,947,247...87,964,490
Ensembl chr 8:87,930,566...87,964,488 		JBrowse link
G Gypa glycophorin A multiple interactions ISO pyrazolanthrone inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased expression of GYPA protein] CTD PMID:20523355 NCBI chr19:44,354,669...44,370,304
Ensembl chr19:44,354,706...44,370,291 		JBrowse link
G H2ax H2A.X variant histone multiple interactions ISO pyrazolanthrone inhibits the reaction [4-methoxy-2,2,6,6-tetramethylpiperidinyl-1-oxy results in increased phosphorylation of H2AX protein]; pyrazolanthrone inhibits the reaction [Resveratrol results in increased phosphorylation of H2AX protein] CTD PMID:25619392 PMID:28993908 NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079 		JBrowse link
G H3f4 H3.4 histone, cluster member multiple interactions ISO pyrazolanthrone inhibits the reaction [5-(2,4-dihydroxybenzylidene)-2-(phenylimino)-1,3-thiazolidin results in increased phosphorylation of H3-4 protein] CTD PMID:16179969 NCBI chr10:44,240,282...44,240,842 JBrowse link
G Hat1 histone acetyltransferase 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [Quercetin results in increased activity of HAT1 protein] CTD PMID:21165570 NCBI chr 3:76,624,442...76,672,701
Ensembl chr 3:76,624,869...76,672,696 		JBrowse link
G Hbegf heparin-binding EGF-like growth factor multiple interactions ISO pyrazolanthrone inhibits the reaction [Oxygen deficiency promotes the reaction [HBEGF protein mutant form results in increased activity of CASP3 protein]]; pyrazolanthrone inhibits the reaction [Sodium Chloride results in increased expression of HBEGF mRNA] CTD PMID:19193634 PMID:26800359 NCBI chr18:28,380,337...28,390,220
Ensembl chr18:28,380,337...28,390,220 		JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha multiple interactions ISO pyrazolanthrone inhibits the reaction [andrographolide results in decreased expression of HIF1A protein]; pyrazolanthrone inhibits the reaction [manganese chloride results in increased expression of and results in increased activity of and results in increased stability of HIF1A protein] CTD PMID:20152896 PMID:28651835 NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323 		JBrowse link
G Hmgb1 high mobility group box 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [Silicon Dioxide results in increased expression of HMGB1 protein] CTD PMID:27616297 NCBI chr12:11,009,236...11,015,941
Ensembl chr16:39,039,050...39,041,327
Ensembl chr12:39,039,050...39,041,327 		JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions
decreases expression 		ISO
EXP 		pyrazolanthrone inhibits the reaction [10-nitro-oleic acid results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [3-O-caffeoyl-1-methylquinic acid results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [4-hydroxy-2-nonenal results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [[3-hydroxy-4-prenyl-5-methoxystilbene-2-carboxylic acid results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [butein results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [cinnamaldehyde results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [iron protoporphyrin IX results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [lead acetate results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [mevastatin results in increased expression of HMOX1 mRNA]; pyrazolanthrone inhibits the reaction [mevastatin results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [pachastrissamine analog results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [Potassium Dichromate results in increased expression of HMOX1 mRNA]; pyrazolanthrone inhibits the reaction [Quercetin inhibits the reaction [Acetaminophen results in decreased expression of HMOX1 mRNA]]; pyrazolanthrone inhibits the reaction [Quercetin results in increased expression of HMOX1 mRNA]; pyrazolanthrone inhibits the reaction [Quercetin results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [sodium arsenite results in increased expression of HMOX1 mRNA]; pyrazolanthrone inhibits the reaction [sodium arsenite results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [Sulindac promotes the reaction [Arsenic Trioxide results in increased expression of HMOX1 protein]]; pyrazolanthrone inhibits the reaction [tetrachlorobenzoquinone results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [tricarbonyldichlororuthenium (II) dimer results in increased expression of HMOX1 mRNA]; pyrazolanthrone inhibits the reaction [tricarbonyldichlororuthenium (II) dimer results in increased expression of HMOX1 protein]
pyrazolanthrone inhibits the reaction [Acrylamide results in increased expression of HMOX1 mRNA]; pyrazolanthrone inhibits the reaction [aureusidin results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [diphenylarsinic acid results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [Nitroprusside results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [Quercetin results in increased expression of HMOX1 mRNA]; pyrazolanthrone inhibits the reaction [sodium arsenite results in increased expression of HMOX1 mRNA]
pyrazolanthrone results in decreased expression of HMOX1 mRNA
pyrazolanthrone inhibits the reaction [10-nitro-oleic acid results in increased expression of HMOX1 mRNA]; pyrazolanthrone inhibits the reaction [10-nitro-oleic acid results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [4-hydroxy-2-nonenal results in increased expression of HMOX1 mRNA]; pyrazolanthrone inhibits the reaction [4-hydroxy-2-nonenal results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [Copper results in increased expression of HMOX1 mRNA]; pyrazolanthrone inhibits the reaction [Lead results in increased expression of HMOX1 mRNA]; pyrazolanthrone inhibits the reaction [Mercury results in increased expression of HMOX1 mRNA]; pyrazolanthrone inhibits the reaction [Plant Extracts results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [Quercetin results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [sodium arsenite results in increased expression of HMOX1 mRNA]; pyrazolanthrone inhibits the reaction [Triclosan results in increased expression of HMOX1 protein]; pyrazolanthrone promotes the reaction [Quercetin analog results in increased expression of HMOX1 mRNA]
pyrazolanthrone results in decreased expression of HMOX1 protein 		CTD PMID:12637567 PMID:16171798 PMID:16439612 PMID:16631525 PMID:18078826 More... NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818 		JBrowse link
G Hnf1a HNF1 homeobox A multiple interactions ISO pyrazolanthrone inhibits the reaction [Acetaminophen results in decreased expression of HNF1A mRNA]; pyrazolanthrone inhibits the reaction [Acetaminophen results in decreased expression of HNF1A protein] CTD PMID:33959992 NCBI chr12:47,299,171...47,333,457
Ensembl chr12:47,306,245...47,332,755 		JBrowse link
G Hnf4a hepatocyte nuclear factor 4, alpha increases expression
multiple interactions 		ISO pyrazolanthrone results in increased expression of HNF4A mRNA
pyrazolanthrone inhibits the reaction [TNF protein results in decreased expression of HNF4A mRNA] 		CTD PMID:19883121 NCBI chr 3:172,606,220...172,667,758
Ensembl chr 3:172,606,220...172,667,758 		JBrowse link
G Hpx hemopexin multiple interactions ISO pyrazolanthrone inhibits the reaction [Ozone results in increased expression of HPX mRNA] CTD PMID:17460151 NCBI chr 1:169,344,647...169,352,155
Ensembl chr 1:169,344,583...169,352,156 		JBrowse link
G Hrk harakiri, BCL2 interacting protein multiple interactions EXP pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of HRK mRNA]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of HRK protein] CTD PMID:35172196 NCBI chr12:44,048,402...44,070,561
Ensembl chr12:44,048,402...44,070,561 		JBrowse link
G Hsd17b3 hydroxysteroid (17-beta) dehydrogenase 3 multiple interactions EXP pyrazolanthrone inhibits the reaction [nickel sulfate results in decreased expression of HSD17B3 mRNA] CTD PMID:29567110 NCBI chr17:1,032,958...1,064,283
Ensembl chr17:1,032,958...1,064,283 		JBrowse link
G Hsf1 heat shock transcription factor 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [arsenic trioxide results in increased phosphorylation of HSF1 protein] CTD PMID:15978632 NCBI chr 7:110,076,710...110,103,665
Ensembl chr 7:110,076,710...110,103,665 		JBrowse link
G Hsp90b1 heat shock protein 90 beta family member 1 multiple interactions EXP pyrazolanthrone inhibits the reaction [[cupric chloride binds to pyrrolidine dithiocarbamic acid] which results in increased expression of HSP90B1 mRNA] CTD PMID:20920558 NCBI chr 7:22,997,962...23,012,293
Ensembl chr 7:22,997,962...23,012,293 		JBrowse link
G Hspa1a heat shock protein family A (Hsp70) member 1A multiple interactions EXP pyrazolanthrone inhibits the reaction [diphenylarsinic acid results in increased expression of HSPA1A protein] CTD PMID:28087833 NCBI chr20:3,875,411...3,877,866
Ensembl chr20:3,855,780...3,877,979 		JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 multiple interactions EXP
ISO 		pyrazolanthrone inhibits the reaction [4-methyl-2,4-bis(4-hydroxyphenyl)pent-1-ene results in increased expression of HSPA5 protein]; pyrazolanthrone inhibits the reaction [[cupric chloride binds to pyrrolidine dithiocarbamic acid] which results in increased expression of HSPA5 mRNA]
pyrazolanthrone inhibits the reaction [honokiol results in increased expression of HSPA5 protein]; pyrazolanthrone inhibits the reaction [Indomethacin results in increased expression of HSPA5 protein] 		CTD PMID:17341418 PMID:20920558 PMID:33550458 PMID:33922211 NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:38,453,041...38,458,790 		JBrowse link
G Hspa6l-ps1 heat shock protein family A (Hsp70) member 6 like, pseudogene 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased expression of HSPA6 mRNA]; pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased expression of HSPA6 protein] CTD PMID:15978632 NCBI chr13:85,805,911...85,807,052 JBrowse link
G Hspa9 heat shock protein family A (Hsp70) member 9 multiple interactions ISO [sodium arsenite co-treated with pyrazolanthrone] promotes the reaction [HSPA9 protein binds to TP53 protein modified form] CTD PMID:22706169 NCBI chr18:26,810,004...26,832,958
Ensembl chr18:26,804,774...26,828,398 		JBrowse link
G Hspb1 heat shock protein family B (small) member 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [10-nitro-oleic acid results in increased expression of HSPB1 mRNA]; pyrazolanthrone inhibits the reaction [10-nitro-oleic acid results in increased expression of HSPB1 protein]; pyrazolanthrone inhibits the reaction [2-chloroethyl ethyl sulfide results in increased expression of HSPB1 protein] CTD PMID:21457723 PMID:24140437 NCBI chr12:26,430,640...26,432,301
Ensembl chr12:26,430,640...26,432,301 		JBrowse link
G Hspb8 heat shock protein family B (small) member 8 multiple interactions ISO pyrazolanthrone promotes the reaction [Ozone results in increased expression of HSPB8 mRNA] CTD PMID:17460151 NCBI chr12:45,835,899...45,866,449
Ensembl chr12:45,837,066...45,851,937 		JBrowse link
G Ibsp integrin-binding sialoprotein multiple interactions ISO pyrazolanthrone inhibits the reaction [Ketoglutaric Acids results in increased expression of IBSP protein] CTD PMID:31051157 NCBI chr14:5,744,497...5,757,242
Ensembl chr14:5,744,501...5,775,299 		JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of ICAM1 mRNA]; pyrazolanthrone inhibits the reaction [Zinc Oxide results in increased expression of ICAM1] CTD PMID:12832416 PMID:22166487 NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617 		JBrowse link
G Ifng interferon gamma multiple interactions ISO
EXP 		pyrazolanthrone inhibits the reaction [[Diclofenac co-treated with IFNG protein] results in increased phosphorylation of STAT1 protein]; pyrazolanthrone inhibits the reaction [Eosine I Bluish results in increased expression of IFNG mRNA]
[pyrazolanthrone co-treated with Manganese] inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; pyrazolanthrone inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased localization of RELA protein]; pyrazolanthrone inhibits the reaction [[Iodine co-treated with Dibutyl Phthalate] results in increased expression of IFNG protein]; pyrazolanthrone inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; pyrazolanthrone inhibits the reaction [Manganese promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA]]; pyrazolanthrone inhibits the reaction [Manganese promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TNF protein]]; pyrazolanthrone results in decreased susceptibility to [IFNG protein co-treated with Lipopolysaccharides]
pyrazolanthrone inhibits the reaction [[Polysaccharides co-treated with IFNG protein] results in increased expression of TNF protein] 		CTD PMID:16307444 PMID:16488514 PMID:21295052 PMID:22440610 PMID:23831309 More... NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216 		JBrowse link
G Igf1 insulin-like growth factor 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [[IGF1 protein co-treated with Estradiol] results in increased phosphorylation of MAPK1 protein]; pyrazolanthrone inhibits the reaction [[IGF1 protein co-treated with Estradiol] results in increased phosphorylation of MAPK3 protein] CTD PMID:17458902 NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:24,130,137...24,246,764 		JBrowse link
G Ikbkb inhibitor of nuclear factor kappa B kinase subunit beta multiple interactions EXP pyrazolanthrone inhibits the reaction [sodium arsenite results in increased phosphorylation of IKBKB protein] CTD PMID:19616567 NCBI chr16:76,021,968...76,075,717
Ensembl chr16:76,022,008...76,081,911 		JBrowse link
G Il10 interleukin 10 multiple interactions ISO pyrazolanthrone inhibits the reaction [Fungal Polysaccharides results in increased secretion of IL10 protein] CTD PMID:28235615 NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580 		JBrowse link
G Il12b interleukin 12B multiple interactions ISO pyrazolanthrone inhibits the reaction [nickel sulfate results in increased secretion of IL12B protein]
pyrazolanthrone promotes the reaction [Lipopolysaccharides results in increased secretion of IL12B protein] 		CTD PMID:15778123 PMID:19101624 NCBI chr10:29,390,300...29,405,194
Ensembl chr10:29,389,905...29,405,194 		JBrowse link
G Il13 interleukin 13 multiple interactions ISO pyrazolanthrone inhibits the reaction [Toluene 2,4-Diisocyanate results in increased secretion of IL13 protein] CTD PMID:33075463 NCBI chr10:38,290,926...38,293,483
Ensembl chr10:38,290,926...38,293,483 		JBrowse link
G Il17a interleukin 17A multiple interactions EXP pyrazolanthrone inhibits the reaction [[Iodine co-treated with Dibutyl Phthalate] results in increased expression of IL17A protein] CTD PMID:29385629 NCBI chr 9:30,640,844...30,644,331
Ensembl chr 9:30,640,844...30,644,331 		JBrowse link
G Il18 interleukin 18 multiple interactions ISO pyrazolanthrone inhibits the reaction [[Lipopolysaccharides co-treated with irinotecan] results in increased expression of and results in increased secretion of IL18 protein]
pyrazolanthrone inhibits the reaction [Benzo(a)pyrene results in increased secretion of IL18 protein]; pyrazolanthrone inhibits the reaction [Irinotecan results in increased expression of and results in increased secretion of IL18 protein]; pyrazolanthrone inhibits the reaction [Picryl Chloride results in increased expression of IL18 mRNA]; pyrazolanthrone inhibits the reaction [Picryl Chloride results in increased secretion of IL18 protein] 		CTD PMID:20381601 PMID:26431797 PMID:35777681 NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:59,809,592...59,831,286 		JBrowse link
G Il1a interleukin 1 alpha multiple interactions ISO
EXP 		pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of CXCL10 mRNA]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of CXCL8 mRNA]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of FGF2 mRNA]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of GCH1 mRNA]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of ICAM1 mRNA]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of IL1A mRNA]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of IL1B mRNA]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of IL6 mRNA]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of MMP1 mRNA]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of MMP3 mRNA]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of PTGS2 mRNA]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of PTX3 mRNA]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of SERPINB2 mRNA]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of SOD2 mRNA]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased secretion of CXCL8 protein]; pyrazolanthrone promotes the reaction [IL1A protein results in increased expression of BIRC2 mRNA]; pyrazolanthrone promotes the reaction [IL1A protein results in increased expression of CCL8 mRNA]; pyrazolanthrone promotes the reaction [IL1A protein results in increased expression of CXCL3 mRNA]; pyrazolanthrone promotes the reaction [IL1A protein results in increased expression of JUN mRNA]; pyrazolanthrone promotes the reaction [IL1A protein results in increased expression of SAA1 mRNA]
pyrazolanthrone inhibits the reaction [Soot results in increased secretion of IL1A protein] 		CTD PMID:12832416 PMID:19782127 NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013 		JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO
EXP 		[Sulfasalazine co-treated with pyrazolanthrone] inhibits the reaction [IL1B protein results in decreased expression of DIO1 mRNA]; pyrazolanthrone inhibits the reaction [[Lipopolysaccharides co-treated with irinotecan] results in increased expression of and results in increased secretion of IL1B protein]; pyrazolanthrone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL1B mRNA]; pyrazolanthrone inhibits the reaction [APP protein results in increased expression of and results in increased cleavage of IL1B protein]; pyrazolanthrone inhibits the reaction [Benzo(a)pyrene results in increased secretion of IL1B protein]; pyrazolanthrone inhibits the reaction [beta Carotene promotes the reaction [Benzo(a)pyrene results in increased secretion of IL1B protein]]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of IL1B mRNA]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased activity of MMP12 protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of and results in increased activity of JUN protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of CYP4F11 mRNA]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of F3 protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of IL6 protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of JUN mRNA]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of MMP12 mRNA]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of PAPPA mRNA]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of TGFB1 mRNA]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK1 protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK3 protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased secretion of FGF7 protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased secretion of TGFB1 protein]; pyrazolanthrone inhibits the reaction [IL1B results in increased expression of CXCL8 protein]; pyrazolanthrone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL1B mRNA]; pyrazolanthrone inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of IL1B mRNA]; pyrazolanthrone inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of IL1B protein]
pyrazolanthrone inhibits the reaction [2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [ACE2 protein inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]]; pyrazolanthrone inhibits the reaction [7-Ala-angiotensin (1-7) inhibits the reaction [ACE2 protein inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]]; pyrazolanthrone inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased localization of RELA protein]; pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased expression of and results in increased secretion of IL1B protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of BAX protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of HRK mRNA]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of HRK protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [lead acetate results in increased expression of IL1B protein]; pyrazolanthrone inhibits the reaction [Particulate Matter results in increased expression of IL1B mRNA]; pyrazolanthrone inhibits the reaction [Soot results in increased secretion of IL1B protein]
IL1B protein inhibits the reaction [[Sulfasalazine co-treated with pyrazolanthrone] results in decreased expression of THRA mRNA]; IL1B protein inhibits the reaction [pyrazolanthrone results in increased expression of THRA mRNA alternative form]; pyrazolanthrone affects the reaction [Fungal Polysaccharides results in increased expression of IL1B mRNA]; pyrazolanthrone inhibits the reaction [Carbon Tetrachloride results in increased expression of IL1B protein]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; pyrazolanthrone inhibits the reaction [sodium chromate(VI) results in increased expression of IL1B mRNA]; pyrazolanthrone inhibits the reaction [T-2 Toxin results in increased expression of IL1B mRNA] 		CTD PMID:12832416 PMID:15019843 PMID:15677771 PMID:16359550 PMID:16365456 More... NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601 		JBrowse link
G Il4 interleukin 4 multiple interactions EXP
ISO 		pyrazolanthrone inhibits the reaction [dinitrophenyl-bovine serum albumin results in increased expression of IL4 mRNA]; pyrazolanthrone inhibits the reaction [dinitrophenyl-bovine serum albumin results in increased expression of IL4 protein]
pyrazolanthrone inhibits the reaction [Toluene 2,4-Diisocyanate results in increased secretion of IL4 protein] 		CTD PMID:26003274 PMID:33075463 NCBI chr10:38,272,003...38,277,549
Ensembl chr10:38,272,003...38,277,549 		JBrowse link
G Il5 interleukin 5 multiple interactions ISO pyrazolanthrone inhibits the reaction [Toluene 2,4-Diisocyanate results in increased secretion of IL5 protein] CTD PMID:33075463 NCBI chr10:38,375,132...38,378,003
Ensembl chr10:38,375,132...38,378,003 		JBrowse link
G Il6 interleukin 6 multiple interactions ISO
EXP 		pyrazolanthrone inhibits the reaction [7-ketocholesterol results in increased expression of IL6 mRNA]; pyrazolanthrone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL6 mRNA]; pyrazolanthrone inhibits the reaction [Acids results in increased expression of IL6 mRNA]; pyrazolanthrone inhibits the reaction [Acids results in increased secretion of IL6 protein]; pyrazolanthrone inhibits the reaction [Cadmium Chloride results in increased expression of and results in increased secretion of IL6 protein]; pyrazolanthrone inhibits the reaction [cobaltous chloride results in increased secretion of IL6 protein]; pyrazolanthrone inhibits the reaction [doxifluridine results in increased expression of IL6 mRNA]; pyrazolanthrone inhibits the reaction [Fluorouracil results in increased expression of IL6 mRNA]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of IL6 mRNA]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of IL6 protein]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; pyrazolanthrone inhibits the reaction [nickel sulfate results in increased expression of IL6 protein]; pyrazolanthrone inhibits the reaction [nickel sulfate results in increased secretion of IL6 protein]; pyrazolanthrone inhibits the reaction [OSM protein results in increased expression of and results in increased secretion of IL6 protein]; pyrazolanthrone inhibits the reaction [Paraquat results in increased expression of and results in increased secretion of IL6 protein]; pyrazolanthrone inhibits the reaction [polyhexamethyleneguanidine results in increased expression of IL6 mRNA]; pyrazolanthrone promotes the reaction [cadmium acetate results in increased secretion of IL6 protein]
[pyrazolanthrone co-treated with Acrylamide] results in decreased expression of IL6 mRNA; pyrazolanthrone inhibits the reaction [[Iodine co-treated with Dibutyl Phthalate] results in increased expression of IL6 protein]; pyrazolanthrone inhibits the reaction [diphenylarsinic acid results in increased secretion of IL6 protein]; pyrazolanthrone inhibits the reaction [lead acetate results in increased expression of IL6 protein]; pyrazolanthrone inhibits the reaction [Palmitic Acid results in increased expression of IL6 mRNA]; pyrazolanthrone inhibits the reaction [Paraquat results in increased expression of and results in increased secretion of IL6 protein]; pyrazolanthrone inhibits the reaction [Paraquat results in increased expression of IL6 mRNA]; pyrazolanthrone inhibits the reaction [Soot results in increased secretion of IL6 protein]
pyrazolanthrone inhibits the reaction [bisphenol A results in increased expression of IL6 mRNA]; pyrazolanthrone inhibits the reaction [di-n-butyltin results in increased expression of IL6 mRNA]; pyrazolanthrone inhibits the reaction [di-n-butyltin results in increased expression of IL6 protein]; pyrazolanthrone inhibits the reaction [Fungal Polysaccharides results in increased secretion of IL6 protein]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; pyrazolanthrone inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of IL6 mRNA]; pyrazolanthrone inhibits the reaction [perfluorooctane sulfonic acid results in increased secretion of IL6 protein]; pyrazolanthrone inhibits the reaction [T-2 Toxin results in increased expression of IL6 mRNA]; pyrazolanthrone promotes the reaction [Arsenic Trioxide results in increased expression of IL6 mRNA]; pyrazolanthrone promotes the reaction [Ozone results in increased expression of IL6 mRNA] 		CTD PMID:12832416 PMID:17460151 PMID:18515973 PMID:19074641 PMID:19101624 More... NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610 		JBrowse link
G Ins1 insulin 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [bisphenol A inhibits the reaction [INS1 protein results in increased phosphorylation of INSR protein]]; pyrazolanthrone inhibits the reaction [bisphenol A inhibits the reaction [INS1 protein results in increased phosphorylation of MAPK1 protein]]; pyrazolanthrone inhibits the reaction [bisphenol A inhibits the reaction [INS1 protein results in increased phosphorylation of MAPK3 protein]]; pyrazolanthrone inhibits the reaction [bisphenol A inhibits the reaction [INS1 protein results in increased uptake of Glucose]] CTD PMID:24349194 NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682 		JBrowse link
G Ins2 insulin 2 multiple interactions EXP
ISO 		pyrazolanthrone inhibits the reaction [Paroxetine affects the reaction [INS protein affects the phosphorylation of IRS1 protein]]
pyrazolanthrone inhibits the reaction [GW8510 results in increased expression of INS2 mRNA] 		CTD PMID:17728140 PMID:22242153 NCBI chr 1:207,272,738...207,421,998
Ensembl chr 1:207,272,742...207,273,805 		JBrowse link
G Insr insulin receptor multiple interactions ISO
EXP 		pyrazolanthrone inhibits the reaction [bisphenol A inhibits the reaction [INS1 protein results in increased phosphorylation of INSR protein]]; pyrazolanthrone inhibits the reaction [bisphenol A results in decreased expression of INSR protein modified form]
pyrazolanthrone inhibits the reaction [oleoylethanolamide affects the phosphorylation of and affects the activity of INSR protein] 		CTD PMID:19345745 PMID:24349194 PMID:29793316 NCBI chr12:5,991,135...6,129,275
Ensembl chr12:5,981,835...6,128,803 		JBrowse link
G Irs1 insulin receptor substrate 1 multiple interactions EXP
ISO 		pyrazolanthrone inhibits the reaction [Paroxetine affects the reaction [INS protein affects the phosphorylation of IRS1 protein]]
pyrazolanthrone inhibits the reaction [bisphenol A results in increased expression of IRS1 protein modified form] 		CTD PMID:17728140 PMID:29793316 NCBI chr 9:91,001,137...91,053,959
Ensembl chr 9:90,993,519...91,054,538 		JBrowse link
G Itga2b integrin subunit alpha 2b multiple interactions ISO pyrazolanthrone promotes the reaction [THPO protein results in increased expression of ITGA2B protein] CTD PMID:20523355 NCBI chr10:87,908,697...87,926,225
Ensembl chr10:87,908,697...87,925,833 		JBrowse link
G Itgam integrin subunit alpha M multiple interactions ISO pyrazolanthrone promotes the reaction [arsenic disulfide analog results in increased expression of ITGAM mRNA]; pyrazolanthrone promotes the reaction [arsenic disulfide analog results in increased expression of ITGAM protein] CTD PMID:18778786 NCBI chr 1:192,089,496...192,139,947
Ensembl chr 1:192,089,542...192,139,943 		JBrowse link
G Itgb3 integrin subunit beta 3 multiple interactions ISO pyrazolanthrone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ITGB3 protein]; pyrazolanthrone promotes the reaction [THPO protein results in increased expression of ITGB3 protein] CTD PMID:20523355 NCBI chr10:90,009,927...90,067,787
Ensembl chr10:90,009,900...90,067,800 		JBrowse link
G Jag1 jagged canonical Notch ligand 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of JAG1 mRNA] CTD PMID:21843347 NCBI chr 3:144,859,453...144,894,883
Ensembl chr 3:144,859,453...144,894,872 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions
decreases phosphorylation
decreases activity
increases degradation
decreases expression 		ISO
EXP 		[2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one co-treated with 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole co-treated with pyrazolanthrone] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 affects the localization of JUN protein]; [pyrazolanthrone results in decreased phosphorylation of JUN protein] inhibits the reaction [JUN protein binds to TOP1 protein]; [U 0126 co-treated with pyrazolanthrone] inhibits the reaction [2-aminodiphenyl results in increased phosphorylation of and results in increased expression of JUN protein]; pyrazolanthrone inhibits the reaction [2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone analog results in increased expression of JUN protein modified form]; pyrazolanthrone inhibits the reaction [2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [2-aminodiphenyl results in increased expression of and results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [8-bromo-7-methoxychrysin results in increased expression of JUN protein]; pyrazolanthrone inhibits the reaction [[Disulfiram co-treated with Copper co-treated with Doxorubicin] results in increased phosphorylation of and results in increased expression of JUN protein]; pyrazolanthrone inhibits the reaction [[Ethacrynic Acid co-treated with Arsenic Trioxide] results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [[Quercetin co-treated with mibolerone] results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [[Sorafenib co-treated with Vitamin K 1] results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Acetaminophen results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased expression of JUN protein]; pyrazolanthrone inhibits the reaction [Benzo(a)pyrene results in increased expression of JUN protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Cadmium results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Chloramphenicol results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Cisplatin results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [diethyl maleate results in increased expression of JUN protein modified form]; pyrazolanthrone inhibits the reaction [Estradiol results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Fenretinide results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [FSL-1 lipoprotein, synthetic results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [hydroquinone results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of and results in increased activity of JUN protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of JUN mRNA]; pyrazolanthrone inhibits the reaction [Leflunomide results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Methyl Methanesulfonate results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [MIF protein results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Morphine results in increased phosphorylation of and results in increased activity of JUN protein]; pyrazolanthrone inhibits the reaction [O(2)-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Paraquat results in increased activity of JUN protein]; pyrazolanthrone inhibits the reaction [Pulsatilla saponin D results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Quercetin affects the localization of JUN protein]; pyrazolanthrone inhibits the reaction [Silicon Dioxide results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Simvastatin results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [sodium arsenite results in decreased expression of JUN protein modified form]; pyrazolanthrone inhibits the reaction [sodium arsenite results in increased activity of JUN protein]; pyrazolanthrone inhibits the reaction [sodium arsenite results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Sorafenib results in increased expression of JUN mRNA]; pyrazolanthrone inhibits the reaction [Sorafenib results in increased expression of JUN protein]; pyrazolanthrone inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of JUN protein]; pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of JUN mRNA]; pyrazolanthrone inhibits the reaction [TNF protein results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Tretinoin results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Zinc Oxide affects the localization of JUN protein]; pyrazolanthrone inhibits the reaction [Zinc Oxide results in increased phosphorylation of and results in increased activity of JUN protein]; pyrazolanthrone promotes the reaction [IL1A protein results in increased expression of JUN mRNA]
pyrazolanthrone results in decreased activity of JUN protein
pyrazolanthrone results in increased degradation of JUN protein
pyrazolanthrone results in decreased expression of JUN protein
[cypermethrin co-treated with pyrazolanthrone] results in decreased phosphorylation of JUN protein; pyrazolanthrone inhibits the reaction [4-hydroxy-2-nonenal results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Acrolein results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Amphetamine results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Cadmium Chloride results in increased expression of and results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Cadmium Chloride results in increased expression of JUN mRNA]; pyrazolanthrone inhibits the reaction [Cadmium Chloride results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [cypermethrin results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [diphenylarsinic acid results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Indolinone A results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [manganese chloride results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Norepinephrine results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Paraquat results in increased activity of JUN protein]; pyrazolanthrone inhibits the reaction [Patulin results in increased expression of JUN protein]; pyrazolanthrone inhibits the reaction [Phenylephrine results in increased expression of JUN mRNA]; pyrazolanthrone promotes the reaction [celastrol inhibits the reaction [Cadmium Chloride results in increased expression of and results in increased phosphorylation of JUN protein]]
pyrazolanthrone inhibits the reaction [1-hydroxy-2-oxo-3,3-bis(2-aminoethyl)-1-triazene results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [4-hydroxy-2-nonenal results in increased activity of [JUN protein binds to JUN protein]]; pyrazolanthrone inhibits the reaction [[[cupric chloride results in increased abundance of Copper] co-treated with [zinc chloride results in increased abundance of Zinc]] results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [bisphenol A results in increased expression of and results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [bisphenol A results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [monobutyl phthalate results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Ozone results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Pulsatilla saponin D results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [sodium arsenite results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [TNF protein promotes the reaction [diethyl maleate results in increased phosphorylation of JUN protein]]; pyrazolanthrone inhibits the reaction [TNF protein results in increased phosphorylation of JUN protein]; pyrazolanthrone promotes the reaction [[Cisplatin co-treated with TNF protein] results in increased phosphorylation of JUN protein] 		CTD PMID:12169099 PMID:12393500 PMID:12663670 PMID:12774022 PMID:12832416 More... NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285 		JBrowse link
G Jund JunD proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO pyrazolanthrone inhibits the reaction [2-tert-butylhydroquinone results in increased phosphorylation of JUND protein] CTD PMID:24830941 NCBI chr16:18,768,093...18,769,771
Ensembl chr16:18,764,985...18,782,148 		JBrowse link
G Kcnb1 potassium voltage-gated channel subfamily B member 1 multiple interactions EXP pyrazolanthrone inhibits the reaction [Methamphetamine results in increased expression of KCNB1 protein] CTD PMID:29297590 NCBI chr 3:176,239,285...176,332,408
Ensembl chr 3:176,242,589...176,332,408 		JBrowse link
G Kcne4 potassium voltage-gated channel subfamily E regulatory subunit 4 multiple interactions ISO pyrazolanthrone promotes the reaction [Ozone results in increased expression of KCNE4 mRNA] CTD PMID:17460151 NCBI chr 9:87,674,264...87,699,088
Ensembl chr 9:87,650,462...87,704,131 		JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [pachastrissamine analog promotes the reaction [KEAP1 protein binds to SQSTM1 protein]] CTD PMID:35123989 NCBI chr 8:28,044,555...28,054,042
Ensembl chr 8:28,044,555...28,054,042 		JBrowse link
G Klf5 KLF transcription factor 5 multiple interactions ISO pyrazolanthrone inhibits the reaction [Ozone results in increased expression of KLF5 mRNA] CTD PMID:17460151 NCBI chr15:82,472,081...82,487,267
Ensembl chr15:82,472,065...82,487,262 		JBrowse link
G Klf6 KLF transcription factor 6 decreases expression
multiple interactions 		ISO pyrazolanthrone results in decreased expression of KLF6 mRNA
Arachidonic Acid inhibits the reaction [pyrazolanthrone results in decreased expression of KLF6 mRNA]; pyrazolanthrone inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; pyrazolanthrone inhibits the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA] 		CTD PMID:22486562 NCBI chr17:69,449,483...69,458,478
Ensembl chr17:69,441,493...69,498,601 		JBrowse link
G Klhl2 kelch-like family member 2 multiple interactions ISO pyrazolanthrone inhibits the reaction [Ozone results in increased expression of KLHL2 mRNA] CTD PMID:17460151 NCBI chr16:29,627,171...29,739,782
Ensembl chr16:29,627,237...29,739,957 		JBrowse link
G Ldlr low density lipoprotein receptor multiple interactions ISO pyrazolanthrone inhibits the reaction [Quercetin results in increased expression of LDLR mRNA]; pyrazolanthrone inhibits the reaction [Quercetin results in increased expression of LDLR protein] CTD PMID:22388943 NCBI chr 8:28,546,191...28,569,075
Ensembl chr 8:28,546,146...28,570,675 		JBrowse link
G Lep leptin multiple interactions ISO pyrazolanthrone inhibits the reaction [LEP protein results in increased expression of CYP19A1 mRNA]; pyrazolanthrone inhibits the reaction [LEP protein results in increased expression of CYP19A1 protein] CTD PMID:28571770 NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:58,626,523...58,640,661 		JBrowse link
G Lepr leptin receptor affects response to substance ISO LEPR protein affects the susceptibility to pyrazolanthrone CTD PMID:22933112 NCBI chr 5:121,409,735...121,593,201
Ensembl chr 5:121,474,099...121,591,215 		JBrowse link
G Lpl lipoprotein lipase increases expression
multiple interactions 		ISO pyrazolanthrone results in increased expression of LPL mRNA
pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in decreased expression of LPL mRNA] 		CTD PMID:21873422 NCBI chr16:25,596,205...25,621,928
Ensembl chr16:25,596,211...25,622,107 		JBrowse link
G Map1lc3a microtubule-associated protein 1 light chain 3 alpha decreases expression EXP SP600125 decreases expression of protein in oxygen-glucose deprived rat neuronal PC12 cells RGD PMID:27769861 RGD:329853763 NCBI chr 3:164,243,204...164,244,850
Ensembl chr 3:164,243,093...164,244,850 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO pyrazolanthrone inhibits the reaction [butein results in increased lipidation of MAP1LC3B protein]; pyrazolanthrone promotes the reaction [sodium arsenite results in increased expression of and results in increased lipidation of MAP1LC3B protein] CTD PMID:34861471 PMID:35130734 NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358
Ensembl chr16:66,574,407...66,584,358 		JBrowse link
G Map2k6 mitogen-activated protein kinase kinase 6 multiple interactions ISO pyrazolanthrone inhibits the reaction [[MAP2K6 gene mutant form results in increased activity of MAP2K6 protein] which results in increased susceptibility to Tetradecanoylphorbol Acetate] CTD PMID:27278863 NCBI chr10:95,872,747...95,987,747
Ensembl chr10:95,872,546...95,987,721 		JBrowse link
G Map3k1 mitogen-activated protein kinase kinase kinase 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [[MAP3K1 gene mutant form results in increased activity of MAP3K1 protein] which results in increased susceptibility to Tetradecanoylphorbol Acetate]; pyrazolanthrone inhibits the reaction [MAP3K1 protein results in increased expression of ABCB1 mRNA] CTD PMID:15604272 PMID:27278863 NCBI chr 2:45,081,889...45,150,555
Ensembl chr 2:45,081,889...45,149,897 		JBrowse link
G Map3k6 mitogen-activated protein kinase kinase kinase 6 multiple interactions ISO pyrazolanthrone inhibits the reaction [Ozone results in increased expression of MAP3K6 mRNA] CTD PMID:17460151 NCBI chr 5:150,724,029...150,736,113
Ensembl chr 5:150,724,216...150,736,111 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO
EXP 		pyrazolanthrone inhibits the reaction [[IGF1 protein co-treated with Estradiol] results in increased phosphorylation of MAPK1 protein]; pyrazolanthrone inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of MAPK1 protein]; pyrazolanthrone inhibits the reaction [bisphenol A inhibits the reaction [INS1 protein results in increased phosphorylation of MAPK1 protein]]; pyrazolanthrone inhibits the reaction [Diclofenac results in increased phosphorylation of MAPK1 protein]; pyrazolanthrone inhibits the reaction [honokiol results in increased phosphorylation of MAPK1 protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK1 protein]; pyrazolanthrone inhibits the reaction [sanguinarine results in increased phosphorylation of MAPK1 protein]
pyrazolanthrone inhibits the reaction [etoxazole results in increased phosphorylation of MAPK1 protein]; pyrazolanthrone inhibits the reaction [flufenoxuron results in increased phosphorylation of MAPK1 protein]
[pyrazolanthrone co-treated with SB 203580 co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] inhibits the reaction [Quercetin results in increased phosphorylation of MAPK1 protein]; pyrazolanthrone inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAPK1 protein]; pyrazolanthrone inhibits the reaction [diphenylarsinic acid results in increased phosphorylation of MAPK1 protein]; pyrazolanthrone inhibits the reaction [Paraquat results in increased phosphorylation of MAPK1 protein]; pyrazolanthrone inhibits the reaction [Quercetin results in increased phosphorylation of MAPK1 protein]; pyrazolanthrone promotes the reaction [manganese chloride results in increased phosphorylation of MAPK1 protein] 		CTD PMID:15342272 PMID:17458902 PMID:19135517 PMID:21933187 PMID:22727857 More... NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825 		JBrowse link
G Mapk14 mitogen activated protein kinase 14 multiple interactions
decreases phosphorylation
increases expression 		ISO
EXP 		pyrazolanthrone inhibits the reaction [cinnamaldehyde results in increased phosphorylation of MAPK14 protein]
pyrazolanthrone results in decreased phosphorylation of MAPK14 protein
pyrazolanthrone results in increased expression of MAPK14 protein 		CTD PMID:15964311 PMID:16046226 NCBI chr20:6,751,288...6,812,294
Ensembl chr20:6,751,357...6,812,294 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO
EXP 		pyrazolanthrone inhibits the reaction [[IGF1 protein co-treated with Estradiol] results in increased phosphorylation of MAPK3 protein]; pyrazolanthrone inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of MAPK3 protein]; pyrazolanthrone inhibits the reaction [bisphenol A inhibits the reaction [INS1 protein results in increased phosphorylation of MAPK3 protein]]; pyrazolanthrone inhibits the reaction [Diclofenac results in increased phosphorylation of MAPK3 protein]; pyrazolanthrone inhibits the reaction [honokiol results in increased phosphorylation of MAPK3 protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK3 protein]; pyrazolanthrone inhibits the reaction [sanguinarine results in increased phosphorylation of MAPK3 protein]
[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of MAPK3 mRNA; crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of MAPK3 mRNA]; pyrazolanthrone inhibits the reaction [etoxazole results in increased phosphorylation of MAPK3 protein]; pyrazolanthrone inhibits the reaction [flufenoxuron results in increased phosphorylation of MAPK3 protein]
[pyrazolanthrone co-treated with SB 203580 co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] inhibits the reaction [Quercetin results in increased phosphorylation of MAPK3 protein]; pyrazolanthrone inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAPK3 protein]; pyrazolanthrone inhibits the reaction [diphenylarsinic acid results in increased phosphorylation of MAPK3 protein]; pyrazolanthrone inhibits the reaction [Paraquat results in increased phosphorylation of MAPK3 protein]; pyrazolanthrone inhibits the reaction [Quercetin results in increased phosphorylation of MAPK3 protein]; pyrazolanthrone promotes the reaction [manganese chloride results in increased phosphorylation of MAPK3 protein] 		CTD PMID:15342272 PMID:17458902 PMID:19135517 PMID:21933187 PMID:22727857 More... NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411 		JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions
decreases expression
decreases phosphorylation
increases expression
decreases activity 		ISO
EXP 		pyrazolanthrone inhibits the reaction [5-((4-methylphenyl)methylene)-2-(phenylamino)-4(5H)-thiazolone results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [8-bromo-7-methoxychrysin results in increased phosphorylation of and results in increased activity of MAPK8 protein]; pyrazolanthrone inhibits the reaction [[Clioquinol co-treated with Copper] results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Acetaminophen results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [arsenic trichloride results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Benzo(a)pyrene results in increased expression of MAPK8 protein]; pyrazolanthrone inhibits the reaction [benzyl isothiocyanate results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [cinnamaldehyde results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [cordycepin results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [diethyl maleate results in increased expression of MAPK8 protein modified form]; pyrazolanthrone inhibits the reaction [dracorhodin analog results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [glycine-extended gastrin 17 results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [LY 293111 results in increased expression of MAPK8 protein modified form]; pyrazolanthrone inhibits the reaction [mevastatin results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [nickel sulfate results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [o,p'-DDT results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [pachastrissamine analog results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Paraquat results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Plant Extracts results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [polyphyllin I results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Pulsatilla saponin D results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Resveratrol results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [rhoifolin results in increased expression of and results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [sanguinarine results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Silicon Dioxide results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Silybin results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Sodium Selenite results in increased phosphorylation of and results in increased activity of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Arsenic Trioxide results in increased phosphorylation of and results in increased activity of MAPK8 protein]]; pyrazolanthrone inhibits the reaction [TNF protein results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Toluene 2,4-Diisocyanate results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [tricarbonyldichlororuthenium (II) dimer results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone promotes the reaction [dehydrocrenatidine results in decreased phosphorylation of MAPK8 protein]
SP600125 decreases expression of protein in oxygen-glucose deprived rat neuronal PC12 cells
pyrazolanthrone results in decreased phosphorylation of MAPK8 protein
pyrazolanthrone results in increased expression of MAPK8 protein
[cypermethrin co-treated with pyrazolanthrone] results in decreased phosphorylation of MAPK8 protein; pyrazolanthrone inhibits the reaction [[Copper co-treated with pyrrolidine dithiocarbamic acid] results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [cypermethrin results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [nickel chloride results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Palmitic Acid results in increased expression of MAPK8 mRNA]; pyrazolanthrone inhibits the reaction [Palmitic Acid results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Paraquat results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Paroxetine results in increased phosphorylation of and results in increased activity of MAPK8 protein]; pyrazolanthrone inhibits the reaction [pentaacetyl geniposide results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Sertraline results in increased phosphorylation of and results in increased activity of MAPK8 protein]
[pyrazolanthrone co-treated with 6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride] inhibits the reaction [Folic Acid results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone affects the reaction [TALDO1 gene mutant form promotes the reaction [Acetaminophen results in increased activity of and results in increased phosphorylation of MAPK8 protein]]; pyrazolanthrone inhibits the reaction [[[cupric chloride results in increased abundance of Copper] co-treated with [zinc chloride results in increased abundance of Zinc]] results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Acetaminophen results in increased activity of and results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Acetaminophen results in increased phosphorylation of and affects the activity of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Acrylamide results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Cadmium results in increased phosphorylation of and results in increased activity of MAPK8 protein]; pyrazolanthrone inhibits the reaction [flufenoxuron results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Folic Acid results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [o,p'-DDT results in increased phosphorylation of and results in increased activity of MAPK8 protein]; pyrazolanthrone inhibits the reaction [pseudolaric acid B results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Pulsatilla saponin D results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Toluene 2,4-Diisocyanate results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Tretinoin results in increased activity of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Triclosan results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone results in decreased phosphorylation of and results in decreased activity of MAPK8 protein
pyrazolanthrone results in decreased activity of MAPK8 protein 		CTD
RGD		 PMID:12534346 PMID:14610070 PMID:15322261 PMID:15767555 PMID:15831436 More... RGD:329853763 NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427 		JBrowse link
G Mapk9 mitogen-activated protein kinase 9 multiple interactions
decreases phosphorylation
decreases activity 		ISO
EXP 		pyrazolanthrone inhibits the reaction [5-((4-methylphenyl)methylene)-2-(phenylamino)-4(5H)-thiazolone results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [arsenic trichloride results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [diethyl maleate results in increased expression of MAPK9 protein modified form]; pyrazolanthrone inhibits the reaction [LY 293111 results in increased expression of MAPK9 protein modified form]; pyrazolanthrone inhibits the reaction [mevastatin results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [o,p'-DDT results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [Paraquat results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [Plant Extracts results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [polyphyllin I results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [Resveratrol results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [sanguinarine results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [Silicon Dioxide results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [Silybin results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [Sodium Selenite results in increased phosphorylation of and results in increased activity of MAPK9 protein]; pyrazolanthrone inhibits the reaction [TNF protein results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [Toluene 2,4-Diisocyanate results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [tricarbonyldichlororuthenium (II) dimer results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone promotes the reaction [dehydrocrenatidine results in decreased phosphorylation of MAPK9 protein]
pyrazolanthrone results in decreased phosphorylation of MAPK9 protein
pyrazolanthrone inhibits the reaction [[Copper co-treated with pyrrolidine dithiocarbamic acid] results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [nickel chloride results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [Paraquat results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [pentaacetyl geniposide results in increased phosphorylation of MAPK9 protein]
pyrazolanthrone inhibits the reaction [Acrylamide results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [o,p'-DDT results in increased phosphorylation of and results in increased activity of MAPK9 protein]; pyrazolanthrone inhibits the reaction [Toluene 2,4-Diisocyanate results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [Triclosan results in increased phosphorylation of MAPK9 protein]
pyrazolanthrone results in decreased activity of MAPK9 protein 		CTD PMID:12534346 PMID:15322261 PMID:15831436 PMID:16151469 PMID:16687388 More... NCBI chr10:34,670,750...34,711,972
Ensembl chr10:34,670,756...34,712,228 		JBrowse link
G Mapkapk2 MAPK activated protein kinase 2 decreases activity EXP pyrazolanthrone results in decreased activity of MAPKAPK2 protein CTD PMID:15196213 NCBI chr13:45,066,027...45,112,326
Ensembl chr13:45,066,031...45,112,326 		JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member multiple interactions ISO pyrazolanthrone inhibits the reaction [arsenic trioxide promotes the reaction [Ethacrynic Acid results in decreased expression of MCL1 protein]]; pyrazolanthrone promotes the reaction [usnic acid results in decreased expression of MCL1 protein] CTD PMID:23082001 PMID:25078063 NCBI chr 2:185,884,840...185,912,532
Ensembl chr 2:185,908,168...185,938,782 		JBrowse link
G Mcm2 minichromosome maintenance complex component 2 multiple interactions ISO pyrazolanthrone inhibits the reaction [trichostatin A results in decreased expression of MCM2 protein] CTD PMID:23770000 NCBI chr 4:122,903,679...122,918,205
Ensembl chr 4:122,903,682...122,918,094 		JBrowse link
G Mif macrophage migration inhibitory factor multiple interactions ISO pyrazolanthrone inhibits the reaction [MIF protein results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [MIF protein results in increased phosphorylation of PRKCD protein] CTD PMID:16872482 NCBI chr20:12,767,138...12,791,222
Ensembl chr 4:134,041,774...134,042,121
Ensembl chr20:134,041,774...134,042,121 		JBrowse link
G Mir21 microRNA 21 affects expression
multiple interactions 		ISO pyrazolanthrone affects the expression of MIR21 mRNA
pyrazolanthrone affects the reaction [arsenic trichloride affects the expression of MIR21 mRNA] 		CTD PMID:24434654 NCBI chr10:71,902,600...71,902,691 JBrowse link
G Mir328 microRNA 328 increases expression ISO pyrazolanthrone results in increased expression of MIR328 mRNA CTD PMID:25605016 NCBI chr19:50,094,691...50,094,774 JBrowse link
G Mmp1 matrix metallopeptidase 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester results in increased expression of and results in increased activity of MMP1 protein]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of MMP1 mRNA]; pyrazolanthrone inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of and results in increased activity of MMP1 protein]; pyrazolanthrone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP1 protein] CTD PMID:12832416 PMID:20004183 PMID:24469321 NCBI chr 8:12,943,453...12,963,966
Ensembl chr 8:12,943,453...12,963,964 		JBrowse link
G Mmp12 matrix metallopeptidase 12 multiple interactions ISO pyrazolanthrone inhibits the reaction [IL1B protein results in increased activity of MMP12 protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of MMP12 mRNA] CTD PMID:16359550 NCBI chr 8:12,866,652...12,876,554
Ensembl chr 8:12,866,641...12,884,478 		JBrowse link
G Mmp13 matrix metallopeptidase 13 multiple interactions ISO pyrazolanthrone inhibits the reaction [Chloramphenicol results in increased expression of MMP13 mRNA]; pyrazolanthrone inhibits the reaction [S100A4 protein results in increased expression of MMP13 protein]; pyrazolanthrone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP13 protein] CTD PMID:16948116 PMID:20004183 PMID:20338993 NCBI chr 8:12,782,829...12,793,108
Ensembl chr 8:12,782,813...12,793,105 		JBrowse link
G Mmp14 matrix metallopeptidase 14 multiple interactions ISO pyrazolanthrone inhibits the reaction [Acrolein results in increased expression of MMP14 mRNA] CTD PMID:19661247 NCBI chr15:31,857,824...31,867,049
Ensembl chr15:31,857,546...31,869,893 		JBrowse link
G Mmp2 matrix metallopeptidase 2 multiple interactions ISO
EXP 		pyrazolanthrone inhibits the reaction [mangostin analog results in decreased expression of MMP2 protein]; pyrazolanthrone inhibits the reaction [Resveratrol results in decreased expression of MMP2]; pyrazolanthrone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MMP2 protein]; pyrazolanthrone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP2 mRNA]; pyrazolanthrone inhibits the reaction [thymoquinone results in decreased expression of MMP2 protein]; pyrazolanthrone promotes the reaction [dehydrocrenatidine results in decreased expression of MMP2 protein]; pyrazolanthrone promotes the reaction [Resveratrol results in decreased expression of and results in decreased activity of MMP2 protein]
pyrazolanthrone inhibits the reaction [Particulate Matter results in increased methylation of MMP2 promoter]
pyrazolanthrone inhibits the reaction [Doxorubicin results in increased activity of MMP2 protein]; pyrazolanthrone inhibits the reaction [Doxorubicin results in increased expression of MMP2 mRNA] 		CTD PMID:16213474 PMID:20599481 PMID:22355787 PMID:24841706 PMID:25605016 More... NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856 		JBrowse link
G Mmp3 matrix metallopeptidase 3 multiple interactions ISO pyrazolanthrone inhibits the reaction [2,2',4,6,6'-pentachlorobiphenyl results in increased expression of MMP3 mRNA]; pyrazolanthrone inhibits the reaction [Citrinin results in increased expression of MMP3 mRNA]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of MMP3 mRNA]; pyrazolanthrone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP3 protein] CTD PMID:12832416 PMID:16778083 PMID:19361540 PMID:20004183 NCBI chr 8:12,925,267...12,938,828
Ensembl chr 8:12,925,280...12,938,826 		JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions
decreases activity 		ISO
EXP 		[kahweol acetate co-treated with pyrazolanthrone] inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of and results in increased activity of MMP9 protein]; pyrazolanthrone affects the reaction [TNF protein results in increased expression of MMP9 protein]; pyrazolanthrone inhibits the reaction [Cadmium results in increased expression of MMP9 mRNA]; pyrazolanthrone inhibits the reaction [FSL-1 lipoprotein, synthetic results in increased expression of MMP9 mRNA]; pyrazolanthrone inhibits the reaction [FSL-1 lipoprotein, synthetic results in increased secretion of MMP9 protein]; pyrazolanthrone inhibits the reaction [hydroquinone results in increased secretion of MMP9 protein]; pyrazolanthrone inhibits the reaction [mangostin analog results in decreased expression of MMP9 protein]; pyrazolanthrone inhibits the reaction [Resveratrol results in decreased expression of MMP9]; pyrazolanthrone inhibits the reaction [tetrabromobisphenol A results in increased expression of MMP9 mRNA]; pyrazolanthrone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MMP9 protein]; pyrazolanthrone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]; pyrazolanthrone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 protein]; pyrazolanthrone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of and results in increased activity of MMP9 protein]; pyrazolanthrone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of MMP9 protein]; pyrazolanthrone inhibits the reaction [thymoquinone results in decreased expression of MMP9 protein]; pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of and results in increased activity of MMP9 protein]; pyrazolanthrone promotes the reaction [ovatodiolide results in decreased activity of MMP9 protein]
pyrazolanthrone inhibits the reaction [RELA protein binds to MMP9 promoter]; pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of MMP9 protein]; pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]; pyrazolanthrone promotes the reaction [Doxorubicin results in increased expression of MMP9 mRNA]
pyrazolanthrone results in decreased activity of MMP9 protein 		CTD PMID:16213474 PMID:19447859 PMID:20152819 PMID:21354279 PMID:22033475 More... NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442 		JBrowse link
G Mt1a metallothionein 1A multiple interactions ISO pyrazolanthrone inhibits the reaction [Ozone results in increased expression of MT1 mRNA] CTD PMID:17460151 NCBI chr19:10,831,959...10,832,975
Ensembl chr17:79,695,809...79,696,200
Ensembl chr  X:79,695,809...79,696,200
Ensembl chr19:79,695,809...79,696,200 		JBrowse link
G Muc5ac mucin 5AC, oligomeric mucus/gel-forming multiple interactions ISO pyrazolanthrone inhibits the reaction [EGF protein results in increased secretion of MUC5AC protein]; pyrazolanthrone inhibits the reaction [o,p'-DDT results in increased expression of MUC5AC mRNA]; pyrazolanthrone inhibits the reaction [Paraquat results in increased expression of MUC5AC mRNA]; pyrazolanthrone inhibits the reaction [polyhexamethyleneguanidine results in increased expression of MUC5AC mRNA]; pyrazolanthrone inhibits the reaction [polyhexamethyleneguanidine results in increased expression of MUC5AC protein]; pyrazolanthrone inhibits the reaction [Tobacco Smoke Pollution results in increased expression of MUC5AC mRNA]; pyrazolanthrone inhibits the reaction [Tobacco Smoke Pollution results in increased expression of MUC5AC protein]; pyrazolanthrone promotes the reaction [[Smoke results in increased abundance of Particulate Matter] which results in increased expression of MUC5AC mRNA] CTD PMID:21544845 PMID:22766066 PMID:25177032 PMID:30935901 PMID:31944254 More... NCBI chr 1:206,293,717...206,326,006
Ensembl chr 1:206,293,869...206,326,006 		JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor increases expression
multiple interactions 		ISO
EXP 		pyrazolanthrone results in increased expression of MYC protein
pyrazolanthrone inhibits the reaction [Diethylnitrosamine results in increased expression of MYC protein]
MYC affects the reaction [pyrazolanthrone results in increased expression of BAX protein]; MYC affects the reaction [pyrazolanthrone results in increased expression of MYC protein]; MYC affects the reaction [pyrazolanthrone results in increased expression of TP53 protein]; pyrazolanthrone inhibits the reaction [sodium arsenite results in increased expression of MYC protein] 		CTD PMID:15034932 PMID:19418558 PMID:24675390 NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028 		JBrowse link
G Myh2 myosin heavy chain 2 multiple interactions ISO pyrazolanthrone inhibits the reaction [Ozone results in increased expression of MYH2 mRNA] CTD PMID:17460151 NCBI chr10:52,355,739...52,382,235
Ensembl chr10:52,355,739...52,382,235 		JBrowse link
G Myh6 myosin heavy chain 6 multiple interactions ISO pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in decreased expression of MYH6 mRNA] CTD PMID:21873422 NCBI chr15:32,388,102...32,413,663
Ensembl chr15:32,387,487...32,411,333 		JBrowse link
G Myh7 myosin heavy chain 7 multiple interactions ISO pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in decreased expression of MYH7 mRNA] CTD PMID:21873422 NCBI chr15:32,416,525...32,439,851
Ensembl chr15:32,416,527...32,438,194 		JBrowse link
G Ncf1 neutrophil cytosolic factor 1 multiple interactions EXP pyrazolanthrone inhibits the reaction [Glucose results in increased expression of NCF1 protein] CTD PMID:22245600 NCBI chr12:28,121,816...28,131,080
Ensembl chr12:28,121,366...28,131,079 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 multiple interactions
decreases expression 		ISO
EXP 		pyrazolanthrone inhibits the reaction [3-hydroxy-4-prenyl-5-methoxystilbene-2-carboxylic acid results in increased activity of NFE2L2 protein]; pyrazolanthrone inhibits the reaction [3-O-caffeoyl-1-methylquinic acid affects the localization of NFE2L2 protein]; pyrazolanthrone inhibits the reaction [[3-hydroxy-4-prenyl-5-methoxystilbene-2-carboxylic acid results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [mevastatin results in increased phosphorylation of NFE2L2 protein]
pyrazolanthrone inhibits the reaction [[Plant Extracts co-treated with Ethanol] results in increased expression of and affects the localization of NFE2L2 protein]; pyrazolanthrone inhibits the reaction [Triclosan results in increased expression of NFE2L2 protein]
pyrazolanthrone inhibits the reaction [Acrylamide results in increased expression of NFE2L2 protein]; pyrazolanthrone inhibits the reaction [aureusidin affects the localization of NFE2L2 protein]; pyrazolanthrone inhibits the reaction [Chitosan analog inhibits the reaction [Doxorubicin affects the localization of NFE2L2 protein]]; pyrazolanthrone inhibits the reaction [Curcumin affects the localization of NFE2L2 protein]; pyrazolanthrone inhibits the reaction [diphenylarsinic acid results in increased expression of NFE2L2 protein]
pyrazolanthrone results in decreased expression of NFE2L2 protein 		CTD PMID:16631525 PMID:17640564 PMID:23535287 PMID:25449124 PMID:25649257 More... NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090 		JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions ISO
EXP 		pyrazolanthrone affects the reaction [sodium arsenite affects the expression of NFKB1 protein]; pyrazolanthrone inhibits the reaction [Bee Venoms inhibits the reaction [Lipopolysaccharides results in increased localization of NFKB1 protein]]; pyrazolanthrone inhibits the reaction [Bee Venoms inhibits the reaction [Nitroprusside results in increased localization of NFKB1 protein]]; pyrazolanthrone inhibits the reaction [Melitten inhibits the reaction [Lipopolysaccharides results in increased localization of NFKB1 protein]]; pyrazolanthrone inhibits the reaction [Melitten inhibits the reaction [Nitroprusside results in increased localization of NFKB1 protein]]
pyrazolanthrone inhibits the reaction [Palmitic Acid results in increased expression of NFKB1 mRNA]
pyrazolanthrone inhibits the reaction [Bee Venoms inhibits the reaction [Lipopolysaccharides results in increased localization of NFKB1 protein]]; pyrazolanthrone inhibits the reaction [Bee Venoms inhibits the reaction [Nitroprusside results in increased localization of NFKB1 protein]]; pyrazolanthrone inhibits the reaction [Melitten inhibits the reaction [Lipopolysaccharides results in increased localization of NFKB1 protein]]; pyrazolanthrone inhibits the reaction [Melitten inhibits the reaction [Nitroprusside results in increased localization of NFKB1 protein]]; pyrazolanthrone inhibits the reaction [sodium chromate(VI) results in increased phosphorylation of NFKB1 protein] 		CTD PMID:18507870 PMID:22547200 PMID:29528074 PMID:30259999 NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088 		JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions ISO
EXP 		pyrazolanthrone inhibits the reaction [1,2,5,8-tetrahydroxy anthraquinone results in increased expression of NFKBIA protein]; pyrazolanthrone inhibits the reaction [Bee Venoms inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]]; pyrazolanthrone inhibits the reaction [Melitten inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]]; pyrazolanthrone inhibits the reaction [Melitten inhibits the reaction [Nitroprusside results in increased phosphorylation of NFKBIA protein]]
pyrazolanthrone inhibits the reaction [Glucose results in increased phosphorylation of and results in increased degradation of NFKBIA protein] 		CTD PMID:18507870 PMID:22245600 PMID:33030807 NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072 		JBrowse link
G Ngf nerve growth factor multiple interactions ISO
EXP 		pyrazolanthrone inhibits the reaction [Edaravone results in increased expression of NGF mRNA]; pyrazolanthrone inhibits the reaction [Edaravone results in increased expression of NGF protein]
pyrazolanthrone inhibits the reaction [pentaacetyl geniposide results in increased expression of NGF mRNA]; pyrazolanthrone inhibits the reaction [pentaacetyl geniposide results in increased expression of NGF protein] 		CTD PMID:17651887 PMID:19954754 NCBI chr 2:192,589,580...192,642,971
Ensembl chr 2:192,589,582...192,643,834 		JBrowse link
G Ngfr nerve growth factor receptor multiple interactions EXP pyrazolanthrone inhibits the reaction [pentaacetyl geniposide results in increased expression of NGFR mRNA]; pyrazolanthrone inhibits the reaction [pentaacetyl geniposide results in increased expression of NGFR protein] CTD PMID:17651887 NCBI chr10:81,012,077...81,030,305
Ensembl chr10:81,012,089...81,030,305 		JBrowse link
G Nlrp3 NLR family, pyrin domain containing 3 multiple interactions ISO
EXP 		pyrazolanthrone inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of NLRP3 protein]; pyrazolanthrone inhibits the reaction [APP protein results in increased expression of NLRP3 protein]
pyrazolanthrone inhibits the reaction [Palmitic Acid results in increased expression of NLRP3 mRNA] 		CTD PMID:28004443 PMID:30259999 PMID:34510229 NCBI chr10:44,826,299...44,853,373
Ensembl chr10:44,828,014...44,853,394 		JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions ISO
EXP 		pyrazolanthrone inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; pyrazolanthrone inhibits the reaction [[Nitroprusside results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; pyrazolanthrone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of NOS2 protein]
pyrazolanthrone inhibits the reaction [Manganese promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA]]; pyrazolanthrone inhibits the reaction [Palmitic Acid results in increased expression of NOS2 mRNA]
pyrazolanthrone inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide]; pyrazolanthrone inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; pyrazolanthrone inhibits the reaction [[Nitroprusside results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; pyrazolanthrone inhibits the reaction [Acetaminophen results in increased expression of NOS2 mRNA]; pyrazolanthrone inhibits the reaction [Acetaminophen results in increased expression of NOS2 protein]; pyrazolanthrone inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein]; pyrazolanthrone inhibits the reaction [Humic Substances results in increased expression of NOS2 mRNA]; pyrazolanthrone inhibits the reaction [Humic Substances results in increased expression of NOS2 protein]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; pyrazolanthrone inhibits the reaction [lipoteichoic acid results in increased expression of NOS2 protein]; pyrazolanthrone inhibits the reaction [Manganese results in increased expression of NOS2 mRNA]; pyrazolanthrone inhibits the reaction [Manganese results in increased expression of NOS2 protein]; pyrazolanthrone inhibits the reaction [Phosgene results in increased expression of NOS2 protein]; pyrazolanthrone inhibits the reaction [sodium chromate(VI) results in increased expression of NOS2 protein]; pyrazolanthrone inhibits the reaction [zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; pyrazolanthrone inhibits the reaction [zinc protoporphyrin inhibits the reaction [lipoteichoic acid results in increased expression of NOS2 protein]]; pyrazolanthrone inhibits the reaction [zinc protoporphyrin inhibits the reaction [Peptidoglycan results in increased expression of NOS2 protein]] 		CTD PMID:16417967 PMID:16488514 PMID:17570326 PMID:18507870 PMID:19376148 More... NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880 		JBrowse link
G Nox1 NADPH oxidase 1 multiple interactions EXP pyrazolanthrone inhibits the reaction [Doxorubicin results in increased expression of NOX1 mRNA] CTD PMID:16213474 NCBI chr  X:101,572,338...101,625,571
Ensembl chr  X:101,572,340...101,595,520 		JBrowse link
G Nppb natriuretic peptide B multiple interactions ISO pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of NPPB mRNA] CTD PMID:21873422 NCBI chr 5:163,699,955...163,701,314
Ensembl chr 5:163,699,839...163,701,310 		JBrowse link
G Npy neuropeptide Y multiple interactions ISO pyrazolanthrone affects the reaction [bisphenol A affects the expression of NPY mRNA] CTD PMID:32960947 NCBI chr 4:80,212,111...80,219,310
Ensembl chr 4:80,212,111...80,219,310 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions ISO
EXP 		pyrazolanthrone inhibits the reaction [Copper results in increased expression of NQO1 mRNA]; pyrazolanthrone inhibits the reaction [Copper results in increased expression of NQO1 protein]; pyrazolanthrone inhibits the reaction [Lead results in increased expression of NQO1 mRNA]; pyrazolanthrone inhibits the reaction [Lead results in increased expression of NQO1 protein]; pyrazolanthrone inhibits the reaction [Mercury results in increased expression of NQO1 mRNA]; pyrazolanthrone inhibits the reaction [Mercury results in increased expression of NQO1 protein]
pyrazolanthrone inhibits the reaction [pachastrissamine analog affects the expression of NQO1 protein]
pyrazolanthrone inhibits the reaction [Acrylamide results in increased expression of NQO1 mRNA] 		CTD PMID:18752316 PMID:29426002 PMID:35123989 NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260 		JBrowse link
G Nr0b2 nuclear receptor subfamily 0, group B, member 2 multiple interactions ISO pyrazolanthrone inhibits the reaction [Fenofibrate results in increased expression of NR0B2 mRNA] CTD PMID:19593819 NCBI chr 5:151,063,160...151,066,475
Ensembl chr 5:151,063,160...151,066,475 		JBrowse link
G Nr1h3 nuclear receptor subfamily 1, group H, member 3 increases expression ISO pyrazolanthrone results in increased expression of NR1H3 mRNA CTD PMID:19883121 NCBI chr 3:97,614,616...97,632,053
Ensembl chr 3:97,614,616...97,624,532 		JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 multiple interactions ISO pyrazolanthrone inhibits the reaction [NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased expression of CCL2 mRNA]] CTD PMID:28505368 NCBI chr 7:25,733,471...25,829,440
Ensembl chr 7:25,733,471...25,829,389 		JBrowse link
G Nr3c1 nuclear receptor subfamily 3, group C, member 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [Valproic Acid inhibits the reaction [Corticosterone results in increased activity of NR3C1 protein]] CTD PMID:15249158 NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,522,783...31,643,843 		JBrowse link
G Nr4a1 nuclear receptor subfamily 4, group A, member 1 multiple interactions ISO pyrazolanthrone promotes the reaction [Ozone results in increased expression of NR4A1 mRNA] CTD PMID:17460151 NCBI chr 7:134,247,153...134,268,044
Ensembl chr 7:134,247,192...134,268,041 		JBrowse link
G Optn optineurin multiple interactions EXP pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of OPTN protein] CTD PMID:28776281 NCBI chr17:78,118,847...78,169,543
Ensembl chr17:78,118,866...78,169,543 		JBrowse link
G Osm oncostatin M multiple interactions ISO pyrazolanthrone inhibits the reaction [OSM protein results in increased expression of and results in increased secretion of IL6 protein] CTD PMID:21548952 NCBI chr14:83,327,202...83,332,073
Ensembl chr14:83,327,554...83,331,827 		JBrowse link
G Ostm1 osteoclastogenesis associated transmembrane protein 1 multiple interactions ISO [crocin co-treated with pyrazolanthrone co-treated with TNFSF11 protein] results in decreased expression of OSTM1 mRNA; [TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of OSTM1 mRNA; crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of OSTM1 mRNA] CTD PMID:30580027 NCBI chr20:47,653,696...47,769,248
Ensembl chr20:47,653,670...47,769,237 		JBrowse link
G Pappa pappalysin 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of PAPPA mRNA] CTD PMID:24781252 NCBI chr 5:83,513,358...83,751,364
Ensembl chr 5:83,513,358...83,751,361 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO
EXP 		pyrazolanthrone inhibits the reaction [1,4-naphthoquinone analog results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [3-oxo-29-noroleana-1,9(11),12-trien-2,20-dicarbonitrile results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [[Arsenic Trioxide co-treated with Ethacrynic Acid] results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [[cholix toxin, Vibrio cholerae co-treated with TNF protein] results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [[Sulindac co-treated with Arsenic Trioxide] results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [coronarin D results in increased expression of PARP1 protein modified form]; pyrazolanthrone inhibits the reaction [dehydroxymethylepoxyquinomicin results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [Docetaxel results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [Fenretinide results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [Fingolimod Hydrochloride results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [isoliensinine results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [licochalcone B results in increased expression of PARP1 protein]; pyrazolanthrone inhibits the reaction [luteolin-7-glucoside results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [LY 293111 results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [morusin results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [polyphyllin I results in increased expression of PARP1 protein modified form]; pyrazolanthrone inhibits the reaction [Quercetin results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [Rotenone results in increased cleavage of PARP1 protein]; pyrazolanthrone promotes the reaction [dihydromyricetin results in increased cleavage of PARP1 protein]; pyrazolanthrone promotes the reaction [pachastrissamine analog results in increased cleavage of PARP1 protein]; pyrazolanthrone promotes the reaction [picrasidine I results in increased expression of PARP1 protein modified form]; pyrazolanthrone results in increased susceptibility to [[TNFSF10 protein co-treated with kahweol acetate] results in increased cleavage of PARP1 protein]
pyrazolanthrone inhibits the reaction [[sodium arsenite co-treated with Cadmium Chloride co-treated with lead acetate] results in increased expression of PARP1 protein]; pyrazolanthrone inhibits the reaction [bakuchiol results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [cadmium acetate results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [Cadmium Chloride results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [nickel chloride results in increased cleavage of PARP1 protein]
pyrazolanthrone inhibits the reaction [3-dinitrobenzene results in increased cleavage of PARP1 protein] 		CTD PMID:14724571 PMID:15501958 PMID:16151469 PMID:16328441 PMID:16407847 More... NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567 		JBrowse link
G Pcna proliferating cell nuclear antigen multiple interactions
decreases expression 		EXP
ISO 		pyrazolanthrone inhibits the reaction [Diethylnitrosamine results in increased expression of PCNA protein]
pyrazolanthrone results in decreased expression of PCNA protein 		CTD PMID:18593901 PMID:19418558 NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901 		JBrowse link
G Pdgfrb platelet derived growth factor receptor beta decreases expression EXP pyrazolanthrone results in decreased expression of PDGFRB mRNA; pyrazolanthrone results in decreased expression of PDGFRB protein CTD PMID:18332871 NCBI chr18:56,770,348...56,809,228
Ensembl chr18:56,770,348...56,809,233 		JBrowse link
G Pdk4 pyruvate dehydrogenase kinase 4 multiple interactions ISO pyrazolanthrone inhibits the reaction [Ozone results in increased expression of PDK4 mRNA] CTD PMID:17460151 NCBI chr 4:34,558,327...34,568,329
Ensembl chr 4:34,556,330...34,568,381 		JBrowse link
G Plat plasminogen activator, tissue type multiple interactions EXP pyrazolanthrone inhibits the reaction [Valproic Acid results in increased activity of PLAT protein] CTD PMID:23378038 NCBI chr16:75,943,061...76,022,037
Ensembl chr16:75,943,064...75,967,696 		JBrowse link
G Plau plasminogen activator, urokinase multiple interactions ISO pyrazolanthrone inhibits the reaction [TNF protein results in increased activity of PLAU protein]; pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of PLAU protein]; pyrazolanthrone promotes the reaction [resveratrol results in decreased expression of PLAU protein] CTD PMID:19874453 PMID:23437203 NCBI chr15:3,505,485...3,511,987
Ensembl chr15:3,505,487...3,512,030 		JBrowse link
G Plaur plasminogen activator, urokinase receptor multiple interactions ISO pyrazolanthrone inhibits the reaction [Nicotine results in increased expression of PLAUR mRNA] CTD PMID:22261521 NCBI chr 1:89,181,363...89,196,308
Ensembl chr 1:89,178,453...89,198,130 		JBrowse link
G Plcb1 phospholipase C beta 1 multiple interactions EXP pyrazolanthrone inhibits the reaction [Norepinephrine results in increased expression of PLCB1 mRNA] CTD PMID:19225867 NCBI chr 3:142,512,765...143,224,042
Ensembl chr 3:142,513,033...143,225,646 		JBrowse link
G Plcb3 phospholipase C beta 3 multiple interactions EXP pyrazolanthrone inhibits the reaction [Norepinephrine results in increased expression of PLCB3 mRNA] CTD PMID:19225867 NCBI chr 1:213,572,499...213,589,585
Ensembl chr 1:213,574,166...213,589,583 		JBrowse link
G Plcd1 phospholipase C, delta 1 multiple interactions EXP pyrazolanthrone inhibits the reaction [Norepinephrine results in increased expression of PLCD1 mRNA] CTD PMID:19225867 NCBI chr 8:127,672,955...127,695,939
Ensembl chr 8:127,672,980...127,695,939 		JBrowse link
G Plin3 perilipin 3 multiple interactions ISO pyrazolanthrone inhibits the reaction [CpG ODN 1826 results in increased expression of PLIN3 mRNA] CTD PMID:20628022 NCBI chr 9:1,198,336...1,210,212
Ensembl chr 9:1,198,336...1,210,231 		JBrowse link
G Plxna2 plexin A2 multiple interactions ISO pyrazolanthrone inhibits the reaction [Ozone results in increased expression of PLXNA2 mRNA] CTD PMID:17460151 NCBI chr13:108,683,155...108,888,336
Ensembl chr13:108,691,530...108,887,453 		JBrowse link
G Pon1 paraoxonase 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [Chenodeoxycholic Acid results in decreased expression of PON1 mRNA]; pyrazolanthrone inhibits the reaction [FGF19 protein results in decreased expression of PON1 mRNA]; pyrazolanthrone inhibits the reaction [GW 4064 results in decreased expression of PON1 mRNA] CTD PMID:16269825 NCBI chr 4:34,261,312...34,292,327
Ensembl chr 4:34,261,289...34,287,924 		JBrowse link
G Pon2 paraoxonase 2 decreases expression ISO pyrazolanthrone results in decreased expression of PON2 protein CTD PMID:15544923 NCBI chr 4:34,356,270...34,391,684
Ensembl chr 4:34,356,274...34,391,996 		JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions
increases expression 		ISO pyrazolanthrone inhibits the reaction [TNF protein results in decreased expression of PPARA mRNA]
pyrazolanthrone results in increased expression of PPARA mRNA
pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in decreased expression of PPARA mRNA] 		CTD PMID:19883121 PMID:21873422 NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714 		JBrowse link
G Ppard peroxisome proliferator-activated receptor delta multiple interactions ISO pyrazolanthrone inhibits the reaction [Indomethacin results in increased expression of PPARD protein] CTD PMID:17341418 NCBI chr20:6,300,527...6,365,707
Ensembl chr20:6,352,183...6,365,707 		JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma increases expression
multiple interactions 		EXP pyrazolanthrone results in increased expression of PPARG mRNA; pyrazolanthrone results in increased expression of PPARG protein
pyrazolanthrone inhibits the reaction [[sodium arsenite co-treated with Cadmium Chloride co-treated with lead acetate] results in increased expression of PPARG protein] 		CTD PMID:17372590 PMID:28283887 NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104 		JBrowse link
G Ppargc1a PPARG coactivator 1 alpha increases expression
multiple interactions 		ISO pyrazolanthrone results in increased expression of PPARGC1A mRNA
6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride affects the reaction [pyrazolanthrone affects the reaction [[TGFB1 protein co-treated with TNF protein] affects the expression of PPARGC1A protein]]; 6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride promotes the reaction [pyrazolanthrone inhibits the reaction [Folic Acid results in decreased expression of PPARGC1A protein]]; pyrazolanthrone affects the reaction [6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride affects the reaction [[TGFB1 protein co-treated with TNF protein] affects the expression of PPARGC1A protein]]; pyrazolanthrone affects the reaction [[TGFB1 protein co-treated with TNF protein] affects the expression of PPARGC1A protein]; pyrazolanthrone inhibits the reaction [Folic Acid results in decreased expression of PPARGC1A protein]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in decreased expression of PPARGC1A mRNA]; pyrazolanthrone promotes the reaction [6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride inhibits the reaction [Folic Acid results in decreased expression of PPARGC1A protein]] 		CTD PMID:21873422 PMID:31447676 NCBI chr14:63,073,505...63,729,215
Ensembl chr14:63,273,189...63,729,213 		JBrowse link
G Prf1 perforin 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [resveratrol results in increased expression of PRF1 protein] CTD PMID:20082299 NCBI chr20:29,789,040...29,794,550
Ensembl chr20:29,788,972...29,795,124 		JBrowse link
G Prkcd protein kinase C, delta multiple interactions ISO pyrazolanthrone inhibits the reaction [MIF protein results in increased phosphorylation of PRKCD protein] CTD PMID:16872482 NCBI chr16:5,775,681...5,806,122
Ensembl chr16:5,775,681...5,805,839 		JBrowse link
G Procr protein C receptor multiple interactions ISO pyrazolanthrone inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased cleavage of PROCR protein] CTD PMID:24632454 NCBI chr 3:164,714,727...164,718,994
Ensembl chr 3:164,711,636...164,718,989 		JBrowse link
G Psat1 phosphoserine aminotransferase 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [Ozone results in increased expression of PSAT1 mRNA] CTD PMID:17460151 NCBI chr 1:222,623,553...222,646,187
Ensembl chr 1:222,623,556...222,655,693 		JBrowse link
G Pten phosphatase and tensin homolog multiple interactions ISO pyrazolanthrone inhibits the reaction [arsenic trioxide results in increased expression of PTEN protein] CTD PMID:20534739 NCBI chr 1:240,043,707...240,110,330
Ensembl chr 1:240,043,707...240,110,330 		JBrowse link
G Ptgds prostaglandin D2 synthase multiple interactions ISO pyrazolanthrone affects the reaction [2-chloroethyl ethyl sulfide results in increased expression of PTGDS mRNA] CTD PMID:20382172 NCBI chr 3:28,680,044...28,682,978
Ensembl chr 3:28,680,044...28,682,978 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO
EXP 		pyrazolanthrone inhibits the reaction [[Nitroprusside results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; pyrazolanthrone inhibits the reaction [Aflatoxin B1 results in increased expression of PTGS2 protein]; pyrazolanthrone inhibits the reaction [Chlorpyrifos results in increased expression of PTGS2 protein]; pyrazolanthrone inhibits the reaction [Homocysteine results in increased expression of PTGS2 mRNA]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of PTGS2 mRNA]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; pyrazolanthrone inhibits the reaction [sodium arsenite results in increased expression of PTGS2 mRNA]; pyrazolanthrone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein]; pyrazolanthrone inhibits the reaction [VEGFA protein results in increased expression of PTGS2 mRNA]; pyrazolanthrone inhibits the reaction [VEGFA protein results in increased expression of PTGS2 protein]; pyrazolanthrone promotes the reaction [Sodium Fluoride results in increased expression of PTGS2 protein]; pyrazolanthrone promotes the reaction [U 0126 inhibits the reaction [2-aminodiphenyl results in increased expression of PTGS2 protein]]
pyrazolanthrone inhibits the reaction [cadmium sulfate results in increased expression of PTGS2 mRNA]; pyrazolanthrone inhibits the reaction [cadmium sulfate results in increased expression of PTGS2 protein]; pyrazolanthrone inhibits the reaction [lead acetate results in increased expression of PTGS2 protein]; pyrazolanthrone inhibits the reaction [manganese chloride results in increased expression of PTGS2 protein]; pyrazolanthrone inhibits the reaction [Serotonin results in increased expression of PTGS2 mRNA]
pyrazolanthrone inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; pyrazolanthrone inhibits the reaction [[Nitroprusside results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; pyrazolanthrone inhibits the reaction [arsenite results in increased expression of PTGS2 protein]; pyrazolanthrone inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 protein]; pyrazolanthrone inhibits the reaction [Endosulfan results in increased expression of PTGS2 protein]; pyrazolanthrone inhibits the reaction [Humic Substances results in increased expression of PTGS2 mRNA]; pyrazolanthrone inhibits the reaction [Humic Substances results in increased expression of PTGS2 protein]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; pyrazolanthrone inhibits the reaction [lipoteichoic acid results in increased expression of PTGS2 protein]; pyrazolanthrone inhibits the reaction [o,p'-DDT results in increased expression of PTGS2 mRNA]; pyrazolanthrone inhibits the reaction [o,p'-DDT results in increased expression of PTGS2 protein]; pyrazolanthrone inhibits the reaction [Phosgene results in increased expression of PTGS2 protein]; pyrazolanthrone inhibits the reaction [sodium chromate(VI) results in increased expression of PTGS2 protein]; pyrazolanthrone inhibits the reaction [T-2 Toxin results in increased expression of PTGS2 mRNA]; pyrazolanthrone promotes the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; Sodium Selenite inhibits the reaction [pyrazolanthrone promotes the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]] 		CTD PMID:12832416 PMID:17084486 PMID:18481333 PMID:18507870 PMID:18596194 More... NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320 		JBrowse link
G Ptx3 pentraxin 3 multiple interactions ISO pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of PTX3 mRNA] CTD PMID:12832416 NCBI chr 2:152,797,563...152,803,372
Ensembl chr 2:152,781,955...152,803,372 		JBrowse link
G Rad51 RAD51 recombinase multiple interactions ISO pyrazolanthrone inhibits the reaction [Prodigiosin results in decreased expression of RAD51 mRNA] CTD PMID:22579953 NCBI chr 3:126,554,210...126,578,888
Ensembl chr 3:126,554,190...126,579,469 		JBrowse link
G Rapgef4 Rap guanine nucleotide exchange factor 4 multiple interactions ISO pyrazolanthrone inhibits the reaction [Ozone results in increased expression of RAPGEF4 mRNA] CTD PMID:17460151 NCBI chr 3:77,217,024...77,509,933
Ensembl chr 3:77,217,039...77,509,978 		JBrowse link
G Rb1 RB transcriptional corepressor 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [Calcitriol results in increased expression of RB1 mRNA]; pyrazolanthrone inhibits the reaction [Calcitriol results in increased expression of RB1 protein] CTD PMID:14729647 NCBI chr15:54,780,858...54,911,989
Ensembl chr15:54,780,858...54,911,857 		JBrowse link
G Reg3g regenerating family member 3 gamma multiple interactions ISO pyrazolanthrone inhibits the reaction [Ozone results in increased expression of REG3G mRNA] CTD PMID:17460151 NCBI chr 4:112,482,183...112,484,738
Ensembl chr 4:112,482,183...112,484,738 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions
decreases expression 		ISO
EXP 		pyrazolanthrone affects the reaction [sodium arsenite affects the expression of RELA protein]; pyrazolanthrone inhibits the reaction [Acids results in increased activity of RELA protein]; pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in decreased activity of RELA protein]; pyrazolanthrone inhibits the reaction [arsenite results in increased phosphorylation of RELA protein]; pyrazolanthrone inhibits the reaction [Bee Venoms inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein]]; pyrazolanthrone inhibits the reaction [Bee Venoms inhibits the reaction [Nitroprusside results in increased localization of RELA protein]]; pyrazolanthrone inhibits the reaction [Homocysteine results in increased activity of RELA protein]; pyrazolanthrone inhibits the reaction [Melitten inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein]]; pyrazolanthrone inhibits the reaction [Melitten inhibits the reaction [Nitroprusside results in increased localization of RELA protein]]; pyrazolanthrone inhibits the reaction [Paraquat results in increased activity of RELA protein]; pyrazolanthrone inhibits the reaction [sodium arsenite affects the localization of RELA protein]; pyrazolanthrone inhibits the reaction [Sodium Fluoride affects the localization of RELA protein]; pyrazolanthrone inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of RELA protein]
pyrazolanthrone results in decreased expression of RELA protein
pyrazolanthrone inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased localization of RELA protein]; pyrazolanthrone inhibits the reaction [Acrylamide results in increased expression of RELA protein]; pyrazolanthrone inhibits the reaction [RELA protein binds to MMP9 promoter]; pyrazolanthrone inhibits the reaction [sodium arsenite results in increased phosphorylation of RELA protein]; pyrazolanthrone inhibits the reaction [TNF protein affects the localization of RELA protein]
pyrazolanthrone inhibits the reaction [Bee Venoms inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein]]; pyrazolanthrone inhibits the reaction [Bee Venoms inhibits the reaction [Nitroprusside results in increased localization of RELA protein]]; pyrazolanthrone inhibits the reaction [Cisplatin inhibits the reaction [TNF protein affects the localization of RELA protein]]; pyrazolanthrone inhibits the reaction [Cyclosporine affects the localization of RELA protein]; pyrazolanthrone inhibits the reaction [Melitten inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein]]; pyrazolanthrone inhibits the reaction [Melitten inhibits the reaction [Nitroprusside results in increased localization of RELA protein]]; pyrazolanthrone inhibits the reaction [perfluorooctane sulfonic acid results in increased phosphorylation of RELA protein]; pyrazolanthrone inhibits the reaction [sodium chromate(VI) results in increased phosphorylation of RELA protein] 		CTD PMID:18507870 PMID:19074641 PMID:19616567 PMID:20534739 PMID:21295052 More... NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817 		JBrowse link
G Riox2 ribosomal oxygenase 2 multiple interactions ISO pyrazolanthrone inhibits the reaction [arsenic trichloride results in increased expression of RIOX2 mRNA]; pyrazolanthrone inhibits the reaction [arsenic trichloride results in increased phosphorylation of RIOX2 protein] CTD PMID:24434654 NCBI chr11:54,327,311...54,353,989
Ensembl chr11:54,330,605...54,353,752 		JBrowse link
G Robo1 roundabout guidance receptor 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [JZL 184 affects the localization of and affects the expression of ROBO1 protein] CTD PMID:25030704 NCBI chr11:24,067,869...25,108,694
Ensembl chr11:24,067,878...25,108,694 		JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 multiple interactions
decreases activity 		ISO pyrazolanthrone affects the reaction [flufenoxuron results in decreased phosphorylation of RPS6KB1 protein]; pyrazolanthrone inhibits the reaction [arsenite results in decreased phosphorylation of RPS6KB1 protein]; pyrazolanthrone inhibits the reaction [Ketoglutaric Acids results in increased phosphorylation of RPS6KB1 protein]
pyrazolanthrone results in decreased activity of RPS6KB1 protein 		CTD PMID:12534346 PMID:20589738 PMID:31051157 PMID:33771252 NCBI chr10:71,817,794...71,865,211
Ensembl chr10:71,815,614...71,865,238 		JBrowse link
G Runx2 RUNX family transcription factor 2 multiple interactions EXP
ISO 		[pyrazolanthrone co-treated with SB 203580 co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] inhibits the reaction [Quercetin results in increased expression of RUNX2 mRNA]
pyrazolanthrone inhibits the reaction [Ethanol results in increased activity of RUNX2 protein] 		CTD PMID:26136938 PMID:32198086 NCBI chr 9:23,661,278...23,990,248
Ensembl chr 9:23,664,952...23,990,027 		JBrowse link
G Rxra retinoid X receptor alpha multiple interactions ISO pyrazolanthrone inhibits the reaction [Anisomycin results in increased phosphorylation of RXRA protein]
pyrazolanthrone inhibits the reaction [arsenic trioxide results in increased phosphorylation of RXRA protein] 		CTD PMID:16038797 PMID:16184197 NCBI chr 3:31,387,892...31,474,415
Ensembl chr 3:31,388,223...31,474,417 		JBrowse link
G S100a4 S100 calcium-binding protein A4 multiple interactions ISO pyrazolanthrone inhibits the reaction [S100A4 protein results in increased expression of MMP13 protein] CTD PMID:16948116 NCBI chr 2:178,388,529...178,390,838
Ensembl chr 2:178,388,526...178,390,837 		JBrowse link
G Scd stearoyl-CoA desaturase multiple interactions ISO pyrazolanthrone inhibits the reaction [FGF7 protein results in increased expression of SCD protein] CTD PMID:16162944 NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:253,218,970...253,231,785 		JBrowse link
G Serpina7 serpin family A member 7 multiple interactions EXP pyrazolanthrone inhibits the reaction [[Iodine co-treated with Dibutyl Phthalate] results in increased expression of SERPINA7 protein] CTD PMID:29385629 NCBI chr  X:107,452,044...107,510,958
Ensembl chr  X:107,452,044...107,457,681 		JBrowse link
G Serpinb2 serpin family B member 2 multiple interactions ISO pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of SERPINB2 mRNA] CTD PMID:12832416 NCBI chr13:24,051,933...24,065,032
Ensembl chr13:24,056,021...24,065,031 		JBrowse link
G Serpine1 serpin family E member 1 multiple interactions ISO
EXP 		pyrazolanthrone inhibits the reaction [Catechin results in decreased expression of SERPINE1 mRNA]; pyrazolanthrone inhibits the reaction [Quercetin results in decreased expression of SERPINE1 mRNA]
pyrazolanthrone inhibits the reaction [Valproic Acid results in decreased activity of and results in decreased secretion of SERPINE1 protein] 		CTD PMID:17379280 PMID:23378038 NCBI chr12:25,237,977...25,248,356
Ensembl chr12:25,237,952...25,248,357 		JBrowse link
G Sftpa1 surfactant protein A1 multiple interactions ISO pyrazolanthrone inhibits the reaction [Silicon Dioxide results in decreased expression of SFTPA1 protein] CTD PMID:35689653 NCBI chr16:17,042,264...17,045,770
Ensembl chr16:17,042,255...17,045,769 		JBrowse link
G Sftpb surfactant protein B multiple interactions ISO pyrazolanthrone inhibits the reaction [Silicon Dioxide results in decreased expression of SFTPB protein] CTD PMID:35689653 NCBI chr 4:105,917,495...105,926,631
Ensembl chr 4:105,917,578...105,927,646 		JBrowse link
G Sgk1 serum/glucocorticoid regulated kinase 1 decreases activity ISO pyrazolanthrone results in decreased activity of SGK1 protein CTD PMID:12534346 NCBI chr 1:24,799,391...24,916,886
Ensembl chr 1:24,799,396...24,807,231 		JBrowse link
G Shc1 SHC adaptor protein 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [diallyl trisulfide results in increased phosphorylation of SHC1 protein] CTD PMID:21616139 PMID:22020565 NCBI chr 2:177,135,649...177,147,257
Ensembl chr 2:177,135,659...177,147,914 		JBrowse link
G Sirt1 sirtuin 1 multiple interactions EXP
ISO 		pyrazolanthrone inhibits the reaction [cobaltous chloride results in increased expression of SIRT1 protein]
pyrazolanthrone inhibits the reaction [Silicon Dioxide promotes the reaction [Cycloheximide results in decreased expression of SIRT1 protein]]; pyrazolanthrone inhibits the reaction [Silicon Dioxide results in decreased expression of SIRT1 protein] 		CTD PMID:22669716 PMID:31082419 NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,305,476...25,328,000 		JBrowse link
G Slc18a2 solute carrier family 18 member A2 multiple interactions ISO pyrazolanthrone inhibits the reaction [Rotenone results in decreased activity of SLC18A2 protein] CTD PMID:25496994 NCBI chr 1:268,399,815...268,435,229
Ensembl chr 1:268,400,016...268,435,231 		JBrowse link
G Slc27a1 solute carrier family 27 member 1 multiple interactions
increases expression 		ISO pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in decreased expression of SLC27A1 mRNA]
pyrazolanthrone results in increased expression of SLC27A1 mRNA 		CTD PMID:21873422 NCBI chr16:18,311,859...18,337,024
Ensembl chr16:18,313,015...18,330,045 		JBrowse link
G Smad3 SMAD family member 3 multiple interactions EXP
ISO 		pyrazolanthrone inhibits the reaction [Diethylnitrosamine affects the phosphorylation of SMAD3 protein]
[pyrazolanthrone co-treated with 6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride] inhibits the reaction [Folic Acid results in increased phosphorylation of SMAD3 protein] 		CTD PMID:19418558 PMID:31447676 NCBI chr 8:73,022,204...73,132,324
Ensembl chr 8:73,024,760...73,132,324 		JBrowse link
G Snai1 snail family transcriptional repressor 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 mRNA]; pyrazolanthrone inhibits the reaction [thymoquinone results in decreased expression of SNAI1 protein] CTD PMID:27060453 PMID:33396024 NCBI chr 3:176,667,476...176,671,965 JBrowse link
G Snai2 snail family transcriptional repressor 2 multiple interactions ISO pyrazolanthrone inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 mRNA]; pyrazolanthrone inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 protein] CTD PMID:33396024 NCBI chr11:99,686,934...99,690,349
Ensembl chr11:99,686,934...99,690,349 		JBrowse link
G Sod1 superoxide dismutase 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [Acetaminophen results in decreased activity of SOD1 protein] CTD PMID:33959992 NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399 		JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions ISO pyrazolanthrone inhibits the reaction [BDNF protein results in increased expression of SOD2 protein]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of SOD2 mRNA] CTD PMID:12832416 PMID:22261313 NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168 		JBrowse link
G Sorbs3 sorbin and SH3 domain containing 3 multiple interactions ISO pyrazolanthrone inhibits the reaction [sodium arsenite promotes the reaction [CPEB4 protein binds to SORBS3 protein]] CTD PMID:25237887 NCBI chr15:51,662,639...51,699,161
Ensembl chr15:51,663,095...51,694,522 		JBrowse link
G Sox2 SRY-box transcription factor 2 multiple interactions ISO pyrazolanthrone inhibits the reaction [sodium arsenite results in increased expression of SOX2 protein] CTD PMID:23219847 NCBI chr 2:119,465,131...119,467,542
Ensembl chr 2:119,454,541...119,496,350 		JBrowse link
G Sox9 SRY-box transcription factor 9 multiple interactions ISO pyrazolanthrone promotes the reaction [resveratrol results in increased expression of SOX9] CTD PMID:24841706 NCBI chr10:98,305,744...98,311,250
Ensembl chr10:98,305,744...98,311,250 		JBrowse link
G Sp1 Sp1 transcription factor multiple interactions ISO
EXP 		pyrazolanthrone inhibits the reaction [tricarbonyldichlororuthenium (II) dimer results in increased phosphorylation of SP1 protein]
[cypermethrin co-treated with pyrazolanthrone] results in decreased phosphorylation of SP1 protein 		CTD PMID:26385185 PMID:34794910 NCBI chr 7:135,419,864...135,450,513
Ensembl chr 7:135,420,050...135,450,513 		JBrowse link
G Spp1 secreted phosphoprotein 1 multiple interactions EXP
ISO 		pyrazolanthrone inhibits the reaction [FGF1 protein results in increased expression of SPP1 mRNA]
pyrazolanthrone inhibits the reaction [Ketoglutaric Acids results in increased expression of SPP1 protein] 		CTD PMID:15121739 PMID:31051157 NCBI chr14:5,613,569...5,620,695
Ensembl chr14:5,613,576...5,619,820 		JBrowse link
G Sprr2a small proline rich protein 2A multiple interactions ISO pyrazolanthrone inhibits the reaction [Ozone results in increased expression of SPRR2A mRNA] CTD PMID:17460151 NCBI chr 2:180,511,568...180,511,840 JBrowse link
G Sqstm1 sequestosome 1 multiple interactions
decreases expression
increases expression 		ISO
EXP 		pyrazolanthrone affects the reaction [sodium arsenite affects the expression of SQSTM1 protein]; pyrazolanthrone inhibits the reaction [morusin results in decreased expression of SQSTM1 protein]; pyrazolanthrone inhibits the reaction [pachastrissamine analog promotes the reaction [KEAP1 protein binds to SQSTM1 protein]]; pyrazolanthrone inhibits the reaction [pachastrissamine analog results in increased expression of SQSTM1 protein]; pyrazolanthrone inhibits the reaction [Quercetin results in increased expression of SQSTM1 protein]; pyrazolanthrone inhibits the reaction [tetrachlorobenzoquinone results in increased expression of SQSTM1 protein]
pyrazolanthrone inhibits the reaction [Colistin results in increased degradation of SQSTM1 protein]
pyrazolanthrone inhibits the reaction [methylmercuric chloride results in increased expression of SQSTM1 protein]; pyrazolanthrone inhibits the reaction [triethylene glycol dimethacrylate results in increased expression of SQSTM1 protein]
pyrazolanthrone results in decreased expression of SQSTM1 protein
pyrazolanthrone results in increased expression of SQSTM1 protein 		CTD PMID:24833599 PMID:25881548 PMID:27393035 PMID:27667695 PMID:28842171 More... NCBI chr10:35,026,598...35,037,750
Ensembl chr10:35,026,598...35,037,750 		JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [FGF7 protein results in increased expression of SREBF1 protein] CTD PMID:16162944 NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,507,152...45,529,164 		JBrowse link
G Srebf2 sterol regulatory element binding transcription factor 2 multiple interactions ISO pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of SREBF2 protein]; pyrazolanthrone inhibits the reaction [Quercetin results in increased metabolism of and affects the localization of SREBF2 protein] CTD PMID:22388943 PMID:33677747 NCBI chr 7:115,542,774...115,600,945
Ensembl chr 7:115,543,290...115,600,943 		JBrowse link
G Srrt serrate, RNA effector molecule multiple interactions ISO pyrazolanthrone inhibits the reaction [sodium arsenite results in increased expression of SRRT protein] CTD PMID:23219847 NCBI chr12:25,027,883...25,042,847
Ensembl chr12:25,029,334...25,042,845 		JBrowse link
G St8sia3 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 3 multiple interactions ISO pyrazolanthrone inhibits the reaction [Tretinoin results in increased expression of ST8SIA3 mRNA] CTD PMID:17069899 NCBI chr18:60,024,555...60,031,050
Ensembl chr18:60,024,236...60,032,473 		JBrowse link
G Star steroidogenic acute regulatory protein multiple interactions EXP
ISO 		pyrazolanthrone inhibits the reaction [nickel sulfate results in decreased expression of STAR mRNA]; pyrazolanthrone inhibits the reaction [nickel sulfate results in decreased expression of STAR protein]
pyrazolanthrone inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of STAR protein] 		CTD PMID:29567110 PMID:32199951 NCBI chr16:72,969,824...72,974,447
Ensembl chr16:72,961,518...72,974,447 		JBrowse link
G Stat1 signal transducer and activator of transcription 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [[Diclofenac co-treated with IFNG protein] results in increased phosphorylation of STAT1 protein]; pyrazolanthrone inhibits the reaction [Aluminum Chloride results in increased activity of STAT1 protein]; pyrazolanthrone inhibits the reaction [Aluminum Chloride results in increased phosphorylation of STAT1 protein] CTD PMID:26609140 PMID:36154299 NCBI chr 9:56,911,522...56,951,926
Ensembl chr 9:56,911,523...57,077,346 		JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions
increases phosphorylation 		ISO
EXP 		pyrazolanthrone inhibits the reaction [1,2,5,8-tetrahydroxy anthraquinone results in decreased phosphorylation of STAT3 protein]; pyrazolanthrone inhibits the reaction [1,4-naphthoquinone analog results in decreased phosphorylation of STAT3 protein]; pyrazolanthrone inhibits the reaction [arsenic trichloride results in increased phosphorylation of STAT3 protein]; pyrazolanthrone inhibits the reaction [bisphenol A results in increased phosphorylation of STAT3 protein]; pyrazolanthrone inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of STAT3 protein]
pyrazolanthrone results in increased phosphorylation of STAT3 protein
pyrazolanthrone inhibits the reaction [arsenic trioxide results in increased phosphorylation of and affects the localization of STAT3 protein] 		CTD PMID:19429262 PMID:22696236 PMID:24349194 PMID:27174766 PMID:30871965 More... NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359 		JBrowse link
G Stc2 stanniocalcin 2 multiple interactions ISO pyrazolanthrone promotes the reaction [Cadmium results in decreased expression of STC2 protein] CTD PMID:33396178 NCBI chr10:16,755,508...16,765,275
Ensembl chr10:16,755,267...16,767,447 		JBrowse link
G Sult1a1 sulfotransferase family 1A member 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [Gallic Acid results in increased expression of SULT1A1 protein] CTD PMID:16308312 NCBI chr 1:190,702,592...190,706,112
Ensembl chr 1:190,702,592...190,706,131 		JBrowse link
G Syt11 synaptotagmin 11 multiple interactions ISO pyrazolanthrone inhibits the reaction [Ozone results in increased expression of SYT11 mRNA] CTD PMID:17460151 NCBI chr 2:176,503,845...176,530,354
Ensembl chr 2:176,503,845...176,529,775 		JBrowse link
G Tac1 tachykinin, precursor 1 multiple interactions EXP pyrazolanthrone promotes the reaction [GR 73632 promotes the reaction [Capsaicin results in increased secretion of TAC1 protein]] CTD PMID:18809416 NCBI chr 4:36,645,344...36,653,548
Ensembl chr 4:36,645,571...36,653,546 		JBrowse link
G Taldo1 transaldolase 1 multiple interactions ISO pyrazolanthrone affects the reaction [TALDO1 gene mutant form promotes the reaction [Acetaminophen results in increased activity of and results in increased phosphorylation of MAPK8 protein]] CTD PMID:19436114 NCBI chr 1:205,923,196...205,933,526
Ensembl chr 1:205,923,165...205,933,535 		JBrowse link
G Tardbp TAR DNA binding protein multiple interactions ISO pyrazolanthrone promotes the reaction [Paraquat results in increased expression of TARDBP protein modified form] CTD PMID:22879928 NCBI chr 5:164,330,452...164,348,435
Ensembl chr 5:164,334,924...164,345,204 		JBrowse link
G Tat tyrosine aminotransferase multiple interactions ISO pyrazolanthrone inhibits the reaction [Colchicine results in decreased expression of TAT mRNA] CTD PMID:15744361 NCBI chr19:54,856,604...54,867,168
Ensembl chr19:54,856,563...54,867,482 		JBrowse link
G Tert telomerase reverse transcriptase multiple interactions ISO [pyrazolanthrone co-treated with SB 203580 co-treated with U 0126] inhibits the reaction [Isothiocyanates results in increased expression of TERT mRNA] CTD PMID:23382840 NCBI chr 1:31,465,766...31,488,650
Ensembl chr 1:31,466,056...31,488,111 		JBrowse link
G Tgfa transforming growth factor alpha multiple interactions ISO pyrazolanthrone inhibits the reaction [arsenite results in increased expression of and results in increased secretion of TGFA protein] CTD PMID:36343453 NCBI chr 4:120,175,549...120,258,342
Ensembl chr 4:120,175,593...120,258,339 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO
EXP 		pyrazolanthrone inhibits the reaction [Asbestos, Serpentine results in increased secretion of TGFB1 protein]; pyrazolanthrone inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Cisplatin]]; pyrazolanthrone inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of TGFB1 mRNA]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased secretion of TGFB1 protein]
pyrazolanthrone inhibits the reaction [Patulin results in increased expression of TGFB1 protein]
6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride affects the reaction [pyrazolanthrone affects the reaction [[TGFB1 protein co-treated with TNF protein] affects the expression of PPARGC1A protein]]; pyrazolanthrone affects the reaction [6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride affects the reaction [[TGFB1 protein co-treated with TNF protein] affects the expression of PPARGC1A protein]]; pyrazolanthrone affects the reaction [[TGFB1 protein co-treated with TNF protein] affects the expression of PPARGC1A protein] 		CTD PMID:16365456 PMID:21613822 PMID:25358858 PMID:31447676 PMID:34896196 NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899 		JBrowse link
G Thpo thrombopoietin multiple interactions ISO pyrazolanthrone promotes the reaction [THPO protein results in increased expression of GP1BA protein]; pyrazolanthrone promotes the reaction [THPO protein results in increased expression of ITGA2B protein]; pyrazolanthrone promotes the reaction [THPO protein results in increased expression of ITGB3 protein] CTD PMID:20523355 Ensembl chr11:93,686,834...93,693,320 JBrowse link
G Thra thyroid hormone receptor alpha increases expression
multiple interactions 		ISO pyrazolanthrone results in increased expression of THRA mRNA alternative form
[Sulfasalazine co-treated with pyrazolanthrone] results in decreased expression of THRA mRNA; IL1B protein inhibits the reaction [[Sulfasalazine co-treated with pyrazolanthrone] results in decreased expression of THRA mRNA]; IL1B protein inhibits the reaction [pyrazolanthrone results in increased expression of THRA mRNA alternative form] 		CTD PMID:17641275 NCBI chr10:84,198,141...84,225,659
Ensembl chr10:84,197,011...84,225,657 		JBrowse link
G Timp1 TIMP metallopeptidase inhibitor 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [thymoquinone results in increased expression of TIMP1 protein] CTD PMID:27060453 NCBI chr  X:3,766,509...3,772,578
Ensembl chr  X:3,766,510...3,771,135 		JBrowse link
G Timp2 TIMP metallopeptidase inhibitor 2 multiple interactions ISO pyrazolanthrone inhibits the reaction [thymoquinone results in increased expression of TIMP2 protein] CTD PMID:27060453 NCBI chr10:104,041,604...104,089,214
Ensembl chr10:104,041,604...104,089,214 		JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO
EXP 		pyrazolanthrone affects the reaction [TNF protein results in increased expression of MMP9 protein]; pyrazolanthrone inhibits the reaction [[cholix toxin, Vibrio cholerae co-treated with TNF protein] results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [[ochratoxin A co-treated with Citrinin] results in increased expression of TNF mRNA]; pyrazolanthrone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of TNF mRNA]; pyrazolanthrone inhibits the reaction [Benzo(a)pyrene results in increased secretion of TNF protein]; pyrazolanthrone inhibits the reaction [beta Carotene promotes the reaction [Benzo(a)pyrene results in increased secretion of TNF protein]]; pyrazolanthrone inhibits the reaction [lead acetate results in increased expression of TNF mRNA]; pyrazolanthrone inhibits the reaction [Paraquat results in increased expression of and results in increased secretion of TNF protein]; pyrazolanthrone inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; pyrazolanthrone inhibits the reaction [polyhexamethyleneguanidine results in increased expression of TNF mRNA]; pyrazolanthrone inhibits the reaction [TNF protein results in decreased expression of HNF4A mRNA]; pyrazolanthrone inhibits the reaction [TNF protein results in decreased expression of PPARA mRNA]; pyrazolanthrone inhibits the reaction [TNF protein results in increased activity of PLAU protein]; pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of and results in increased activity of MMP9 protein]; pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of CXCL8 protein]; pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of CYP4F11 mRNA]; pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of F3 mRNA]; pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of JUN mRNA]; pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of PLAU protein]; pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; pyrazolanthrone inhibits the reaction [TNF protein results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [TNF protein results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [TNF protein results in increased phosphorylation of MAPK9 protein]
pyrazolanthrone inhibits the reaction [2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [ACE2 protein inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]]; pyrazolanthrone inhibits the reaction [7-Ala-angiotensin (1-7) inhibits the reaction [ACE2 protein inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]]; pyrazolanthrone inhibits the reaction [Acetaminophen results in increased expression of TNF protein]; pyrazolanthrone inhibits the reaction [Acrylamide results in increased expression of TNF mRNA]; pyrazolanthrone inhibits the reaction [lead acetate results in increased expression of TNF protein]; pyrazolanthrone inhibits the reaction [Manganese promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TNF protein]]; pyrazolanthrone inhibits the reaction [Palmitic Acid results in increased expression of TNF mRNA]; pyrazolanthrone inhibits the reaction [Paraquat results in increased expression of and results in increased secretion of TNF protein]; pyrazolanthrone inhibits the reaction [Paraquat results in increased expression of TNF mRNA]; pyrazolanthrone inhibits the reaction [Particulate Matter results in increased expression of TNF mRNA]; pyrazolanthrone inhibits the reaction [TNF protein affects the localization of RELA protein]; pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of MMP9 protein]; pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]; pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of OPTN protein]
6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride affects the reaction [pyrazolanthrone affects the reaction [[TGFB1 protein co-treated with TNF protein] affects the expression of PPARGC1A protein]]; pyrazolanthrone affects the reaction [6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride affects the reaction [[TGFB1 protein co-treated with TNF protein] affects the expression of PPARGC1A protein]]; pyrazolanthrone affects the reaction [[TGFB1 protein co-treated with TNF protein] affects the expression of PPARGC1A protein]; pyrazolanthrone inhibits the reaction [[Cisplatin co-treated with TNF protein] results in increased expression of XAF1 mRNA]; pyrazolanthrone inhibits the reaction [[Polysaccharides co-treated with IFNG protein] results in increased expression of TNF protein]; pyrazolanthrone inhibits the reaction [Acetaminophen results in increased expression of TNF protein]; pyrazolanthrone inhibits the reaction [bisphenol A results in increased expression of TNF mRNA]; pyrazolanthrone inhibits the reaction [bisphenol A results in increased secretion of TNF protein]; pyrazolanthrone inhibits the reaction [Cisplatin inhibits the reaction [TNF protein affects the localization of RELA protein]]; pyrazolanthrone inhibits the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; pyrazolanthrone inhibits the reaction [nivalenol results in increased secretion of TNF protein]; pyrazolanthrone inhibits the reaction [Ozone results in increased expression of TNF mRNA]; pyrazolanthrone inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of TNF mRNA]; pyrazolanthrone inhibits the reaction [perfluorooctane sulfonic acid results in increased secretion of TNF protein]; pyrazolanthrone inhibits the reaction [T-2 Toxin results in increased expression of TNFA mRNA]; pyrazolanthrone inhibits the reaction [TNF protein promotes the reaction [diethyl maleate results in increased phosphorylation of JUN protein]]; pyrazolanthrone inhibits the reaction [TNF protein results in decreased expression of ADIPOQ mRNA]; pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; pyrazolanthrone inhibits the reaction [TNF protein results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [TNF protein results in increased susceptibility to Acetaminophen]; pyrazolanthrone inhibits the reaction [TNF protein results in increased susceptibility to Chlorpromazine]; pyrazolanthrone inhibits the reaction [trovafloxacin promotes the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; pyrazolanthrone inhibits the reaction [trovafloxacin results in increased expression of TNF mRNA]; pyrazolanthrone promotes the reaction [[Cisplatin co-treated with TNF protein] results in increased phosphorylation of JUN protein] 		CTD PMID:12774022 PMID:14644621 PMID:15302094 PMID:15322261 PMID:16271621 More... NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303 		JBrowse link
G Tnfrsf11b TNF receptor superfamily member 11B multiple interactions ISO pyrazolanthrone inhibits the reaction [Alprostadil results in increased secretion of TNFRSF11B protein]; pyrazolanthrone inhibits the reaction [Dinoprost results in increased expression of and results in increased secretion of TNFRSF11B protein]; pyrazolanthrone inhibits the reaction [Dinoprostone results in increased secretion of TNFRSF11B protein]; pyrazolanthrone inhibits the reaction [FGF2 protein results in increased secretion of TNFRSF11B protein]; pyrazolanthrone inhibits the reaction [Prostaglandin D2 results in increased secretion of TNFRSF11B protein] CTD PMID:24333336 PMID:24813642 PMID:25234201 PMID:25290095 PMID:25677506 NCBI chr 7:87,456,318...87,484,324
Ensembl chr 7:87,456,319...87,485,075 		JBrowse link
G Tnfsf10 TNF superfamily member 10 multiple interactions ISO pyrazolanthrone inhibits the reaction [sodium arsenite results in increased expression of TNFSF10 mRNA]; pyrazolanthrone results in increased susceptibility to [[TNFSF10 protein co-treated with kahweol acetate] results in increased cleavage of PARP1 protein] CTD PMID:17545621 PMID:20403343 NCBI chr 2:112,136,550...112,155,903 JBrowse link
G Tnfsf11 TNF superfamily member 11 multiple interactions ISO [crocin co-treated with pyrazolanthrone co-treated with TNFSF11 protein] results in decreased expression of OSTM1 mRNA; [TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of AKT2 mRNA; [TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of MAPK3 mRNA; [TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of OSTM1 mRNA; [TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of TRAF6 mRNA; crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of AKT2 mRNA]; crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of MAPK3 mRNA]; crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of OSTM1 mRNA]; crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of TRAF6 mRNA]; crocin promotes the reaction [pyrazolanthrone inhibits the reaction [TNFSF11 protein results in increased activity of ACP5 protein]]; pyrazolanthrone inhibits the reaction [TNFSF11 protein results in increased activity of ACP5 protein] CTD PMID:30580027 NCBI chr15:60,083,008...60,114,479
Ensembl chr15:60,083,008...60,114,479 		JBrowse link
G Tnni2 troponin I2, fast skeletal type multiple interactions ISO pyrazolanthrone promotes the reaction [Ozone results in increased expression of TNNI2 mRNA] CTD PMID:17460151 NCBI chr 1:206,882,358...207,027,034
Ensembl chr 1:207,024,416...207,027,038 		JBrowse link
G Top1 DNA topoisomerase I multiple interactions ISO [pyrazolanthrone results in decreased phosphorylation of JUN protein] inhibits the reaction [JUN protein binds to TOP1 protein] CTD PMID:15923621 NCBI chr 3:169,713,195...169,796,330
Ensembl chr 3:169,713,130...169,796,327 		JBrowse link
G Tp53 tumor protein p53 multiple interactions
increases phosphorylation
increases expression
decreases expression 		ISO
EXP 		[sodium arsenite co-treated with pyrazolanthrone] promotes the reaction [HSPA9 protein binds to TP53 protein modified form]; MYC affects the reaction [pyrazolanthrone results in increased expression of TP53 protein]; pyrazolanthrone inhibits the reaction [2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone analog results in increased expression of TP53 protein modified form]; pyrazolanthrone inhibits the reaction [2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone analog results in increased expression of TP53 protein]; pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased expression of TP53 protein]; pyrazolanthrone inhibits the reaction [Capsaicin results in increased expression of and results in increased phosphorylation of and results in increased activity of TP53 protein]; pyrazolanthrone inhibits the reaction [Cisplatin results in increased stability of TP53 protein]; pyrazolanthrone inhibits the reaction [Fingolimod Hydrochloride results in increased phosphorylation of TP53 protein]; pyrazolanthrone inhibits the reaction [Pyrogallol results in increased expression of TP53 protein]; pyrazolanthrone inhibits the reaction [sodium arsenite results in increased phosphorylation of TP53 protein]; pyrazolanthrone inhibits the reaction [tributyltin results in increased expression of TP53 protein]
pyrazolanthrone inhibits the reaction [Colistin results in increased expression of TP53 protein]
pyrazolanthrone results in increased phosphorylation of TP53 protein
pyrazolanthrone promotes the reaction [TRP53 gene mutant form results in decreased susceptibility to sodium arsenite]
pyrazolanthrone results in increased expression of TP53 protein; pyrazolanthrone results in increased expression of TP53 protein modified form
pyrazolanthrone results in decreased expression of TP53 protein 		CTD PMID:15034932 PMID:16046226 PMID:16061660 PMID:16166651 PMID:16450001 More... NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299 		JBrowse link
G Traf6 TNF receptor associated factor 6 multiple interactions ISO [TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of TRAF6 mRNA; crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of TRAF6 mRNA] CTD PMID:30580027 NCBI chr 3:108,418,537...108,443,330
Ensembl chr 3:108,418,513...108,443,328 		JBrowse link
G Trhr thyrotropin releasing hormone receptor multiple interactions ISO pyrazolanthrone inhibits the reaction [2,4,5,2',4',5'-hexachlorobiphenyl results in decreased expression of TRHR protein] CTD PMID:22889935 NCBI chr 7:77,233,175...77,277,988
Ensembl chr 7:77,233,354...77,277,987 		JBrowse link
G Twist1 twist family bHLH transcription factor 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [thymoquinone results in decreased expression of TWIST1 protein] CTD PMID:27060453 NCBI chr 6:56,402,309...56,404,303
Ensembl chr 6:56,398,061...56,404,965 		JBrowse link
G Uba7 ubiquitin-like modifier activating enzyme 7 decreases expression ISO pyrazolanthrone results in decreased expression of UBA7 protein CTD PMID:25649257 NCBI chr 8:117,543,902...117,552,709
Ensembl chr 8:117,543,957...117,556,142 		JBrowse link
G Ugt1a1 UDP glucuronosyltransferase family 1 member A1 multiple interactions ISO pyrazolanthrone inhibits the reaction [chrysin results in increased expression of UGT1A1 mRNA] CTD PMID:17256720 NCBI chr 9:96,249,143...96,256,264
Ensembl chr 9:96,144,786...96,256,264 		JBrowse link
G Vcam1 vascular cell adhesion molecule 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]
pyrazolanthrone inhibits the reaction [Cadmium results in increased expression of VCAM1 mRNA]; pyrazolanthrone inhibits the reaction [Cadmium results in increased expression of VCAM1 protein]; pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] 		CTD PMID:16271621 PMID:19609071 PMID:28483571 NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:206,723,044...206,742,801 		JBrowse link
G Vdr vitamin D receptor multiple interactions ISO pyrazolanthrone inhibits the reaction [Estradiol results in increased expression of VDR protein] CTD PMID:15930183 NCBI chr 7:130,864,764...130,916,757
Ensembl chr 7:130,866,745...130,916,757 		JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions ISO pyrazolanthrone inhibits the reaction [andrographolide results in decreased expression of VEGFA mRNA]; pyrazolanthrone inhibits the reaction [andrographolide results in decreased expression of VEGFA protein]; pyrazolanthrone inhibits the reaction [hydroxyethyl methacrylate results in decreased secretion of VEGFA protein]; pyrazolanthrone inhibits the reaction [sodium arsenite results in increased expression of VEGFA protein]; pyrazolanthrone inhibits the reaction [VEGFA protein results in increased expression of PTGS2 mRNA]; pyrazolanthrone inhibits the reaction [VEGFA protein results in increased expression of PTGS2 protein] CTD PMID:18596194 PMID:19176594 PMID:23968725 PMID:28651835 NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194 		JBrowse link
G Vim vimentin multiple interactions ISO pyrazolanthrone inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM mRNA]; pyrazolanthrone inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM protein]; pyrazolanthrone inhibits the reaction [thymoquinone results in decreased expression of VIM protein] CTD PMID:27060453 PMID:33396024 NCBI chr17:81,577,261...81,585,746
Ensembl chr17:81,568,272...81,585,746 		JBrowse link
G Xaf1 XIAP associated factor 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [[Cisplatin co-treated with TNF protein] results in increased expression of XAF1 mRNA] CTD PMID:23103562 NCBI chr10:57,415,935...57,428,348
Ensembl chr10:57,415,658...57,428,349 		JBrowse link
G Xiap X-linked inhibitor of apoptosis multiple interactions ISO pyrazolanthrone inhibits the reaction [trimethyltin chloride results in decreased expression of XIAP protein] CTD PMID:23423712 NCBI chr  X:125,756,107...125,803,979
Ensembl chr  X:125,737,971...125,803,978 		JBrowse link
G Xpo1 exportin 1 multiple interactions ISO pyrazolanthrone inhibits the reaction [Cadmium results in increased expression of XPO1 protein] CTD PMID:33396178 NCBI chr14:101,434,450...101,476,705
Ensembl chr14:101,434,517...101,476,714 		JBrowse link
G Ywhaz tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta multiple interactions ISO pyrazolanthrone inhibits the reaction [Methylmercury Compounds inhibits the reaction [BAX protein binds to YWHAZ protein]] CTD PMID:34999165 NCBI chr 7:69,826,404...69,848,702
Ensembl chr 7:69,826,404...69,849,007 		JBrowse link
G Yy1 YY1 transcription factor multiple interactions EXP [pyrazolanthrone co-treated with cypermethrin] results in decreased expression of YY1 protein CTD PMID:34794910 NCBI chr 6:133,471,615...133,500,875
Ensembl chr 6:133,471,562...133,497,257 		JBrowse link
G Zc3h12a zinc finger CCCH type containing 12A multiple interactions EXP pyrazolanthrone inhibits the reaction [Silicon Dioxide results in increased expression of ZC3H12A protein] CTD PMID:26865670 NCBI chr 5:142,661,193...142,670,051
Ensembl chr 5:142,661,199...142,669,985 		JBrowse link
auraptene term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb1a ATP binding cassette subfamily B member 1A multiple interactions ISO aurapten promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]; aurapten promotes the reaction [ABCB1 protein results in increased import of Daunorubicin] CTD PMID:18955043 NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135 		JBrowse link
G Ccna2 cyclin A2 affects expression ISO aurapten affects the expression of CCNA2 mRNA CTD PMID:23320178 NCBI chr 2:121,355,363...121,361,762
Ensembl chr 2:121,355,363...121,361,701 		JBrowse link
G Ccnb2 cyclin B2 affects expression ISO aurapten affects the expression of CCNB2 mRNA CTD PMID:23320178 NCBI chr 8:79,968,459...79,981,717
Ensembl chr 8:79,968,465...79,981,682 		JBrowse link
G Cdc45 cell division cycle 45 affects expression ISO aurapten affects the expression of CDC45 mRNA CTD PMID:23320178 NCBI chr11:95,689,702...95,714,980
Ensembl chr11:95,689,919...95,714,981 		JBrowse link
G Cdk1 cyclin-dependent kinase 1 affects expression ISO aurapten affects the expression of CDK1 mRNA CTD PMID:23320178 NCBI chr20:19,265,252...19,280,456
Ensembl chr20:19,265,289...19,280,455 		JBrowse link
G Cdkn2b cyclin-dependent kinase inhibitor 2B affects expression ISO aurapten affects the expression of CDKN2B mRNA CTD PMID:23320178 NCBI chr 5:109,123,308...109,134,906
Ensembl chr 5:109,114,322...109,134,855 		JBrowse link
G Cdkn2c cyclin-dependent kinase inhibitor 2C affects expression ISO aurapten affects the expression of CDKN2C mRNA CTD PMID:23320178 NCBI chr 5:129,639,736...129,645,564
Ensembl chr 5:129,639,736...129,644,891 		JBrowse link
G Chek1 checkpoint kinase 1 affects expression ISO aurapten affects the expression of CHEK1 mRNA CTD PMID:23320178 NCBI chr 8:44,609,417...44,629,867
Ensembl chr 8:44,609,417...44,629,359 		JBrowse link
G Chek2 checkpoint kinase 2 affects expression ISO aurapten affects the expression of CHEK2 mRNA CTD PMID:23320178 NCBI chr12:51,448,838...51,481,159
Ensembl chr12:51,449,140...51,480,667 		JBrowse link
G Ctnnb1 catenin beta 1 decreases expression EXP aurapten results in decreased expression of CTNNB1 protein mutant form CTD PMID:16012713 NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:129,517,545...129,544,662 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions ISO aurapten inhibits the reaction [DDT results in increased expression of CYP1A1 mRNA]; aurapten inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] CTD PMID:20865247 NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 affects expression ISO aurapten affects the expression of DDIT3 mRNA CTD PMID:23320178 NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509 		JBrowse link
G Dusp1 dual specificity phosphatase 1 affects expression ISO aurapten affects the expression of DUSP1 mRNA CTD PMID:23320178 NCBI chr10:17,184,853...17,187,646
Ensembl chr10:17,184,823...17,187,644 		JBrowse link
G E2f1 E2F transcription factor 1 affects expression ISO aurapten affects the expression of E2F1 mRNA CTD PMID:23320178 NCBI chr 3:163,524,739...163,535,563
Ensembl chr 3:163,524,739...163,535,563 		JBrowse link
G E2f2 E2F transcription factor 2 affects expression ISO aurapten affects the expression of E2F2 mRNA CTD PMID:23320178 NCBI chr 5:153,682,789...153,706,087
Ensembl chr 5:153,682,789...153,706,087 		JBrowse link
G Gadd45a growth arrest and DNA-damage-inducible, alpha affects expression ISO aurapten affects the expression of GADD45A mRNA CTD PMID:23320178 NCBI chr 4:97,484,497...97,486,799
Ensembl chr 4:97,484,502...97,486,807 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit affects expression ISO aurapten affects the expression of JUN mRNA CTD PMID:23320178 NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285 		JBrowse link
G Kif20b kinesin family member 20B affects expression ISO aurapten affects the expression of KIF20B mRNA CTD PMID:23320178 NCBI chr 1:241,840,898...241,896,451
Ensembl chr 1:241,840,987...241,896,451 		JBrowse link
G Mcm3 minichromosome maintenance complex component 3 affects expression ISO aurapten affects the expression of MCM3 mRNA CTD PMID:23320178 NCBI chr 9:30,715,602...30,733,746
Ensembl chr 9:30,715,602...30,733,746 		JBrowse link
G Mcm6 minichromosome maintenance complex component 6 affects expression ISO aurapten affects the expression of MCM6 mRNA CTD PMID:23320178 NCBI chr13:42,379,161...42,404,352
Ensembl chr13:42,379,162...42,465,467 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 affects response to substance ISO NFE2L2 protein affects the susceptibility to aurapten CTD PMID:19150646 NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO aurapten inhibits the reaction [DDT results in increased expression of PTGS2 mRNA]; aurapten inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA] CTD PMID:20865247 NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320 		JBrowse link
G Uhrf1 ubiquitin-like with PHD and ring finger domains 1 affects expression ISO aurapten affects the expression of UHRF1 mRNA CTD PMID:23320178 NCBI chr 9:1,220,162...1,241,792
Ensembl chr 9:1,222,063...1,241,792 		JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions ISO aurapten inhibits the reaction [DDT results in increased expression of VEGFA mRNA]; aurapten inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of VEGFA mRNA] CTD PMID:20865247 NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194 		JBrowse link
binimetinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 multiple interactions ISO [NADP co-treated with binimetinib] results in decreased activity of CYP1A2 protein CTD PMID:33728909 NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149 		JBrowse link
cobimetinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bcl2l11 Bcl2-like 11 increases expression
multiple interactions 		ISO cobimetinib results in increased expression of BCL2L11 protein; cobimetinib results in increased expression of BCL2L11 protein alternative form
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [cobimetinib results in increased expression of BCL2L11 protein alternative form]; 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [cobimetinib results in increased expression of BCL2L11 protein]; [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine co-treated with cobimetinib] results in decreased phosphorylation of BCL2L11 protein alternative form; cobimetinib promotes the reaction [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine results in increased expression of BCL2L11 protein alternative form] 		CTD PMID:22084396 NCBI chr 3:135,820,042...135,857,330
Ensembl chr 3:135,817,562...135,960,695 		JBrowse link
G Braf B-Raf proto-oncogene, serine/threonine kinase multiple interactions
increases response to substance 		ISO 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [BRAF protein mutant form results in increased susceptibility to cobimetinib] CTD PMID:22084396 NCBI chr 4:69,329,772...69,476,931
Ensembl chr 4:69,342,813...69,476,931 		JBrowse link
G Ccnd1 cyclin D1 decreases expression
multiple interactions 		ISO cobimetinib results in decreased expression of CCND1 protein
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [cobimetinib results in decreased expression of CCND1 protein] 		CTD PMID:22084396 NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810 		JBrowse link
G Gpt glutamic--pyruvic transaminase increases secretion EXP cobimetinib results in increased secretion of GPT protein CTD PMID:29655783 NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160 		JBrowse link
G Kras KRAS proto-oncogene, GTPase increases response to substance
multiple interactions 		ISO KRAS protein mutant form results in increased susceptibility to cobimetinib
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [KRAS protein mutant form results in increased susceptibility to cobimetinib]; cobimetinib promotes the reaction [KRAS protein mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] 		CTD PMID:22084396 NCBI chr 4:179,916,255...179,949,613
Ensembl chr 4:179,919,802...179,949,320 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 decreases phosphorylation ISO cobimetinib results in decreased phosphorylation of MAPK1 protein CTD PMID:22084396 NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 decreases phosphorylation ISO cobimetinib results in decreased phosphorylation of MAPK3 protein CTD PMID:22084396 NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411 		JBrowse link
G Nras NRAS proto-oncogene, GTPase increases response to substance ISO NRAS protein mutant form results in increased susceptibility to cobimetinib CTD PMID:22084396 NCBI chr 2:193,271,399...193,282,023
Ensembl chr 2:193,271,430...193,278,543 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases cleavage 		ISO 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [cobimetinib results in increased cleavage of PARP1 protein]; cobimetinib promotes the reaction [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine results in increased cleavage of PARP1 protein] CTD PMID:22084396 NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567 		JBrowse link
G Rps6 ribosomal protein S6 multiple interactions ISO cobimetinib promotes the reaction [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine results in decreased phosphorylation of RPS6 protein] CTD PMID:22084396 NCBI chr 5:106,417,680...106,420,540
Ensembl chr 5:106,417,680...106,420,566 		JBrowse link
doramapimod term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcc2 ATP binding cassette subfamily C member 2 increases expression ISO doramapimod results in increased expression of ABCC2 mRNA CTD PMID:21328587 NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471 		JBrowse link
G Actg2 actin gamma 2, smooth muscle increases expression EXP doramapimod results in increased expression of ACTG2 mRNA CTD PMID:24303162 NCBI chr 4:117,579,513...117,604,379
Ensembl chr 4:117,579,514...117,604,295 		JBrowse link
G Adh7 alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide increases expression EXP doramapimod results in increased expression of ADH7 mRNA CTD PMID:24303162 NCBI chr 2:229,422,125...229,436,584
Ensembl chr 2:229,421,252...229,436,691 		JBrowse link
G Ahsg alpha-2-HS-glycoprotein decreases expression ISO doramapimod results in decreased expression of AHSG mRNA CTD PMID:21328587 NCBI chr11:91,625,975...91,632,583
Ensembl chr11:91,625,975...91,634,039 		JBrowse link
G Ak5 adenylate kinase 5 increases expression EXP doramapimod results in increased expression of AK5 mRNA CTD PMID:24303162 NCBI chr 2:244,057,240...244,241,372
Ensembl chr 2:244,057,240...244,241,366 		JBrowse link
G Akr1b7 aldo-keto reductase family 1, member B7 increases expression ISO doramapimod results in increased expression of AKR1B7 mRNA CTD PMID:21328587 NCBI chr 4:64,043,901...64,083,751
Ensembl chr 4:64,020,686...64,064,909 		JBrowse link
G Apoa4 apolipoprotein A4 decreases expression ISO doramapimod results in decreased expression of APOA4 mRNA CTD PMID:21328587 NCBI chr 8:55,435,779...55,438,160
Ensembl chr 8:55,434,168...55,438,164 		JBrowse link
G C1qa complement C1q A chain decreases expression ISO doramapimod results in decreased expression of C1QA mRNA CTD PMID:21328587 NCBI chr 5:154,417,086...154,419,933
Ensembl chr 5:154,417,087...154,427,732 		JBrowse link
G C1qb complement C1q B chain decreases expression ISO doramapimod results in decreased expression of C1QB mRNA CTD PMID:21328587 NCBI chr 5:154,402,276...154,407,827
Ensembl chr 5:154,402,279...154,407,840 		JBrowse link
G Ca3 carbonic anhydrase 3 decreases expression ISO doramapimod results in decreased expression of CAR3 mRNA CTD PMID:21328587 NCBI chr 2:88,491,666...88,501,299
Ensembl chr 2:88,491,670...88,500,524 		JBrowse link
G Casp3 caspase 3 multiple interactions ISO doramapimod promotes the reaction [TNF protein results in increased activity of CASP3 protein] CTD PMID:28629242 NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732 		JBrowse link
G Cd5l Cd5 molecule-like decreases expression ISO doramapimod results in decreased expression of CD5L mRNA CTD PMID:21328587 NCBI chr 2:175,088,915...175,099,928
Ensembl chr 2:175,088,884...175,099,926 		JBrowse link
G Cd74 CD74 molecule decreases expression ISO doramapimod results in decreased expression of CD74 mRNA CTD PMID:21328587 NCBI chr18:56,527,071...56,536,406
Ensembl chr18:56,527,132...56,536,410 		JBrowse link
G Ceacam1 CEA cell adhesion molecule 1 decreases expression EXP doramapimod results in decreased expression of CEACAM1 mRNA CTD PMID:24303162 NCBI chr 1:90,171,401...90,187,810
Ensembl chr 1:90,171,401...90,187,798 		JBrowse link
G Ces3a carboxylesterase 3a increases expression ISO doramapimod results in increased expression of CES3 mRNA CTD PMID:21328587 NCBI chr19:49,902,312...49,910,484 JBrowse link
G Clec1b C-type lectin domain family 1, member B decreases expression ISO doramapimod results in decreased expression of CLEC1B mRNA CTD PMID:21328587 NCBI chr 4:164,533,987...164,542,320
Ensembl chr 4:164,534,055...164,542,867 		JBrowse link
G Ctss cathepsin S decreases expression ISO doramapimod results in decreased expression of CTSS mRNA CTD PMID:21328587 NCBI chr 2:185,775,316...185,803,440
Ensembl chr 2:185,775,296...185,803,440 		JBrowse link
G Cxcl1 C-X-C motif chemokine ligand 1 multiple interactions ISO doramapimod inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL1 protein] CTD PMID:14997032 NCBI chr14:17,477,542...17,479,321
Ensembl chr14:17,477,549...17,479,811 		JBrowse link
G Cxcl10 C-X-C motif chemokine ligand 10 decreases secretion ISO doramapimod results in decreased secretion of CXCL10 protein CTD PMID:17996064 NCBI chr14:15,989,066...15,991,263
Ensembl chr14:15,989,018...15,991,261 		JBrowse link
G Cxcl3 C-X-C motif chemokine ligand 3 multiple interactions ISO doramapimod inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL1 protein] CTD PMID:14997032 NCBI chr14:17,571,900...17,573,624
Ensembl chr14:17,571,900...17,573,624 		JBrowse link
G Cxcr1 C-X-C motif chemokine receptor 1 multiple interactions ISO doramapimod inhibits the reaction [Lipopolysaccharides results in decreased expression of CXCR1 protein] CTD PMID:14997032 NCBI chr 9:83,216,040...83,220,225
Ensembl chr 9:83,215,292...83,226,872 		JBrowse link
G Cxcr2 C-X-C motif chemokine receptor 2 multiple interactions ISO doramapimod inhibits the reaction [Lipopolysaccharides results in decreased expression of CXCR2 protein] CTD PMID:14997032 NCBI chr 9:83,178,645...83,185,017
Ensembl chr 9:83,183,808...83,188,602 		JBrowse link
G Cyp2a3 cytochrome P450, family 2, subfamily a, polypeptide 3 increases expression ISO doramapimod results in increased expression of CYP2A4 mRNA CTD PMID:21328587 NCBI chr 1:91,299,584...91,307,650
Ensembl chr 1:91,299,561...91,307,649 		JBrowse link
G Cyss cystatin S decreases expression EXP doramapimod results in decreased expression of CYSS mRNA CTD PMID:24303162 NCBI chr 3:157,892,660...157,897,265
Ensembl chr 3:157,892,660...157,897,265 		JBrowse link
G Egr1 early growth response 1 increases expression ISO doramapimod results in increased expression of EGR1 mRNA CTD PMID:21328587 NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,736,838...26,740,843 		JBrowse link
G Fcgr2b Fc gamma receptor 2B decreases expression ISO doramapimod results in decreased expression of FCGR2B mRNA CTD PMID:21328587 NCBI chr13:85,725,897...85,740,517
Ensembl chr13:85,725,897...85,740,517 		JBrowse link
G Fgf8 fibroblast growth factor 8 decreases expression EXP doramapimod results in decreased expression of FGF8 mRNA CTD PMID:24303162 NCBI chr 1:254,533,504...254,539,605
Ensembl chr 1:254,533,504...254,539,605 		JBrowse link
G G6pc1 glucose-6-phosphatase catalytic subunit 1 decreases expression ISO doramapimod results in decreased expression of G6PC1 mRNA CTD PMID:21328587 NCBI chr10:86,807,659...86,819,023
Ensembl chr10:86,757,899...86,818,033 		JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit increases expression ISO doramapimod results in increased expression of GCLC mRNA CTD PMID:21328587 NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893 		JBrowse link
G Gpx2 glutathione peroxidase 2 increases expression ISO doramapimod results in increased expression of GPX2 mRNA CTD PMID:21328587 NCBI chr 6:101,226,745...101,230,033
Ensembl chr 6:101,226,745...101,230,862 		JBrowse link
G Grm8 glutamate metabotropic receptor 8 increases expression EXP doramapimod results in increased expression of GRM8 mRNA CTD PMID:24303162 NCBI chr 4:56,771,247...57,696,951
Ensembl chr 4:56,770,771...57,687,639 		JBrowse link
G Gsta2 glutathione S-transferase alpha 2 increases expression ISO doramapimod results in increased expression of GSTA1 mRNA CTD PMID:21328587 NCBI chr 8:88,064,829...88,077,168
Ensembl chr 8:88,064,616...88,077,092 		JBrowse link
G Gstm2 glutathione S-transferase mu 2 increases expression ISO doramapimod results in increased expression of GSTM2 mRNA CTD PMID:21328587 NCBI chr 2:198,312,179...198,316,962 JBrowse link
G Gstm5 glutathione S-transferase, mu 5 increases expression ISO doramapimod results in increased expression of GSTM3 mRNA CTD PMID:21328587 NCBI chr 2:198,219,769...198,222,732
Ensembl chr 2:198,219,647...198,222,731 		JBrowse link
G Hp haptoglobin decreases expression ISO doramapimod results in decreased expression of HP mRNA CTD PMID:21328587 NCBI chr19:54,449,151...54,453,701
Ensembl chr19:54,446,217...54,467,518 		JBrowse link
G Hpd 4-hydroxyphenylpyruvate dioxygenase decreases expression EXP doramapimod results in decreased expression of HPD mRNA CTD PMID:24303162 NCBI chr12:39,042,246...39,053,596
Ensembl chr12:39,042,238...39,053,612 		JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions ISO doramapimod inhibits the reaction [Dinitrofluorobenzene results in increased expression of ICAM1 protein] CTD PMID:19427879 NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617 		JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO doramapimod inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein] CTD PMID:28629242 NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601 		JBrowse link
G Kcnk1 potassium two pore domain channel subfamily K member 1 decreases expression EXP doramapimod results in decreased expression of KCNK1 mRNA CTD PMID:24303162 NCBI chr19:70,856,985...70,895,053
Ensembl chr19:70,856,985...70,895,051 		JBrowse link
G Lmod1 leiomodin 1 increases expression EXP doramapimod results in increased expression of LMOD1 mRNA CTD PMID:24303162 NCBI chr13:49,305,693...49,347,970
Ensembl chr13:49,305,830...49,348,116 		JBrowse link
G Mapk14 mitogen activated protein kinase 14 decreases activity ISO doramapimod results in decreased activity of MAPK14 protein CTD PMID:28629242 NCBI chr20:6,751,288...6,812,294
Ensembl chr20:6,751,357...6,812,294 		JBrowse link
G Meig1 meiosis/spermiogenesis associated 1 increases expression ISO doramapimod results in increased expression of MEIG1 mRNA CTD PMID:21328587 NCBI chr17:79,718,630...79,737,604
Ensembl chr17:79,723,811...79,737,533 		JBrowse link
G Mt1a metallothionein 1A increases expression ISO doramapimod results in increased expression of MT1 mRNA CTD PMID:21328587 NCBI chr19:10,831,959...10,832,975
Ensembl chr17:79,695,809...79,696,200
Ensembl chr  X:79,695,809...79,696,200
Ensembl chr19:79,695,809...79,696,200 		JBrowse link
G Mybpc1 myosin binding protein C1 decreases expression EXP doramapimod results in decreased expression of MYBPC1 mRNA CTD PMID:24303162 NCBI chr 7:24,817,770...24,903,681
Ensembl chr 7:24,817,561...24,903,544 		JBrowse link
G Myh11 myosin heavy chain 11 increases expression EXP doramapimod results in increased expression of MYH11 mRNA CTD PMID:24303162 NCBI chr10:1,250,554...1,345,681
Ensembl chr10:1,263,194...1,345,678 		JBrowse link
G Myh3 myosin heavy chain 3 increases expression EXP doramapimod results in increased expression of MYH3 mRNA CTD PMID:24303162 NCBI chr10:52,269,185...52,293,000
Ensembl chr10:52,269,185...52,293,000 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 increases expression ISO doramapimod results in increased expression of NQO1 mRNA CTD PMID:21328587 NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260 		JBrowse link
G Olr59 olfactory receptor 59 increases expression EXP doramapimod results in increased expression of OLR59 mRNA CTD PMID:24303162 NCBI chr 1:166,604,972...166,639,634
Ensembl chr 1:166,604,141...166,623,265 		JBrowse link
G Otog otogelin decreases expression EXP doramapimod results in decreased expression of OTOG mRNA CTD PMID:24303162 NCBI chr 1:105,882,747...105,951,825
Ensembl chr 1:105,882,747...105,951,824 		JBrowse link
G Pfn2 profilin 2 increases expression ISO doramapimod results in increased expression of PFN2 mRNA CTD PMID:21328587 NCBI chr 2:144,217,100...144,222,936
Ensembl chr 2:144,205,636...144,222,936 		JBrowse link
G Pon1 paraoxonase 1 decreases expression EXP doramapimod results in decreased expression of PON1 mRNA CTD PMID:24303162 NCBI chr 4:34,261,312...34,292,327
Ensembl chr 4:34,261,289...34,287,924 		JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma increases expression ISO doramapimod results in increased expression of PPARG mRNA CTD PMID:21328587 NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104 		JBrowse link
G Prm2 protamine 2 increases expression ISO doramapimod results in increased expression of PRM2 mRNA CTD PMID:21328587 NCBI chr10:5,383,208...5,383,949
Ensembl chr10:5,379,029...5,384,004 		JBrowse link
G Rgs4 regulator of G-protein signaling 4 increases expression EXP doramapimod results in increased expression of RGS4 mRNA CTD PMID:24303162 NCBI chr13:84,469,593...84,475,884
Ensembl chr13:84,469,593...84,475,884 		JBrowse link
G RT1-Bb RT1 class II, locus Bb decreases expression ISO doramapimod results in decreased expression of H2-AB1 mRNA CTD PMID:21328587 NCBI chr20:4,598,475...4,604,118
Ensembl chr20:4,598,475...4,604,118 		JBrowse link
G Slc7a11 solute carrier family 7 member 11 increases expression ISO doramapimod results in increased expression of SLC7A11 mRNA CTD PMID:21328587 NCBI chr 2:136,532,912...136,668,560
Ensembl chr 2:136,532,246...136,695,695 		JBrowse link
G Spock2 SPARC/osteonectin, cwcv and kazal like domains proteoglycan 2 decreases expression EXP doramapimod results in decreased expression of SPOCK2 mRNA CTD PMID:24303162 NCBI chr20:28,580,262...28,607,198
Ensembl chr20:28,580,226...28,608,409 		JBrowse link
G Spsb1 splA/ryanodine receptor domain and SOCS box containing 1 decreases expression ISO doramapimod results in decreased expression of SPSB1 mRNA CTD PMID:21328587 NCBI chr 5:165,641,255...165,701,482
Ensembl chr 5:165,642,851...165,654,225 		JBrowse link
G Srxn1 sulfiredoxin 1 increases expression ISO doramapimod results in increased expression of SRXN1 mRNA CTD PMID:21328587 NCBI chr 3:161,064,812...161,070,372
Ensembl chr 3:161,059,931...161,088,765 		JBrowse link
G Stmn2 stathmin 2 increases expression EXP doramapimod results in increased expression of STMN2 mRNA CTD PMID:24303162 NCBI chr 2:95,112,017...95,159,642
Ensembl chr 2:95,112,019...95,159,335 		JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO doramapimod inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; doramapimod promotes the reaction [TNF protein results in increased activity of CASP3 protein]
doramapimod inhibits the reaction [nivalenol results in increased secretion of TNF protein] 		CTD PMID:28629242 PMID:38616237 NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303 		JBrowse link
G Vsig4 V-set and immunoglobulin domain containing 4 decreases expression ISO doramapimod results in decreased expression of VSIG4 mRNA CTD PMID:21328587 NCBI chr  X:65,154,422...65,179,708
Ensembl chr  X:65,154,424...65,179,708 		JBrowse link
luteolin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb1a ATP binding cassette subfamily B member 1A increases activity
decreases expression
multiple interactions 		ISO Luteolin results in increased activity of ABCB1 protein
Luteolin results in decreased expression of ABCB1 protein
Luteolin inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin] 		CTD PMID:34217736 NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135 		JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 decreases activity ISO Luteolin results in decreased activity of ABCC1 protein CTD PMID:15670588 NCBI chr10:1,022,041...1,162,431
Ensembl chr10:1,038,947...1,162,404 		JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 multiple interactions ISO [Luteolin co-treated with Cisplatin] results in increased expression of ABCC2 protein; Luteolin inhibits the reaction [Cisplatin results in increased expression of ABCC2 protein] CTD PMID:23770416 NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471 		JBrowse link
G Abcc4 ATP binding cassette subfamily C member 4 multiple interactions ISO Luteolin inhibits the reaction [Cisplatin results in increased expression of ABCC4 protein] CTD PMID:23770416 NCBI chr15:101,948,387...102,182,912
Ensembl chr15:101,949,433...102,181,375 		JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 affects activity ISO Luteolin affects the activity of ABCG2 protein CTD PMID:20403331 NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493 		JBrowse link
G Ache acetylcholinesterase multiple interactions EXP Luteolin inhibits the reaction [cobaltous chloride results in increased activity of ACHE protein] CTD PMID:31362009 NCBI chr12:25,042,882...25,050,608
Ensembl chr12:25,043,461...25,050,410 		JBrowse link
G Acta2 actin alpha 2, smooth muscle multiple interactions ISO Luteolin inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein]
[kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; [kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; dorsomorphin inhibits the reaction [[kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]]; Luteolin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] 		CTD PMID:19747501 PMID:37308028 NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503 		JBrowse link
G Ager advanced glycosylation end product-specific receptor multiple interactions ISO Luteolin inhibits the reaction [Glucose results in increased expression of AGER mRNA] CTD PMID:19557821 NCBI chr20:4,152,758...4,155,956
Ensembl chr20:4,151,965...4,155,685 		JBrowse link
G Ahr aryl hydrocarbon receptor multiple interactions ISO Luteolin binds to and results in decreased activity of AHR protein
Luteolin inhibits the reaction [Tetrachlorodibenzodioxin results in increased localization of AHR protein] 		CTD PMID:14644660 PMID:20450880 NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions
decreases expression
decreases phosphorylation
increases phosphorylation 		ISO
EXP 		Luteolin inhibits the reaction [chromium hexavalent ion results in increased phosphorylation of AKT1 protein]; Luteolin inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; Luteolin inhibits the reaction [Oxygen deficiency results in increased phosphorylation of AKT1 protein]
Luteolin results in decreased expression of AKT1 mRNA
Luteolin results in decreased phosphorylation of AKT1 protein
Luteolin results in increased phosphorylation of AKT1 protein
Luteolin inhibits the reaction [Antimycin A results in decreased activity of AKT1 protein]; Luteolin inhibits the reaction [INS1 protein results in increased activity of AKT1 protein]; Luteolin inhibits the reaction [Lipopolysaccharides results in decreased expression of AKT1 mRNA]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of AKT1 protein]
[Luteolin co-treated with Hydrogen Peroxide] results in increased expression of AKT1 protein; Luteolin inhibits the reaction [lipoteichoic acid results in increased phosphorylation of AKT1 protein]; Luteolin inhibits the reaction [Methamphetamine results in increased phosphorylation of AKT1 protein]
Luteolin results in decreased expression of AKT1 mRNA; Luteolin results in decreased expression of AKT1 protein 		CTD PMID:18591783 PMID:18720166 PMID:19344998 PMID:20153296 PMID:20685402 More... NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610 		JBrowse link
G Alox5 arachidonate 5-lipoxygenase multiple interactions ISO Luteolin inhibits the reaction [ALOX5 protein results in increased chemical synthesis of Leukotriene B4] CTD PMID:18096136 NCBI chr 4:151,203,948...151,251,126
Ensembl chr 4:151,203,949...151,251,126 		JBrowse link
G Asns asparagine synthetase (glutamine-hydrolyzing) multiple interactions ISO Luteolin inhibits the reaction [Tunicamycin results in increased expression of ASNS mRNA] CTD PMID:32407927 NCBI chr 4:36,752,061...36,769,970
Ensembl chr 4:36,751,802...36,776,050 		JBrowse link
G Atf6 activating transcription factor 6 multiple interactions ISO Luteolin inhibits the reaction [Thapsigargin results in increased expression of ATF6 protein modified form]; Luteolin inhibits the reaction [Tunicamycin results in increased expression of ATF6 protein modified form] CTD PMID:32407927 NCBI chr13:85,460,312...85,639,959
Ensembl chr13:85,462,840...85,640,033 		JBrowse link
G Atg5 autophagy related 5 multiple interactions
increases expression 		EXP
ISO 		Luteolin inhibits the reaction [Methamphetamine results in increased expression of ATG5 protein]
Luteolin results in increased expression of ATG5 protein 		CTD PMID:32035215 PMID:32268164 NCBI chr20:49,380,835...49,471,826
Ensembl chr20:49,380,813...49,471,821 		JBrowse link
G Atp7b ATPase copper transporting beta increases expression EXP Luteolin results in increased expression of ATP7B mRNA CTD PMID:31201582 NCBI chr16:76,654,725...76,726,092
Ensembl chr16:76,653,660...76,728,801 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions
increases expression 		EXP
ISO 		Luteolin inhibits the reaction [Hydrogen Peroxide results in increased expression of BAX protein]; Luteolin inhibits the reaction [Methamphetamine results in increased expression of BAX protein]
Luteolin inhibits the reaction [Cisplatin results in increased expression of BAX protein]
Luteolin results in increased expression of BAX protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Luteolin results in increased expression of BAX protein]; Luteolin affects the reaction [[Lead co-treated with Cadmium co-treated with Mercury co-treated with Copper co-treated with Zinc co-treated with Manganese co-treated with Chromium co-treated with Nickel] results in increased expression of BAX protein]; Luteolin affects the reaction [Metals, Heavy results in increased expression of BAX protein] 		CTD PMID:21601631 PMID:27474067 PMID:27525270 PMID:29115570 PMID:32035215 More... NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429 		JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
decreases expression 		ISO 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Luteolin results in decreased expression of BCL2 protein]; Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of BCL2 protein]; Luteolin inhibits the reaction [Glucose results in increased degradation of and results in decreased expression of BCL2 protein]
Luteolin inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein] 		CTD PMID:19557821 PMID:25448439 PMID:27474067 PMID:32268164 PMID:38103742 NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900 		JBrowse link
G Bcl2l1 Bcl2-like 1 decreases expression
multiple interactions 		ISO Luteolin results in decreased expression of BCL2L1 protein
Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of BCL2L1 protein] 		CTD PMID:21601631 PMID:25448439 NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907
Ensembl chr 1:161,745,540...161,764,907 		JBrowse link
G Becn1 beclin 1 increases expression
multiple interactions 		ISO
EXP 		Luteolin results in increased expression of BECN1 protein
Luteolin inhibits the reaction [Methamphetamine results in increased expression of BECN1 protein] 		CTD PMID:32035215 PMID:32268164 NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,731,650...86,747,002 		JBrowse link
G Birc2 baculoviral IAP repeat-containing 2 multiple interactions ISO Luteolin inhibits the reaction [TNF protein results in increased expression of BIRC2 protein] CTD PMID:15334063 NCBI chr 8:13,253,697...13,273,672
Ensembl chr 8:13,253,706...13,271,911 		JBrowse link
G Casp1 caspase 1 multiple interactions EXP
ISO 		Luteolin inhibits the reaction [Freund's Adjuvant results in increased cleavage of CASP1 protein]
Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein] 		CTD PMID:25450234 PMID:34217685 NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:10,746,333...10,882,275 		JBrowse link
G Casp3 caspase 3 multiple interactions
increases expression
increases cleavage
increases activity 		ISO
EXP 		2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Luteolin results in increased cleavage of CASP3 protein]; [Luteolin co-treated with Paclitaxel] results in increased cleavage of CASP3 protein; CYP1A1 protein promotes the reaction [Luteolin results in increased cleavage of CASP3 protein]; CYP1A2 protein promotes the reaction [Luteolin results in increased cleavage of CASP3 protein]; Luteolin inhibits the reaction [[Lead co-treated with Cadmium co-treated with Mercury co-treated with Copper co-treated with Zinc co-treated with Manganese co-treated with Chromium co-treated with Nickel] results in increased cleavage of CASP3 protein]; Luteolin inhibits the reaction [Metals, Heavy results in increased cleavage of CASP3 protein]; Luteolin promotes the reaction [TNFSF10 protein results in increased activity of CASP3 protein]; Luteolin results in increased expression of and results in increased cleavage of CASP3 protein
Luteolin results in increased expression of CASP3 mRNA
Luteolin results in increased expression of CASP3 protein
Luteolin inhibits the reaction [Doxorubicin results in increased expression of CASP3 protein]; Luteolin inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]; Luteolin inhibits the reaction [Methamphetamine results in increased cleavage of CASP3 protein]
Luteolin results in increased activity of CASP3 protein
Luteolin inhibits the reaction [Cisplatin results in increased cleavage of and results in increased expression of CASP3 protein]; Luteolin inhibits the reaction [Tunicamycin results in increased expression of CASP3 protein modified form] 		CTD PMID:16140950 PMID:18331776 PMID:19397994 PMID:21074525 PMID:21601631 More... NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732 		JBrowse link
G Casp7 caspase 7 increases activity ISO Luteolin results in increased activity of CASP7 protein CTD PMID:21074525 NCBI chr 1:265,442,647...265,481,938
Ensembl chr 1:265,442,676...265,482,512 		JBrowse link
G Casp8 caspase 8 multiple interactions ISO
EXP 		[Luteolin co-treated with Paclitaxel] results in increased cleavage of CASP8 protein; Luteolin promotes the reaction [TNF protein results in increased cleavage of and results in increased activity of CASP8 protein]; Luteolin promotes the reaction [TNFSF10 protein results in increased activity of CASP8 protein]
Luteolin inhibits the reaction [Hydrogen Peroxide results in increased expression of CASP8 protein] 		CTD PMID:15334063 PMID:16140950 PMID:24525192 PMID:27525270 NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699 		JBrowse link
G Casp9 caspase 9 increases activity
multiple interactions
increases cleavage 		ISO
EXP 		Luteolin results in increased activity of CASP9 protein
Luteolin inhibits the reaction [Doxorubicin results in increased expression of CASP9 protein]
Luteolin inhibits the reaction [[Lead co-treated with Cadmium co-treated with Mercury co-treated with Copper co-treated with Zinc co-treated with Manganese co-treated with Chromium co-treated with Nickel] results in increased cleavage of CASP9 protein]; Luteolin inhibits the reaction [Metals, Heavy results in increased cleavage of CASP9 protein]
Luteolin results in increased cleavage of CASP9 protein 		CTD PMID:18331776 PMID:19397994 PMID:21601631 PMID:27474067 PMID:27489195 More... Ensembl chr 5:159,391,188...159,409,648 JBrowse link
G Cat catalase affects activity
multiple interactions
decreases activity 		ISO
EXP 		Luteolin affects the activity of CAT protein
Luteolin inhibits the reaction [Doxorubicin results in decreased activity of CAT protein]
Luteolin results in decreased activity of CAT protein
Fluorouracil promotes the reaction [Luteolin results in decreased activity of CAT protein]; Luteolin inhibits the reaction [Doxorubicin results in increased activity of CAT protein]; Luteolin promotes the reaction [Fluorouracil results in decreased activity of CAT protein] 		CTD PMID:18503759 PMID:31288002 PMID:33827303 NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526 		JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions ISO HMOX1 protein affects the reaction [Luteolin inhibits the reaction [Indican results in increased expression of CCL2 protein]]; Luteolin inhibits the reaction [IL1B protein results in increased secretion of CCL2 protein]; Luteolin inhibits the reaction [Indican results in increased expression of CCL2 mRNA]; Luteolin inhibits the reaction [Indican results in increased expression of CCL2 protein] CTD PMID:24134915 PMID:39105397 NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875 		JBrowse link
G Ccn5 cellular communication network factor 5 decreases expression ISO Luteolin results in decreased expression of CCN5 mRNA CTD PMID:19397994 NCBI chr 3:172,910,670...172,922,064
Ensembl chr 3:172,910,681...172,922,062 		JBrowse link
G Ccna2 cyclin A2 decreases expression ISO Luteolin results in decreased expression of CCNA2 protein CTD PMID:22926442 NCBI chr 2:121,355,363...121,361,762
Ensembl chr 2:121,355,363...121,361,701 		JBrowse link
G Ccnb1 cyclin B1 decreases expression ISO Luteolin results in decreased expression of CCNB1 mRNA; Luteolin results in decreased expression of CCNB1 protein CTD PMID:18331776 PMID:19397994 PMID:22926442 NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:33,646,252...33,655,225 		JBrowse link
G Ccnd1 cyclin D1 multiple interactions
decreases expression 		ISO Fluorouracil promotes the reaction [Luteolin results in decreased expression of CCND1 protein]; Luteolin promotes the reaction [Fluorouracil results in decreased expression of CCND1 protein] CTD PMID:31288002 NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810 		JBrowse link
G Cd40 CD40 molecule multiple interactions ISO Luteolin inhibits the reaction [[Calcimycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CD40 protein]; Luteolin inhibits the reaction [Calcimycin results in increased expression of CD40 protein]; Luteolin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of CD40 protein] CTD PMID:16601352 NCBI chr 3:174,209,113...174,224,592
Ensembl chr 3:174,209,719...174,224,847 		JBrowse link
G Cd74 CD74 molecule decreases expression ISO Luteolin results in decreased expression of CD74 mRNA CTD PMID:18818744 NCBI chr18:56,527,071...56,536,406
Ensembl chr18:56,527,132...56,536,410 		JBrowse link
G Cdh1 cadherin 1 multiple interactions
increases expression 		ISO 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Luteolin results in increased expression of CDH1 protein] CTD PMID:27474067 PMID:32268164 NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565 		JBrowse link
G Cdh2 cadherin 2 multiple interactions
decreases expression 		ISO 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Luteolin results in decreased expression of CDH2 protein] CTD PMID:27474067 NCBI chr18:8,051,097...8,265,288
Ensembl chr18:8,051,097...8,265,288 		JBrowse link
G Cdh5 cadherin 5 multiple interactions EXP Luteolin inhibits the reaction [Methamphetamine results in increased expression of CDH5 mRNA] CTD PMID:32035215 NCBI chr19:821,875...860,931
Ensembl chr19:822,464...860,822 		JBrowse link
G Cdk1 cyclin-dependent kinase 1 decreases expression ISO Luteolin results in decreased expression of CDK1 protein CTD PMID:22926442 NCBI chr20:19,265,252...19,280,456
Ensembl chr20:19,265,289...19,280,455 		JBrowse link
G Cdk2 cyclin dependent kinase 2 decreases activity
decreases expression 		ISO Luteolin results in decreased activity of CDK2 protein
Luteolin results in decreased expression of CDK2 protein 		CTD PMID:11322924 PMID:22926442 NCBI chr 7:1,714,392...1,721,964
Ensembl chr 7:1,714,392...1,721,878 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases expression
affects localization
multiple interactions 		ISO
EXP 		Luteolin results in increased expression of CDKN1A mRNA; Luteolin results in increased expression of CDKN1A protein
Luteolin affects the localization of CDKN1A protein
Fluorouracil promotes the reaction [Luteolin results in increased expression of CDKN1A protein]; Luteolin promotes the reaction [Fluorouracil results in increased expression of CDKN1A protein] 		CTD PMID:11322924 PMID:11790449 PMID:19397994 PMID:22926442 PMID:31201582 More... NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969 		JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B increases expression ISO Luteolin results in increased expression of CDKN1B protein CTD PMID:11322924 NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:169,490,876...169,496,498 		JBrowse link
G Cdkn2c cyclin-dependent kinase inhibitor 2C decreases expression ISO Luteolin results in decreased expression of CDKN2C mRNA CTD PMID:18331776 NCBI chr 5:129,639,736...129,645,564
Ensembl chr 5:129,639,736...129,644,891 		JBrowse link
G Ces1d carboxylesterase 1D decreases activity EXP Luteolin results in decreased activity of CES1 protein CTD PMID:37353134 NCBI chr19:30,046,494...30,085,039
Ensembl chr19:30,046,449...30,085,449 		JBrowse link
G Chuk component of inhibitor of nuclear factor kappa B kinase complex multiple interactions ISO Luteolin inhibits the reaction [chromium hexavalent ion results in increased activity of CHUK protein]
Luteolin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of CHUK protein] 		CTD PMID:25448439 PMID:37390879 NCBI chr 1:252,908,748...252,944,273
Ensembl chr 1:252,908,749...252,944,273 		JBrowse link
G Cldn1 claudin 1 multiple interactions ISO Luteolin inhibits the reaction [decabromobiphenyl ether results in decreased expression of CLDN1 protein]; Luteolin promotes the reaction [decabromobiphenyl ether results in decreased expression of CLDN1 mRNA] CTD PMID:33675858 NCBI chr11:87,926,376...87,941,533
Ensembl chr11:87,926,337...87,941,529 		JBrowse link
G Csf2 colony stimulating factor 2 decreases expression
multiple interactions 		ISO
EXP 		Luteolin results in decreased expression of CSF2 mRNA
Luteolin inhibits the reaction [Calcimycin results in increased expression of CSF2 mRNA] 		CTD PMID:10718847 PMID:17950587 NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,887,692...38,890,031 		JBrowse link
G Ctnnb1 catenin beta 1 decreases expression ISO Luteolin results in decreased expression of CTNNB1 protein CTD PMID:32268164 NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:129,517,545...129,544,662 		JBrowse link
G Cxcl10 C-X-C motif chemokine ligand 10 multiple interactions ISO Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; Luteolin inhibits the reaction [Poly I-C results in increased expression of CXCL10 mRNA] CTD PMID:19426678 NCBI chr14:15,989,066...15,991,263
Ensembl chr14:15,989,018...15,991,261 		JBrowse link
G Cxcl12 C-X-C motif chemokine ligand 12 multiple interactions EXP Luteolin inhibits the reaction [Methamphetamine results in increased expression of CXCL12 mRNA] CTD PMID:32035215 NCBI chr 4:152,060,781...152,073,628
Ensembl chr 4:152,060,780...152,073,627 		JBrowse link
G Cxcl9 C-X-C motif chemokine ligand 9 multiple interactions ISO Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL9 mRNA]; Luteolin inhibits the reaction [Poly I-C results in increased expression of CXCL9 mRNA] CTD PMID:19426678 NCBI chr14:16,007,166...16,012,077
Ensembl chr14:16,007,204...16,014,299 		JBrowse link
G Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 decreases expression EXP Luteolin results in decreased expression of CYP17A1 mRNA CTD PMID:31201582 NCBI chr 1:255,476,861...255,484,547
Ensembl chr 1:255,476,861...255,482,974 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions
increases response to substance
decreases expression
increases expression
decreases activity 		ISO [CYP1A1 protein results in increased susceptibility to Luteolin] which results in decreased abundance of diosmetin; CYP1A1 protein promotes the reaction [Luteolin results in increased cleavage of CASP3 protein]; CYP1A1 protein promotes the reaction [Luteolin results in increased cleavage of PARP1 protein]; CYP1A1 protein promotes the reaction [Luteolin results in increased expression of H2AX protein]; Luteolin inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]; Luteolin inhibits the reaction [Dust analog results in increased expression of CYP1A1 mRNA]; Luteolin inhibits the reaction [Particulate Matter analog results in increased expression of CYP1A1 mRNA]; Luteolin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Luteolin inhibits the reaction [Vehicle Emissions analog results in increased expression of CYP1A1 mRNA]
Luteolin results in decreased expression of CYP1A1 protein
Luteolin results in increased expression of CYP1A1 mRNA
Luteolin affects the reaction [beta-Naphthoflavone results in increased expression of CYP1A1 mRNA]
Luteolin results in decreased activity of CYP1A1 protein 		CTD PMID:16263508 PMID:17090139 PMID:20403331 PMID:20930378 PMID:21482471 More... NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012 		JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 decreases activity
increases response to substance
multiple interactions
decreases expression 		ISO Luteolin results in decreased activity of CYP1A2 protein
CYP1A2 protein results in increased susceptibility to Luteolin
[CYP1A2 protein results in increased susceptibility to Luteolin] which results in decreased abundance of diosmetin; CYP1A2 protein promotes the reaction [Luteolin results in increased cleavage of CASP3 protein]; CYP1A2 protein promotes the reaction [Luteolin results in increased cleavage of PARP1 protein]; CYP1A2 protein promotes the reaction [Luteolin results in increased expression of H2AX protein]
Luteolin results in decreased expression of CYP1A2 protein 		CTD PMID:29753067 PMID:33727136 NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149 		JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 decreases activity
increases expression 		ISO Luteolin results in decreased activity of CYP1B1 protein
Luteolin results in increased expression of CYP1B1 mRNA 		CTD PMID:21482471 PMID:23994263 NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142 		JBrowse link
G Cyp2c6 cytochrome P450, family 2, subfamily C, polypeptide 6 decreases activity ISO Luteolin results in decreased activity of CYP2C19 protein CTD PMID:29753067 NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:247,879,078...247,916,798 		JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 multiple interactions ISO Luteolin inhibits the reaction [Cisplatin results in increased expression of CYP2E1 protein] CTD PMID:23770416 NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions ISO Luteolin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Luteolin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 4-hydroxymidazolam] CTD PMID:18191104 NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857 		JBrowse link
G Cyp3a9 cytochrome P450, family 3, subfamily a, polypeptide 9 multiple interactions ISO Luteolin inhibits the reaction [CYP3A5 protein results in increased chemical synthesis of 4-hydroxymidazolam] CTD PMID:18191104 NCBI chr12:21,919,955...21,960,160
Ensembl chr12:21,919,940...21,960,154 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions ISO
EXP 		Luteolin inhibits the reaction [Thapsigargin results in increased expression of DDIT3 protein]; Luteolin inhibits the reaction [Tunicamycin results in increased expression of DDIT3 mRNA]; Luteolin inhibits the reaction [Tunicamycin results in increased expression of DDIT3 protein]
Luteolin inhibits the reaction [Thapsigargin results in increased expression of DDIT3 mRNA]; Luteolin inhibits the reaction [Thapsigargin results in increased expression of DDIT3 protein]; Luteolin inhibits the reaction [Tunicamycin results in increased expression of DDIT3 mRNA]; Luteolin inhibits the reaction [Tunicamycin results in increased expression of DDIT3 protein]; SESN2 protein promotes the reaction [Luteolin inhibits the reaction [Tunicamycin results in increased expression of DDIT3 mRNA]] 		CTD PMID:32407927 NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509 		JBrowse link
G Derl3 derlin 3 increases expression EXP Luteolin results in increased expression of DERL3 mRNA CTD PMID:31201582 NCBI chr20:12,753,926...12,766,478
Ensembl chr20:12,762,981...12,766,477 		JBrowse link
G Dhrs11 dehydrogenase/reductase 11 decreases activity ISO Luteolin results in decreased activity of DHRS11 protein CTD PMID:30926317 NCBI chr10:70,195,637...70,205,735
Ensembl chr10:70,195,637...70,205,893 		JBrowse link
G Dnajb9 DnaJ heat shock protein family (Hsp40) member B9 multiple interactions ISO Luteolin inhibits the reaction [Tunicamycin results in increased expression of DNAJB9 mRNA] CTD PMID:32407927 NCBI chr 6:66,997,842...67,007,371
Ensembl chr 6:66,997,842...67,009,344 		JBrowse link
G Dram1 DNA-damage regulated autophagy modulator 1 increases expression
multiple interactions 		ISO Luteolin results in increased expression of DRAM1 protein
Fluorouracil promotes the reaction [Luteolin results in increased expression of DRAM1 protein]; Luteolin promotes the reaction [Fluorouracil results in increased expression of DRAM1 protein] 		CTD PMID:31288002 NCBI chr 7:24,630,233...24,665,270
Ensembl chr 7:24,630,238...24,664,354 		JBrowse link
G Egf epidermal growth factor multiple interactions ISO EGF protein inhibits the reaction [Luteolin results in decreased phosphorylation of EGFR protein]; EGF protein inhibits the reaction [Luteolin results in decreased phosphorylation of PTK2 protein]; Luteolin inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; Luteolin inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of EGFR protein]; Luteolin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Luteolin inhibits the reaction [EGF protein results in increased phosphorylation of PTK2 protein]; Luteolin inhibits the reaction [EGF protein results in increased secretion of MMP9 protein] CTD PMID:10556937 PMID:12168845 PMID:15135307 PMID:22926442 NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:220,893,660...220,976,297 		JBrowse link
G Egfr epidermal growth factor receptor decreases expression
multiple interactions
affects response to substance 		ISO Luteolin results in decreased expression of EGFR mRNA
EGF protein inhibits the reaction [Luteolin results in decreased phosphorylation of EGFR protein]; Luteolin affects the activity of and results in decreased phosphorylation of EGFR protein; Luteolin inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of EGFR protein]; Luteolin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Luteolin results in decreased phosphorylation of and results in increased activity of EGFR protein
EGFR protein affects the susceptibility to Luteolin 		CTD PMID:10556937 PMID:12168845 PMID:15135307 PMID:22926442 PMID:36819991 NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358 		JBrowse link
G Egr1 early growth response 1 increases expression ISO Luteolin results in increased expression of EGR1 mRNA CTD PMID:19397994 NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,736,838...26,740,843 		JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2 subunit alpha multiple interactions ISO Luteolin inhibits the reaction [Thapsigargin results in increased phosphorylation of EIF2S1 protein]; Luteolin inhibits the reaction [Tunicamycin results in increased phosphorylation of EIF2S1 protein] CTD PMID:32407927 NCBI chr 6:103,405,880...103,430,549
Ensembl chr 6:103,405,788...103,431,649 		JBrowse link
G Ern1 endoplasmic reticulum to nucleus signaling 1 multiple interactions ISO Luteolin inhibits the reaction [Thapsigargin results in increased expression of and results in increased phosphorylation of ERN1 protein]; Luteolin inhibits the reaction [Tunicamycin results in increased expression of and results in increased phosphorylation of ERN1 protein] CTD PMID:32407927 NCBI chr10:91,826,663...91,920,976
Ensembl chr10:91,830,428...91,920,791 		JBrowse link
G Esr1 estrogen receptor 1 affects binding
multiple interactions 		ISO Luteolin binds to ESR1 protein
Luteolin inhibits the reaction [Estradiol binds to ESR1 protein] 		CTD PMID:14579009 NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354 		JBrowse link
G Esr2 estrogen receptor 2 increases activity
affects binding 		ISO Luteolin results in increased activity of ESR2 protein
Luteolin binds to ESR2 protein 		CTD PMID:12224631 PMID:16860978 NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:100,545,206...100,644,709 		JBrowse link
G F11r F11 receptor multiple interactions EXP Luteolin inhibits the reaction [Methamphetamine results in increased expression of F11R mRNA] CTD PMID:32035215 NCBI chr13:86,406,229...86,429,819
Ensembl chr13:86,406,218...86,429,816 		JBrowse link
G Fas Fas cell surface death receptor increases expression EXP Luteolin results in increased expression of FAS mRNA CTD PMID:31201582 NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:241,205,935...241,246,104 		JBrowse link
G Fasn fatty acid synthase multiple interactions ISO Luteolin inhibits the reaction [Tunicamycin results in increased expression of FASN mRNA] CTD PMID:32407927 NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,570,413...106,588,583 		JBrowse link
G Fbp1 fructose-bisphosphatase 1 decreases expression ISO Luteolin results in decreased expression of FBP1 mRNA CTD PMID:18331776 NCBI chr17:2,212,941...2,235,749
Ensembl chr17:2,213,492...2,235,746 		JBrowse link
G Fgf2 fibroblast growth factor 2 multiple interactions ISO Luteolin inhibits the reaction [Sodium Chloride results in increased expression of FGF2 mRNA] CTD PMID:26800359 NCBI chr 2:122,164,454...122,218,796
Ensembl chr 2:122,164,454...122,224,493 		JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions
decreases activity 		ISO
EXP 		Luteolin inhibits the reaction [TNF protein results in increased activity of [FOS protein binds to JUN protein]]; Luteolin inhibits the reaction [TNF protein results in increased expression of FOS mRNA]
Luteolin inhibits the reaction [Calcimycin results in increased expression of FOS mRNA]
Luteolin results in decreased activity of FOS protein 		CTD PMID:15322261 PMID:16343431 PMID:17950587 NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598 		JBrowse link
G Fosb FosB proto-oncogene, AP-1 transcription factor subunit decreases activity ISO Luteolin results in decreased activity of FOSB protein CTD PMID:16343431 NCBI chr 1:88,082,324...88,089,506
Ensembl chr 1:88,082,127...88,089,477 		JBrowse link
G Foxo3 forkhead box O3 multiple interactions ISO Luteolin results in increased expression of and results in increased phosphorylation of FOXO3 protein; mirdametinib inhibits the reaction [Luteolin results in increased phosphorylation of FOXO3 protein]; mirdametinib promotes the reaction [Luteolin results in increased expression of FOXO3 protein] CTD PMID:32268164 NCBI chr20:47,251,968...47,348,254
Ensembl chr20:47,255,878...47,346,845 		JBrowse link
G Gadd45b growth arrest and DNA-damage-inducible, beta increases expression ISO Luteolin results in increased expression of GADD45B mRNA; Luteolin results in increased expression of GADD45B protein CTD PMID:18331776 NCBI chr 7:9,428,689...9,430,991
Ensembl chr 7:9,428,689...9,430,718 		JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit increases expression
multiple interactions 		EXP Luteolin results in increased expression of GCLC mRNA; Luteolin results in increased expression of GCLC protein
[Luteolin results in increased expression of GCLC mRNA] which results in decreased susceptibility to tert-Butylhydroperoxide 		CTD PMID:22864849 NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893 		JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit increases expression EXP Luteolin results in increased expression of GCLM mRNA; Luteolin results in increased expression of GCLM protein CTD PMID:22864849 NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:213,031,838...213,055,003 		JBrowse link
G Gdf15 growth differentiation factor 15 multiple interactions
decreases expression 		ISO Luteolin inhibits the reaction [SOX4 protein binds to GDF15 promoter]; SOX4 protein inhibits the reaction [Luteolin inhibits the reaction [SOX4 protein binds to GDF15 promoter]]; SOX4 protein inhibits the reaction [Luteolin results in decreased expression of GDF15 mRNA] CTD PMID:39231684 NCBI chr16:18,838,436...18,842,022
Ensembl chr16:18,838,436...18,842,022 		JBrowse link
G Gfap glial fibrillary acidic protein multiple interactions ISO Luteolin inhibits the reaction [Carbon Tetrachloride results in increased expression of GFAP protein] CTD PMID:19747501 NCBI chr10:88,352,987...88,361,661
Ensembl chr10:88,352,986...88,361,685 		JBrowse link
G Gpr35 G protein-coupled receptor 35 multiple interactions EXP
ISO 		Luteolin binds to and results in increased activity of GPR35 protein CTD PMID:20919992 NCBI chr 9:100,974,580...100,995,330
Ensembl chr 9:100,962,538...100,986,985 		JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions EXP Luteolin inhibits the reaction [Doxorubicin results in increased activity of GPT protein] CTD PMID:33827303 NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160 		JBrowse link
G Gpx1 glutathione peroxidase 1 multiple interactions ISO [Luteolin co-treated with 4(G)-alpha-glucopyranosyl-rutin] inhibits the reaction [Doxorubicin results in decreased activity of GPX1 protein] CTD PMID:9242351 NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:117,905,280...117,906,581 		JBrowse link
G Gpx4 glutathione peroxidase 4 decreases expression ISO Luteolin results in decreased expression of GPX4 protein CTD PMID:39231684 NCBI chr 7:10,300,833...10,303,629
Ensembl chr 7:10,300,832...10,303,629 		JBrowse link
G Gsdmd gasdermin D multiple interactions ISO Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of GSDMD protein]
Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of GSDMD protein] 		CTD PMID:34217685 PMID:37379125 NCBI chr 7:109,423,209...109,427,771
Ensembl chr 7:109,422,910...109,430,722 		JBrowse link
G Gsta1 glutathione S-transferase alpha 1 increases expression EXP Luteolin results in increased expression of GSTA1 mRNA CTD PMID:31201582 NCBI chr 9:31,199,887...31,216,606
Ensembl chr 9:31,199,888...31,211,528 		JBrowse link
G Gstt2 glutathione S-transferase theta 2 increases expression EXP Luteolin results in increased expression of GSTT2 mRNA CTD PMID:31201582 NCBI chr20:12,819,053...12,822,724
Ensembl chr20:12,818,540...12,822,718 		JBrowse link
G H2ax H2A.X variant histone multiple interactions
increases expression 		ISO CYP1A1 protein promotes the reaction [Luteolin results in increased expression of H2AX protein]; CYP1A2 protein promotes the reaction [Luteolin results in increased expression of H2AX protein] CTD PMID:33727136 NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079 		JBrowse link
G Hbegf heparin-binding EGF-like growth factor multiple interactions ISO Luteolin inhibits the reaction [Sodium Chloride results in increased expression of HBEGF mRNA] CTD PMID:26800359 NCBI chr18:28,380,337...28,390,220
Ensembl chr18:28,380,337...28,390,220 		JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha multiple interactions
decreases activity 		ISO Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of HIF1A mRNA]; Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of HIF1A protein]; Luteolin inhibits the reaction [Oxygen deficiency results in increased activity of HIF1A protein]; Luteolin promotes the reaction [Oxygen deficiency results in increased expression of HIF1A protein]; Luteolin results in increased expression of and results in increased activity of HIF1A protein
Luteolin results in decreased activity of HIF1A protein 		CTD PMID:19958256 PMID:20153296 PMID:25448439 NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323 		JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions
increases expression 		ISO
EXP 		Luteolin inhibits the reaction [Vehicle Emissions analog results in increased expression of HMOX1 protein]
[Indican co-treated with Luteolin] results in increased expression of HMOX1 protein; HMOX1 protein affects the reaction [Luteolin inhibits the reaction [Indican results in increased expression of CCL2 protein]]; HMOX1 protein affects the reaction [Luteolin inhibits the reaction [Indican results in increased expression of ICAM1 protein]]; Luteolin promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of HMOX1 protein]; Luteolin promotes the reaction [Irinotecan results in increased expression of HMOX1 mRNA]
Luteolin results in increased expression of HMOX1 mRNA; Luteolin results in increased expression of HMOX1 protein
[Luteolin results in increased expression of HMOX1 mRNA] which results in decreased susceptibility to tert-Butylhydroperoxide; Luteolin inhibits the reaction [bisphenol A results in decreased expression of HMOX1 protein] 		CTD PMID:10975858 PMID:22864849 PMID:31091348 PMID:32268164 PMID:34217685 More... NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818 		JBrowse link
G Hmox2 heme oxygenase 2 multiple interactions ISO HMOX2 protein affects the reaction [Luteolin inhibits the reaction [Indican results in increased expression of JUN protein]]; HMOX2 protein affects the reaction [Luteolin inhibits the reaction [Indican results in increased expression of RELA protein]] CTD PMID:39105397 NCBI chr10:11,303,512...11,337,640
Ensembl chr10:11,303,512...11,318,800 		JBrowse link
G Hsd17b7 hydroxysteroid (17-beta) dehydrogenase 7 decreases expression EXP Luteolin results in decreased expression of HSD17B7 mRNA CTD PMID:31201582 NCBI chr13:84,702,875...84,722,810
Ensembl chr13:84,705,631...84,722,754 		JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 multiple interactions ISO Luteolin inhibits the reaction [Tunicamycin results in increased expression of HSPA5 mRNA]; Luteolin inhibits the reaction [Tunicamycin results in increased expression of HSPA5 protein] CTD PMID:32407927 NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:38,453,041...38,458,790 		JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions ISO HMOX1 protein affects the reaction [Luteolin inhibits the reaction [Indican results in increased expression of ICAM1 protein]]; Luteolin inhibits the reaction [Indican results in increased expression of ICAM1 mRNA]; Luteolin inhibits the reaction [Indican results in increased expression of ICAM1 protein]; Luteolin inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; Luteolin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein] CTD PMID:15113938 PMID:15322261 PMID:39105397 NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617 		JBrowse link
G Ifnb1 interferon beta 1 multiple interactions ISO Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of IFNB1 mRNA]; Luteolin inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA] CTD PMID:19426678 NCBI chr 5:108,066,650...108,067,487
Ensembl chr 5:108,066,650...108,067,487 		JBrowse link
G Ifng interferon gamma increases expression
multiple interactions 		ISO
EXP 		Luteolin results in increased expression of IFNG protein
Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] affects the localization of and results in increased activity of NFKB1 protein]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] affects the localization of and results in increased activity of RELA protein]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in decreased secretion of INS1 protein]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased degradation of NFKBIA protein]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased expression of NOS2 protein] 		CTD PMID:12755373 PMID:18090225 NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216 		JBrowse link
G Il10 interleukin 10 multiple interactions ISO
EXP 		Luteolin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL10 protein]
Luteolin inhibits the reaction [Doxorubicin results in decreased expression of IL10 protein]
Luteolin inhibits the reaction [nickel chloride results in increased expression of IL10 protein] 		CTD PMID:16934226 PMID:30016632 PMID:33827303 NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580 		JBrowse link
G Il12b interleukin 12B multiple interactions ISO Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of IL12B mRNA]; Luteolin inhibits the reaction [Poly I-C results in increased expression of IL12B mRNA] CTD PMID:19426678 NCBI chr10:29,390,300...29,405,194
Ensembl chr10:29,389,905...29,405,194 		JBrowse link
G Il13 interleukin 13 multiple interactions EXP Luteolin inhibits the reaction [Calcimycin results in increased expression of IL13 mRNA] CTD PMID:17950587 NCBI chr10:38,290,926...38,293,483
Ensembl chr10:38,290,926...38,293,483 		JBrowse link
G Il17a interleukin 17A multiple interactions EXP Luteolin inhibits the reaction [Freund's Adjuvant results in increased expression of IL17A protein] CTD PMID:25450234 NCBI chr 9:30,640,844...30,644,331
Ensembl chr 9:30,640,844...30,644,331 		JBrowse link
G Il1b interleukin 1 beta multiple interactions
decreases expression 		ISO
EXP 		Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; Luteolin inhibits the reaction [chromium hexavalent ion results in increased secretion of IL1B protein]; Luteolin inhibits the reaction [decabromobiphenyl ether results in increased expression of IL1B protein]; Luteolin inhibits the reaction [Glucose results in increased expression of IL1B mRNA]; Luteolin inhibits the reaction [Glucose results in increased expression of IL1B protein]; Luteolin inhibits the reaction [IL1B protein results in increased secretion of CCL2 protein]; Luteolin inhibits the reaction [IL1B protein results in increased secretion of IL6 protein]; Luteolin inhibits the reaction [Irinotecan results in increased expression of IL1B mRNA]; Luteolin inhibits the reaction [Irinotecan results in increased secretion of IL1B protein]; Luteolin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL1B protein]; Luteolin inhibits the reaction [nickel chloride results in increased expression of IL1B protein]
Luteolin results in decreased expression of IL1B protein
Luteolin results in decreased expression of IL1B mRNA
Luteolin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; Luteolin inhibits the reaction [Rotenone results in increased secretion of IL1B protein]
Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] affects the localization of and results in increased activity of NFKB1 protein]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] affects the localization of and results in increased activity of RELA protein]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in decreased secretion of INS1 protein]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased degradation of NFKBIA protein]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; Luteolin inhibits the reaction [bisphenol A results in decreased expression of IL1B protein]; Luteolin inhibits the reaction [cobaltous chloride results in increased expression of IL1B protein]; Luteolin inhibits the reaction [Doxorubicin results in increased expression of IL1B protein]; Luteolin inhibits the reaction [Freund's Adjuvant results in increased expression of IL1B protein]; Luteolin inhibits the reaction [lipoteichoic acid results in increased expression of IL1B] 		CTD PMID:18090225 PMID:18946510 PMID:19557821 PMID:20685402 PMID:24134915 More... NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601 		JBrowse link
G Il27 interleukin 27 multiple interactions ISO Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of IL27 mRNA]; Luteolin inhibits the reaction [Poly I-C results in increased expression of IL27 mRNA] CTD PMID:19426678 NCBI chr 1:190,603,684...190,609,292
Ensembl chr 1:190,603,522...190,609,258 		JBrowse link
G Il3 interleukin 3 multiple interactions EXP Luteolin inhibits the reaction [Calcimycin results in increased expression of IL3 mRNA] CTD PMID:17950587 NCBI chr10:38,906,460...38,908,810
Ensembl chr10:38,906,460...38,908,810 		JBrowse link
G Il33 interleukin 33 multiple interactions ISO Luteolin inhibits the reaction [Irinotecan results in increased expression of IL33 mRNA]; Luteolin inhibits the reaction [Irinotecan results in increased secretion of IL33 protein] CTD PMID:34699766 NCBI chr 1:237,115,478...237,149,897
Ensembl chr 1:237,115,572...237,150,901 		JBrowse link
G Il4 interleukin 4 multiple interactions
decreases expression 		ISO
EXP 		Luteolin inhibits the reaction [[Calcimycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL4]
Luteolin inhibits the reaction [Calcimycin results in increased expression of IL4 mRNA]
Luteolin results in decreased expression of IL4 protein 		CTD PMID:12755373 PMID:16343431 PMID:16601352 PMID:17950587 NCBI chr10:38,272,003...38,277,549
Ensembl chr10:38,272,003...38,277,549 		JBrowse link
G Il5 interleukin 5 decreases expression ISO Luteolin results in decreased expression of IL5 protein CTD PMID:12755373 NCBI chr10:38,375,132...38,378,003
Ensembl chr10:38,375,132...38,378,003 		JBrowse link
G Il6 interleukin 6 multiple interactions ISO
EXP 		Luteolin inhibits the reaction [chromium hexavalent ion results in increased secretion of IL6 protein]; Luteolin inhibits the reaction [decabromobiphenyl ether results in increased expression of IL6 protein]; Luteolin inhibits the reaction [IL1B protein results in increased secretion of IL6 protein]; Luteolin inhibits the reaction [nickel chloride results in increased expression of IL6 protein]
Luteolin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of IL6 protein]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Luteolin inhibits the reaction [Poly I-C results in increased expression of IL6 mRNA]; Luteolin inhibits the reaction [TNF protein results in increased expression of IL6 protein]
Luteolin inhibits the reaction [bisphenol A results in decreased expression of IL6 protein]; Luteolin inhibits the reaction [Freund's Adjuvant results in increased expression of IL6 protein] 		CTD PMID:11123379 PMID:18720166 PMID:19426678 PMID:24134915 PMID:25448439 More... NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610 		JBrowse link
G Ins1 insulin 1 multiple interactions ISO
EXP 		Luteolin inhibits the reaction [INS1 protein affects the localization of SLC2A4 protein]; Luteolin inhibits the reaction [INS1 protein results in increased activity of AKT1 protein]; Luteolin inhibits the reaction [INS1 protein results in increased phosphorylation of INSR protein]; Luteolin inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]
Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in decreased secretion of INS1 protein]; Luteolin inhibits the reaction [Fructose results in increased expression of INS1 protein] 		CTD PMID:18090225 PMID:18591783 PMID:25169908 NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682 		JBrowse link
G Insr insulin receptor multiple interactions ISO Luteolin inhibits the reaction [INS1 protein results in increased phosphorylation of INSR protein] CTD PMID:18591783 NCBI chr12:5,991,135...6,129,275
Ensembl chr12:5,981,835...6,128,803 		JBrowse link
G Irf3 interferon regulatory factor 3 multiple interactions ISO Luteolin inhibits the reaction [Lipopolysaccharides promotes the reaction [IRF3 protein binds to IRF3 protein]]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of IRF3 protein] CTD PMID:19426678 NCBI chr 1:104,616,608...104,621,402
Ensembl chr 1:104,616,469...104,621,401 		JBrowse link
G Jak1 Janus kinase 1 multiple interactions ISO Luteolin inhibits the reaction [Cisplatin results in increased phosphorylation of JAK1 protein] CTD PMID:38103742 NCBI chr 5:120,895,606...121,004,207
Ensembl chr 5:120,896,046...120,996,758 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions
decreases expression
decreases phosphorylation 		ISO
EXP 		HMOX2 protein affects the reaction [Luteolin inhibits the reaction [Indican results in increased expression of JUN protein]]; Luteolin analog inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of JUN protein]; Luteolin inhibits the reaction [Indican results in increased expression of JUN protein]; Luteolin inhibits the reaction [TNF protein results in increased activity of [FOS protein binds to JUN protein]]; Luteolin inhibits the reaction [TNF protein results in increased expression of JUN mRNA]; Luteolin promotes the reaction [TNF protein results in increased phosphorylation of JUN protein]; Luteolin results in decreased phosphorylation of and results in decreased activity of JUN protein
Luteolin results in decreased expression of JUN mRNA
Luteolin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of JUN protein]
Luteolin results in decreased phosphorylation of JUN protein 		CTD PMID:15322261 PMID:15334063 PMID:16343431 PMID:17950587 PMID:30133131 More... NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285 		JBrowse link
G Junb JunB proto-oncogene, AP-1 transcription factor subunit decreases activity ISO Luteolin results in decreased activity of JUNB protein CTD PMID:16343431 NCBI chr19:40,081,126...40,082,910
Ensembl chr19:40,073,541...40,085,218 		JBrowse link
G Jund JunD proto-oncogene, AP-1 transcription factor subunit decreases activity ISO Luteolin results in decreased activity of JUND protein CTD PMID:16343431 NCBI chr16:18,768,093...18,769,771
Ensembl chr16:18,764,985...18,782,148 		JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 multiple interactions ISO Luteolin inhibits the reaction [decabromobiphenyl ether results in decreased expression of KEAP1 protein] CTD PMID:33675858 NCBI chr 8:28,044,555...28,054,042
Ensembl chr 8:28,044,555...28,054,042 		JBrowse link
G Lrrk2 leucine-rich repeat kinase 2 multiple interactions ISO [Rotenone co-treated with Luteolin] results in increased expression of LRRK2 mRNA; Luteolin inhibits the reaction [Rotenone results in increased expression of LRRK2 mRNA] CTD PMID:30207190 NCBI chr 7:124,706,246...124,867,234
Ensembl chr 7:124,706,080...124,867,239 		JBrowse link
G Lss lanosterol synthase decreases expression EXP Luteolin results in decreased expression of LSS mRNA CTD PMID:31201582 NCBI chr20:12,090,641...12,118,230
Ensembl chr20:12,073,543...12,118,253 		JBrowse link
G Maoa monoamine oxidase A decreases activity
multiple interactions 		ISO Luteolin results in decreased activity of MAOA protein
Luteolin inhibits the reaction [[MAOA protein results in increased metabolism of Serotonin] which results in increased abundance of hydroxyindoleacetaldehyde]; Luteolin inhibits the reaction [MAOA protein results in increased abundance of hydroxyindoleacetaldehyde]; Luteolin inhibits the reaction [MAOA protein results in increased metabolism of Serotonin] 		CTD PMID:23009399 NCBI chr  X:8,615,239...8,681,372
Ensembl chr  X:8,615,239...8,682,631 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO Luteolin results in increased expression of and results in increased lipidation of MAP1LC3B protein; mirdametinib inhibits the reaction [Luteolin results in increased expression of and results in increased lipidation of MAP1LC3B protein] CTD PMID:32268164 NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358
Ensembl chr16:66,574,407...66,584,358 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
decreases expression
decreases phosphorylation
increases phosphorylation
increases activity 		ISO
EXP 		2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Luteolin results in increased phosphorylation of MAPK1 protein]; Luteolin inhibits the reaction [chromium hexavalent ion results in increased phosphorylation of MAPK1 protein]; Luteolin inhibits the reaction [decabromobiphenyl ether results in increased phosphorylation of MAPK1 protein]; Luteolin inhibits the reaction [Glucose results in increased phosphorylation of MAPK1 protein]; Luteolin inhibits the reaction [TNF protein results in increased activity of MAPK1 protein]; Luteolin results in decreased phosphorylation of and results in decreased activity of MAPK1 protein; mirdametinib inhibits the reaction [Luteolin results in increased phosphorylation of MAPK1 protein]
Luteolin results in decreased expression of MAPK1 mRNA
Luteolin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]
Luteolin results in decreased phosphorylation of MAPK1 protein
Luteolin results in increased activity of MAPK1 protein 		CTD PMID:10718847 PMID:15322261 PMID:17950587 PMID:17982879 PMID:19344998 More... NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825 		JBrowse link
G Mapk10 mitogen activated protein kinase 10 increases phosphorylation ISO Luteolin results in increased phosphorylation of MAPK10 protein CTD PMID:21601631 NCBI chr14:6,802,247...7,094,103
Ensembl chr14:6,802,295...7,094,100 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
decreases phosphorylation
increases phosphorylation
increases activity 		ISO
EXP 		2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Luteolin results in increased phosphorylation of MAPK3 protein]; Luteolin inhibits the reaction [chromium hexavalent ion results in increased phosphorylation of MAPK3 protein]; Luteolin inhibits the reaction [decabromobiphenyl ether results in increased phosphorylation of MAPK3 protein]; Luteolin inhibits the reaction [Glucose results in increased phosphorylation of MAPK3 protein]; Luteolin results in decreased phosphorylation of and results in decreased activity of MAPK3 protein; mirdametinib inhibits the reaction [Luteolin results in increased phosphorylation of MAPK3 protein]
Luteolin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]
Luteolin results in decreased phosphorylation of MAPK3 protein
Luteolin inhibits the reaction [lipoteichoic acid results in increased phosphorylation of MAPK3 protein]; Luteolin results in decreased phosphorylation of and results in decreased activity of MAPK3 protein
Luteolin results in increased activity of MAPK3 protein 		CTD PMID:10718847 PMID:17950587 PMID:17982879 PMID:19344998 PMID:19557821 More... NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411 		JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions
increases phosphorylation 		ISO Luteolin analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK8 protein]; Luteolin promotes the reaction [TNF protein results in increased phosphorylation of MAPK8 protein]; Luteolin results in decreased phosphorylation of and results in decreased activity of MAPK8 protein
Luteolin results in increased phosphorylation of MAPK8 protein 		CTD PMID:10718847 PMID:15334063 PMID:21601631 PMID:30133131 NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427 		JBrowse link
G Mapk9 mitogen-activated protein kinase 9 increases phosphorylation
multiple interactions 		ISO Luteolin results in increased phosphorylation of MAPK9 protein
Luteolin analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK9 protein] 		CTD PMID:21601631 PMID:30133131 NCBI chr10:34,670,750...34,711,972
Ensembl chr10:34,670,756...34,712,228 		JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member decreases expression ISO Luteolin results in decreased expression of MCL1 protein CTD PMID:33727136 NCBI chr 2:185,884,840...185,912,532
Ensembl chr 2:185,908,168...185,938,782 		JBrowse link
G Mdm2 MDM2 proto-oncogene multiple interactions
increases expression 		EXP Luteolin promotes the reaction [Hydrogen Peroxide results in increased expression of MDM2 mRNA]
Luteolin results in increased expression of MDM2 mRNA 		CTD PMID:27525270 PMID:31201582 NCBI chr 7:55,176,558...55,201,757
Ensembl chr 7:55,176,560...55,200,791 		JBrowse link
G Mir320a microRNA 320a multiple interactions EXP luteolin inhibits the reaction [ischemia-reperfusion injury increases expression of Mir320a miRNA in nucleus] RGD PMID:31089916 RGD:155882543 NCBI chr15:51,926,088...51,926,169
Ensembl chr15:51,926,088...51,926,169 		JBrowse link
G Mmp1 matrix metallopeptidase 1 decreases expression ISO Luteolin results in decreased expression of MMP1 mRNA; Luteolin results in decreased expression of MMP1 protein CTD PMID:21112745 NCBI chr 8:12,943,453...12,963,966
Ensembl chr 8:12,943,453...12,963,964 		JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions
increases expression
decreases secretion 		ISO Luteolin analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]; Luteolin analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 protein]; Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of MMP9 protein]; Luteolin inhibits the reaction [EGF protein results in increased secretion of MMP9 protein]
Luteolin results in increased expression of MMP9 protein
Luteolin inhibits the reaction [Carbon Tetrachloride results in decreased expression of MMP9 protein]
Luteolin results in decreased secretion of MMP9 protein 		CTD PMID:10556937 PMID:15135307 PMID:19747501 PMID:25448439 PMID:30133131 NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442 		JBrowse link
G Mpo myeloperoxidase multiple interactions EXP Luteolin inhibits the reaction [Doxorubicin results in increased activity of MPO protein] CTD PMID:33827303 NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056 		JBrowse link
G Mylk myosin light chain kinase multiple interactions ISO Luteolin inhibits the reaction [decabromobiphenyl ether results in increased expression of MYLK protein]; triptolide inhibits the reaction [Luteolin inhibits the reaction [decabromobiphenyl ether results in increased expression of MYLK protein]] CTD PMID:33675858 NCBI chr11:79,288,243...79,535,450
Ensembl chr11:79,288,243...79,535,659 		JBrowse link
G Nfat5 nuclear factor of activated T-cells 5 multiple interactions ISO Luteolin inhibits the reaction [Sodium Chloride results in increased expression of NFAT5 mRNA] CTD PMID:26800359 NCBI chr19:52,108,982...52,196,418
Ensembl chr19:52,109,483...52,196,418 		JBrowse link
G Nfe2 nuclear factor, erythroid 2 decreases expression EXP Luteolin results in decreased expression of NFE2 mRNA CTD PMID:31201582 NCBI chr 7:136,261,234...136,273,850
Ensembl chr 7:136,261,236...136,268,585 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 multiple interactions
increases activity 		EXP
ISO 		[Luteolin results in increased activity of NFE2L2 protein] which results in decreased susceptibility to 1-Methyl-4-phenylpyridinium; Luteolin affects the localization of and results in increased activity of NFE2L2 protein; Luteolin inhibits the reaction [bisphenol A results in decreased expression of NFE2L2 protein]
luteolin inhibits the reaction [ischemia-reperfusion injury increases expression of Nfe2l2 protein in nucleus]
Luteolin promotes the reaction [Rotenone results in increased expression of NFE2L2 mRNA]
[Luteolin results in increased phosphorylation of and affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of SESN2 mRNA; Luteolin inhibits the reaction [decabromobiphenyl ether results in decreased expression of NFE2L2 protein]; Luteolin inhibits the reaction [Irinotecan results in increased expression of NFE2L2 mRNA]; Luteolin promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] affects the localization of NFE2L2 protein]; Luteolin results in increased phosphorylation of and affects the localization of and results in increased activity of NFE2L2 protein 		CTD
RGD		 PMID:17982879 PMID:22864849 PMID:30207190 PMID:31091348 PMID:32407927 More... RGD:155882543 NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090 		JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions ISO
EXP 		Luteolin inhibits the reaction [decabromobiphenyl ether results in increased phosphorylation of and affects the localization of NFKB1 protein]; Luteolin inhibits the reaction [TNF protein results in increased activity of NFKB1 protein]
Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] affects the localization of and results in increased activity of NFKB1 protein] 		CTD PMID:15334063 PMID:18090225 PMID:33675858 NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088 		JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions ISO
EXP 		Luteolin inhibits the reaction [chromium hexavalent ion results in increased degradation of NFKBIA protein]; Luteolin inhibits the reaction [decabromobiphenyl ether results in increased phosphorylation of NFKBIA protein]; Luteolin inhibits the reaction [Glucose results in increased degradation of and results in decreased expression of NFKBIA protein]; Luteolin inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; Luteolin inhibits the reaction [TNF protein results in increased phosphorylation of [NFKBIB protein binds to NFKBIA protein]]
Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased degradation of NFKBIA protein]
Luteolin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in decreased expression of and results in increased phosphorylation of NFKBIA protein]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein] 		CTD PMID:11123379 PMID:15322261 PMID:16934226 PMID:18090225 PMID:19557821 More... NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072 		JBrowse link
G Nfkbib NFKB inhibitor beta multiple interactions ISO Luteolin inhibits the reaction [TNF protein results in increased phosphorylation of [NFKBIB protein binds to NFKBIA protein]] CTD PMID:15322261 NCBI chr 1:93,173,817...93,181,387
Ensembl chr 1:93,173,820...93,326,366 		JBrowse link
G Nlrp1a NLR family, pyrin domain containing 1A multiple interactions EXP Luteolin inhibits the reaction [Freund's Adjuvant results in increased expression of NLRP1A protein] CTD PMID:25450234 NCBI chr10:56,277,134...56,332,229
Ensembl chr10:56,277,134...56,323,880 		JBrowse link
G Nlrp3 NLR family, pyrin domain containing 3 multiple interactions ISO Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein] CTD PMID:34217685 NCBI chr10:44,826,299...44,853,373
Ensembl chr10:44,828,014...44,853,394 		JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions
decreases expression 		ISO
EXP 		Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]
Luteolin results in decreased expression of NOS2 mRNA
Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of NOS2 mRNA]; Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of NOS2 protein]; Luteolin inhibits the reaction [Irinotecan results in increased expression of NOS2 mRNA]
Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased expression of NOS2 protein] 		CTD PMID:16934226 PMID:18090225 PMID:19426678 PMID:25448439 PMID:34699766 More... NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880 		JBrowse link
G Nos3 nitric oxide synthase 3 multiple interactions EXP [Luteolin co-treated with linarin] results in increased expression of NOS3 protein modified form CTD PMID:29052401 NCBI chr 4:11,686,088...11,706,604
Ensembl chr 4:11,686,268...11,706,664 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions ISO Luteolin inhibits the reaction [decabromobiphenyl ether results in decreased expression of NQO1 protein]; Luteolin inhibits the reaction [Irinotecan results in increased expression of NQO1 mRNA]; PPARG protein affects the reaction [Luteolin inhibits the reaction [Irinotecan results in increased expression of NQO1 mRNA]] CTD PMID:33675858 PMID:34699766 NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260 		JBrowse link
G Nr1d1 nuclear receptor subfamily 1, group D, member 1 decreases expression ISO Luteolin results in decreased expression of NR1D1 mRNA CTD PMID:19397994 NCBI chr10:84,224,599...84,231,812
Ensembl chr10:84,224,540...84,231,812 		JBrowse link
G Nsdhl NAD(P) dependent 3-beta-hydroxysteroid dehydrogenase NSDHL decreases expression EXP Luteolin results in decreased expression of NSDHL mRNA CTD PMID:31201582 NCBI chr  X:155,817,301...155,848,224
Ensembl chr  X:155,817,340...155,848,220 		JBrowse link
G Ocln occludin multiple interactions ISO Luteolin inhibits the reaction [decabromobiphenyl ether results in decreased expression of OCLN mRNA]; Luteolin inhibits the reaction [decabromobiphenyl ether results in decreased expression of OCLN protein] CTD PMID:33675858 NCBI chr 2:33,391,303...33,442,207
Ensembl chr 2:33,391,303...33,430,411 		JBrowse link
G P2rx4 purinergic receptor P2X 4 multiple interactions EXP Luteolin inhibits the reaction [Freund's Adjuvant results in increased expression of P2RX4 protein] CTD PMID:25450234 NCBI chr12:39,505,438...39,523,349
Ensembl chr12:39,505,438...39,523,094 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases cleavage 		ISO
EXP 		[Luteolin co-treated with Paclitaxel] results in decreased expression of PARP1 protein; CYP1A1 protein promotes the reaction [Luteolin results in increased cleavage of PARP1 protein]; CYP1A2 protein promotes the reaction [Luteolin results in increased cleavage of PARP1 protein]; Luteolin inhibits the reaction [[Lead co-treated with Cadmium co-treated with Mercury co-treated with Copper co-treated with Zinc co-treated with Manganese co-treated with Chromium co-treated with Nickel] results in increased cleavage of PARP1 protein]; Luteolin inhibits the reaction [Metals, Heavy results in increased cleavage of PARP1 protein]; mirdametinib promotes the reaction [Luteolin results in increased cleavage of PARP1 protein]
Luteolin inhibits the reaction [Tunicamycin results in increased expression of PARP1 protein modified form] 		CTD PMID:12168845 PMID:24525192 PMID:29115570 PMID:31201582 PMID:32268164 More... NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567 		JBrowse link
G Pdgfb platelet derived growth factor subunit B multiple interactions EXP Luteolin inhibits the reaction [Methamphetamine results in increased expression of PDGFB mRNA] CTD PMID:32035215 NCBI chr 7:113,419,882...113,438,343
Ensembl chr 7:113,420,710...113,438,343 		JBrowse link
G Pkm pyruvate kinase M1/2 increases activity ISO Luteolin results in increased activity of PKM protein CTD PMID:25388478 NCBI chr 8:68,949,731...68,975,394
Ensembl chr 8:68,948,815...68,975,396 		JBrowse link
G Plk1 polo-like kinase 1 decreases expression ISO Luteolin results in decreased expression of PLK1 protein CTD PMID:22926442 NCBI chr 1:186,147,658...186,157,637
Ensembl chr 1:186,147,658...186,157,637 		JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma increases expression
multiple interactions 		ISO Luteolin results in increased expression of PPARG mRNA
[kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in decreased expression of PPARG mRNA]; dorsomorphin inhibits the reaction [[kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in decreased expression of PPARG mRNA]]; Luteolin inhibits the reaction [Irinotecan results in decreased expression of PPARG mRNA]; PPARG protein affects the reaction [Luteolin inhibits the reaction [Irinotecan results in increased expression of NQO1 mRNA]]; PPARG protein affects the reaction [Luteolin inhibits the reaction [Irinotecan results in increased expression of TNF mRNA]] 		CTD PMID:34699766 PMID:37308028 NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104 		JBrowse link
G Prkaa1 protein kinase AMP-activated catalytic subunit alpha 1 multiple interactions ISO [kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in decreased expression of PRKAA1 mRNA]; dorsomorphin inhibits the reaction [[kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in decreased expression of PRKAA1 mRNA]] CTD PMID:37308028 NCBI chr 2:55,967,766...56,003,450
Ensembl chr 2:55,967,351...56,003,450 		JBrowse link
G Prkca protein kinase C, alpha multiple interactions ISO Luteolin analog inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of PRKCA protein] CTD PMID:30133131 NCBI chr10:93,388,991...93,787,617
Ensembl chr10:93,388,991...93,787,572 		JBrowse link
G Prkn parkin RBR E3 ubiquitin protein ligase multiple interactions ISO [Rotenone co-treated with Luteolin] results in increased expression of PRKN mRNA; Luteolin inhibits the reaction [Rotenone results in decreased expression of PRKN mRNA] CTD PMID:30207190 NCBI chr 1:51,236,410...52,430,242
Ensembl chr 1:51,210,330...52,430,304 		JBrowse link
G Psca prostate stem cell antigen decreases expression ISO Luteolin results in decreased expression of PSCA mRNA CTD PMID:18331776 PMID:19397994 NCBI chr 7:108,483,974...108,492,098
Ensembl chr 7:108,484,184...108,492,097 		JBrowse link
G Pten phosphatase and tensin homolog multiple interactions EXP Luteolin inhibits the reaction [Methamphetamine results in increased expression of PTEN protein] CTD PMID:32035215 NCBI chr 1:240,043,707...240,110,330
Ensembl chr 1:240,043,707...240,110,330 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions
increases expression 		ISO
EXP 		Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of PTGS2 mRNA]; Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of PTGS2 protein]; Luteolin inhibits the reaction [Dust analog results in increased expression of PTGS2 mRNA]; Luteolin inhibits the reaction [Dust results in increased expression of PTGS2 mRNA]; Luteolin inhibits the reaction [Glucose results in increased expression of PTGS2 mRNA]; Luteolin inhibits the reaction [Glucose results in increased expression of PTGS2 protein]; Luteolin inhibits the reaction [Particulate Matter analog results in increased expression of PTGS2 mRNA]; Luteolin inhibits the reaction [Particulate Matter results in increased expression of PTGS2 mRNA]; Luteolin inhibits the reaction [Vehicle Emissions analog results in increased expression of PTGS2 mRNA]; Luteolin inhibits the reaction [Vehicle Emissions results in increased expression of PTGS2 mRNA]
Luteolin results in increased expression of PTGS2 mRNA
Luteolin inhibits the reaction [Cisplatin results in increased expression of PTGS2 protein] 		CTD PMID:16263508 PMID:19557821 PMID:23770416 PMID:25448439 PMID:31201582 NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320 		JBrowse link
G Ptk2 protein tyrosine kinase 2 multiple interactions
decreases phosphorylation 		ISO EGF protein inhibits the reaction [Luteolin results in decreased phosphorylation of PTK2 protein]; Luteolin inhibits the reaction [chromium hexavalent ion results in increased phosphorylation of PTK2 protein]; Luteolin inhibits the reaction [EGF protein results in increased phosphorylation of PTK2 protein] CTD PMID:15135307 PMID:25448439 NCBI chr 7:107,015,730...107,220,865
Ensembl chr 7:107,015,733...107,172,091 		JBrowse link
G Pycard PYD and CARD domain containing multiple interactions EXP Luteolin inhibits the reaction [Freund's Adjuvant results in increased expression of PYCARD protein] CTD PMID:25450234 NCBI chr 1:192,032,124...192,033,419
Ensembl chr 1:192,032,124...192,033,419 		JBrowse link
G Rac1 Rac family small GTPase 1 decreases expression ISO luteolin decreases expression of RAC1 protein in lung cancer cells RGD PMID:32256987 RGD:153345548 NCBI chr12:16,150,411...16,170,864
Ensembl chr12:16,128,649...16,172,109 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO
EXP 		HMOX2 protein affects the reaction [Luteolin inhibits the reaction [Indican results in increased expression of RELA protein]]; Luteolin analog inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of RELA protein]; Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased phosphorylation of and affects the localization of RELA protein]; Luteolin inhibits the reaction [chromium hexavalent ion results in increased activity of and affects the localization of RELA protein]; Luteolin inhibits the reaction [Glucose affects the localization of RELA protein]; Luteolin inhibits the reaction [Indican results in increased expression of RELA protein]; Luteolin inhibits the reaction [TNF protein affects the localization of RELA protein]; Luteolin inhibits the reaction [TNF protein results in increased activity of RELA protein]
Luteolin inhibits the reaction [Cisplatin results in increased expression of RELA protein]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein]
Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] affects the localization of and results in increased activity of RELA protein] 		CTD PMID:15113938 PMID:15334063 PMID:18090225 PMID:19557821 PMID:23770416 More... NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817 		JBrowse link
G Sele selectin E multiple interactions ISO Luteolin inhibits the reaction [TNF protein results in increased expression of SELE mRNA]; Luteolin inhibits the reaction [TNF protein results in increased expression of SELE protein] CTD PMID:15113938 NCBI chr13:78,935,997...78,945,905
Ensembl chr13:78,936,036...78,945,903 		JBrowse link
G Sesn2 sestrin 2 increases expression
multiple interactions 		ISO Luteolin results in increased expression of SESN2 mRNA; Luteolin results in increased expression of SESN2 protein
Luteolin inhibits the reaction [Tunicamycin results in increased expression of SESN2 mRNA]; Luteolin inhibits the reaction [Tunicamycin results in increased expression of SESN2 protein]
[Luteolin results in increased phosphorylation of and affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of SESN2 mRNA; SESN2 protein promotes the reaction [Luteolin inhibits the reaction [Tunicamycin results in increased expression of DDIT3 mRNA]] 		CTD PMID:32407927 NCBI chr 5:149,986,304...150,005,255
Ensembl chr 5:149,986,317...150,005,255 		JBrowse link
G Sfn stratifin increases expression ISO Luteolin results in increased expression of SFN mRNA; Luteolin results in increased expression of SFN protein CTD PMID:18331776 NCBI chr 5:151,110,582...151,111,854
Ensembl chr 5:151,110,530...151,111,995 		JBrowse link
G Slc16a1 solute carrier family 16 member 1 multiple interactions EXP [[Luteolin co-treated with Phloretin] results in decreased activity of SLC16A1 protein] which results in decreased uptake of Sodium Oxybate; [Luteolin results in decreased activity of SLC16A1 protein] which results in decreased uptake of Sodium Oxybate CTD PMID:17108059 NCBI chr 2:194,805,556...194,832,966
Ensembl chr 2:194,812,502...194,832,977 		JBrowse link
G Slc22a6 solute carrier family 22 member 6 decreases activity ISO Luteolin results in decreased activity of SLC22A6 protein CTD PMID:32159797 NCBI chr 1:214,951,493...214,960,317
Ensembl chr 1:214,951,867...214,960,311 		JBrowse link
G Slc22a8 solute carrier family 22 member 8 decreases activity ISO Luteolin results in decreased activity of SLC22A8 protein CTD PMID:32159797 NCBI chr 1:214,925,506...214,945,516
Ensembl chr 1:214,925,508...214,946,588 		JBrowse link
G Slc2a1 solute carrier family 2 member 1 multiple interactions ISO Luteolin inhibits the reaction [SLC2A1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose] CTD PMID:36870413 NCBI chr 5:138,002,522...138,030,742
Ensembl chr 5:138,002,522...138,030,742 		JBrowse link
G Slc2a3 solute carrier family 2 member 3 multiple interactions ISO [Luteolin co-treated with Oxygen deficiency] results in decreased expression of SLC2A3 mRNA CTD PMID:20153296 NCBI chr 4:157,632,887...157,698,034
Ensembl chr 4:157,632,887...157,646,186 		JBrowse link
G Slc2a4 solute carrier family 2 member 4 multiple interactions ISO Luteolin inhibits the reaction [INS1 protein affects the localization of SLC2A4 protein] CTD PMID:18591783 NCBI chr10:55,164,721...55,170,289
Ensembl chr10:55,164,721...55,170,270 		JBrowse link
G Slc5a1 solute carrier family 5 member 1 multiple interactions ISO Luteolin inhibits the reaction [SLC5A1 protein results in increased uptake of methylglucoside] CTD PMID:17495124 NCBI chr14:81,778,495...81,843,084
Ensembl chr14:81,778,348...81,846,624 		JBrowse link
G Slco1c1 solute carrier organic anion transporter family, member 1c1 decreases activity
multiple interactions 		EXP Luteolin results in decreased activity of SLCO1B1 protein
[Luteolin results in decreased activity of SLCO1B1 protein] which results in decreased uptake of Bosentan; [Luteolin results in decreased activity of SLCO1B1 protein] which results in decreased uptake of Methotrexate 		CTD PMID:32259555 NCBI chr 4:176,197,736...176,244,401
Ensembl chr 4:176,197,741...176,244,395 		JBrowse link
G Snai1 snail family transcriptional repressor 1 multiple interactions ISO Luteolin inhibits the reaction [decabromobiphenyl ether results in increased expression of SNAI1 protein] CTD PMID:33675858 NCBI chr 3:176,667,476...176,671,965 JBrowse link
G Sod1 superoxide dismutase 1 affects activity
increases expression
multiple interactions 		ISO Luteolin affects the activity of SOD1 protein
Luteolin results in increased expression of SOD1 mRNA
Luteolin inhibits the reaction [Irinotecan results in decreased expression of SOD1 protein]; Luteolin inhibits the reaction [Irinotecan results in increased expression of SOD1 mRNA]
Luteolin inhibits the reaction [Carbon Tetrachloride results in increased activity of SOD1 protein] 		CTD PMID:18503759 PMID:19747501 PMID:34699766 NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399 		JBrowse link
G Sod2 superoxide dismutase 2 increases expression ISO Luteolin results in increased expression of SOD2 protein CTD PMID:32268164 NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168 		JBrowse link
G Sox4 SRY-box transcription factor 4 multiple interactions
decreases expression 		ISO Luteolin inhibits the reaction [SOX4 protein binds to GDF15 promoter]; SOX4 protein inhibits the reaction [Luteolin inhibits the reaction [SOX4 protein binds to GDF15 promoter]]; SOX4 protein inhibits the reaction [Luteolin results in decreased expression of GDF15 mRNA]
Luteolin results in decreased expression of SOX4 mRNA; Luteolin results in decreased expression of SOX4 protein 		CTD PMID:39231684 NCBI chr17:35,876,298...35,881,004
Ensembl chr17:35,875,756...35,884,024 		JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions ISO Luteolin inhibits the reaction [Tunicamycin results in increased expression of SREBF1 mRNA] CTD PMID:32407927 NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,507,152...45,529,164 		JBrowse link
G Star steroidogenic acute regulatory protein increases expression EXP Luteolin results in increased expression of STAR mRNA; Luteolin results in increased expression of STAR protein CTD PMID:31201582 NCBI chr16:72,969,824...72,974,447
Ensembl chr16:72,961,518...72,974,447 		JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions
decreases phosphorylation 		ISO Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of STAT3 protein]; Luteolin promotes the reaction [Paclitaxel results in decreased phosphorylation of STAT3 protein]; Paclitaxel promotes the reaction [Luteolin results in decreased phosphorylation of STAT3 protein]
Luteolin inhibits the reaction [Cisplatin results in increased phosphorylation of STAT3 protein] 		CTD PMID:24525192 PMID:25448439 PMID:38103742 NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359 		JBrowse link
G Tbk1 TANK-binding kinase 1 decreases activity ISO Luteolin results in decreased activity of TBK1 protein CTD PMID:19426678 NCBI chr 7:58,963,319...58,996,357
Ensembl chr 7:58,963,325...58,996,357 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO [kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in decreased expression of PPARG mRNA]; [kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in decreased expression of PRKAA1 mRNA]; [kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; [kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; dorsomorphin inhibits the reaction [[kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in decreased expression of PPARG mRNA]]; dorsomorphin inhibits the reaction [[kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in decreased expression of PRKAA1 mRNA]]; dorsomorphin inhibits the reaction [[kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]]; Luteolin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] CTD PMID:37308028 NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899 		JBrowse link
G Tjp1 tight junction protein 1 multiple interactions ISO 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Luteolin inhibits the reaction [decabromobiphenyl ether results in decreased expression of TJP1 protein]]; Luteolin inhibits the reaction [decabromobiphenyl ether results in decreased expression of TJP1 mRNA]; Luteolin inhibits the reaction [decabromobiphenyl ether results in decreased expression of TJP1 protein]; ML 7 inhibits the reaction [Luteolin inhibits the reaction [decabromobiphenyl ether results in decreased expression of TJP1 protein]]; triptolide inhibits the reaction [Luteolin inhibits the reaction [decabromobiphenyl ether results in decreased expression of TJP1 protein]] CTD PMID:33675858 NCBI chr 1:128,260,330...128,505,018
Ensembl chr 1:128,260,330...128,505,158 		JBrowse link
G Tm7sf2 transmembrane 7 superfamily member 2 decreases expression EXP Luteolin results in decreased expression of TM7SF2 mRNA CTD PMID:31201582 NCBI chr 1:212,785,217...212,789,572
Ensembl chr 1:212,785,217...212,789,557 		JBrowse link
G Tnf tumor necrosis factor multiple interactions
decreases expression 		ISO
EXP 		Luteolin inhibits the reaction [chromium hexavalent ion results in increased secretion of TNF protein]; Luteolin inhibits the reaction [decabromobiphenyl ether results in increased expression of TNF protein]; Luteolin inhibits the reaction [Glucose results in increased expression of TNF mRNA]; Luteolin inhibits the reaction [Glucose results in increased expression of TNF protein]; Luteolin inhibits the reaction [Irinotecan results in increased expression of TNF mRNA]; Luteolin inhibits the reaction [nickel chloride results in increased expression of TNF protein]; Luteolin inhibits the reaction [TNF protein affects the localization of RELA protein]; Luteolin inhibits the reaction [TNF protein results in increased activity of [FOS protein binds to JUN protein]]; Luteolin inhibits the reaction [TNF protein results in increased activity of MAPK1 protein]; Luteolin inhibits the reaction [TNF protein results in increased activity of NFKB1 protein]; Luteolin inhibits the reaction [TNF protein results in increased activity of RELA protein]; Luteolin inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; Luteolin inhibits the reaction [TNF protein results in increased expression of BIRC2 protein]; Luteolin inhibits the reaction [TNF protein results in increased expression of FOS mRNA]; Luteolin inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; Luteolin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; Luteolin inhibits the reaction [TNF protein results in increased expression of JUN mRNA]; Luteolin inhibits the reaction [TNF protein results in increased expression of SELE mRNA]; Luteolin inhibits the reaction [TNF protein results in increased expression of SELE protein]; Luteolin inhibits the reaction [TNF protein results in increased expression of TNFAIP3 protein]; Luteolin inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; Luteolin inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; Luteolin inhibits the reaction [TNF protein results in increased phosphorylation of [NFKBIB protein binds to NFKBIA protein]]; Luteolin promotes the reaction [TNF protein results in increased cleavage of and results in increased activity of CASP8 protein]; Luteolin promotes the reaction [TNF protein results in increased phosphorylation of JUN protein]; Luteolin promotes the reaction [TNF protein results in increased phosphorylation of MAPK8 protein]; PPARG protein affects the reaction [Luteolin inhibits the reaction [Irinotecan results in increased expression of TNF mRNA]]
Luteolin results in decreased expression of TNF protein
Luteolin results in decreased expression of TNF mRNA
Luteolin inhibits the reaction [Cisplatin results in increased expression of TNF protein]; Luteolin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Luteolin inhibits the reaction [Poly I-C results in increased expression of TNF mRNA]; Luteolin inhibits the reaction [TNF protein results in increased expression of IL6 protein]
Luteolin inhibits the reaction [bisphenol A results in decreased expression of TNF protein]; Luteolin inhibits the reaction [Calcimycin results in increased expression of TNF mRNA]; Luteolin inhibits the reaction [cobaltous chloride results in increased expression of TNF protein]; Luteolin inhibits the reaction [Doxorubicin results in increased expression of TNF protein]; Luteolin inhibits the reaction [Freund's Adjuvant results in increased expression of TNF protein] 		CTD PMID:11123379 PMID:15113938 PMID:15322261 PMID:15334063 PMID:16934226 More... NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303 		JBrowse link
G Tnfaip3 TNF alpha induced protein 3 multiple interactions ISO Luteolin inhibits the reaction [TNF protein results in increased expression of TNFAIP3 protein] CTD PMID:15334063 NCBI chr 1:15,528,921...15,543,993
Ensembl chr 1:15,528,921...15,543,979 		JBrowse link
G Tnfsf10 TNF superfamily member 10 multiple interactions ISO Luteolin promotes the reaction [TNFSF10 protein results in increased activity of CASP3 protein]; Luteolin promotes the reaction [TNFSF10 protein results in increased activity of CASP8 protein]; Luteolin promotes the reaction [TNFSF10 protein results in increased ubiquitination of and results in increased degradation of and results in decreased expression of XIAP protein] CTD PMID:16140950 NCBI chr 2:112,136,550...112,155,903 JBrowse link
G Top1 DNA topoisomerase I multiple interactions EXP Luteolin binds to and results in decreased activity of TOP1 protein CTD PMID:12027807 NCBI chr 3:169,713,195...169,796,330
Ensembl chr 3:169,713,130...169,796,327 		JBrowse link
G Tp53 tumor protein p53 multiple interactions
decreases expression
increases expression 		ISO
EXP 		Fluorouracil promotes the reaction [Luteolin results in increased expression of TRP53 protein]; Luteolin inhibits the reaction [Cisplatin results in increased expression of TRP53 protein]; Luteolin promotes the reaction [Fluorouracil results in increased expression of TRP53 protein]
Luteolin results in decreased expression of TRP53 mRNA
Luteolin results in increased expression of TP53 mRNA
Luteolin inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein]; Luteolin inhibits the reaction [Methamphetamine results in increased expression of TP53 protein] 		CTD PMID:23770416 PMID:27525270 PMID:31201582 PMID:31288002 PMID:32035215 More... NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299 		JBrowse link
G Tp53i3 tumor protein p53 inducible protein 3 increases expression ISO Luteolin results in increased expression of TP53I3 mRNA; Luteolin results in increased expression of TP53I3 protein CTD PMID:18331776 PMID:19397994 NCBI chr 6:33,537,779...33,545,204 JBrowse link
G Tp63 tumor protein p63 increases expression ISO Luteolin results in increased expression of TP63 protein CTD PMID:18331776 PMID:19397994 NCBI chr11:88,343,647...88,554,543
Ensembl chr11:88,343,651...88,554,177 		JBrowse link
G Tp73 tumor protein p73 increases expression ISO Luteolin results in increased expression of TP73 protein CTD PMID:18331776 PMID:19397994 NCBI chr 5:169,903,801...169,988,075
Ensembl chr 5:169,903,801...169,963,552 		JBrowse link
G Txn1 thioredoxin 1 multiple interactions ISO Luteolin promotes the reaction [Rotenone results in increased expression of TXN1 mRNA] CTD PMID:30207190 NCBI chr 5:77,507,455...77,519,685
Ensembl chr 5:77,507,321...77,520,307 		JBrowse link
G Txnrd1 thioredoxin reductase 1 decreases activity ISO Luteolin results in decreased activity of TXNRD1 protein CTD PMID:31288002 NCBI chr 7:22,717,620...22,802,553
Ensembl chr 7:22,719,317...22,739,817 		JBrowse link
G Tyr tyrosinase increases expression ISO Luteolin results in increased expression of TYR mRNA CTD PMID:21071833 NCBI chr 1:150,527,687...150,622,857
Ensembl chr 1:150,527,687...150,622,857 		JBrowse link
G Ugt1a1 UDP glucuronosyltransferase family 1 member A1 multiple interactions
increases expression 		ISO Luteolin inhibits the reaction [Benzo(a)pyrene results in increased expression of UGT1A1 mRNA]
Luteolin results in increased expression of UGT1A1 mRNA 		CTD PMID:20403331 PMID:29584932 NCBI chr 9:96,249,143...96,256,264
Ensembl chr 9:96,144,786...96,256,264 		JBrowse link
G Ugt1a2 UDP glucuronosyltransferase 1 family, polypeptide A2 affects glucuronidation
increases glucuronidation 		ISO UGT1A3 mutant form affects the glucuronidation of Luteolin
UGT1A3 protein results in increased glucuronidation of Luteolin 		CTD PMID:16738032 NCBI chr 9:96,239,019...96,256,264
Ensembl chr 9:96,144,786...96,256,264 		JBrowse link
G Ugt1a9 UDP glucuronosyltransferase family 1 member A9 increases glucuronidation ISO UGT1A9 protein results in increased glucuronidation of Luteolin CTD PMID:32009392 NCBI chr 9:96,144,786...96,256,264
Ensembl chr 9:96,144,786...96,256,264 		JBrowse link
G Vav3 vav guanine nucleotide exchange factor 3 decreases expression ISO Luteolin results in decreased expression of VAV3 mRNA CTD PMID:19397994 NCBI chr 2:199,699,861...200,042,344
Ensembl chr 2:199,700,445...200,042,343 		JBrowse link
G Vcam1 vascular cell adhesion molecule 1 multiple interactions ISO Luteolin inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; Luteolin inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] CTD PMID:15113938 NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:206,723,044...206,742,801 		JBrowse link
G Vegfa vascular endothelial growth factor A decreases expression
multiple interactions 		ISO Luteolin results in decreased expression of VEGFA mRNA; Luteolin results in decreased expression of VEGFA protein
Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of VEGFA protein]; Luteolin inhibits the reaction [cobaltous chloride results in increased expression of VEGFA mRNA]; Luteolin inhibits the reaction [Oxygen deficiency results in increased expression of VEGFA mRNA]; Luteolin inhibits the reaction [Oxygen deficiency results in increased secretion of VEGFA protein] 		CTD PMID:19005980 PMID:20153296 PMID:25448439 PMID:26800359 PMID:36819991 More... NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194 		JBrowse link
G Vwf von Willebrand factor multiple interactions EXP Luteolin inhibits the reaction [Methamphetamine results in increased expression of VWF mRNA] CTD PMID:32035215 NCBI chr 4:160,042,900...160,177,757
Ensembl chr 4:160,047,982...160,177,757 		JBrowse link
G Wnt3 Wnt family member 3 decreases expression ISO Luteolin results in decreased expression of WNT3 protein CTD PMID:32268164 NCBI chr10:89,180,224...89,224,195
Ensembl chr10:89,216,801...89,224,195 		JBrowse link
G Xbp1 X-box binding protein 1 multiple interactions ISO Luteolin inhibits the reaction [Thapsigargin results in increased expression of XBP1 mRNA alternative form]; Luteolin inhibits the reaction [Tunicamycin results in increased expression of XBP1 mRNA alternative form] CTD PMID:32407927 NCBI chr14:84,604,623...84,609,707
Ensembl chr14:84,604,107...84,609,706 		JBrowse link
G Xdh xanthine dehydrogenase multiple interactions EXP Luteolin inhibits the reaction [Doxorubicin results in increased activity of XDH protein] CTD PMID:33827303 NCBI chr 6:27,282,319...27,344,022
Ensembl chr 6:27,282,057...27,344,350 		JBrowse link
G Xiap X-linked inhibitor of apoptosis multiple interactions ISO Luteolin promotes the reaction [TNFSF10 protein results in increased ubiquitination of and results in increased degradation of and results in decreased expression of XIAP protein] CTD PMID:16140950 NCBI chr  X:125,756,107...125,803,979
Ensembl chr  X:125,737,971...125,803,978 		JBrowse link
SB 203580 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca1 ATP binding cassette subfamily A member 1 multiple interactions ISO SB 203580 inhibits the reaction [Quercetin results in increased expression of ABCA1 mRNA]; SB 203580 inhibits the reaction [Quercetin results in increased expression of ABCA1 protein] CTD PMID:22711909 NCBI chr 5:72,473,676...72,596,563
Ensembl chr 5:72,473,676...72,596,473 		JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 multiple interactions ISO SB 203580 inhibits the reaction [Mercuric Chloride results in increased expression of and affects the localization of ABCC1 protein] CTD PMID:15585369 NCBI chr10:1,022,041...1,162,431
Ensembl chr10:1,038,947...1,162,404 		JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 multiple interactions ISO SB 203580 inhibits the reaction [Anisomycin results in increased expression of ABCC3 mRNA]; SB 203580 inhibits the reaction [Clotrimazole results in increased expression of ABCC3 mRNA] CTD PMID:27507784 NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,793,583...79,839,494 		JBrowse link
G Ace2 angiotensin converting enzyme 2 multiple interactions EXP SB 203580 inhibits the reaction [2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [ACE2 protein inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]]; SB 203580 inhibits the reaction [2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [ACE2 protein inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]]; SB 203580 inhibits the reaction [7-Ala-angiotensin (1-7) inhibits the reaction [ACE2 protein inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]]; SB 203580 inhibits the reaction [7-Ala-angiotensin (1-7) inhibits the reaction [ACE2 protein inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]] CTD PMID:27302421 NCBI chr  X:33,925,458...33,972,851
Ensembl chr  X:33,925,458...33,971,596 		JBrowse link
G Acta2 actin alpha 2, smooth muscle multiple interactions
decreases expression 		ISO SB 203580 inhibits the reaction [Amiodarone results in increased expression of ACTA2 mRNA]; SB 203580 inhibits the reaction [Amiodarone results in increased expression of ACTA2 protein]; SB 203580 inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]
SB 203580 results in decreased expression of ACTA2 mRNA 		CTD PMID:11591817 PMID:21712382 PMID:28694203 PMID:29673704 PMID:31071512 NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503 		JBrowse link
G Actg2 actin gamma 2, smooth muscle multiple interactions EXP SB203580 inhibited the reaction [[Leptin cotreatment with acetaldehyde] increased expression of aSMA protein in cultured rat hepatic stellate cells] RGD PMID:21294755 RGD:598108049 NCBI chr 4:117,579,513...117,604,379
Ensembl chr 4:117,579,514...117,604,295 		JBrowse link
G Adipoq adiponectin, C1Q and collagen domain containing multiple interactions
increases secretion
increases expression 		EXP
ISO 		SB 203580 inhibits the reaction [Ethanol results in decreased secretion of ADIPOQ protein]
SB 203580 inhibits the reaction [ADIPOQ protein results in increased expression of CXCL1 protein]; SB 203580 inhibits the reaction [ADIPOQ protein results in increased expression of CXCL8 protein]
SB 203580 results in increased secretion of ADIPOQ protein
SB 203580 results in increased expression of ADIPOQ mRNA 		CTD PMID:24412557 PMID:28176455 NCBI chr11:91,226,524...91,240,244
Ensembl chr11:91,226,180...91,240,169 		JBrowse link
G Adm adrenomedullin multiple interactions
increases secretion 		EXP SB 203580 inhibits the reaction [diphenylarsinic acid results in increased secretion of ADM protein]
SB 203580 results in increased secretion of ADM protein 		CTD PMID:28087833 NCBI chr 1:174,164,178...174,182,372
Ensembl chr 1:174,178,773...174,182,371 		JBrowse link
G Ager advanced glycosylation end product-specific receptor multiple interactions EXP SB 203580 inhibits the reaction [Vitamin A results in increased expression of AGER protein] CTD PMID:21807062 NCBI chr20:4,152,758...4,155,956
Ensembl chr20:4,151,965...4,155,685 		JBrowse link
G Ago2 argonaute RISC catalytic component 2 multiple interactions ISO SB 203580 inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased localization of AGO2 protein] CTD PMID:18476811 NCBI chr 7:106,907,209...106,994,124
Ensembl chr 7:106,918,125...106,993,980 		JBrowse link
G Agt angiotensinogen multiple interactions
decreases response to substance 		ISO
EXP 		SB 203580 inhibits the reaction [AGT protein modified form results in decreased susceptibility to Acetylcholine]; SB 203580 inhibits the reaction [AGT protein modified form results in increased expression of ARG1 protein]; SB 203580 inhibits the reaction [AGT protein modified form results in increased expression of ARG2 protein]
SB 203580 inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; SB 203580 inhibits the reaction [AGT protein modified form results in increased activity of GATA4 protein]; SB 203580 inhibits the reaction [AGT protein modified form results in increased expression of FGF2 mRNA]; SB 203580 inhibits the reaction [AGT protein modified form results in increased expression of FGF2 protein]; SB 203580 inhibits the reaction [AGT protein results in increased expression of POSTN mRNA]; SB 203580 inhibits the reaction [AGT protein results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [AGT protein results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [AGT protein results in increased expression of REG3G mRNA]; SB 203580 inhibits the reaction [AGT protein results in increased phosphorylation of CREB1 protein]; SB 203580 inhibits the reaction [Glucose results in increased expression of AGT mRNA]; SB 203580 inhibits the reaction [Glucose results in increased expression of AGT protein]
SB 203580 results in decreased susceptibility to AGT protein modified form 		CTD PMID:12130563 PMID:17485602 PMID:19145780 PMID:21108934 PMID:21289285 More... NCBI chr19:69,426,540...69,447,017
Ensembl chr19:69,421,638...69,446,944 		JBrowse link
G Ahr aryl hydrocarbon receptor multiple interactions
increases activity 		ISO
EXP 		[alpha-naphthoflavone binds to and results in decreased activity of AHR protein] results in decreased susceptibility to [SB 203580 results in increased expression of CYP1A1]; AHR protein affects the susceptibility to [SB 203580 results in increased expression of CYP1A1]
SB 203580 results in increased activity of AHR protein
[SB 203580 binds to and results in increased activity of AHR protein] which results in increased susceptibility to sunitinib
SB 203580 affects the localization of and affects the activity of AHR protein 		CTD PMID:15659807 PMID:21732638 PMID:24247421 NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901 		JBrowse link
G Aifm1 apoptosis inducing factor, mitochondria associated 1 multiple interactions ISO SB 203580 inhibits the reaction [nitrofen affects the localization of AIFM1 protein]
SB 203580 inhibits the reaction [Cadmium Chloride affects the localization of AIFM1 protein] 		CTD PMID:17439724 PMID:18506790 NCBI chr  X:132,528,107...132,567,237
Ensembl chr  X:132,528,107...132,567,237 		JBrowse link
G Akna AT-hook transcription factor multiple interactions EXP SB 203580 inhibits the reaction [T-2 Toxin results in decreased expression of AKNA mRNA] CTD PMID:29079362 NCBI chr 5:81,792,928...81,839,936
Ensembl chr 5:81,792,929...81,831,528 		JBrowse link
G Akr1b1 aldo-keto reductase family 1 member B1 multiple interactions EXP SB 203580 inhibits the reaction [Curcumin results in increased expression of AKR1B1 mRNA] CTD PMID:17640564 NCBI chr 4:63,899,222...63,913,315
Ensembl chr 4:63,899,222...63,913,315 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions
decreases phosphorylation
decreases activity 		ISO SB 203580 inhibits the reaction [arsenite results in increased phosphorylation of and results in increased activity of AKT1 protein]; SB 203580 inhibits the reaction [Indomethacin results in increased phosphorylation of AKT1 protein]; SB 203580 inhibits the reaction [N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the phosphorylation of AKT1 protein]; SB 203580 inhibits the reaction [Zinc results in increased phosphorylation of AKT1 protein]; SB 203580 promotes the reaction [Emodin results in decreased phosphorylation of AKT1 protein]
SB 203580 results in decreased phosphorylation of AKT1 protein
SB 203580 results in decreased activity of AKT1 protein 		CTD PMID:10998351 PMID:11788791 PMID:15980035 PMID:17341418 PMID:17640974 More... NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610 		JBrowse link
G Alb albumin multiple interactions ISO SB 203580 inhibits the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased expression of CCL5 protein]; SB 203580 inhibits the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased expression of CSF2 protein]; SB 203580 inhibits the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased expression of CXCL8 protein] CTD PMID:16908450 NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,891,582...17,911,865 		JBrowse link
G Alox5 arachidonate 5-lipoxygenase multiple interactions ISO
EXP 		SB 203580 inhibits the reaction [Calcimycin results in increased phosphorylation of and results in increased activity of ALOX5 protein]; SB 203580 inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of ALOX5 protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased activity of ALOX5 protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of ALOX5 protein]; SB 203580 inhibits the reaction [Sorbitol results in increased activity of ALOX5 protein]; SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of and results in increased activity of ALOX5 protein]; SB 203580 inhibits the reaction [Thapsigargin results in increased phosphorylation of and results in increased activity of ALOX5 protein]; SB 203580 inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased activity of ALOX5 protein]; SB 203580 results in decreased phosphorylation of and results in decreased activity of ALOX5 protein
SB 203580 inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] affects the localization of ALOX5 protein]; SB 203580 inhibits the reaction [Hydrogen Peroxide affects the localization of ALOX5 protein]
SB 203580 inhibits the reaction [2-chloroethyl ethyl sulfide results in increased expression of ALOX5 mRNA] 		CTD PMID:10779545 PMID:18951527 PMID:20382172 NCBI chr 4:151,203,948...151,251,126
Ensembl chr 4:151,203,949...151,251,126 		JBrowse link
G Alpl alkaline phosphatase, biomineralization associated multiple interactions ISO SB 203580 inhibits the reaction [(4-(7-chloroquinolin-4-yl)piperazino)(1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl)methanone promotes the reaction [BMP2 protein results in increased expression of ALPL mRNA]] CTD PMID:25789987 NCBI chr 5:155,234,770...155,289,785
Ensembl chr 5:155,234,775...155,254,167 		JBrowse link
G Apoa1 apolipoprotein A1 multiple interactions ISO [pirinixic acid co-treated with SB 203580] inhibits the reaction [TNF protein results in decreased expression of APOA1 mRNA] CTD PMID:19883121 NCBI chr 8:55,423,945...55,425,729
Ensembl chr 8:55,423,825...55,425,729 		JBrowse link
G App amyloid beta precursor protein multiple interactions ISO SB 203580 inhibits the reaction [APP protein results in increased expression of and results in increased cleavage of CASP1 protein]; SB 203580 inhibits the reaction [APP protein results in increased expression of and results in increased cleavage of IL1B protein]; SB 203580 inhibits the reaction [APP protein results in increased expression of NLRP3 protein]; SB 203580 inhibits the reaction [Copper results in increased expression of APP mRNA] CTD PMID:18583042 PMID:28004443 NCBI chr11:37,506,207...37,724,351
Ensembl chr11:37,506,408...37,722,971 		JBrowse link
G Aqp1 aquaporin 1 multiple interactions ISO SB 203580 inhibits the reaction [cobaltous chloride results in increased expression of AQP1 protein]; SB 203580 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of AQP1 protein]; SB 203580 inhibits the reaction [Peptidoglycan results in decreased expression of AQP1 protein] CTD PMID:21647617 PMID:22415096 NCBI chr 4:85,812,784...85,824,964
Ensembl chr 4:85,812,784...85,830,504 		JBrowse link
G Aqp4 aquaporin 4 multiple interactions ISO SB 203580 inhibits the reaction [[ferrous chloride results in increased abundance of Iron] which results in increased expression of AQP4 protein] CTD PMID:30914277 NCBI chr18:6,782,389...6,799,034
Ensembl chr18:6,782,389...6,799,098 		JBrowse link
G Areg amphiregulin decreases activity EXP SB 203580 results in decreased activity of AREG protein CTD PMID:12589827 NCBI chr14:17,256,384...17,265,641
Ensembl chr14:17,256,384...17,265,641 		JBrowse link
G Arg1 arginase 1 multiple interactions ISO SB 203580 inhibits the reaction [AGT protein modified form results in increased expression of ARG1 protein] CTD PMID:21289285 NCBI chr 1:22,295,093...22,307,720
Ensembl chr 1:22,295,322...22,307,713 		JBrowse link
G Arg2 arginase 2 multiple interactions ISO SB 203580 inhibits the reaction [AGT protein modified form results in increased expression of ARG2 protein] CTD PMID:21289285 NCBI chr 6:103,669,001...103,694,375
Ensembl chr 6:103,668,988...103,694,375 		JBrowse link
G Arpc2 actin related protein 2/3 complex, subunit 2 multiple interactions EXP SB 203580 inhibits the reaction [Hydrogen Peroxide results in increased expression of ARPC2 protein] CTD PMID:24152438 NCBI chr 9:83,269,884...83,300,610
Ensembl chr 9:83,269,932...83,305,409 		JBrowse link
G Atf1 activating transcription factor 1 multiple interactions ISO
EXP 		[SB 203580 co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] inhibits the reaction [Anisomycin results in increased phosphorylation of ATF1 protein]; SB 203580 inhibits the reaction [Anisomycin results in increased phosphorylation of ATF1 protein]
SB 203580 inhibits the reaction [manganese chloride results in increased phosphorylation of ATF1 protein]; SB 203580 inhibits the reaction [Manganese results in increased phosphorylation of ATF1 protein]
SB 203580 inhibits the reaction [deoxynivalenol results in increased phosphorylation of ATF1 protein]; SB 203580 inhibits the reaction [Oxygen deficiency results in increased phosphorylation of ATF1 protein] 		CTD PMID:12660819 PMID:16424113 PMID:16787641 PMID:18579531 NCBI chr 7:133,240,774...133,283,488
Ensembl chr 7:133,241,197...133,283,485 		JBrowse link
G Atf2 activating transcription factor 2 multiple interactions ISO
EXP 		SB 203580 inhibits the reaction [2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester results in increased phosphorylation of ATF2 protein]; SB 203580 inhibits the reaction [IL18 protein results in increased phosphorylation of ATF2 protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased expression of ATF2 mRNA]; SB 203580 inhibits the reaction [sodium arsenite results in increased expression of ATF2 protein modified form]; SB 203580 inhibits the reaction [sodium arsenite results in increased expression of ATF2 protein]; SB 203580 inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of ATF2 protein]; SB 203580 inhibits the reaction [TGFB1 protein results in increased phosphorylation of ATF2 protein]; SB 203580 inhibits the reaction [Tobacco Smoke Pollution analog results in increased phosphorylation of ATF2 protein]
SB 203580 inhibits the reaction [Anisomycin results in increased phosphorylation of ATF2 protein]; SB 203580 inhibits the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of ATF2 protein]; SB 203580 inhibits the reaction [perfluorooctane sulfonic acid results in increased phosphorylation of ATF2 protein]
SB 203580 inhibits the reaction [dinitrophenyl-human serum albumin conjugate results in increased phosphorylation of ATF2 protein]; SB 203580 inhibits the reaction [Oxaliplatin results in increased phosphorylation of ATF2 protein] 		CTD PMID:10611455 PMID:18215737 PMID:19428505 PMID:21303922 PMID:23591579 More... NCBI chr 3:79,125,814...79,202,896
Ensembl chr 3:79,126,705...79,202,745 		JBrowse link
G Atf3 activating transcription factor 3 multiple interactions ISO SB 203580 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of ATF3 protein]; SB 203580 inhibits the reaction [Clotrimazole results in increased expression of ATF3 mRNA]; SB 203580 inhibits the reaction [deoxynivalenol results in decreased degradation of ATF3 mRNA]; SB 203580 inhibits the reaction [deoxynivalenol results in decreased degradation of ATF3 protein]
SB 203580 inhibits the reaction [Acrylamide results in increased expression of ATF3 protein] 		CTD PMID:19101521 PMID:25531190 PMID:27507784 PMID:33921748 NCBI chr13:105,274,103...105,331,653
Ensembl chr13:105,282,440...105,295,750 		JBrowse link
G Atf4 activating transcription factor 4 multiple interactions ISO SB 203580 inhibits the reaction [honokiol results in increased expression of ATF4 protein] CTD PMID:33550458 NCBI chr 7:113,684,681...113,686,739
Ensembl chr 7:113,684,681...113,686,739 		JBrowse link
G Atg5 autophagy related 5 multiple interactions ISO SB 203580 inhibits the reaction [Calcitriol results in increased activity of ATG5 mRNA] CTD PMID:19748465 NCBI chr20:49,380,835...49,471,826
Ensembl chr20:49,380,813...49,471,821 		JBrowse link
G Atp6v0d2 ATPase H+ transporting V0 subunit D2 multiple interactions ISO [SB 203580 co-treated with CSF1R protein co-treated with TNFSF11 protein] results in decreased expression of ATP6V0D2 mRNA; [SB 203580 co-treated with sodium arsenite co-treated with CSF1R protein co-treated with TNFSF11 protein] results in decreased expression of ATP6V0D2 mRNA; SB 203580 affects the reaction [[NFE2L2 protein affects the susceptibility to sodium arsenite] affects the reaction [[CSF1R protein co-treated with TNFSF11 protein] affects the expression of ATP6V0D2 mRNA]]; SB 203580 inhibits the reaction [[sodium arsenite co-treated with CSF1R protein co-treated with TNFSF11 protein] results in increased expression of ATP6V0D2 mRNA] CTD PMID:30742845 NCBI chr 5:38,133,151...38,182,245
Ensembl chr 5:38,133,158...38,182,245 		JBrowse link
G Bace1 beta-secretase 1 multiple interactions ISO SB 203580 inhibits the reaction [Copper results in increased expression of BACE1 mRNA] CTD PMID:18583042 NCBI chr 8:55,038,842...55,061,138
Ensembl chr 8:55,038,823...55,064,918 		JBrowse link
G Bach1 BTB domain and CNC homolog 1 multiple interactions ISO SB 203580 inhibits the reaction [Cadmium results in decreased activity of BACH1 protein] CTD PMID:14504288 NCBI chr11:40,425,721...40,461,118
Ensembl chr11:40,425,664...40,461,277 		JBrowse link
G Bak1 BCL2-antagonist/killer 1 multiple interactions ISO SB 203580 inhibits the reaction [Sulindac affects the localization of BAK1 protein] CTD PMID:17136320 NCBI chr20:5,102,334...5,111,615
Ensembl chr20:5,102,335...5,110,974 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions
increases expression 		ISO
EXP 		saikosaponin D promotes the reaction [SB 203580 results in increased expression of BAX protein]; SB 203580 affects the reaction [Emodin affects the expression of BAX protein]; SB 203580 inhibits the reaction [3-oxo-29-noroleana-1,9(11),12-trien-2,20-dicarbonitrile results in increased expression of BAX protein]; SB 203580 inhibits the reaction [4-vinyl-2,6-dimethoxyphenol results in increased expression of BAX protein]; SB 203580 inhibits the reaction [[Arsenic Trioxide co-treated with phytosphingosine] results in increased localization of BAX protein]; SB 203580 inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of BAX protein]; SB 203580 inhibits the reaction [Fenbendazole analog results in increased expression of BAX protein]; SB 203580 inhibits the reaction [Fenbendazole results in increased expression of BAX protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of BAX protein]]; SB 203580 inhibits the reaction [nickel sulfate results in increased expression of BAX protein]; SB 203580 inhibits the reaction [Pt(O,O'-acac)(gamma-acac)(DMS) affects the localization of BAX protein]; SB 203580 inhibits the reaction [Stilbenes analog affects the localization of BAX protein]; SB 203580 inhibits the reaction [Sulindac affects the localization of BAX protein]; SB 203580 promotes the reaction [Resveratrol results in increased activity of BAX protein]
SB 203580 inhibits the reaction [Cisplatin results in increased expression of BAX protein]; SB 203580 inhibits the reaction [osthol inhibits the reaction [Antineoplastic Agents, Immunological results in increased expression of BAX protein]]; SB 203580 inhibits the reaction [Oxaliplatin results in increased expression of BAX protein]; SB 203580 promotes the reaction [Cisplatin results in increased expression of BAX protein]
SB 203580 inhibits the reaction [[Nitroprusside results in increased abundance of Nitric Oxide] which affects the localization of BAX protein]; SB 203580 inhibits the reaction [chloroacetic acid results in increased expression of BAX mRNA] 		CTD PMID:17136320 PMID:17237268 PMID:18449500 PMID:19428505 PMID:19578154 More... NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429 		JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
decreases expression 		ISO
EXP 		saikosaponin D promotes the reaction [SB 203580 results in decreased expression of BCL2 protein]; SB 203580 affects the reaction [Emodin affects the expression of BCL2 protein]; SB 203580 inhibits the reaction [1,4-naphthoquinone analog results in decreased expression of BCL2 protein]; SB 203580 inhibits the reaction [3-oxo-29-noroleana-1,9(11),12-trien-2,20-dicarbonitrile results in decreased expression of BCL2 protein]; SB 203580 inhibits the reaction [4-vinyl-2,6-dimethoxyphenol results in decreased expression of BCL2 protein]; SB 203580 inhibits the reaction [Arsenic Trioxide affects the localization of BCL2 protein]; SB 203580 inhibits the reaction [Arsenic Trioxide results in increased expression of BCL2 mRNA]; SB 203580 inhibits the reaction [Arsenic Trioxide results in increased expression of BCL2 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of BCL2 protein]]; SB 203580 inhibits the reaction [nickel sulfate results in decreased expression of BCL2 protein]; SB 203580 inhibits the reaction [Oxidopamine results in decreased expression of BCL2 protein]; SB 203580 inhibits the reaction [Pt(O,O'-acac)(gamma-acac)(DMS) results in decreased expression of BCL2 protein]; SB 203580 promotes the reaction [Arsenic Trioxide results in decreased expression of BCL2 protein]
SB 203580 inhibits the reaction [chloroacetic acid results in decreased expression of BCL2 mRNA]; SB 203580 inhibits the reaction [Sodium Glutamate results in increased expression of BCL2 mRNA]
SB 203580 inhibits the reaction [Cisplatin results in increased phosphorylation of and results in decreased activity of BCL2 protein]; SB 203580 inhibits the reaction [oxaliplatin results in increased phosphorylation of and results in decreased activity of BCL2 protein] 		CTD PMID:16782274 PMID:16818652 PMID:19428505 PMID:21420390 PMID:23103613 More... NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900 		JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions EXP SB 203580 promotes the reaction [Cisplatin results in decreased expression of BCL2L1 protein] CTD PMID:19578154 NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907
Ensembl chr 1:161,745,540...161,764,907 		JBrowse link
G Bcl2l11 Bcl2-like 11 multiple interactions EXP SB 203580 inhibits the reaction [sodium arsenite results in increased phosphorylation of BCL2L11 protein] CTD PMID:16818494 NCBI chr 3:135,820,042...135,857,330
Ensembl chr 3:135,817,562...135,960,695 		JBrowse link
G Bcl3 BCL3, transcription coactivator multiple interactions ISO SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of BCL3 mRNA] CTD PMID:28329830 NCBI chr 1:88,599,321...88,613,555
Ensembl chr 1:88,599,321...88,614,368 		JBrowse link
G Becn1 beclin 1 multiple interactions
decreases expression 		ISO
EXP 		SB 203580 inhibits the reaction [Calcitriol results in increased activity of BECN1 mRNA]
SB203580 decreases expression of protein in oxygen-glucose deprived rat neuronal PC12 cells
SB 203580 inhibits the reaction [decamethrin results in increased expression of BECN1 protein]; SB 203580 inhibits the reaction [osthol inhibits the reaction [Antineoplastic Agents, Immunological results in decreased expression of BECN1 protein]] 		CTD
RGD		 PMID:19748465 PMID:26588882 PMID:37769856 PMID:27769861 RGD:329853763 NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,731,650...86,747,002 		JBrowse link
G Bglap bone gamma-carboxyglutamate protein multiple interactions EXP [pyrazolanthrone co-treated with SB 203580 co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] inhibits the reaction [Quercetin results in increased expression of BGLAP protein]; SB 203580 inhibits the reaction [cobaltous chloride results in increased expression of BGLAP protein]; SB 203580 inhibits the reaction [Quercetin results in increased expression of BGLAP protein] CTD PMID:26136938 PMID:31472278 NCBI chr 2:176,136,341...176,137,318
Ensembl chr 2:176,136,341...176,137,318 		JBrowse link
G Bid BH3 interacting domain death agonist multiple interactions ISO SB 203580 promotes the reaction [Emodin results in increased degradation of BID protein] CTD PMID:27032576 NCBI chr 4:155,785,366...155,808,775
Ensembl chr 4:155,785,377...155,808,275 		JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 multiple interactions
increases expression 		ISO SB 203580 affects the reaction [[gambogic acid co-treated with Doxorubicin] affects the expression of BIRC5 protein]; SB 203580 inhibits the reaction [arsenic trioxide results in decreased expression of BIRC5 protein]; SB 203580 inhibits the reaction [baicalein results in decreased expression of BIRC5 protein]; SB 203580 inhibits the reaction [tanshinone results in decreased expression of BIRC5 mRNA]
SB 203580 results in increased expression of BIRC5 mRNA 		CTD PMID:16328441 PMID:18025287 PMID:21165580 PMID:21594580 PMID:25824409 NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,572,080...103,582,155 		JBrowse link
G Bmp2 bone morphogenetic protein 2 decreases expression
multiple interactions 		ISO
EXP 		SB 203580 results in decreased expression of BMP2 mRNA
SB 203580 inhibits the reaction [Quercetin results in increased expression of BMP2 mRNA]
SB 203580 inhibits the reaction [(4-(7-chloroquinolin-4-yl)piperazino)(1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl)methanone promotes the reaction [BMP2 protein results in increased expression of ALPL mRNA]]; SB 203580 inhibits the reaction [(4-(7-chloroquinolin-4-yl)piperazino)(1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl)methanone promotes the reaction [BMP2 protein results in increased expression of BMP2 mRNA]]; SB 203580 inhibits the reaction [(4-(7-chloroquinolin-4-yl)piperazino)(1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl)methanone promotes the reaction [BMP2 protein results in increased expression of BMP6 mRNA]]; SB 203580 inhibits the reaction [(4-(7-chloroquinolin-4-yl)piperazino)(1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl)methanone promotes the reaction [BMP2 protein results in increased expression of BMP7 mRNA]]; SB 203580 inhibits the reaction [5-Methoxypsoralen results in increased expression of BMP2 mRNA]; SB 203580 inhibits the reaction [imperatorin results in increased expression of BMP2 mRNA] 		CTD PMID:17980360 PMID:20660070 PMID:25789987 PMID:26136938 NCBI chr 3:141,264,648...141,275,416
Ensembl chr 3:141,264,646...141,274,760 		JBrowse link
G Bmp6 bone morphogenetic protein 6 multiple interactions ISO SB 203580 inhibits the reaction [(4-(7-chloroquinolin-4-yl)piperazino)(1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl)methanone promotes the reaction [BMP2 protein results in increased expression of BMP6 mRNA]]
SB 203580 promotes the reaction [tricetin results in decreased expression of BMP6 protein] 		CTD PMID:25789987 PMID:38654487 NCBI chr17:26,523,704...26,785,558
Ensembl chr17:26,523,704...26,675,261 		JBrowse link
G Bmp7 bone morphogenetic protein 7 multiple interactions ISO SB 203580 inhibits the reaction [(4-(7-chloroquinolin-4-yl)piperazino)(1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl)methanone promotes the reaction [BMP2 protein results in increased expression of BMP7 mRNA]] CTD PMID:25789987 NCBI chr 3:182,059,318...182,135,273
Ensembl chr 3:182,052,337...182,135,137 		JBrowse link
G Bsg basigin multiple interactions ISO SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BSG mRNA]; SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BSG protein] CTD PMID:18647594 NCBI chr 7:10,643,788...10,651,005
Ensembl chr 7:10,643,789...10,651,005 		JBrowse link
G Cacna1g calcium voltage-gated channel subunit alpha1 G multiple interactions EXP SB 203580 inhibits the reaction [telmisartan results in decreased expression of CACNA1G mRNA] CTD PMID:19292980 NCBI chr10:79,851,886...79,919,926
Ensembl chr10:79,851,896...79,919,634 		JBrowse link
G Cacna1h calcium voltage-gated channel subunit alpha1 H multiple interactions EXP SB 203580 inhibits the reaction [telmisartan results in decreased expression of CACNA1H mRNA] CTD PMID:19292980 NCBI chr10:14,894,630...14,952,317
Ensembl chr10:14,894,641...14,952,771 		JBrowse link
G Camp cathelicidin antimicrobial peptide multiple interactions ISO SB 203580 promotes the reaction [Calcitriol promotes the reaction [resveratrol results in increased expression of CAMP mRNA]]; SB 203580 promotes the reaction [resveratrol promotes the reaction [Calcitriol results in increased expression of CAMP mRNA]] CTD PMID:24039193 NCBI chr 8:118,720,184...118,721,998
Ensembl chr 8:118,720,184...118,721,998 		JBrowse link
G Casp1 caspase 1 multiple interactions ISO
EXP 		SB 203580 inhibits the reaction [APP protein results in increased expression of and results in increased cleavage of CASP1 protein]
SB 203580 inhibits the reaction [Acrolein results in increased cleavage of CASP1 protein] 		CTD PMID:28004443 PMID:31639409 NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:10,746,333...10,882,275 		JBrowse link
G Casp3 caspase 3 multiple interactions
increases expression 		ISO
EXP 		saikosaponin D promotes the reaction [SB 203580 results in increased cleavage of and results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [(1R,3S,3aR,8bS)-3a-(4-Bromophenyl)-6,8-dimethoxy-3-phenyl-2,3,3a,8b-tetrahydro-1H-cyclopenta(b)benzofuran-1,8b-diol results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [(3,5-bis((4-fluorophenyl)methylidene)-1-((1-hydroxy-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methyl)piperidin-4-one) results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [1,4-naphthoquinone analog results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [3-oxo-29-noroleana-1,9(11),12-trien-2,20-dicarbonitrile results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [[Arsenic Trioxide co-treated with phytosphingosine] results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [[ESR1 protein results in increased susceptibility to Quercetin] which results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [[ESR2 protein results in increased susceptibility to Estradiol] which results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [[ESR2 protein results in increased susceptibility to Quercetin] which results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of and results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [Acetaldehyde results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [Arsenic Trioxide results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [Biological Products results in increased expression of CASP3 mRNA]; SB 203580 inhibits the reaction [cantharidic acid results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [Chlorpyrifos results in increased expression of CASP3 protein modified form]; SB 203580 inhibits the reaction [DDT results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [Emodin results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [ferruginol results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [Indomethacin results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CASP3 protein]]; SB 203580 inhibits the reaction [licochalcone A results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [malvidin results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [Paraquat results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [Pyrogallol results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [Thimerosal results in increased activity of CASP3 protein]; SB 203580 promotes the reaction [Cadmium results in increased activity of and results in increased cleavage of CASP3 protein]; SB 203580 promotes the reaction [Resveratrol results in increased activity of CASP3 protein]; SB 203580 results in increased cleavage of and results in increased activity of CASP3 protein
SB 203580 inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; SB 203580 inhibits the reaction [Arsenic Trioxide results in increased expression of CASP3 protein]; SB 203580 inhibits the reaction [cobaltous chloride results in increased cleavage of and results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [Cocaine results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [decamethrin results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [Doxorubicin results in increased expression of CASP3 protein]; SB 203580 inhibits the reaction [Methamphetamine results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [osthol inhibits the reaction [Antineoplastic Agents, Immunological results in increased expression of CASP3 protein]]; SB 203580 inhibits the reaction [satratoxin H results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [tributyltin results in increased expression of CASP3 protein]; SB 203580 promotes the reaction [Cadmium results in increased activity of and results in increased cleavage of CASP3 protein]; SB 203580 promotes the reaction [Cisplatin results in increased activity of CASP3 protein]
SB 203580 inhibits the reaction [[GMFB protein co-treated with Hydrogen Peroxide] results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [[Nitroprusside results in increased abundance of Nitric Oxide] which results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [chloroacetic acid results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [deoxynivalenol results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [Mercuric Chloride results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [Methylmercury Compounds results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [Morphine results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [tetrabromobisphenol A results in increased cleavage of and results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [Uranyl Nitrate results in increased activity of CASP3 protein]
SB 203580 results in increased expression of CASP3 protein modified form 		CTD PMID:12791701 PMID:14722101 PMID:15050407 PMID:15365088 PMID:15603917 More... NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732 		JBrowse link
G Casp6 caspase 6 multiple interactions ISO SB 203580 inhibits the reaction [Indomethacin results in increased activity of CASP6 protein] CTD PMID:17341418 NCBI chr 2:221,140,287...221,152,727
Ensembl chr 2:221,140,256...221,152,726 		JBrowse link
G Casp7 caspase 7 multiple interactions ISO SB 203580 inhibits the reaction [DDT results in increased activity of CASP7 protein]
SB 203580 inhibits the reaction [chloroacetic acid results in increased activity of CASP7 protein]; SB 203580 inhibits the reaction [tetrabromobisphenol A results in increased cleavage of CASP7 protein] 		CTD PMID:15603917 PMID:23103613 PMID:39586487 NCBI chr 1:265,442,647...265,481,938
Ensembl chr 1:265,442,676...265,482,512 		JBrowse link
G Casp8 caspase 8 multiple interactions ISO [Resveratrol co-treated with SB 203580] results in increased activity of CASP8 protein; SB 203580 inhibits the reaction [(3,5-bis((4-fluorophenyl)methylidene)-1-((1-hydroxy-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methyl)piperidin-4-one) results in increased cleavage of CASP8 protein]; SB 203580 inhibits the reaction [cantharidic acid results in increased cleavage of CASP8 protein]; SB 203580 inhibits the reaction [licochalcone A results in increased cleavage of CASP8 protein]; SB 203580 promotes the reaction [Emodin results in increased activity of CASP8 protein] CTD PMID:22644961 PMID:27032576 PMID:29159945 PMID:30983163 PMID:31916385 More... NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699 		JBrowse link
G Casp9 caspase 9 multiple interactions ISO
EXP 		[Resveratrol co-treated with SB 203580] results in increased activity of CASP9 protein; SB 203580 inhibits the reaction [(3,5-bis((4-fluorophenyl)methylidene)-1-((1-hydroxy-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methyl)piperidin-4-one) results in increased cleavage of CASP9 protein]; SB 203580 inhibits the reaction [[Arsenic Trioxide co-treated with phytosphingosine] results in increased activity of CASP9 protein]; SB 203580 inhibits the reaction [cantharidic acid results in increased cleavage of CASP9 protein]; SB 203580 inhibits the reaction [Indomethacin results in increased activity of CASP9 protein]; SB 203580 inhibits the reaction [licochalcone A results in increased cleavage of CASP9 protein]; SB 203580 inhibits the reaction [Pt(O,O'-acac)(gamma-acac)(DMS) results in increased activity of CASP9 protein]
SB 203580 inhibits the reaction [[sodium arsenite co-treated with Cadmium Chloride co-treated with lead acetate] results in increased cleavage of CASP9 protein]; SB 203580 inhibits the reaction [Cocaine results in increased activity of CASP9 protein] 		CTD PMID:15365088 PMID:17237268 PMID:17341418 PMID:21420390 PMID:22644961 More... Ensembl chr 5:159,391,188...159,409,648 JBrowse link
G Cat catalase multiple interactions ISO SB 203580 promotes the reaction [Pyrogallol results in decreased expression of CAT protein] CTD PMID:20191265 NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526 		JBrowse link
G Cav1 caveolin 1 multiple interactions ISO SB 203580 inhibits the reaction [Hydrogen Peroxide promotes the reaction [SP1 protein results in increased expression of CAV1 protein]]; SB 203580 inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of CAV1 protein]
[SB 203580 results in decreased activity of MAPK14 protein] inhibits the reaction [[octanoic acid co-treated with Dexamethasone] results in increased expression of CAV1 protein]; SB 203580 inhibits the reaction [2-chloroethyl ethyl sulfide results in increased expression of CAV1 mRNA]; SB 203580 inhibits the reaction [2-chloroethyl ethyl sulfide results in increased expression of CAV1 protein]; SB 203580 inhibits the reaction [Hydrogen Peroxide results in increased expression of CAV1 protein] 		CTD PMID:14984747 PMID:17108117 PMID:21457723 PMID:25512378 NCBI chr 4:46,606,538...46,639,616
Ensembl chr 4:46,600,738...46,639,740 		JBrowse link
G Ccl11 C-C motif chemokine ligand 11 multiple interactions ISO SB 203580 inhibits the reaction [TNF protein results in increased expression of CCL11 protein] CTD PMID:23707484 NCBI chr10:67,525,975...67,530,576
Ensembl chr10:67,525,862...67,530,575 		JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions ISO
EXP 		SB 203580 inhibits the reaction [Allopurinol results in increased expression of CCL2 mRNA]; SB 203580 inhibits the reaction [chlorobenzene results in increased expression of CCL2 protein]; SB 203580 inhibits the reaction [Diclofenac analog results in increased expression of CCL2 mRNA]; SB 203580 inhibits the reaction [Folic Acid deficiency results in increased expression of and results in increased secretion of CCL2 protein]; SB 203580 inhibits the reaction [Folic Acid deficiency results in increased expression of CCL2 mRNA]; SB 203580 inhibits the reaction [Glucose results in increased expression of CCL2 mRNA]; SB 203580 inhibits the reaction [Glucose results in increased expression of CCL2 protein]; SB 203580 inhibits the reaction [Hydrogen Peroxide results in increased expression of CCL2 mRNA]; SB 203580 inhibits the reaction [IL17A protein results in increased expression of CCL2 protein]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; SB 203580 inhibits the reaction [melamine results in increased expression of CCL2 mRNA]; SB 203580 inhibits the reaction [Particulate Matter analog results in decreased secretion of CCL2 protein]; SB 203580 inhibits the reaction [TNF results in increased expression of CCL2 protein]; SB 203580 inhibits the reaction [Vehicle Emissions analog results in decreased secretion of CCL2 protein]; SB 203580 promotes the reaction [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Dermatophagoides pteronyssinus antigen p 1 results in increased secretion of CCL2 protein]]; SB 203580 promotes the reaction [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Particulate Matter analog results in decreased secretion of CCL2 protein]]; SB 203580 promotes the reaction [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Vehicle Emissions analog results in decreased secretion of CCL2 protein]]
SB 203580 inhibits the reaction [[Paraquat results in increased abundance of Reactive Oxygen Species] which results in increased secretion of CCL2 protein]; SB 203580 inhibits the reaction [diphenylarsinic acid results in increased secretion of CCL2 protein]
SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of CCL2 mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA] 		CTD PMID:10919993 PMID:12016129 PMID:16143069 PMID:17655880 PMID:18645721 More... NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875 		JBrowse link
G Ccl26 C-C motif chemokine ligand 26 multiple interactions ISO SB 203580 inhibits the reaction [CCL26 protein binds to and results in increased activity of CCR3 protein] CTD PMID:37788752 NCBI chr12:26,745,972...26,750,924 JBrowse link
G Ccl3 C-C motif chemokine ligand 3 multiple interactions ISO SB 203580 inhibits the reaction [Methotrexate results in decreased expression of CCL3 protein] CTD PMID:19100307 NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,948,889...68,950,439 		JBrowse link
G Ccl4 C-C motif chemokine ligand 4 multiple interactions ISO SB 203580 affects the reaction [Methotrexate results in decreased expression of CCL4 protein] CTD PMID:19100307 NCBI chr10:68,963,893...68,965,728
Ensembl chr10:68,950,289...68,965,722 		JBrowse link
G Ccl5 C-C motif chemokine ligand 5 multiple interactions ISO SB 203580 inhibits the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased expression of CCL5 protein]; SB 203580 inhibits the reaction [Buthionine Sulfoximine promotes the reaction [TNF protein results in increased expression of CCL5 protein]]; SB 203580 inhibits the reaction [Dermatophagoides pteronyssinus antigen p 1 results in increased secretion of CCL5 protein]; SB 203580 inhibits the reaction [Particulate Matter analog results in increased secretion of CCL5 protein]; SB 203580 inhibits the reaction [TNF protein results in increased expression of CCL5 protein]; SB 203580 inhibits the reaction [Vehicle Emissions analog results in increased secretion of CCL5 protein]; SB 203580 promotes the reaction [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Particulate Matter analog results in decreased secretion of CCL5 protein]]; SB 203580 promotes the reaction [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Vehicle Emissions analog results in decreased secretion of CCL5 protein]]; SB 203580 promotes the reaction [Methotrexate results in increased expression of CCL5 protein] CTD PMID:10919993 PMID:11167962 PMID:16908450 PMID:19100307 NCBI chr10:68,820,330...68,824,906
Ensembl chr10:68,738,651...68,824,884 		JBrowse link
G Ccl7 C-C motif chemokine ligand 7 multiple interactions ISO SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of CCL7 mRNA] CTD PMID:28329830 NCBI chr10:67,514,095...67,515,945
Ensembl chr10:67,514,091...67,515,947 		JBrowse link
G Ccn1 cellular communication network factor 1 increases expression
multiple interactions 		ISO SB 203580 results in increased expression of CCN1 protein
[sclareol co-treated with SB 203580] results in increased expression of CCN1 protein 		CTD PMID:33423118 NCBI chr 2:237,222,730...237,225,689
Ensembl chr 2:237,222,432...237,225,883 		JBrowse link
G Ccn2 cellular communication network factor 2 multiple interactions
decreases expression 		ISO SB 203580 analog inhibits the reaction [TGFB1 protein results in increased expression of CCN2 protein]; SB 203580 inhibits the reaction [Glucose results in increased expression of CCN2 protein]
SB 203580 results in decreased expression of CCN2 protein 		CTD PMID:19369054 PMID:20864298 PMID:26054450 NCBI chr 1:22,621,498...22,624,614
Ensembl chr 1:22,621,501...22,624,976 		JBrowse link
G Ccnb1 cyclin B1 multiple interactions ISO SB 203580 inhibits the reaction [ochratoxin A inhibits the reaction [CDK1 protein binds to CCNB1 protein]]; SB 203580 inhibits the reaction [ochratoxin A results in decreased expression of CCNB1 protein] CTD PMID:22230261 NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:33,646,252...33,655,225 		JBrowse link
G Ccnd1 cyclin D1 multiple interactions
decreases expression 		ISO
EXP 		SB 203580 inhibits the reaction [Furazolidone results in increased expression of CCND1 mRNA]; SB 203580 inhibits the reaction [Furazolidone results in increased expression of CCND1 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CCND1 protein]]; SB 203580 inhibits the reaction [TGFB1 protein results in decreased expression of CCND1 protein]
SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of CCND1 protein]
SB 203580 results in decreased expression of CCND1 protein 		CTD PMID:21712382 PMID:23112108 PMID:30801954 PMID:32890875 PMID:34571074 NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810 		JBrowse link
G Ccnd3 cyclin D3 multiple interactions ISO SB 203580 inhibits the reaction [Furazolidone results in increased expression of CCND3 mRNA]; SB 203580 inhibits the reaction [Furazolidone results in increased expression of CCND3 protein] CTD PMID:23112108 NCBI chr 9:20,891,696...20,987,199
Ensembl chr 9:20,891,704...20,987,033 		JBrowse link
G Ccr2 C-C motif chemokine receptor 2 multiple interactions ISO SB 203580 inhibits the reaction [Silicon Dioxide results in increased expression of CCR2 protein] CTD PMID:26163174 NCBI chr 8:132,611,883...132,619,106
Ensembl chr 8:132,611,410...132,620,059 		JBrowse link
G Ccr3 C-C motif chemokine receptor 3 multiple interactions ISO SB 203580 inhibits the reaction [CCL26 protein binds to and results in increased activity of CCR3 protein] CTD PMID:37788752 NCBI chr 8:132,463,533...132,511,601
Ensembl chr 8:132,463,788...132,511,593 		JBrowse link
G Ccr7 C-C motif chemokine receptor 7 multiple interactions ISO SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of CCR7 mRNA] CTD PMID:28329830 NCBI chr10:84,594,399...84,604,514
Ensembl chr10:84,593,594...84,604,501 		JBrowse link
G Cd14 CD14 molecule multiple interactions ISO SB 203580 inhibits the reaction [gefitinib promotes the reaction [arsenic trioxide results in increased expression of CD14 protein]]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of CD14 protein] CTD PMID:18180316 PMID:20226526 NCBI chr18:28,609,558...28,611,409
Ensembl chr18:28,608,883...28,611,292 		JBrowse link
G Cd38 CD38 molecule multiple interactions ISO SB 203580 inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased cleavage of CD38 protein] CTD PMID:15494208 NCBI chr14:71,384,532...71,424,794
Ensembl chr14:71,384,532...71,424,505 		JBrowse link
G Cd63 Cd63 molecule multiple interactions ISO SB 203580 inhibits the reaction [Mustard Gas promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of CD63 protein]] CTD PMID:22036725 NCBI chr 7:1,909,538...1,924,937
Ensembl chr 7:1,922,169...1,924,938 		JBrowse link
G Cd83 CD83 molecule multiple interactions ISO SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of CD83 protein]; SB 203580 inhibits the reaction [Poly I-C results in increased expression of CD83 protein]; SB 203580 inhibits the reaction [Zymosan results in increased expression of CD83 protein] CTD PMID:17698565 NCBI chr17:21,093,281...21,113,223
Ensembl chr17:21,093,281...21,113,047 		JBrowse link
G Cd86 CD86 molecule multiple interactions ISO SB 203580 inhibits the reaction [1,10-phenanthroline results in increased expression of CD86 mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of CD86 protein]; SB 203580 inhibits the reaction [Poly I-C results in increased expression of CD86 protein]; SB 203580 inhibits the reaction [Zymosan results in increased expression of CD86 protein] CTD PMID:17698565 PMID:19641517 NCBI chr11:77,647,565...77,706,178
Ensembl chr11:77,647,600...77,725,361 		JBrowse link
G Cdc25c cell division cycle 25C multiple interactions ISO SB 203580 inhibits the reaction [ochratoxin A results in decreased expression of CDC25C protein modified form]; SB 203580 inhibits the reaction [ochratoxin A results in decreased expression of CDC25C protein] CTD PMID:22230261 NCBI chr18:26,608,483...26,630,292
Ensembl chr18:26,609,959...26,630,292 		JBrowse link
G Cdc6 cell division cycle 6 multiple interactions ISO SB 203580 inhibits the reaction [arsenic trioxide results in increased expression of CDC6 protein] CTD PMID:20862710 NCBI chr10:84,360,361...84,374,239
Ensembl chr10:84,360,381...84,374,241 		JBrowse link
G Cdh1 cadherin 1 multiple interactions ISO SB 203580 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 mRNA]; SB 203580 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 protein]; SB 203580 inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 protein] CTD PMID:28694203 PMID:33396024 NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565 		JBrowse link
G Cdh5 cadherin 5 multiple interactions ISO SB 203580 inhibits the reaction [Varenicline results in decreased expression of CDH5] CTD PMID:28842382 NCBI chr19:821,875...860,931
Ensembl chr19:822,464...860,822 		JBrowse link
G Cdk1 cyclin-dependent kinase 1 multiple interactions ISO SB 203580 inhibits the reaction [baicalein results in decreased phosphorylation of CDK1 protein]; SB 203580 inhibits the reaction [ochratoxin A inhibits the reaction [CDK1 protein binds to CCNB1 protein]]; SB 203580 inhibits the reaction [ochratoxin A results in decreased expression of CDK1 protein modified form]; SB 203580 inhibits the reaction [ochratoxin A results in decreased expression of CDK1 protein] CTD PMID:18025287 PMID:22230261 NCBI chr20:19,265,252...19,280,456
Ensembl chr20:19,265,289...19,280,455 		JBrowse link
G Cdk2 cyclin dependent kinase 2 multiple interactions ISO
EXP 		SB 203580 inhibits the reaction [sodium arsenite results in decreased activity of CDK2 protein]
SB 203580 inhibits the reaction [esculetin results in decreased expression of CDK2 protein] 		CTD PMID:11807808 PMID:21600278 NCBI chr 7:1,714,392...1,721,964
Ensembl chr 7:1,714,392...1,721,878 		JBrowse link
G Cdk4 cyclin-dependent kinase 4 multiple interactions EXP SB 203580 inhibits the reaction [esculetin results in decreased expression of CDK4 protein] CTD PMID:21600278 NCBI chr 7:64,771,453...64,774,891
Ensembl chr 7:64,771,147...64,775,163 		JBrowse link
G Cdk5r1 cyclin-dependent kinase 5 regulatory subunit 1 multiple interactions ISO SB 203580 inhibits the reaction [resveratrol results in decreased expression of CDK5R1 mRNA] CTD PMID:21736731 NCBI chr10:65,981,692...65,985,831
Ensembl chr10:65,978,911...65,989,272 		JBrowse link
G Cdk6 cyclin-dependent kinase 6 multiple interactions ISO SB 203580 inhibits the reaction [Furazolidone results in increased expression of CDK6 mRNA]; SB 203580 inhibits the reaction [Furazolidone results in increased expression of CDK6 protein] CTD PMID:23112108 NCBI chr 4:31,592,384...31,784,732
Ensembl chr 4:31,601,192...31,781,701 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions ISO
EXP 		SB 203580 inhibits the reaction [[sodium arsenite co-treated with Vitamin K 3] results in increased expression of CDKN1A protein]; SB 203580 inhibits the reaction [Cadmium results in increased expression of CDKN1A protein]; SB 203580 inhibits the reaction [Hemin results in increased expression of CDKN1A protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased expression of CDKN1A protein]
SB 203580 inhibits the reaction [esculetin results in increased expression of CDKN1A protein]; SB 203580 inhibits the reaction [pyrrolidine dithiocarbamic acid results in increased expression of CDKN1A protein]
SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of CDKN1A mRNA]; SB 203580 inhibits the reaction [Hydrogen Peroxide results in increased expression of CDKN1A protein]; SB 203580 inhibits the reaction [Methylcholanthrene results in increased expression of CDKN1A mRNA]; SB 203580 inhibits the reaction [sodium arsenite results in increased expression of CDKN1A protein] 		CTD PMID:11807808 PMID:14603533 PMID:14647439 PMID:15734884 PMID:15882963 More... NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969 		JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B multiple interactions ISO SB 203580 inhibits the reaction [[sodium arsenite co-treated with Vitamin K 3] results in increased expression of CDKN1B protein] CTD PMID:19082730 NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:169,490,876...169,496,498 		JBrowse link
G Cdkn2a cyclin-dependent kinase inhibitor 2A multiple interactions ISO SB 203580 inhibits the reaction [Arsenic Trioxide results in increased expression of CDKN2A protein] CTD PMID:31734849 NCBI chr 5:109,100,763...109,114,448
Ensembl chr 5:109,100,772...109,119,248 		JBrowse link
G Cdon cell adhesion associated, oncogene regulated multiple interactions ISO SB 203580 inhibits the reaction [bakuchiol results in increased expression of CDON protein] CTD PMID:26902638 NCBI chr 8:42,032,921...42,119,451
Ensembl chr 8:42,033,042...42,119,345 		JBrowse link
G Cebpa CCAAT/enhancer binding protein alpha multiple interactions ISO SB 203580 inhibits the reaction [Glucose results in increased localization of and results in increased activity of CEBPA protein] CTD PMID:24376792 NCBI chr 1:96,896,584...96,899,256
Ensembl chr 1:96,896,171...96,899,309 		JBrowse link
G Cebpb CCAAT/enhancer binding protein beta multiple interactions ISO SB 203580 inhibits the reaction [Glucose results in increased localization of and results in increased activity of CEBPB protein]; SB 203580 inhibits the reaction [IFNG protein results in increased phosphorylation of CEBPB protein] CTD PMID:16355272 PMID:24376792 NCBI chr 3:176,817,005...176,818,436
Ensembl chr 3:176,816,859...176,838,072 		JBrowse link
G Cebpd CCAAT/enhancer binding protein delta multiple interactions ISO SB 203580 inhibits the reaction [Glucose results in increased localization of and results in increased activity of CEBPD protein] CTD PMID:24376792 NCBI chr11:98,268,856...98,269,994
Ensembl chr11:98,265,651...98,280,824 		JBrowse link
G Ces1d carboxylesterase 1D multiple interactions ISO SB 203580 inhibits the reaction [Lipopolysaccharides results in decreased expression of CES1 mRNA] CTD PMID:21237253 NCBI chr19:30,046,494...30,085,039
Ensembl chr19:30,046,449...30,085,449 		JBrowse link
G Ces2h carboxylesterase 2H multiple interactions ISO SB 203580 inhibits the reaction [Lipopolysaccharides results in decreased expression of CES2 mRNA] CTD PMID:21237253 NCBI chr19:49,884,164...49,898,764
Ensembl chr19:49,884,164...49,898,752 		JBrowse link
G Chrm3 cholinergic receptor, muscarinic 3 multiple interactions EXP SB 203580 inhibits the reaction [Particulate Matter results in increased expression of CHRM3 mRNA]; SB 203580 inhibits the reaction [Particulate Matter results in increased expression of CHRM3 protein] CTD PMID:26916448 NCBI chr17:64,696,549...65,158,622
Ensembl chr17:64,696,066...65,173,304 		JBrowse link
G Chuk component of inhibitor of nuclear factor kappa B kinase complex multiple interactions EXP SB 203580 inhibits the reaction [sodium arsenite results in increased phosphorylation of CHUK protein] CTD PMID:19616567 NCBI chr 1:252,908,748...252,944,273
Ensembl chr 1:252,908,749...252,944,273 		JBrowse link
G Cldn1 claudin 1 multiple interactions
increases expression 		ISO [SB 203580 co-treated with Dextran Sulfate] results in decreased expression of CLDN1 protein
SB 203580 results in increased expression of CLDN1 protein 		CTD PMID:27920472 PMID:34506768 NCBI chr11:87,926,376...87,941,533
Ensembl chr11:87,926,337...87,941,529 		JBrowse link
G Cldn11 claudin 11 multiple interactions ISO SB 203580 inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of CLDN11 protein] CTD PMID:23761298 NCBI chr 2:114,136,234...114,149,539
Ensembl chr 2:114,136,234...114,149,539 		JBrowse link
G Cldn2 claudin 2 multiple interactions EXP SB 203580 inhibits the reaction [CLDN2 protein results in increased expression of IL1B mRNA]; SB 203580 inhibits the reaction [CLDN2 protein results in increased expression of IL1B protein] CTD PMID:15350541 NCBI chr  X:108,248,383...108,258,847
Ensembl chr  X:108,237,676...108,262,377 		JBrowse link
G Cnn1 calponin 1 multiple interactions ISO SB 203580 inhibits the reaction [TGFB1 protein results in increased expression of CNN1 protein] CTD PMID:21712382 NCBI chr 8:28,908,437...28,917,099
Ensembl chr 8:28,908,330...28,919,482 		JBrowse link
G Cnr1 cannabinoid receptor 1 multiple interactions ISO SB 203580 inhibits the reaction [Dextran Sulfate results in increased expression of CNR1 protein] CTD PMID:27920472 NCBI chr 5:53,204,867...53,230,396
Ensembl chr 5:53,204,260...53,239,252 		JBrowse link
G Cnr2 cannabinoid receptor 2 multiple interactions ISO SB 203580 inhibits the reaction [Dextran Sulfate results in increased expression of CNR2 protein] CTD PMID:27920472 NCBI chr 5:153,408,968...153,435,092
Ensembl chr 5:153,409,147...153,435,961 		JBrowse link
G Col18a1 collagen type XVIII alpha 1 chain multiple interactions
decreases expression 		ISO SB 203580 inhibits the reaction [Oxygen deficiency results in increased expression of COL18A1 mRNA]
SB 203580 results in decreased expression of COL18A1 mRNA 		CTD PMID:13679210 NCBI chr20:11,473,645...11,582,111
Ensembl chr20:11,473,645...11,582,112 		JBrowse link
G Col1a1 collagen type I alpha 1 chain multiple interactions
decreases expression 		ISO
EXP 		SB 203580 inhibits the reaction [TGFB2 protein results in increased expression of COL1A1 mRNA]
SB 203580 inhibits the reaction [Acetaldehyde results in increased expression of COL1A1 mRNA]
SB 203580 results in decreased expression of COL1A1 mRNA 		CTD PMID:12065697 PMID:18253093 PMID:27235791 NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460 		JBrowse link
G Col1a2 collagen type I alpha 2 chain multiple interactions EXP SB 203580 inhibits the reaction [cobaltous chloride results in increased expression of COL1A2 mRNA]; SB 203580 inhibits the reaction [cobaltous chloride results in increased expression of COL1A2 protein] CTD PMID:31472278 NCBI chr 4:33,518,557...33,553,484
Ensembl chr 4:33,518,420...33,553,995 		JBrowse link
G Cp ceruloplasmin multiple interactions ISO SB 203580 inhibits the reaction [CP protein results in increased abundance of Nitrites] CTD PMID:17727827 NCBI chr 2:104,368,336...104,427,119
Ensembl chr 2:104,368,456...104,427,087 		JBrowse link
G Creb1 cAMP responsive element binding protein 1 multiple interactions
decreases phosphorylation 		ISO
EXP 		SB 203580 inhibits the reaction [Anisomycin results in increased phosphorylation of CREB1 protein]; SB 203580 inhibits the reaction [Cannabidiol results in increased phosphorylation of CREB1 protein]; SB 203580 inhibits the reaction [Formaldehyde results in increased phosphorylation of CREB1 protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased phosphorylation of CREB1 protein]
[N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with SB 203580] inhibits the reaction [perfluorooctane sulfonic acid inhibits the reaction [[CRTC2 protein binds to CREB1 protein modified form] which binds to STAR promoter]]; [N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with SB 203580] inhibits the reaction [perfluorooctane sulfonic acid results in increased phosphorylation of CREB1 protein]; SB 203580 inhibits the reaction [deoxynivalenol results in increased phosphorylation of CREB1 protein]; SB 203580 inhibits the reaction [perfluorooctane sulfonic acid inhibits the reaction [[CRTC2 protein binds to CREB1 protein modified form] which binds to STAR promoter]]; SB 203580 inhibits the reaction [perfluorooctane sulfonic acid results in increased phosphorylation of CREB1 protein]
SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of CREB1 protein]; SB 203580 inhibits the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased phosphorylation of CREB1 protein]; SB 203580 inhibits the reaction [AGT protein results in increased phosphorylation of CREB1 protein]; SB 203580 inhibits the reaction [diphenylarsinic acid results in increased phosphorylation of CREB1 protein]; SB 203580 inhibits the reaction [EDN1 protein results in increased phosphorylation of CREB1 protein]; SB 203580 inhibits the reaction [manganese chloride results in increased phosphorylation of CREB1 protein]; SB 203580 inhibits the reaction [Manganese results in increased phosphorylation of CREB1 protein]
SB 203580 results in decreased phosphorylation of CREB1 protein 		CTD PMID:12660819 PMID:14741741 PMID:16424113 PMID:16787641 PMID:19145780 More... NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:73,397,306...73,466,339 		JBrowse link
G Crebbp CREB binding protein multiple interactions ISO SB 203580 inhibits the reaction [o,p'-DDT results in increased activity of CREBBP protein] CTD PMID:22609851 NCBI chr10:11,842,307...11,968,266
Ensembl chr10:11,822,620...11,968,266 		JBrowse link
G Crh corticotropin releasing hormone multiple interactions EXP
ISO 		SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of CRH mRNA]
SB 203580 inhibits the reaction [2,2',4,4'-tetrabromodiphenyl ether results in increased expression of CRH mRNA] 		CTD PMID:21959975 PMID:28189027 NCBI chr 2:104,059,184...104,061,048
Ensembl chr 2:104,058,770...104,061,386 		JBrowse link
G Crp C-reactive protein multiple interactions ISO SB 203580 inhibits the reaction [[IL1B protein co-treated with IL6 protein] results in increased expression of and results in increased secretion of CRP protein] CTD PMID:17388968 NCBI chr13:87,694,062...87,695,978
Ensembl chr13:87,657,317...87,707,514 		JBrowse link
G Crtc2 CREB regulated transcription coactivator 2 multiple interactions ISO [N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with SB 203580] inhibits the reaction [perfluorooctane sulfonic acid inhibits the reaction [[CRTC2 protein binds to CREB1 protein modified form] which binds to STAR promoter]]; [N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with SB 203580] inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of CRTC2 protein]; SB 203580 inhibits the reaction [perfluorooctane sulfonic acid inhibits the reaction [[CRTC2 protein binds to CREB1 protein modified form] which binds to STAR promoter]]; SB 203580 inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of CRTC2 protein] CTD PMID:33359577 NCBI chr 2:178,007,233...178,017,397
Ensembl chr 2:178,007,240...178,017,389 		JBrowse link
G Csf1r colony stimulating factor 1 receptor multiple interactions ISO [SB 203580 co-treated with CSF1R protein co-treated with TNFSF11 protein] results in decreased expression of ATP6V0D2 mRNA; [SB 203580 co-treated with CSF1R protein co-treated with TNFSF11 protein] results in decreased expression of CTSK mRNA; [SB 203580 co-treated with sodium arsenite co-treated with CSF1R protein co-treated with TNFSF11 protein] results in decreased expression of ATP6V0D2 mRNA; [SB 203580 co-treated with sodium arsenite co-treated with CSF1R protein co-treated with TNFSF11 protein] results in decreased expression of CTSK mRNA; SB 203580 affects the reaction [[NFE2L2 protein affects the susceptibility to sodium arsenite] affects the reaction [[CSF1R protein co-treated with TNFSF11 protein] affects the expression of ATP6V0D2 mRNA]]; SB 203580 affects the reaction [[NFE2L2 protein affects the susceptibility to sodium arsenite] affects the reaction [[CSF1R protein co-treated with TNFSF11 protein] affects the expression of CTSK mRNA]]; SB 203580 inhibits the reaction [[sodium arsenite co-treated with CSF1R protein co-treated with TNFSF11 protein] results in increased expression of ATP6V0D2 mRNA]; SB 203580 inhibits the reaction [[sodium arsenite co-treated with CSF1R protein co-treated with TNFSF11 protein] results in increased expression of CTSK mRNA] CTD PMID:30742845 NCBI chr18:56,834,152...56,860,804
Ensembl chr18:56,817,049...56,860,806 		JBrowse link
G Csf2 colony stimulating factor 2 multiple interactions ISO SB 203580 inhibits the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased expression of CSF2 protein]; SB 203580 inhibits the reaction [Particulate Matter results in increased secretion of CSF2 protein]; SB 203580 inhibits the reaction [Vehicle Emissions results in increased secretion of CSF2 protein] CTD PMID:10645887 PMID:16908450 NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,887,692...38,890,031 		JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions ISO SB 203580 inhibits the reaction [DEFA1 protein results in decreased phosphorylation of and results in increased activity of CTNNB1 protein]; SB 203580 inhibits the reaction [DEFA2 protein results in decreased phosphorylation of and results in increased activity of CTNNB1 protein] CTD PMID:19814765 NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:129,517,545...129,544,662 		JBrowse link
G Ctsk cathepsin K multiple interactions ISO [SB 203580 co-treated with CSF1R protein co-treated with TNFSF11 protein] results in decreased expression of CTSK mRNA; [SB 203580 co-treated with sodium arsenite co-treated with CSF1R protein co-treated with TNFSF11 protein] results in decreased expression of CTSK mRNA; SB 203580 affects the reaction [[NFE2L2 protein affects the susceptibility to sodium arsenite] affects the reaction [[CSF1R protein co-treated with TNFSF11 protein] affects the expression of CTSK mRNA]]; SB 203580 inhibits the reaction [[sodium arsenite co-treated with CSF1R protein co-treated with TNFSF11 protein] results in increased expression of CTSK mRNA] CTD PMID:30742845 NCBI chr 2:185,747,548...185,758,512
Ensembl chr 2:185,747,165...185,765,582 		JBrowse link
G Cx3cl1 C-X3-C motif chemokine ligand 1 multiple interactions ISO SB 203580 inhibits the reaction [Glucose results in increased expression of CX3CL1 mRNA]; SB 203580 inhibits the reaction [Glucose results in increased expression of CX3CL1 protein] CTD PMID:19132243 NCBI chr19:10,233,326...10,244,856
Ensembl chr19:10,233,329...10,242,999 		JBrowse link
G Cxcl1 C-X-C motif chemokine ligand 1 multiple interactions
decreases secretion 		EXP
ISO 		SB 203580 inhibits the reaction [diphenylarsinic acid results in increased secretion of CXCL1 protein]; SB 203580 inhibits the reaction [resveratrol results in decreased expression of CXCL1 protein]; SB 203580 inhibits the reaction [tropisetron results in decreased expression of CXCL1 protein]
SB 203580 inhibits the reaction [ADIPOQ protein results in increased expression of CXCL1 protein]; SB 203580 inhibits the reaction [nickel monoxide results in increased expression of CXCL1 protein]
SB 203580 results in decreased secretion of CXCL1 protein 		CTD PMID:21192278 PMID:23285267 PMID:28087833 PMID:28176455 PMID:35006638 NCBI chr14:17,477,542...17,479,321
Ensembl chr14:17,477,549...17,479,811 		JBrowse link
G Cxcl2 C-X-C motif chemokine ligand 2 multiple interactions ISO
EXP 		SB 203580 inhibits the reaction [endotoxin, Escherichia coli results in increased expression of CXCL2 protein]; SB 203580 inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of CXCL2 protein]; SB 203580 inhibits the reaction [Paraquat promotes the reaction [endotoxin, Escherichia coli results in increased expression of CXCL2 protein]]; SB 203580 inhibits the reaction [Paraquat results in increased expression of CXCL2 protein]
SB 203580 inhibits the reaction [nickel monoxide results in increased expression of CXCL2 protein]
SB 203580 inhibits the reaction [[Paraquat results in increased abundance of Reactive Oxygen Species] which results in increased secretion of CXCL2 protein]; SB 203580 inhibits the reaction [resveratrol results in decreased expression of CXCL2 protein]; SB 203580 inhibits the reaction [tropisetron results in decreased expression of CXCL2 protein] 		CTD PMID:16919916 PMID:21192278 PMID:21507677 PMID:23285267 PMID:24376630 More... NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,465,242...17,467,255 		JBrowse link
G Cxcl3 C-X-C motif chemokine ligand 3 multiple interactions ISO SB 203580 inhibits the reaction [ADIPOQ protein results in increased expression of CXCL1 protein]; SB 203580 inhibits the reaction [nickel monoxide results in increased expression of CXCL1 protein] CTD PMID:28176455 PMID:35006638 NCBI chr14:17,571,900...17,573,624
Ensembl chr14:17,571,900...17,573,624 		JBrowse link
G Cxcr2 C-X-C motif chemokine receptor 2 multiple interactions ISO SB 203580 inhibits the reaction [Lipopolysaccharides results in decreased expression of CXCR2 protein] CTD PMID:10950785 NCBI chr 9:83,178,645...83,185,017
Ensembl chr 9:83,183,808...83,188,602 		JBrowse link
G Cyba cytochrome b-245 alpha chain multiple interactions ISO SB 203580 inhibits the reaction [Ethanol results in increased expression of CYBA mRNA] CTD PMID:23978445 NCBI chr19:67,396,143...67,404,214
Ensembl chr19:67,396,143...67,404,214 		JBrowse link
G Cybb cytochrome b-245 beta chain multiple interactions ISO SB 203580 inhibits the reaction [Ethanol results in increased expression of CYBB mRNA] CTD PMID:23978445 NCBI chr  X:16,030,596...16,065,065
Ensembl chr  X:16,030,596...16,065,065 		JBrowse link
G Cycs cytochrome c, somatic multiple interactions EXP
ISO 		SB 203580 promotes the reaction [Cisplatin affects the localization of CYCS protein]
SB 203580 inhibits the reaction [4-vinyl-2,6-dimethoxyphenol results in increased expression of CYCS protein] 		CTD PMID:19578154 PMID:30653946 NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816
Ensembl chr18:80,982,668...80,984,816 		JBrowse link
G Cyp11a1 cytochrome P450, family 11, subfamily a, polypeptide 1 multiple interactions EXP SB 203580 inhibits the reaction [nickel sulfate results in decreased expression of CYP11A1 mRNA]; SB 203580 inhibits the reaction [nickel sulfate results in decreased expression of CYP11A1 protein] CTD PMID:29567110 NCBI chr 8:67,318,665...67,330,196
Ensembl chr 8:67,270,556...67,330,196 		JBrowse link
G Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 multiple interactions EXP SB 203580 inhibits the reaction [nickel sulfate results in decreased expression of CYP17A1 mRNA]; SB 203580 inhibits the reaction [nickel sulfate results in decreased expression of CYP17A1 protein] CTD PMID:29567110 NCBI chr 1:255,476,861...255,484,547
Ensembl chr 1:255,476,861...255,482,974 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 increases activity
multiple interactions
increases expression 		ISO
EXP 		SB 203580 results in increased activity of CYP1A1 protein
SB203580 increases expression of mRNA and potentiates the reaction [sunitinib increases expression of mRNA] in rat cardiomyocytes
SB 203580 inhibits the reaction [Nicotine results in increased expression of CYP1A1 mRNA]
SB 203580 results in increased expression of CYP1A1 mRNA
SB 203580 promotes the reaction [sunitinib results in increased expression of CYP1A1 mRNA]
SB 203580 results in increased expression of CYP1A1 mRNA; SB 203580 results in increased expression of CYP1A1 protein
[alpha-naphthoflavone binds to and results in decreased activity of AHR protein] results in decreased susceptibility to [SB 203580 results in increased expression of CYP1A1]; AHR protein affects the susceptibility to [SB 203580 results in increased expression of CYP1A1]; Dactinomycin inhibits the reaction [SB 203580 results in increased expression of CYP1A1 mRNA]; SB 203580 inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; SB 203580 inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]; SB 203580 inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1]; SB 203580 results in increased expression of and results in increased activity of CYP1A1 protein 		CTD
RGD		 PMID:18078826 PMID:21732638 PMID:24247421 PMID:34171359 PMID:24247421 RGD:401793741 NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012 		JBrowse link
G Cyp27b1 cytochrome P450, family 27, subfamily b, polypeptide 1 multiple interactions ISO SB 203580 inhibits the reaction [IFNG protein results in increased expression of CYP27B1 mRNA] CTD PMID:16355272 NCBI chr 7:64,756,626...64,761,570
Ensembl chr 7:64,756,626...64,761,570 		JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 multiple interactions ISO SB 203580 promotes the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; SB 203580 promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA] CTD PMID:22486562 NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495 		JBrowse link
G Daxx death-domain associated protein multiple interactions ISO SB 203580 inhibits the reaction [Cadmium Chloride affects the localization of DAXX protein] CTD PMID:12508112 NCBI chr20:4,971,973...4,978,062
Ensembl chr20:4,971,941...4,977,720 		JBrowse link
G Dct dopachrome tautomerase multiple interactions ISO SB 203580 inhibits the reaction [Cannabidiol results in increased expression of DCT mRNA] CTD PMID:28601556 NCBI chr15:101,469,159...101,508,029
Ensembl chr15:101,469,159...101,508,029 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions ISO SB 203580 inhibits the reaction [baicalein-7-O-diglucoside results in increased expression of DDIT3 protein]; SB 203580 inhibits the reaction [honokiol results in increased expression of DDIT3 protein]; SB 203580 inhibits the reaction [Indomethacin results in increased expression of DDIT3 protein]
SB 203580 inhibits the reaction [alpha-naphthoflavone results in increased expression of DDIT3 protein]; SB 203580 inhibits the reaction [tetrabromobisphenol A results in increased expression of DDIT3 protein] 		CTD PMID:17341418 PMID:26253462 PMID:30508555 PMID:33550458 PMID:39586487 NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509 		JBrowse link
G Ddit4 DNA-damage-inducible transcript 4 multiple interactions ISO SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of DDIT4 mRNA] CTD PMID:28329830 NCBI chr20:28,434,938...28,437,037
Ensembl chr20:28,434,944...28,437,037 		JBrowse link
G Dio2 iodothyronine deiodinase 2 multiple interactions EXP SB 203580 inhibits the reaction [Hydrogen Peroxide results in increased expression of DIO2 mRNA] CTD PMID:18420745 NCBI chr 6:115,396,308...115,410,594
Ensembl chr 6:115,396,308...115,410,594 		JBrowse link
G Dio3 iodothyronine deiodinase 3 decreases expression
multiple interactions 		ISO
EXP 		SB 203580 results in decreased expression of DIO3
SB 203580 inhibits the reaction [Fluoxetine results in increased expression of DIO3 mRNA]; SB 203580 inhibits the reaction [Hydrogen Peroxide results in increased activity of DIO3 protein]; SB 203580 inhibits the reaction [Hydrogen Peroxide results in increased expression of DIO3 mRNA] 		CTD PMID:15456934 PMID:18420745 PMID:26825960 NCBI chr 6:135,107,072...135,108,933
Ensembl chr 6:135,107,074...135,107,985 		JBrowse link
G Dnajb9 DnaJ heat shock protein family (Hsp40) member B9 multiple interactions ISO SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of DNAJB9 mRNA] CTD PMID:28329830 NCBI chr 6:66,997,842...67,007,371
Ensembl chr 6:66,997,842...67,009,344 		JBrowse link
G Dusp1 dual specificity phosphatase 1 multiple interactions ISO
EXP 		SB 203580 inhibits the reaction [arsenite results in increased expression of DUSP1 mRNA]
SB 203580 inhibits the reaction [Cadmium results in increased expression of DUSP1 mRNA]; SB 203580 inhibits the reaction [Cadmium results in increased expression of DUSP1 protein]; SB 203580 inhibits the reaction [Oxygen deficiency results in increased expression of DUSP1 mRNA]; SB 203580 promotes the reaction [Lipopolysaccharides results in increased phosphorylation of DUSP1 protein] 		CTD PMID:11577072 PMID:11689710 PMID:18573614 PMID:20885979 NCBI chr10:17,184,853...17,187,646
Ensembl chr10:17,184,823...17,187,644 		JBrowse link
G Dusp5 dual specificity phosphatase 5 multiple interactions ISO SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of DUSP5 mRNA] CTD PMID:28329830 NCBI chr 1:262,543,774...262,557,201
Ensembl chr 1:262,543,738...262,562,417 		JBrowse link
G Dusp6 dual specificity phosphatase 6 multiple interactions ISO SB 203580 inhibits the reaction [Asbestos, Crocidolite results in increased expression of DUSP6 mRNA] CTD PMID:18314537 NCBI chr 7:35,979,502...35,983,834
Ensembl chr 7:35,977,921...35,983,833 		JBrowse link
G Ece1 endothelin converting enzyme 1 affects expression EXP SB 203580 affects the expression of ECE1 mRNA CTD PMID:21084678 NCBI chr 5:155,361,031...155,462,723
Ensembl chr 5:155,360,639...155,462,719 		JBrowse link
G Edn1 endothelin 1 multiple interactions ISO
EXP 		SB 203580 inhibits the reaction [cobaltous chloride results in increased secretion of EDN1 protein]; SB 203580 inhibits the reaction [EDN1 protein results in increased expression of CXCL8 mRNA]; SB 203580 inhibits the reaction [EDN1 protein results in increased expression of EDN1 mRNA]; SB 203580 inhibits the reaction [EDN1 protein results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [EDN1 protein results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [EDN1 protein results in increased expression of VCAM1 mRNA]; SB 203580 inhibits the reaction [Glucose results in increased expression of EDN1 mRNA]
SB 203580 inhibits the reaction [EDN1 protein results in increased phosphorylation of CREB1 protein] 		CTD PMID:14741741 PMID:18457675 PMID:24376792 PMID:27297870 NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687 		JBrowse link
G Ednra endothelin receptor type A multiple interactions EXP SB 203580 inhibits the reaction [Smoke results in increased expression of EDNRA protein] CTD PMID:36183783 NCBI chr19:47,137,360...47,207,961
Ensembl chr19:47,137,771...47,201,284 		JBrowse link
G Ednrb endothelin receptor type B multiple interactions EXP SB 203580 inhibits the reaction [Cyclosporine results in increased expression of EDNRB mRNA]; SB 203580 inhibits the reaction [Cyclosporine results in increased expression of EDNRB protein]; SB 203580 inhibits the reaction [Particulate Matter results in increased expression of EDNRB mRNA]; SB 203580 inhibits the reaction [Particulate Matter results in increased expression of EDNRB protein]; SB 203580 inhibits the reaction [Smoke results in increased expression of EDNRB mRNA]; SB 203580 inhibits the reaction [Smoke results in increased expression of EDNRB protein] CTD PMID:18718921 PMID:20561571 PMID:25772258 PMID:26496744 PMID:36183783 NCBI chr15:87,055,490...87,086,765
Ensembl chr15:87,057,691...87,086,765 		JBrowse link
G Egf epidermal growth factor multiple interactions ISO
EXP 		SB 203580 inhibits the reaction [EGF protein results in increased secretion of MUC5AC protein]
SB 203580 results in decreased activity of [arsenite co-treated with EGF protein] 		CTD PMID:9733710 PMID:22766066 NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:220,893,660...220,976,297 		JBrowse link
G Egr1 early growth response 1 multiple interactions ISO
EXP 		SB 203580 inhibits the reaction [Fluorouracil results in increased expression of EGR1 mRNA]; SB 203580 inhibits the reaction [Fluorouracil results in increased expression of EGR1 protein]; SB 203580 promotes the reaction [3,4-dihydroxyphenylethanol results in increased expression of EGR1 mRNA]; SB 203580 promotes the reaction [pyrrolidine dithiocarbamic acid results in increased expression of EGR1 mRNA]; SB 203580 promotes the reaction [Resveratrol results in increased expression of EGR1 mRNA]
SB 203580 inhibits the reaction [Quercetin results in increased expression of EGR1 mRNA]; SB 203580 inhibits the reaction [Quercetin results in increased expression of EGR1 protein]
SB 203580 inhibits the reaction [Anisomycin results in increased expression of EGR1 mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of EGR1 mRNA]; SB 203580 inhibits the reaction [Particulate Matter promotes the reaction [Tobacco Smoke Pollution results in increased expression of EGR1 mRNA]]; SB 203580 inhibits the reaction [Tobacco Smoke Pollution promotes the reaction [Particulate Matter results in increased expression of EGR1 mRNA]]; SB 203580 inhibits the reaction [Tobacco Smoke Pollution results in increased expression of EGR1 mRNA]; SB 203580 promotes the reaction [sodium arsenite results in increased expression of EGR1 mRNA] 		CTD PMID:9671412 PMID:12482581 PMID:18757417 PMID:22046279 PMID:22174042 More... NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,736,838...26,740,843 		JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2 subunit alpha increases phosphorylation ISO SB 203580 results in increased phosphorylation of EIF2S1 protein CTD PMID:21090173 NCBI chr 6:103,405,880...103,430,549
Ensembl chr 6:103,405,788...103,431,649 		JBrowse link
G Eif4e eukaryotic translation initiation factor 4E multiple interactions ISO 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of EIF4E protein]]; [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one co-treated with SB 203580] inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of EIF4E protein]; MAPK14 protein mutant form inhibits the reaction [SB 203580 inhibits the reaction [arsenite results in increased phosphorylation of EIF4E protein]]; SB 203580 inhibits the reaction [Anisomycin results in increased phosphorylation of EIF4E protein]; SB 203580 inhibits the reaction [arsenite results in increased phosphorylation of EIF4E protein]; SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of EIF4E protein]; SB 203580 inhibits the reaction [TNF protein results in increased phosphorylation of EIF4E protein]; SB 203580 promotes the reaction [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of EIF4E protein]]
[SB 203580 co-treated with U 0126] inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of EIF4E protein]; SB 203580 inhibits the reaction [Anisomycin results in increased phosphorylation of EIF4E protein] 		CTD PMID:9545260 PMID:12781867 PMID:16431125 NCBI chr 2:229,736,309...229,772,628
Ensembl chr 2:229,739,897...229,774,105 		JBrowse link
G Eif4g1 eukaryotic translation initiation factor 4 gamma 1 multiple interactions ISO [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one co-treated with SB 203580] inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of EIF4G1 protein] CTD PMID:12781867 NCBI chr11:93,726,322...93,746,387
Ensembl chr11:93,726,322...93,746,367 		JBrowse link
G Elk1 ETS transcription factor ELK1 multiple interactions
affects activity 		ISO
EXP 		[SB 203580 co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] inhibits the reaction [sodium arsenite results in increased phosphorylation of ELK1 protein]; SB 203580 inhibits the reaction [IL1B protein results in increased phosphorylation of ELK1 protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased phosphorylation of ELK1 protein]
SB 203580 affects the activity of ELK1 protein 		CTD PMID:10903806 PMID:12660819 PMID:21084678 PMID:21642427 NCBI chr  X:3,692,367...3,709,252
Ensembl chr  X:3,693,293...3,709,249 		JBrowse link
G Enc1 ectodermal-neural cortex 1 multiple interactions ISO SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of ENC1 mRNA] CTD PMID:28329830 NCBI chr 2:30,285,274...30,297,194
Ensembl chr 2:30,283,736...30,315,721 		JBrowse link
G Ep300 E1A binding protein p300 multiple interactions EXP SB 203580 inhibits the reaction [Doxorubicin results in decreased expression of EP300 protein]; SB 203580 inhibits the reaction [MAP2K6 protein results in decreased expression of EP300 protein] CTD PMID:15767673 NCBI chr 7:114,987,857...115,058,652
Ensembl chr 7:114,946,982...115,058,574 		JBrowse link
G Erbb2 erb-b2 receptor tyrosine kinase 2 multiple interactions ISO SB 203580 inhibits the reaction [ERBB2 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of CXCL8 mRNA]]; SB 203580 inhibits the reaction [ERBB2 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased secretion of CXCL8 protein]] CTD PMID:33396024 NCBI chr10:83,907,491...83,931,365
Ensembl chr10:83,907,460...83,931,481 		JBrowse link
G Ercc1 ERCC excision repair 1, endonuclease non-catalytic subunit increases expression
multiple interactions 		ISO SB 203580 results in increased expression of ERCC1 mRNA
SB 203580 inhibits the reaction [tanshinone results in decreased expression of ERCC1 mRNA] 		CTD PMID:21165580 NCBI chr 1:88,099,308...88,135,966
Ensembl chr 1:88,118,891...88,139,120 		JBrowse link
G Errfi1 ERBB receptor feedback inhibitor 1 multiple interactions ISO SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of ERRFI1 mRNA] CTD PMID:28329830 NCBI chr 5:166,606,841...166,620,124
Ensembl chr 5:166,606,834...166,620,432 		JBrowse link
G Esr1 estrogen receptor 1 multiple interactions
decreases expression 		ISO [SB 203580 co-treated with naringenin] results in increased degradation of ESR1 protein; SB 203580 inhibits the reaction [[ESR1 protein results in increased susceptibility to Quercetin] which results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [[ESR1 protein results in increased susceptibility to Quercetin] which results in increased cleavage of PARP1 protein]; SB 203580 promotes the reaction [Estradiol results in increased degradation of ESR1 protein]
SB 203580 results in decreased expression of ESR1 protein
SB 203580 inhibits the reaction [Estradiol results in increased expression of ESR1 protein] 		CTD PMID:19194971 PMID:19340542 PMID:24586459 NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354 		JBrowse link
G Esr2 estrogen receptor 2 multiple interactions ISO SB 203580 inhibits the reaction [[ESR2 protein results in increased susceptibility to Estradiol] which results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [[ESR2 protein results in increased susceptibility to Estradiol] which results in increased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [[ESR2 protein results in increased susceptibility to Quercetin] which results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [[ESR2 protein results in increased susceptibility to Quercetin] which results in increased cleavage of PARP1 protein] CTD PMID:21732360 NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:100,545,206...100,644,709 		JBrowse link
G Ets1 ETS proto-oncogene 1, transcription factor multiple interactions ISO SB 203580 inhibits the reaction [benz(a)anthracene results in increased expression of ETS1 mRNA]; SB 203580 inhibits the reaction [benzo(k)fluoranthene results in increased expression of ETS1 mRNA]; SB 203580 inhibits the reaction [indeno(1,2,3-cd)pyrene results in increased expression of ETS1 mRNA] CTD PMID:21635667 NCBI chr 8:39,303,936...39,426,022
Ensembl chr 8:39,303,925...39,426,021 		JBrowse link
G Ezr ezrin multiple interactions ISO SB 203580 inhibits the reaction [cyanoginosin LR results in increased phosphorylation of EZR protein] CTD PMID:24677693 NCBI chr 1:49,373,033...49,416,573
Ensembl chr 1:49,373,035...49,416,573 		JBrowse link
G F11r F11 receptor multiple interactions ISO SB 203580 inhibits the reaction [Poly I-C results in decreased expression of F11R protein] CTD PMID:20932985 NCBI chr13:86,406,229...86,429,819
Ensembl chr13:86,406,218...86,429,816 		JBrowse link
G F3 coagulation factor III, tissue factor multiple interactions
decreases expression 		ISO SB 203580 inhibits the reaction [Asbestos, Crocidolite results in increased expression of F3 mRNA]; SB 203580 inhibits the reaction [Histamine results in increased expression of F3]; SB 203580 inhibits the reaction [IL1B protein results in increased expression of F3 protein]; SB 203580 inhibits the reaction [indoleacetic acid results in increased expression of F3 mRNA]; SB 203580 inhibits the reaction [indoleacetic acid results in increased expression of F3 protein]; SB 203580 inhibits the reaction [TNF protein results in increased expression of F3 mRNA]
SB 203580 results in decreased expression of F3 mRNA 		CTD PMID:15371228 PMID:16009787 PMID:20118172 PMID:27556861 PMID:30324315 NCBI chr 2:212,511,675...212,523,375
Ensembl chr 2:212,511,680...212,523,369 		JBrowse link
G Fadd Fas associated via death domain multiple interactions ISO SB 203580 inhibits the reaction [S-allylcysteine promotes the reaction [FAS protein binds to FADD protein]] CTD PMID:31067004 NCBI chr 1:209,169,245...209,175,423
Ensembl chr 1:209,169,318...209,174,976 		JBrowse link
G Fancd2 FA complementation group D2 multiple interactions ISO SB 203580 inhibits the reaction [Ouabain inhibits the reaction [Mitomycin results in increased expression of and affects the ubiquitination of FANCD2 protein]] CTD PMID:24124520 NCBI chr 4:148,234,633...148,299,035
Ensembl chr 4:148,234,708...148,299,035 		JBrowse link
G Fas Fas cell surface death receptor multiple interactions ISO SB 203580 inhibits the reaction [S-allylcysteine promotes the reaction [FAS protein binds to FADD protein]]; SB 203580 inhibits the reaction [S-allylcysteine promotes the reaction [FAS protein binds to FASLG protein]] CTD PMID:31067004 NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:241,205,935...241,246,104 		JBrowse link
G Faslg Fas ligand multiple interactions ISO SB 203580 affects the reaction [Temozolomide results in increased expression of FASLG mRNA]; SB 203580 inhibits the reaction [S-allylcysteine promotes the reaction [FAS protein binds to FASLG protein]]; SB 203580 promotes the reaction [Emodin results in increased expression of FASLG protein]; SB 203580 promotes the reaction [Resveratrol results in increased cleavage of FASLG protein]
SB 203580 inhibits the reaction [Sodium Glutamate results in increased expression of FASL mRNA] 		CTD PMID:16782274 PMID:22644961 PMID:26418950 PMID:27032576 PMID:31067004 NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503 		JBrowse link
G Fgf1 fibroblast growth factor 1 multiple interactions EXP SB 203580 inhibits the reaction [FGF1 protein results in increased expression of POSTN mRNA] CTD PMID:15121739 NCBI chr18:30,937,670...31,023,786
Ensembl chr18:30,939,870...30,961,393 		JBrowse link
G Fgf2 fibroblast growth factor 2 multiple interactions
increases secretion
decreases activity 		ISO
EXP 		SB 203580 inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK14 protein]; SB 203580 inhibits the reaction [FGF2 protein results in increased phosphorylation of RB1 protein]; SB 203580 inhibits the reaction [Sodium Chloride results in increased expression of FGF2 mRNA]
SB 203580 results in increased secretion of FGF2 protein
SB 203580 inhibits the reaction [AGT protein modified form results in increased expression of FGF2 mRNA]; SB 203580 inhibits the reaction [AGT protein modified form results in increased expression of FGF2 protein]; SB 203580 promotes the reaction [diphenylarsinic acid results in increased secretion of FGF2 protein]
SB 203580 inhibits the reaction [FGF2 protein results in increased secretion of TNFRSF11B protein]
SB 203580 results in decreased activity of FGF2 protein 		CTD PMID:15249425 PMID:15631803 PMID:21108934 PMID:25290095 PMID:26800359 More... NCBI chr 2:122,164,454...122,218,796
Ensembl chr 2:122,164,454...122,224,493 		JBrowse link
G Fgf23 fibroblast growth factor 23 multiple interactions ISO SB 203580 inhibits the reaction [FGF23 protein results in increased chemical synthesis of and affects the secretion of Dinoprostone] CTD PMID:16144964 NCBI chr 4:161,600,439...161,609,991
Ensembl chr 4:161,600,383...161,609,991 		JBrowse link
G Fgf7 fibroblast growth factor 7 multiple interactions ISO SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of FGF7 mRNA] CTD PMID:28329830 NCBI chr 3:133,734,557...133,786,678
Ensembl chr 3:133,734,673...133,786,328 		JBrowse link
G Fn1 fibronectin 1 multiple interactions EXP SB 203580 inhibits the reaction [[sphingosine 1-phosphate co-treated with Glucose] results in increased expression of FN1 protein]; SB 203580 inhibits the reaction [Pyruvaldehyde results in increased expression of FN1 mRNA] CTD PMID:17635749 PMID:22406263 NCBI chr 9:80,645,507...80,714,200
Ensembl chr 9:80,645,507...80,714,137 		JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions
decreases expression
increases expression 		ISO
EXP 		SB 203580 inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased expression of FOS protein]; SB 203580 inhibits the reaction [IL1B protein results in increased expression of FOS mRNA]; SB 203580 inhibits the reaction [IL1B protein results in increased phosphorylation of FOS protein]; SB 203580 inhibits the reaction [Nicotine results in increased phosphorylation of FOS protein]; SB 203580 inhibits the reaction [TNF protein results in increased expression of FOS mRNA]; SB 203580 promotes the reaction [sodium arsenite results in increased expression of FOS mRNA]
SB 203580 promotes the reaction [diphenylarsinic acid results in increased expression of and results in increased phosphorylation of FOS protein]
SB 203580 results in decreased expression of FOS mRNA
SB 203580 results in increased expression of FOS protein
SB 203580 inhibits the reaction [icariin results in increased expression of FOS protein] 		CTD PMID:11053056 PMID:12547826 PMID:15322261 PMID:18423597 PMID:18982426 More... NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598 		JBrowse link
G Fosl1 FOS like 1, AP-1 transcription factor subunit multiple interactions ISO SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of FOSL1 mRNA] CTD PMID:28329830 NCBI chr 1:212,183,885...212,192,391
Ensembl chr 1:212,183,833...212,192,391 		JBrowse link
G Foxo3 forkhead box O3 multiple interactions ISO
EXP 		SB 203580 inhibits the reaction [Cadmium Chloride results in decreased activity of FOXO3 protein]; SB 203580 inhibits the reaction [Cadmium Chloride results in increased phosphorylation of FOXO3 protein]
SB 203580 inhibits the reaction [Manganese results in increased phosphorylation of FOXO3 protein] 		CTD PMID:23673518 PMID:24787138 NCBI chr20:47,251,968...47,348,254
Ensembl chr20:47,255,878...47,346,845 		JBrowse link
G Fshb follicle stimulating hormone subunit beta multiple interactions EXP SB 203580 inhibits the reaction [FSHB protein results in increased abundance of Estradiol] CTD PMID:22067323 NCBI chr 3:114,003,262...114,007,072
Ensembl chr 3:114,003,262...114,007,072 		JBrowse link
G Gabpa GA binding protein transcription factor subunit alpha multiple interactions ISO SB 203580 inhibits the reaction [Gallic Acid results in increased expression of GABPA protein] CTD PMID:16308312 NCBI chr11:37,375,040...37,404,060
Ensembl chr11:37,375,084...37,404,059 		JBrowse link
G Gadd45a growth arrest and DNA-damage-inducible, alpha multiple interactions ISO troglitazone promotes the reaction [SB 203580 results in increased expression of GADD45A mRNA] CTD PMID:15064713 NCBI chr 4:97,484,497...97,486,799
Ensembl chr 4:97,484,502...97,486,807 		JBrowse link
G Galnt3 polypeptide N-acetylgalactosaminyltransferase 3 multiple interactions ISO SB 203580 inhibits the reaction [Cadmium results in increased expression of GALNT3 mRNA] CTD PMID:24614234 NCBI chr 3:71,150,559...71,187,321
Ensembl chr 3:71,150,571...71,174,323 		JBrowse link
G Gata2 GATA binding protein 2 multiple interactions ISO SB 203580 inhibits the reaction [Lipopolysaccharides affects the localization of and results in increased activity of GATA2 protein] CTD PMID:23940812 NCBI chr 4:122,211,501...122,225,058
Ensembl chr 4:122,211,829...122,225,055 		JBrowse link
G Gata4 GATA binding protein 4 affects activity
multiple interactions 		EXP SB 203580 affects the activity of GATA4 protein
SB 203580 inhibits the reaction [AGT protein modified form results in increased activity of GATA4 protein] 		CTD PMID:21084678 PMID:21108934 NCBI chr15:41,635,572...41,707,252
Ensembl chr15:41,635,572...41,681,609 		JBrowse link
G Gcg glucagon multiple interactions ISO SB 203580 inhibits the reaction [Chitosan results in increased expression of GCG mRNA]; SB 203580 inhibits the reaction [Chitosan results in increased secretion of GCG protein] CTD PMID:23611362 NCBI chr 3:67,522,489...67,531,533
Ensembl chr 3:67,522,489...67,531,533 		JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit multiple interactions ISO SB 203580 inhibits the reaction [Plant Extracts results in increased expression of GCLC protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased expression of GCLC protein]
SB 203580 inhibits the reaction [2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone results in increased expression of GCLC mRNA] 		CTD PMID:25201354 PMID:30626086 PMID:31029725 NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893 		JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit multiple interactions ISO SB 203580 inhibits the reaction [Quercetin results in increased expression of GCLM mRNA] CTD PMID:22197970 NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:213,031,838...213,055,003 		JBrowse link
G Gdf15 growth differentiation factor 15 multiple interactions ISO [SB 203580 co-treated with 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine] inhibits the reaction [jasplakinolide results in increased expression of GDF15 protein]; [SB 203580 co-treated with 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine] inhibits the reaction [latrunculin B results in increased expression of GDF15 protein]; [SB 203580 co-treated with 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine] inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of GDF15 protein]; SB 203580 inhibits the reaction [rottlerin results in increased expression of GDF15 protein]; SB 203580 inhibits the reaction [silybin results in increased expression of GDF15 protein] CTD PMID:22410117 PMID:23996089 PMID:24440808 NCBI chr16:18,838,436...18,842,022
Ensembl chr16:18,838,436...18,842,022 		JBrowse link
G Gfap glial fibrillary acidic protein multiple interactions EXP SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP mRNA]; SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP protein] CTD PMID:34571074 NCBI chr10:88,352,987...88,361,661
Ensembl chr10:88,352,986...88,361,685 		JBrowse link
G Ggt1 gamma-glutamyltransferase 1 multiple interactions EXP SB 203580 inhibits the reaction [4-hydroxy-2-nonenal results in increased expression of GGT1 mRNA] CTD PMID:16195535 NCBI chr20:13,074,141...13,103,551
Ensembl chr20:13,074,141...13,088,050 		JBrowse link
G Gh1 growth hormone 1 multiple interactions EXP SB 203580 inhibits the reaction [deoxynivalenol results in decreased expression of GH1 mRNA]; SB 203580 inhibits the reaction [deoxynivalenol results in decreased expression of GH1 protein]; SB 203580 inhibits the reaction [T-2 Toxin results in decreased expression of GH1 mRNA] CTD PMID:26141394 PMID:29079362 NCBI chr10:91,727,883...91,729,860
Ensembl chr10:91,727,884...91,729,859 		JBrowse link
G Gja1 gap junction protein, alpha 1 multiple interactions ISO
EXP 		SB 203580 inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of and results in decreased phosphorylation of GJA1 protein]; SB 203580 inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of GJA1 protein]; SB 203580 inhibits the reaction [resveratrol results in increased expression of GJA1 protein]
SB 203580 inhibits the reaction [fulvestrant promotes the reaction [NEDD4 protein binds to and results in increased ubiquitination of GJA1 protein]]; SB 203580 inhibits the reaction [fulvestrant results in decreased expression of GJA1 mRNA]; SB 203580 inhibits the reaction [fulvestrant results in decreased expression of GJA1 protein]
SB 203580 inhibits the reaction [Phenylephrine results in increased expression of GJA1 mRNA]; SB 203580 inhibits the reaction [Phenylephrine results in increased expression of GJA1 protein] 		CTD PMID:18445782 PMID:23761298 PMID:24449132 PMID:27818224 PMID:29180066 NCBI chr20:36,302,490...36,315,010
Ensembl chr20:36,302,352...36,319,689 		JBrowse link
G Gjb1 gap junction protein, beta 1 multiple interactions ISO SB 203580 inhibits the reaction [1-methylanthracene affects the expression of and affects the activity of GJB1 protein]; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] affects the expression of and affects the activity of GJB1 protein]; SB 203580 inhibits the reaction [fluoranthene affects the expression of and affects the activity of GJB1 protein] CTD PMID:28329830 NCBI chr  X:70,541,845...70,549,776
Ensembl chr  X:70,541,862...70,549,843 		JBrowse link
G Glb1 galactosidase, beta 1 multiple interactions ISO pyrazolanthrone promotes the reaction [SB 203580 inhibits the reaction [Arsenic Trioxide results in increased activity of GLB1 protein]]; SB 203580 inhibits the reaction [Arsenic Trioxide results in increased activity of GLB1 protein]; SB 203580 promotes the reaction [pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased activity of GLB1 protein]] CTD PMID:31734849 NCBI chr 8:122,963,718...123,036,326
Ensembl chr 8:122,963,718...123,036,326 		JBrowse link
G Glul glutamate-ammonia ligase multiple interactions EXP SB 203580 inhibits the reaction [[Paraquat results in increased abundance of Reactive Oxygen Species] which results in decreased expression of GLUL protein] CTD PMID:24376630 NCBI chr13:68,519,500...68,585,554
Ensembl chr13:68,576,067...68,585,520 		JBrowse link
G Gmfb glia maturation factor, beta multiple interactions ISO SB 203580 inhibits the reaction [[GMFB protein co-treated with Hydrogen Peroxide] results in increased abundance of Hydrogen Peroxide]; SB 203580 inhibits the reaction [[GMFB protein co-treated with Hydrogen Peroxide] results in increased activity of CASP3 protein] CTD PMID:12791701 NCBI chr15:22,549,705...22,560,125
Ensembl chr15:22,547,034...22,560,308 		JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions ISO SB 203580 inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein] CTD PMID:26218279 NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160 		JBrowse link
G Gpx1 glutathione peroxidase 1 multiple interactions ISO SB 203580 inhibits the reaction [Quercetin results in increased expression of GPX1 mRNA] CTD PMID:22197970 NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:117,905,280...117,906,581 		JBrowse link
G Gria2 glutamate ionotropic receptor AMPA type subunit 2 multiple interactions EXP SB 203580 affects the reaction [Sodium Glutamate affects the expression of GRIA2] CTD PMID:15139026 NCBI chr 2:168,247,490...168,367,616
Ensembl chr 2:168,247,496...168,367,616 		JBrowse link
G Gsdmd gasdermin D multiple interactions ISO SB 203580 inhibits the reaction [Paraquat results in increased cleavage of GSDMD protein] CTD PMID:38237652 NCBI chr 7:109,423,209...109,427,771
Ensembl chr 7:109,422,910...109,430,722 		JBrowse link
G Gsk3b glycogen synthase kinase 3 beta multiple interactions
decreases activity 		ISO SB 203580 inhibits the reaction [DEFA1 protein results in increased phosphorylation of GSK3B protein]; SB 203580 inhibits the reaction [DEFA2 protein results in increased phosphorylation of GSK3B protein]
SB 203580 results in decreased activity of GSK3B protein 		CTD PMID:10998351 PMID:19814765 NCBI chr11:76,004,502...76,154,665
Ensembl chr11:76,009,507...76,153,249 		JBrowse link
G Gsr glutathione-disulfide reductase multiple interactions ISO SB 203580 inhibits the reaction [Quercetin results in increased expression of GSR mRNA] CTD PMID:22197970 NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394 		JBrowse link
G Gstp1 glutathione S-transferase pi 1 multiple interactions ISO SB 203580 inhibits the reaction [Quercetin results in increased expression of GSTP1 mRNA] CTD PMID:22197970 NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:210,767,237...210,769,705 		JBrowse link
G Has2 hyaluronan synthase 2 multiple interactions ISO SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of HAS2 mRNA] CTD PMID:28329830 NCBI chr 7:90,002,929...90,028,933
Ensembl chr 7:90,002,929...90,018,535 		JBrowse link
G Hbegf heparin-binding EGF-like growth factor multiple interactions ISO SB 203580 inhibits the reaction [Hydrogen Peroxide results in increased expression of HBEGF mRNA]; SB 203580 inhibits the reaction [Sodium Chloride results in increased expression of HBEGF mRNA]; SB 203580 inhibits the reaction [vanadium pentoxide results in increased expression of HBEGF mRNA] CTD PMID:11159045 PMID:12676768 PMID:26800359 NCBI chr18:28,380,337...28,390,220
Ensembl chr18:28,380,337...28,390,220 		JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha multiple interactions
decreases expression 		ISO [U 0126 co-treated with SB 203580] inhibits the reaction [[nickel sulfate co-treated with macrophage stimulatory lipopeptide 2] results in increased expression of HIF1A protein]; SB 203580 inhibits the reaction [[nickel sulfate co-treated with Dinoprostone] results in increased expression of HIF1A protein]; SB 203580 inhibits the reaction [cobaltous chloride results in increased activity of HIF1A protein]; SB 203580 inhibits the reaction [cobaltous chloride results in increased expression of HIF1A mRNA]; SB 203580 inhibits the reaction [cobaltous chloride results in increased expression of HIF1A protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of HIF1A protein]]; SB 203580 inhibits the reaction [manganese chloride results in increased expression of and results in increased activity of and results in increased stability of HIF1A protein]; SB 203580 inhibits the reaction [manganese chloride results in increased expression of and results in increased activity of HIF1A protein]; SB 203580 inhibits the reaction [nickel sulfate results in increased expression of HIF1A protein]; SB 203580 inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased expression of HIF1A protein]
SB 203580 results in decreased expression of HIF1A protein 		CTD PMID:12482858 PMID:13679210 PMID:14695184 PMID:17082639 PMID:20152896 More... NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323 		JBrowse link
G Hmga2 high mobility group AT-hook 2 multiple interactions ISO SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of HMGA2 mRNA] CTD PMID:28329830 NCBI chr 7:57,762,710...57,884,555
Ensembl chr 7:57,765,675...57,880,341 		JBrowse link
G Hmgb1 high mobility group box 1 multiple interactions ISO SB 203580 inhibits the reaction [Silicon Dioxide results in increased expression of HMGB1 protein] CTD PMID:27616297 NCBI chr12:11,009,236...11,015,941
Ensembl chr16:39,039,050...39,041,327
Ensembl chr12:39,039,050...39,041,327 		JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions
increases expression
decreases expression 		ISO
EXP 		2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [SB 203580 inhibits the reaction [Quercetin promotes the reaction [Ethanol results in increased activity of HMOX1 protein]]]; [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one co-treated with SB 203580] inhibits the reaction [Quercetin results in increased activity of HMOX1 protein]; SB 203580 inhibits the reaction [10-nitro-oleic acid results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [2-butenal results in increased expression of HMOX1 mRNA]; SB 203580 inhibits the reaction [2-butenal results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [4-hydroxy-2-nonenal results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [Cadmium results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [coniferaldehyde results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [Curcumin results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [Dimethyl Fumarate results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [gallium nitrate results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [kahweol results in increased expression of and results in increased activity of HMOX1 protein]; SB 203580 inhibits the reaction [lead acetate results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [Plant Extracts results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [Potassium Dichromate results in increased expression of HMOX1 mRNA]; SB 203580 inhibits the reaction [Quercetin promotes the reaction [Ethanol results in increased activity of HMOX1 protein]]; SB 203580 inhibits the reaction [Quercetin results in increased activity of HMOX1 protein]; SB 203580 inhibits the reaction [Quercetin results in increased expression of HMOX1 mRNA]; SB 203580 inhibits the reaction [Ritonavir results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [Silver results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [Simvastatin results in increased expression of HMOX1 mRNA]; SB 203580 inhibits the reaction [sodium arsenite results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [Sulindac promotes the reaction [Arsenic Trioxide results in increased expression of HMOX1 protein]]; SB 203580 inhibits the reaction [tricarbonyldichlororuthenium (II) dimer results in increased expression of HMOX1 protein]; SB 203580 promotes the reaction [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Quercetin promotes the reaction [Ethanol results in increased activity of HMOX1 protein]]]
SB 203580 results in increased expression of HMOX1 mRNA
SB 203580 results in decreased expression of HMOX1 mRNA
SB 203580 inhibits the reaction [15-deoxyprostaglandin J2 results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [Ascorbic Acid results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [aureusidin results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [diphenylarsinic acid results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [manganese chloride results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [Methamphetamine results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [Quercetin results in increased expression of HMOX1 mRNA]; SB 203580 inhibits the reaction [Resveratrol results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [Tropisetron results in increased expression of HMOX1 protein]; SB 203580 promotes the reaction [[Paraquat results in increased abundance of Reactive Oxygen Species] which results in increased expression of HMOX1 mRNA]
SB 203580 inhibits the reaction [10-nitro-oleic acid results in increased expression of HMOX1 mRNA]; SB 203580 inhibits the reaction [10-nitro-oleic acid results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [17-hydroxyjolkinolide B promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]]; SB 203580 inhibits the reaction [2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone results in increased expression of HMOX1 mRNA]; SB 203580 inhibits the reaction [4-hydroxy-2-nonenal results in increased expression of HMOX1 mRNA]; SB 203580 inhibits the reaction [4-hydroxy-2-nonenal results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of HMOX1 mRNA]; SB 203580 inhibits the reaction [Arsenic Trioxide results in increased expression of HMOX1 mRNA]; SB 203580 inhibits the reaction [Cadmium Chloride results in increased expression of HMOX1 mRNA]; SB 203580 inhibits the reaction [Copper results in increased expression of HMOX1 mRNA]; SB 203580 inhibits the reaction [Dieldrin results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [farrerol results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [hydroquinone results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [Lead results in increased expression of HMOX1 mRNA]; SB 203580 inhibits the reaction [lipoteichoic acid results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [Mercury results in increased expression of HMOX1 mRNA]; SB 203580 inhibits the reaction [Quercetin analog results in increased expression of HMOX1 mRNA]; SB 203580 inhibits the reaction [Quercetin results in increased expression of HMOX1 protein] 		CTD PMID:10874044 PMID:14647439 PMID:15504750 PMID:15770161 PMID:16171798 More... NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818 		JBrowse link
G Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 multiple interactions ISO SB 203580 inhibits the reaction [[trimethyltin chloride results in increased abundance of trimethyltin] which results in increased expression of HSD11B1 mRNA] CTD PMID:30993381 NCBI chr13:107,277,526...107,327,462
Ensembl chr13:107,257,239...107,327,432 		JBrowse link
G Hsd17b3 hydroxysteroid (17-beta) dehydrogenase 3 multiple interactions EXP SB 203580 inhibits the reaction [nickel sulfate results in decreased expression of HSD17B3 mRNA] CTD PMID:29567110 NCBI chr17:1,032,958...1,064,283
Ensembl chr17:1,032,958...1,064,283 		JBrowse link
G Hsf1 heat shock transcription factor 1 multiple interactions EXP SB 203580 inhibits the reaction [Cadmium Chloride results in increased phosphorylation of HSF1 protein] CTD PMID:9822662 NCBI chr 7:110,076,710...110,103,665
Ensembl chr 7:110,076,710...110,103,665 		JBrowse link
G Hspa1b heat shock protein family A (Hsp70) member 1B multiple interactions ISO SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of HSPA1B mRNA] CTD PMID:28329830 NCBI chr20:3,859,756...3,863,800
Ensembl chr20:3,855,780...3,877,979 		JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 multiple interactions ISO SB 203580 inhibits the reaction [Arsenic Trioxide results in increased expression of HSPA5 protein]; SB 203580 inhibits the reaction [honokiol results in increased expression of HSPA5 protein]; SB 203580 inhibits the reaction [Indomethacin results in increased expression of HSPA5 protein] CTD PMID:17341418 PMID:33550458 PMID:34560123 NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:38,453,041...38,458,790 		JBrowse link
G Hspb1 heat shock protein family B (small) member 1 multiple interactions
decreases phosphorylation 		ISO
EXP 		SB 203580 inhibits the reaction [IL1B protein results in increased phosphorylation of HSPB1 protein]; SB 203580 inhibits the reaction [Methotrexate results in increased expression of HSPB1 protein]
[SB 203580 inhibits the reaction [Lipopolysaccharides co-treated with TNF protein]] which results in increased phosphorylation of HSPB1 protein; SB 203580 inhibits the reaction [cyanoginosin LR results in increased phosphorylation of HSPB1 protein]; SB 203580 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of HSPB1 protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased phosphorylation of HSPB1 protein]
SB 203580 inhibits the reaction [2-chloroethyl ethyl sulfide results in increased expression of HSPB1 protein]
SB 203580 results in decreased phosphorylation of HSPB1 protein 		CTD PMID:10903806 PMID:19100307 PMID:20864298 PMID:21457723 PMID:22000993 More... NCBI chr12:26,430,640...26,432,301
Ensembl chr12:26,430,640...26,432,301 		JBrowse link
G Hspb2 heat shock protein family B (small) member 2 multiple interactions ISO SB 203580 inhibits the reaction [Fluorouracil results in increased phosphorylation of HSPB2 protein] CTD PMID:18757417 NCBI chr 8:59,989,640...59,991,215
Ensembl chr 8:59,976,623...59,990,901 		JBrowse link
G Htr2a 5-hydroxytryptamine receptor 2A multiple interactions EXP SB 203580 inhibits the reaction [Particulate Matter results in increased expression of HTR2A mRNA]; SB 203580 inhibits the reaction [Particulate Matter results in increased expression of HTR2A protein] CTD PMID:31199065 NCBI chr15:56,360,647...56,428,703
Ensembl chr15:56,359,596...56,431,619 		JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions ISO
EXP 		SB 203580 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of ICAM1 mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein]; SB 203580 inhibits the reaction [Particulate Matter results in increased expression of ICAM1 mRNA]; SB 203580 inhibits the reaction [TNF results in increased expression of ICAM1 protein]; SB 203580 inhibits the reaction [Vehicle Emissions results in increased expression of ICAM1 mRNA]; SB 203580 inhibits the reaction [Vehicle Emissions results in increased expression of ICAM1 protein]
SB 203580 inhibits the reaction [resveratrol results in decreased expression of ICAM1 protein]; SB 203580 inhibits the reaction [tropisetron results in decreased expression of ICAM1 protein] 		CTD PMID:10792388 PMID:16582018 PMID:19020780 PMID:21192278 PMID:22226621 More... NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617 		JBrowse link
G Ifng interferon gamma multiple interactions ISO
EXP 		[2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one co-treated with SB 203580] inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased chemical synthesis of Nitrites]; [SB 203580 co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] results in decreased susceptibility to [IL1B protein co-treated with IFNG protein]; SB 203580 inhibits the reaction [[IFNG protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of NOS2 mRNA]; SB 203580 inhibits the reaction [[IL12A protein binds to IL12B protein] which results in increased expression of IFNG protein]; SB 203580 inhibits the reaction [deoxynivalenol inhibits the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased expression of NOS2 protein]]; SB 203580 inhibits the reaction [IFNG protein results in increased expression of CYP27B1 mRNA]; SB 203580 inhibits the reaction [IFNG protein results in increased phosphorylation of CEBPB protein]; SB 203580 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]; SB 203580 inhibits the reaction [nickel monoxide results in decreased expression of IFNG protein]
[SB 203580 co-treated with Manganese] inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; SB 203580 inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [[IFNG protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased abundance of Nitric Oxide]; SB 203580 inhibits the reaction [[IFNG protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of NOS2 protein]; SB 203580 inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide]; SB 203580 inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of NOS2 protein]; SB 203580 inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; SB 203580 inhibits the reaction [Manganese promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA]]; SB 203580 inhibits the reaction [Manganese promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TNF protein]]
SB 203580 inhibits the reaction [[Polysaccharides co-treated with IFNG protein] results in increased expression of TNF protein] 		CTD PMID:10903806 PMID:10952721 PMID:12911628 PMID:16307444 PMID:16355272 More... NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216 		JBrowse link
G Igf1 insulin-like growth factor 1 multiple interactions ISO SB 203580 inhibits the reaction [TGFB1 protein inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of and results in decreased secretion of IGF1 protein]] CTD PMID:26254549 NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:24,130,137...24,246,764 		JBrowse link
G Igf2 insulin-like growth factor 2 multiple interactions
decreases response to substance 		ISO SB 203580 inhibits the reaction [IGF2 protein results in increased expression of STS mRNA]
SB 203580 results in decreased susceptibility to IGF2 protein 		CTD PMID:24055520 NCBI chr 1:207,243,873...207,261,263
Ensembl chr 1:207,243,873...207,260,667 		JBrowse link
G Ikbkb inhibitor of nuclear factor kappa B kinase subunit beta multiple interactions ISO
EXP 		SB 203580 inhibits the reaction [Lipopolysaccharides results in increased activity of IKBKB protein]
SB 203580 inhibits the reaction [sodium arsenite results in increased phosphorylation of IKBKB protein] 		CTD PMID:16765938 PMID:19616567 NCBI chr16:76,021,968...76,075,717
Ensembl chr16:76,022,008...76,081,911 		JBrowse link
G Il10 interleukin 10 multiple interactions ISO SB 203580 inhibits the reaction [Drugs, Chinese Herbal results in increased secretion of IL10 protein]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of IL10 mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL10 protein]; SB 203580 inhibits the reaction [Methotrexate results in increased expression of IL10 protein]; SB 203580 inhibits the reaction [nickel monoxide results in decreased expression of IL10 protein]; SB 203580 inhibits the reaction [Poly I-C results in increased secretion of IL10 protein]; SB 203580 inhibits the reaction [Polysaccharides results in increased secretion of IL10 protein]; SB 203580 inhibits the reaction [Zymosan results in increased secretion of IL10 protein]
SB 203580 inhibits the reaction [Folic Acid promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL10 protein]]; SB 203580 inhibits the reaction [Folic Acid results in increased secretion of IL10 protein]; SB 203580 inhibits the reaction [Fungal Polysaccharides results in increased secretion of IL10 protein]; SB 203580 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL10 protein]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of IL10 mRNA]; SB 203580 inhibits the reaction [morroniside results in increased expression of IL10 mRNA] 		CTD PMID:15894585 PMID:17698565 PMID:19100307 PMID:21135123 PMID:21586572 More... NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580 		JBrowse link
G Il11 interleukin 11 multiple interactions ISO SB 203580 inhibits the reaction [Formaldehyde results in increased expression of IL11 mRNA]; SB 203580 inhibits the reaction [Formaldehyde results in increased secretion of IL11 protein] CTD PMID:22138297 NCBI chr 1:78,098,622...78,104,915
Ensembl chr 1:78,096,930...78,104,915 		JBrowse link
G Il12a interleukin 12A multiple interactions ISO SB 203580 inhibits the reaction [[IL12A protein binds to IL12B protein] which results in increased expression of IFNG protein]; SB 203580 inhibits the reaction [Drugs, Chinese Herbal results in increased secretion of [IL12A protein binds to IL12B protein]]; SB 203580 inhibits the reaction [Polysaccharides results in increased secretion of [IL12A protein binds to IL12B protein]]
SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of IL12A mRNA] 		CTD PMID:10952721 PMID:11006016 PMID:15894585 NCBI chr 2:155,275,734...155,282,997
Ensembl chr 2:155,275,625...155,282,997 		JBrowse link
G Il12b interleukin 12B multiple interactions ISO SB 203580 inhibits the reaction [2,2-dichloroacetyl chloride results in increased expression of IL12B mRNA]; SB 203580 inhibits the reaction [[IL12A protein binds to IL12B protein] which results in increased expression of IFNG protein]; SB 203580 inhibits the reaction [Drugs, Chinese Herbal results in increased secretion of [IL12A protein binds to IL12B protein]]; SB 203580 inhibits the reaction [Drugs, Chinese Herbal results in increased secretion of IL12B protein]; SB 203580 inhibits the reaction [nickel sulfate results in increased secretion of IL12B protein]; SB 203580 inhibits the reaction [Polysaccharides results in increased secretion of [IL12A protein binds to IL12B protein]]; SB 203580 inhibits the reaction [Polysaccharides results in increased secretion of IL12B protein]
SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of IL12B mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein] 		CTD PMID:10952721 PMID:11006016 PMID:15778123 PMID:15894585 PMID:19101624 More... NCBI chr10:29,390,300...29,405,194
Ensembl chr10:29,389,905...29,405,194 		JBrowse link
G Il13ra2 interleukin 13 receptor subunit alpha 2 decreases expression ISO SB 203580 results in decreased expression of IL13RA2 mRNA CTD PMID:20660070 NCBI chr  X:115,814,620...115,886,080
Ensembl chr  X:115,814,622...115,841,455 		JBrowse link
G Il17a interleukin 17A multiple interactions ISO SB 203580 inhibits the reaction [IL17A protein promotes the reaction [TNF protein results in increased expression of IL6 mRNA]]; SB 203580 inhibits the reaction [IL17A protein results in increased expression of CCL2 protein]; SB 203580 inhibits the reaction [IL17A protein results in increased expression of CXCL8 protein]; SB 203580 inhibits the reaction [IL17A protein results in increased expression of IL6 protein] CTD PMID:12016129 NCBI chr 9:30,640,844...30,644,331
Ensembl chr 9:30,640,844...30,644,331 		JBrowse link
G Il18 interleukin 18 multiple interactions ISO SB 203580 inhibits the reaction [IL18 protein results in increased expression of PTEN mRNA]; SB 203580 inhibits the reaction [IL18 protein results in increased phosphorylation of and results in increased activity of RELA protein]; SB 203580 inhibits the reaction [IL18 protein results in increased phosphorylation of ATF2 protein] CTD PMID:18215737 NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:59,809,592...59,831,286 		JBrowse link
G Il1a interleukin 1 alpha multiple interactions ISO SB 203580 inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]; SB 203580 inhibits the reaction [IL1A protein results in increased secretion of IL6 protein]; SB 203580 inhibits the reaction [IL1A results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [IL1A results in increased expression of PTGS2 protein] CTD PMID:14742690 PMID:15728660 PMID:16532021 NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013 		JBrowse link
G Il1b interleukin 1 beta multiple interactions
decreases expression 		ISO
EXP 		[2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one co-treated with SB 203580] inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased chemical synthesis of Nitrites]; [SB 203580 co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] inhibits the reaction [IL1B protein results in increased chemical synthesis of Nitrites]; [SB 203580 co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] results in decreased susceptibility to [IL1B protein co-treated with IFNG protein]; SB 203580 affects the reaction [IL1B results in increased expression of CXCL8 protein]; SB 203580 analog inhibits the reaction [IL1B results in increased expression of MMP13 mRNA]; SB 203580 analog inhibits the reaction [IL1B results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [[IFNG protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of NOS2 mRNA]; SB 203580 inhibits the reaction [[IL1B protein co-treated with IL6 protein] results in increased expression of and results in increased secretion of CRP protein]; SB 203580 inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL1B mRNA]; SB 203580 inhibits the reaction [APP protein results in increased expression of and results in increased cleavage of IL1B protein]; SB 203580 inhibits the reaction [deoxynivalenol inhibits the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased expression of NOS2 protein]]; SB 203580 inhibits the reaction [IL1B protein results in decreased expression of TNFRSF11B protein]; SB 203580 inhibits the reaction [IL1B protein results in increased expression of CXCL8 mRNA]; SB 203580 inhibits the reaction [IL1B protein results in increased expression of CXCL8 protein]; SB 203580 inhibits the reaction [IL1B protein results in increased expression of F3 protein]; SB 203580 inhibits the reaction [IL1B protein results in increased expression of FOS mRNA]; SB 203580 inhibits the reaction [IL1B protein results in increased expression of IL6 protein]; SB 203580 inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [IL1B protein results in increased phosphorylation of ELK1 protein]; SB 203580 inhibits the reaction [IL1B protein results in increased phosphorylation of FOS protein]; SB 203580 inhibits the reaction [IL1B protein results in increased phosphorylation of HSPB1 protein]; SB 203580 inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK1 protein]; SB 203580 inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK3 protein]; SB 203580 inhibits the reaction [IL1B protein results in increased secretion of CXCL8 protein]; SB 203580 inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; SB 203580 inhibits the reaction [IL1B results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; SB 203580 inhibits the reaction [Methotrexate results in increased expression of IL1B protein]; SB 203580 inhibits the reaction [Mustard Gas results in increased expression of IL1B protein]; SB 203580 inhibits the reaction [nickel monoxide results in increased expression of IL1B protein]; SB 203580 inhibits the reaction [T-2 Toxin promotes the reaction [IL1B protein results in increased secretion of CXCL8 protein]]; SB 203580 promotes the reaction [bufalin results in increased expression of IL1B mRNA]
SB 203580 results in decreased expression of IL1B protein
SB 203580 inhibits the reaction [Carbon Tetrachloride results in increased expression of IL1B protein]; SB 203580 inhibits the reaction [Fungal Polysaccharides results in increased expression of IL1B mRNA]; SB 203580 inhibits the reaction [IL1B protein results in increased expression of IL6 protein]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; SB 203580 inhibits the reaction [TGFB1 protein inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of and results in increased secretion of IL1B protein]]
SB 203580 inhibits the reaction [2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [ACE2 protein inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]]; SB 203580 inhibits the reaction [7-Ala-angiotensin (1-7) inhibits the reaction [ACE2 protein inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]]; SB 203580 inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [Acrolein results in increased cleavage of IL1B protein]; SB 203580 inhibits the reaction [Acrolein results in increased expression of and results in increased secretion of IL1B protein]; SB 203580 inhibits the reaction [CLDN2 protein results in increased expression of IL1B mRNA]; SB 203580 inhibits the reaction [CLDN2 protein results in increased expression of IL1B protein]; SB 203580 inhibits the reaction [lead acetate results in increased expression of IL1B protein]; SB 203580 inhibits the reaction [Particulate Matter results in increased expression of IL1B mRNA]; SB 203580 inhibits the reaction [T-2 Toxin results in increased expression of IL1B mRNA] 		CTD PMID:10704466 PMID:10712238 PMID:10903806 PMID:11854442 PMID:15251176 More... NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601 		JBrowse link
G Il2 interleukin 2 multiple interactions ISO SB 203580 affects the reaction [Methotrexate results in increased expression of IL2 protein]; SB 203580 inhibits the reaction [norcantharidin inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]] CTD PMID:19100307 PMID:21075198 NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:121,932,968...121,937,672 		JBrowse link
G Il27 interleukin 27 multiple interactions ISO SB 203580 inhibits the reaction [nickel sulfate results in increased expression of IL27 mRNA] CTD PMID:30421605 NCBI chr 1:190,603,684...190,609,292
Ensembl chr 1:190,603,522...190,609,258 		JBrowse link
G Il4 interleukin 4 multiple interactions ISO
EXP 		SB 203580 inhibits the reaction [Methadone results in increased expression of IL4 mRNA]; SB 203580 inhibits the reaction [Methotrexate results in decreased expression of IL4 protein]; SB 203580 inhibits the reaction [Morphine results in increased expression of IL4 mRNA]
SB 203580 inhibits the reaction [dinitrophenyl-human serum albumin conjugate results in increased expression of IL4 mRNA]; SB 203580 promotes the reaction [dinitrophenyl-human serum albumin conjugate results in increased secretion of IL4 protein] 		CTD PMID:10611455 PMID:19100307 PMID:23965172 NCBI chr10:38,272,003...38,277,549
Ensembl chr10:38,272,003...38,277,549 		JBrowse link
G Il6 interleukin 6 multiple interactions
decreases secretion
decreases expression 		ISO
EXP 		magnolin promotes the reaction [SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL6 mRNA]]; magnolin promotes the reaction [SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of IL6 protein]]; SB 203580 affects the reaction [Methotrexate results in decreased expression of IL6 protein]; SB 203580 inhibits the reaction [7-ketocholesterol results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [[IL1B protein co-treated with IL6 protein] results in increased expression of and results in increased secretion of CRP protein]; SB 203580 inhibits the reaction [[nickel sulfate co-treated with macrophage stimulatory lipopeptide 2] results in increased secretion of IL6 protein]; SB 203580 inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [Cadmium Chloride results in increased expression of and results in increased secretion of IL6 protein]; SB 203580 inhibits the reaction [cobaltous chloride results in increased secretion of IL6 protein]; SB 203580 inhibits the reaction [doxifluridine results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [doxifluridine results in increased secretion of IL6 protein]; SB 203580 inhibits the reaction [EDN1 protein results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [Fluorouracil results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [hexabromocyclododecane results in increased expression of IL6 protein]; SB 203580 inhibits the reaction [IL17A protein promotes the reaction [TNF protein results in increased expression of IL6 mRNA]]; SB 203580 inhibits the reaction [IL17A protein results in increased expression of IL6 protein]; SB 203580 inhibits the reaction [IL1A protein results in increased secretion of IL6 protein]; SB 203580 inhibits the reaction [IL1B protein results in increased expression of IL6 protein]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; SB 203580 inhibits the reaction [melamine results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [Mustard Gas results in increased expression of IL6 protein]; SB 203580 inhibits the reaction [Mustard Gas results in increased secretion of IL6 protein]; SB 203580 inhibits the reaction [nickel monoxide results in increased expression of IL6 protein]; SB 203580 inhibits the reaction [nickel sulfate results in increased expression of IL6 protein]; SB 203580 inhibits the reaction [nickel sulfate results in increased secretion of IL6 protein]; SB 203580 inhibits the reaction [OSM protein results in increased expression of and results in increased secretion of IL6 protein]; SB 203580 inhibits the reaction [OSM protein results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [Particulate Matter results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [Particulate Matter results in increased secretion of IL6 protein]; SB 203580 inhibits the reaction [pentabromodiphenyl ether results in increased expression of IL6 protein]; SB 203580 inhibits the reaction [Poly I-C results in increased secretion of IL6 protein]; SB 203580 inhibits the reaction [tetrabromobisphenol A results in increased expression of IL6 protein]; SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of IL6 protein]; SB 203580 inhibits the reaction [TNF protein results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [Tobacco Smoke Pollution analog results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [Vehicle Emissions results in increased secretion of IL6 protein]; SB 203580 inhibits the reaction [Zymosan results in increased secretion of IL6 protein]; SB 203580 promotes the reaction [magnolin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL6 mRNA]]; SB 203580 promotes the reaction [magnolin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of IL6 protein]]; SB 203580 results in decreased susceptibility to [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL6 protein]
SB 203580 inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]]; SB 203580 inhibits the reaction [[Paraquat results in increased abundance of Reactive Oxygen Species] which results in increased secretion of IL6 protein]; SB 203580 inhibits the reaction [Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]]; SB 203580 inhibits the reaction [cobaltous chloride results in increased secretion of IL6 protein]; SB 203580 inhibits the reaction [diphenylarsinic acid results in increased secretion of IL6 protein]; SB 203580 inhibits the reaction [lead acetate results in increased expression of IL6 protein]; SB 203580 inhibits the reaction [Resveratrol results in decreased expression of IL6 protein]; SB 203580 inhibits the reaction [Tropisetron results in decreased expression of IL6 protein]
SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [[trimethyltin chloride results in increased abundance of trimethyltin] which results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [cobaltous chloride results in increased expression of IL6 protein]; SB 203580 inhibits the reaction [deoxynivalenol results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; SB 203580 inhibits the reaction [Fungal Polysaccharides results in increased secretion of IL6 protein]; SB 203580 inhibits the reaction [IL1B protein results in increased expression of IL6 protein]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; SB 203580 inhibits the reaction [Particulate Matter promotes the reaction [Tobacco Smoke Pollution results in increased expression of IL6 mRNA]]; SB 203580 inhibits the reaction [Particulate Matter results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [Tobacco Smoke Pollution promotes the reaction [Particulate Matter results in increased expression of IL6 mRNA]]; SB 203580 inhibits the reaction [Tobacco Smoke Pollution results in increased expression of IL6 mRNA]
SB 203580 results in decreased secretion of IL6 protein
SB 203580 results in decreased expression of IL6 protein 		CTD PMID:1970628 PMID:10704466 PMID:12016129 PMID:12794122 PMID:15251176 More... NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610 		JBrowse link
G Ins1 insulin 1 multiple interactions EXP SB 203580 inhibits the reaction [INS1 protein results in increased activity of MAPK14 protein] CTD PMID:8971075 NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682 		JBrowse link
G Ins2 insulin 2 multiple interactions ISO
EXP 		[SB 203580 co-treated with INS protein] inhibits the reaction [Glucose affects the localization of PDX1 protein]
SB 203580 inhibits the reaction [conophylline results in increased expression of INS protein] 		CTD PMID:11574405 PMID:14568228 NCBI chr 1:207,272,738...207,421,998
Ensembl chr 1:207,272,742...207,273,805 		JBrowse link
G Insr insulin receptor multiple interactions EXP SB 203580 inhibits the reaction [oleoylethanolamide affects the phosphorylation of and affects the activity of INSR protein] CTD PMID:19345745 NCBI chr12:5,991,135...6,129,275
Ensembl chr12:5,981,835...6,128,803 		JBrowse link
G Irgm immunity-related GTPase M multiple interactions ISO SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of IRGM1 mRNA] CTD PMID:28329830 NCBI chr10:33,734,640...33,742,720
Ensembl chr10:33,732,961...33,743,228 		JBrowse link
G Irs1 insulin receptor substrate 1 multiple interactions ISO SB 203580 inhibits the reaction [bisphenol A results in increased expression of IRS1 protein modified form] CTD PMID:29793316 NCBI chr 9:91,001,137...91,053,959
Ensembl chr 9:90,993,519...91,054,538 		JBrowse link
G Itga2 integrin subunit alpha 2 multiple interactions ISO SB 203580 inhibits the reaction [benz(a)anthracene results in increased expression of ITGA2 mRNA]; SB 203580 inhibits the reaction [benzo(k)fluoranthene results in increased expression of ITGA2 mRNA]; SB 203580 inhibits the reaction [indeno(1,2,3-cd)pyrene results in increased expression of ITGA2 mRNA] CTD PMID:21635667 NCBI chr 2:48,253,412...48,354,509
Ensembl chr 2:48,253,412...48,354,509 		JBrowse link
G Itgam integrin subunit alpha M multiple interactions ISO SB 203580 inhibits the reaction [TGFB1 protein inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of ITGAM protein]] CTD PMID:26254549 NCBI chr 1:192,089,496...192,139,947
Ensembl chr 1:192,089,542...192,139,943 		JBrowse link
G Itgb6 integrin subunit beta 6 multiple interactions ISO SB 203580 inhibits the reaction [TGFB1 protein results in increased expression of ITGB6 mRNA] CTD PMID:21303922 NCBI chr 3:65,454,964...65,579,179
Ensembl chr 3:65,456,713...65,530,333 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO
EXP 		SB 203580 inhibits the reaction [benz(a)anthracene results in increased expression of JUN mRNA]; SB 203580 inhibits the reaction [benzo(k)fluoranthene results in increased expression of JUN mRNA]; SB 203580 inhibits the reaction [Glucose results in increased phosphorylation of JUN protein]; SB 203580 inhibits the reaction [indeno(1,2,3-cd)pyrene results in increased expression of JUN mRNA]
SB 203580 inhibits the reaction [Cadmium Chloride results in increased expression of JUN mRNA]; SB 203580 inhibits the reaction [Phenylephrine results in increased expression of JUN mRNA]; SB 203580 promotes the reaction [diphenylarsinic acid results in increased expression of and results in increased phosphorylation of JUN protein]
SB 203580 inhibits the reaction [icariin results in increased expression of JUN protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased phosphorylation of JUN protein] 		CTD PMID:11035063 PMID:15252869 PMID:18423597 PMID:19002563 PMID:19132243 More... NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285 		JBrowse link
G Junb JunB proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO SB 203580 inhibits the reaction [TGFB1 protein affects the localization of JUNB protein]; SB 203580 inhibits the reaction [TGFB1 protein results in increased expression of JUNB mRNA] CTD PMID:21303922 NCBI chr19:40,081,126...40,082,910
Ensembl chr19:40,073,541...40,085,218 		JBrowse link
G Kcnb1 potassium voltage-gated channel subfamily B member 1 multiple interactions EXP SB 203580 inhibits the reaction [Methamphetamine results in increased expression of KCNB1 protein] CTD PMID:29297590 NCBI chr 3:176,239,285...176,332,408
Ensembl chr 3:176,242,589...176,332,408 		JBrowse link
G Kitlg KIT ligand decreases expression ISO SB 203580 results in decreased expression of SCF protein CTD PMID:15585325 NCBI chr 7:36,782,621...36,863,796
Ensembl chr 7:36,782,638...36,863,793 		JBrowse link
G Klf4 KLF transcription factor 4 multiple interactions ISO SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of KLF4 mRNA] CTD PMID:28329830 NCBI chr 5:75,074,107...75,079,182
Ensembl chr 5:75,074,236...75,078,592 		JBrowse link
G Klf5 KLF transcription factor 5 multiple interactions ISO SB 203580 inhibits the reaction [TGFB1 protein results in decreased expression of KLF5 mRNA]
SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of KLF5 mRNA] 		CTD PMID:21712382 PMID:28329830 NCBI chr15:82,472,081...82,487,267
Ensembl chr15:82,472,065...82,487,262 		JBrowse link
G Klf6 KLF transcription factor 6 multiple interactions ISO [Arachidonic Acid co-treated with SB 203580] results in decreased expression of KLF6 mRNA; SB 203580 promotes the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; SB 203580 promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA] CTD PMID:22486562 NCBI chr17:69,449,483...69,458,478
Ensembl chr17:69,441,493...69,498,601 		JBrowse link
G Krt1 keratin 1 multiple interactions
decreases expression 		ISO SB 203580 inhibits the reaction [Calcium results in increased expression of KRT1 mRNA]; SB 203580 inhibits the reaction [Calcium results in increased expression of KRT1 protein]; SB 203580 inhibits the reaction [Mustard Gas results in increased expression of KRT1 mRNA]; SB 203580 inhibits the reaction [Mustard Gas results in increased expression of KRT1 protein]
SB 203580 results in decreased expression of KRT1 mRNA; SB 203580 results in decreased expression of KRT1 protein 		CTD PMID:21524694 NCBI chr 7:134,855,311...134,860,537
Ensembl chr 7:134,855,313...134,860,537 		JBrowse link
G Krt18 keratin 18 multiple interactions ISO SB 203580 inhibits the reaction [cyanoginosin LR results in increased phosphorylation of KRT18 protein] CTD PMID:22960429 NCBI chr 7:135,036,168...135,039,844
Ensembl chr 7:135,035,982...135,039,848
Ensembl chr10:135,035,982...135,039,848 		JBrowse link
G Krt8 keratin 8 multiple interactions ISO SB 203580 inhibits the reaction [cyanoginosin LR results in increased phosphorylation of KRT8 protein] CTD PMID:22960429 NCBI chr 7:135,002,886...135,010,339
Ensembl chr 7:135,002,894...135,010,403 		JBrowse link
G Lck LCK proto-oncogene, Src family tyrosine kinase decreases activity ISO SB 203580 results in decreased activity of LCK protein CTD PMID:10998351 NCBI chr 5:147,172,642...147,201,267
Ensembl chr 5:147,172,642...147,201,267 		JBrowse link
G Lep leptin multiple interactions
decreases response to substance 		ISO SB 203580 inhibits the reaction [LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]]; SB 203580 inhibits the reaction [Vitamin K 3 results in increased expression of LEP mRNA]
SB 203580 results in decreased susceptibility to LEP protein 		CTD PMID:16996477 PMID:19849856 NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:58,626,523...58,640,661 		JBrowse link
G Lepr leptin receptor affects response to substance ISO LEPR protein affects the susceptibility to SB 203580 CTD PMID:22933112 NCBI chr 5:121,409,735...121,593,201
Ensembl chr 5:121,474,099...121,591,215 		JBrowse link
G Lif LIF, interleukin 6 family cytokine multiple interactions ISO SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of LIF mRNA] CTD PMID:28329830 NCBI chr14:83,354,602...83,364,053
Ensembl chr14:83,358,164...83,364,053 		JBrowse link
G Loricrin loricrin cornified envelope precursor protein multiple interactions
decreases expression 		ISO SB 203580 inhibits the reaction [Calcium results in increased expression of LORICRIN mRNA]; SB 203580 inhibits the reaction [Calcium results in increased expression of LORICRIN protein]; SB 203580 inhibits the reaction [Mustard Gas results in increased expression of LORICRIN mRNA]; SB 203580 inhibits the reaction [Mustard Gas results in increased expression of LORICRIN protein]
SB 203580 results in decreased expression of LORICRIN protein 		CTD PMID:21524694 NCBI chr 2:180,253,674...180,256,572
Ensembl chr 2:180,253,674...180,256,572 		JBrowse link
G Lrp1 LDL receptor related protein 1 multiple interactions
increases expression 		ISO SB 203580 inhibits the reaction [tanshinone results in decreased expression of LRP1 mRNA]
SB 203580 results in increased expression of LRP1 mRNA 		CTD PMID:21165580 NCBI chr 7:65,265,639...65,346,196
Ensembl chr 7:65,265,639...65,346,196 		JBrowse link
G Lta4h leukotriene A4 hydrolase multiple interactions ISO SB 203580 inhibits the reaction [2-chloroethyl ethyl sulfide results in increased expression of LTA4H mRNA] CTD PMID:20382172 NCBI chr 7:29,856,846...29,888,642
Ensembl chr 7:29,856,802...29,888,641 		JBrowse link
G Ltc4s leukotriene C4 synthase multiple interactions ISO SB 203580 inhibits the reaction [2-chloroethyl ethyl sulfide results in increased expression of LTC4S mRNA] CTD PMID:20382172 NCBI chr10:35,060,002...35,066,466
Ensembl chr10:35,061,437...35,063,768 		JBrowse link
G Lyz2 lysozyme 2 multiple interactions ISO SB 203580 inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; SB 203580 inhibits the reaction [Heme analog results in increased secretion of LYZ protein] CTD PMID:23355332 NCBI chr 7:54,792,715...54,798,060
Ensembl chr 7:54,792,716...54,798,011 		JBrowse link
G Map1lc3a microtubule-associated protein 1 light chain 3 alpha decreases expression EXP SB203580 decreases expression of protein in oxygen-glucose deprived rat neuronal PC12 cells RGD PMID:27769861 RGD:329853763 NCBI chr 3:164,243,204...164,244,850
Ensembl chr 3:164,243,093...164,244,850 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO
EXP 		SB 203580 promotes the reaction [sodium arsenite results in increased expression of and results in increased lipidation of MAP1LC3B protein]
SB 203580 inhibits the reaction [osthol inhibits the reaction [Antineoplastic Agents, Immunological results in decreased lipidation of MAP1LC3B protein]] 		CTD PMID:34861471 PMID:37769856 NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358
Ensembl chr16:66,574,407...66,584,358 		JBrowse link
G Map2k6 mitogen-activated protein kinase kinase 6 multiple interactions EXP
ISO 		SB 203580 inhibits the reaction [MAP2K6 protein results in decreased expression of EP300 protein]
SB 203580 inhibits the reaction [[MAP2K6 gene mutant form results in increased activity of MAP2K6 protein] which results in increased susceptibility to Tetradecanoylphorbol Acetate] 		CTD PMID:15767673 PMID:27278863 NCBI chr10:95,872,747...95,987,747
Ensembl chr10:95,872,546...95,987,721 		JBrowse link
G Map3k1 mitogen-activated protein kinase kinase kinase 1 multiple interactions ISO SB 203580 inhibits the reaction [[MAP3K1 gene mutant form results in increased activity of MAP3K1 protein] which results in increased susceptibility to Tetradecanoylphorbol Acetate] CTD PMID:27278863 NCBI chr 2:45,081,889...45,150,555
Ensembl chr 2:45,081,889...45,149,897 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases phosphorylation 		ISO
EXP 		[Temozolomide results in decreased susceptibility to Temozolomide] promotes the reaction [[thymoquinone co-treated with SB 203580] results in increased phosphorylation of MAPK1 protein]; [thymoquinone co-treated with SB 203580] results in increased phosphorylation of MAPK1 protein; SB 203580 inhibits the reaction [4-vinyl-2,6-dimethoxyphenol results in decreased phosphorylation of MAPK1 protein]; SB 203580 inhibits the reaction [Dinitrochlorobenzene results in decreased phosphorylation of MAPK1 protein]; SB 203580 inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK1 protein]; SB 203580 inhibits the reaction [honokiol results in increased phosphorylation of MAPK1 protein]; SB 203580 inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK1 protein]; SB 203580 inhibits the reaction [Resveratrol results in increased phosphorylation of and results in increased activity of MAPK1 protein]; SB 203580 inhibits the reaction [Thimerosal results in decreased phosphorylation of MAPK1 protein]; SB 203580 promotes the reaction [bufalin results in increased phosphorylation of MAPK1 protein]; SB 203580 promotes the reaction [sodium arsenite results in increased phosphorylation of MAPK1 protein]; SB 203580 promotes the reaction [TNF protein results in increased phosphorylation of MAPK1 protein]
SB 203580 results in increased phosphorylation of MAPK1 protein
[pyrazolanthrone co-treated with SB 203580 co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] inhibits the reaction [Quercetin results in increased phosphorylation of MAPK1 protein]; SB 203580 inhibits the reaction [esculetin results in increased phosphorylation of MAPK1 protein]; SB 203580 inhibits the reaction [Quercetin results in increased phosphorylation of MAPK1 protein]; SB 203580 promotes the reaction [ferrous sulfate results in increased phosphorylation of MAPK1 protein]; SB 203580 promotes the reaction [Iron results in increased phosphorylation of MAPK1 protein]
SB 203580 promotes the reaction [Anisomycin results in increased phosphorylation of MAPK1 protein]; SB 203580 promotes the reaction [PDGFB protein results in increased phosphorylation of MAPK1 protein]; SB 203580 promotes the reaction [sodium arsenite results in increased phosphorylation of MAPK1 protein]; SB 203580 promotes the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of and results in increased activity of MAPK1 protein] 		CTD PMID:9671412 PMID:10712238 PMID:10993886 PMID:12547826 PMID:15588916 More... NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825 		JBrowse link
G Mapk11 mitogen-activated protein kinase 11 multiple interactions
decreases expression
increases expression
decreases activity 		ISO
EXP 		Cadmium Chloride inhibits the reaction [SB 203580 results in decreased expression of MAPK11 mRNA]; Cadmium Chloride inhibits the reaction [SB 203580 results in increased expression of MAPK11 protein]; SB 203580 inhibits the reaction [Cadmium Chloride results in increased expression of MAPK11 protein]; SB 203580 inhibits the reaction [MAPK11 protein results in increased phosphorylation of SOD2 protein]
SB 203580 results in decreased activity of MAPK11 protein 		CTD PMID:10998351 PMID:19757093 PMID:24376630 PMID:24465521 NCBI chr 7:122,098,120...122,105,023
Ensembl chr 7:122,098,121...122,105,038 		JBrowse link
G Mapk12 mitogen-activated protein kinase 12 decreases expression ISO SB 203580 results in decreased expression of MAPK12 mRNA CTD PMID:19757093 NCBI chr 7:122,085,647...122,096,307
Ensembl chr 7:122,085,913...122,096,307 		JBrowse link
G Mapk13 mitogen activated protein kinase 13 multiple interactions ISO [SB 203580 co-treated with Cadmium Chloride] results in increased expression of MAPK13 mRNA CTD PMID:19757093 NCBI chr20:6,836,979...6,847,197
Ensembl chr20:6,837,013...6,847,191 		JBrowse link
G Mapk14 mitogen activated protein kinase 14 multiple interactions
decreases activity 		ISO
EXP 		MAPK14 protein mutant form inhibits the reaction [SB 203580 inhibits the reaction [arsenite results in increased phosphorylation of EIF4E protein]]; SB 203580 inhibits the reaction [11,11'-dideoxyverticilin results in increased expression of and results in increased phosphorylation of MAPK14 protein]; SB 203580 inhibits the reaction [benz(a)anthracene results in increased phosphorylation of MAPK14 protein]; SB 203580 inhibits the reaction [benzo(k)fluoranthene results in increased phosphorylation of MAPK14 protein]; SB 203580 inhibits the reaction [Cadmium Chloride results in decreased expression of MAPK14 mRNA]; SB 203580 inhibits the reaction [Cadmium results in increased phosphorylation of MAPK14 protein]; SB 203580 inhibits the reaction [cinnamaldehyde results in increased phosphorylation of MAPK14 protein]; SB 203580 inhibits the reaction [dracorhodin analog results in increased phosphorylation of MAPK14 protein]; SB 203580 inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK14 protein]; SB 203580 inhibits the reaction [Geraniin results in increased activity of MAPK14 protein]; SB 203580 inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK14 protein]; SB 203580 inhibits the reaction [icaritin results in increased phosphorylation of MAPK14 protein]; SB 203580 inhibits the reaction [indeno(1,2,3-cd)pyrene results in increased phosphorylation of MAPK14 protein]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK14 protein]; SB 203580 inhibits the reaction [Methotrexate results in increased phosphorylation of MAPK14 protein]; SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Arsenic Trioxide results in increased phosphorylation of and results in increased activity of MAPK14 protein]]
SB203580 inhibited the reaction [[Leptin cotreatment with acetaldehyde] increased expression of aSMA protein in cultured rat hepatic stellate cells]
[SB 203580 inhibits the reaction [Lipopolysaccharides co-treated with TNF protein]] which results in increased phosphorylation of MAPK14 protein; [SB 203580 results in decreased activity of MAPK14 protein] which results in decreased susceptibility to Doxorubicin; SB 203580 inhibits the reaction [[Methionine deficiency co-treated with Cysteine deficiency] results in increased activity of MAPK14 protein]; SB 203580 inhibits the reaction [Acrolein results in increased phosphorylation of MAPK14 protein]; SB 203580 inhibits the reaction [Hydrogen Peroxide results in increased activity of MAPK14 protein]; SB 203580 inhibits the reaction [INS1 protein results in increased activity of MAPK14 protein]; SB 203580 inhibits the reaction [osthol inhibits the reaction [Antineoplastic Agents, Immunological results in decreased phosphorylation of MAPK14 protein]]; SB 203580 inhibits the reaction [sodium arsenite results in increased activity of MAPK14 protein]; SB 203580 promotes the reaction [dibenzo(a,l)pyrene results in increased phosphorylation of MAPK14 protein]
[SB 203580 results in decreased activity of MAPK14 protein] inhibits the reaction [[octanoic acid co-treated with Dexamethasone] results in increased expression of CAV1 protein]; [SB 203580 results in decreased activity of MAPK14 protein] inhibits the reaction [[octanoic acid co-treated with Dexamethasone] results in increased expression of PPARG protein alternative form]; SB 203580 affects the reaction [MAPK14 protein affects the reaction [sodium arsenite results in increased activity of MAPKAPK2 protein]]; SB 203580 inhibits the reaction [1-dodecylsulfonyl-5N,6O-oxomethylidenenojirimycin results in increased phosphorylation of MAPK14 protein] 		CTD
RGD		 PMID:8971075 PMID:9647221 PMID:10704466 PMID:10998351 PMID:11709198 More... RGD:598108049 NCBI chr20:6,751,288...6,812,294
Ensembl chr20:6,751,357...6,812,294 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases phosphorylation 		ISO
EXP 		[Temozolomide results in decreased susceptibility to Temozolomide] promotes the reaction [[thymoquinone co-treated with SB 203580] results in increased phosphorylation of MAPK3 protein]; [thymoquinone co-treated with SB 203580] results in increased phosphorylation of MAPK3 protein; SB 203580 inhibits the reaction [4-vinyl-2,6-dimethoxyphenol results in decreased phosphorylation of MAPK3 protein]; SB 203580 inhibits the reaction [Dinitrochlorobenzene results in decreased phosphorylation of MAPK3 protein]; SB 203580 inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]; SB 203580 inhibits the reaction [honokiol results in increased phosphorylation of MAPK3 protein]; SB 203580 inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK3 protein]; SB 203580 inhibits the reaction [Resveratrol results in increased phosphorylation of and results in increased activity of MAPK3 protein]; SB 203580 inhibits the reaction [Thimerosal results in decreased phosphorylation of MAPK3 protein]; SB 203580 promotes the reaction [bufalin results in increased phosphorylation of MAPK3 protein]; SB 203580 promotes the reaction [sodium arsenite results in increased phosphorylation of MAPK3 protein]; SB 203580 promotes the reaction [TNF protein results in increased phosphorylation of MAPK3 protein]
SB 203580 results in increased phosphorylation of MAPK3 protein
[Oxaliplatin co-treated with SB 203580] results in decreased phosphorylation of MAPK3 protein; [pyrazolanthrone co-treated with SB 203580 co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] inhibits the reaction [Quercetin results in increased phosphorylation of MAPK3 protein]; SB 203580 inhibits the reaction [esculetin results in increased phosphorylation of MAPK3 protein]; SB 203580 inhibits the reaction [Quercetin results in increased phosphorylation of MAPK3 protein]; SB 203580 promotes the reaction [ferrous sulfate results in increased phosphorylation of MAPK3 protein]; SB 203580 promotes the reaction [Iron results in increased phosphorylation of MAPK3 protein]
SB 203580 promotes the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of and results in increased activity of MAPK3 protein] 		CTD PMID:10712238 PMID:10993886 PMID:12547826 PMID:15588916 PMID:17172471 More... NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411 		JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions
increases phosphorylation
decreases activity 		EXP
ISO 		SB 203580 promotes the reaction [Acrolein results in increased phosphorylation of MAPK8 protein]
SB 203580 results in increased phosphorylation of MAPK8 protein
SB 203580 inhibits the reaction [4-vinyl-2,6-dimethoxyphenol results in increased phosphorylation of MAPK8 protein]; SB 203580 inhibits the reaction [cinnamaldehyde results in increased phosphorylation of MAPK8 protein]; SB 203580 inhibits the reaction [Oxygen deficiency results in increased activity of MAPK8 protein]; SB 203580 inhibits the reaction [polyhexamethyleneguanidine results in increased phosphorylation of MAPK8 protein]; SB 203580 promotes the reaction [Arsenic Trioxide results in increased phosphorylation of and results in increased activity of MAPK8 protein]; SB 203580 promotes the reaction [nickel sulfate results in increased phosphorylation of MAPK8 protein]
SB 203580 results in decreased activity of MAPK8 protein 		CTD PMID:12487375 PMID:13679210 PMID:15964311 PMID:16818652 PMID:18089842 More... NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427 		JBrowse link
G Mapk9 mitogen-activated protein kinase 9 multiple interactions ISO SB 203580 inhibits the reaction [4-vinyl-2,6-dimethoxyphenol results in increased phosphorylation of MAPK9 protein]; SB 203580 promotes the reaction [Arsenic Trioxide results in increased phosphorylation of and results in increased activity of MAPK9 protein] CTD PMID:16818652 PMID:30653946 NCBI chr10:34,670,750...34,711,972
Ensembl chr10:34,670,756...34,712,228 		JBrowse link
G Mapkapk2 MAPK activated protein kinase 2 multiple interactions
increases phosphorylation
decreases expression
decreases phosphorylation 		ISO
EXP 		SB 203580 inhibits the reaction [Arsenic Trioxide results in increased activity of MAPKAPK2 protein]; SB 203580 inhibits the reaction [arsenite results in increased activity of MAPKAPK2 protein]; SB 203580 inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAPKAPK2 protein]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased activity of MAPKAPK2 protein]; SB 203580 inhibits the reaction [LY 303511 results in increased phosphorylation of MAPKAPK2 protein]; SB 203580 inhibits the reaction [Methotrexate results in increased expression of MAPKAPK2 protein]; SB 203580 inhibits the reaction [Mustard Gas results in increased phosphorylation of and results in increased activity of MAPKAPK2 protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased activity of MAPKAPK2 protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of MAPKAPK2 protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased phosphorylation of MAPKAPK2 protein]; SB 203580 inhibits the reaction [Sodium Fluoride results in increased phosphorylation of MAPKAPK2 protein]; SB 203580 inhibits the reaction [Sorbitol results in increased phosphorylation of MAPKAPK2 protein]; SB 203580 inhibits the reaction [Tretinoin results in increased phosphorylation of MAPKAPK2 protein]
SB 203580 results in increased phosphorylation of MAPKAPK2 protein
SB 203580 results in decreased expression of MAPKAPK2 protein modified form
SB 203580 inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAPKAPK2 protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased activity of MAPKAPK2 protein]
SB 203580 affects the reaction [MAPK14 protein affects the reaction [sodium arsenite results in increased activity of MAPKAPK2 protein]]; SB 203580 inhibits the reaction [arsenite results in increased phosphorylation of MAPKAPK2 protein]; SB 203580 inhibits the reaction [Ethanol results in increased phosphorylation of MAPKAPK2 protein]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased activity of MAPKAPK2 protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased activity of MAPKAPK2 protein]; SB 203580 inhibits the reaction [trovafloxacin results in increased phosphorylation of MAPKAPK2 protein]
SB 203580 results in decreased phosphorylation of MAPKAPK2 protein 		CTD PMID:9288946 PMID:9545260 PMID:9822662 PMID:9877156 PMID:10704466 More... NCBI chr13:45,066,027...45,112,326
Ensembl chr13:45,066,031...45,112,326 		JBrowse link
G Mapkapk3 MAPK activated protein kinase 3 multiple interactions ISO SB 203580 inhibits the reaction [sodium arsenite results in increased activity of MAPKAPK3 protein] CTD PMID:12547826 NCBI chr 8:116,808,429...116,842,228
Ensembl chr 8:116,808,429...116,842,228 		JBrowse link
G Mapt microtubule-associated protein tau multiple interactions ISO
EXP 		SB 203580 inhibits the reaction [Acrolein results in increased phosphorylation of MAPT protein]; SB 203580 inhibits the reaction [cyanoginosin LR results in increased phosphorylation of MAPT protein]
SB 203580 inhibits the reaction [cyanoginosin LR results in increased localization of MAPT protein]; SB 203580 inhibits the reaction [cyanoginosin LR results in increased phosphorylation of MAPT protein] 		CTD PMID:12605413 PMID:22000993 PMID:23929704 NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,638,599...89,736,108 		JBrowse link
G Mef2c myocyte enhancer factor 2C multiple interactions ISO SB 203580 inhibits the reaction [icariin affects the localization of MEF2C protein]; SB 203580 inhibits the reaction [icariin results in increased expression of MEF2C mRNA] CTD PMID:18423597 NCBI chr 2:15,708,732...15,871,639
Ensembl chr 2:15,708,924...15,871,640 		JBrowse link
G Mgmt O-6-methylguanine-DNA methyltransferase decreases expression
multiple interactions 		ISO SB 203580 results in decreased expression of MGMT protein
[[Temozolomide results in decreased susceptibility to Temozolomide] which results in increased susceptibility to SB 203580] which results in increased expression of MGMT protein; [Temozolomide results in decreased susceptibility to Temozolomide] inhibits the reaction [SB 203580 results in decreased expression of MGMT protein] 		CTD PMID:36176197 NCBI chr 1:201,140,832...201,367,481
Ensembl chr 1:201,140,661...201,367,482 		JBrowse link
G Mir143 microRNA 143 multiple interactions ISO SB 203580 inhibits the reaction [TGFB1 protein results in increased expression of MIR143] CTD PMID:21712382 NCBI chr18:57,371,349...57,371,453 JBrowse link
G Mir145 microRNA 145 multiple interactions ISO SB 203580 inhibits the reaction [TGFB1 protein results in increased expression of MIR145] CTD PMID:21712382 NCBI chr18:57,369,983...57,370,070 JBrowse link
G Mir328 microRNA 328 increases expression
multiple interactions 		ISO SB 203580 results in increased expression of MIR328 mRNA
resveratrol promotes the reaction [SB 203580 results in increased expression of MIR328 mRNA] 		CTD PMID:25605016 NCBI chr19:50,094,691...50,094,774 JBrowse link
G Mitf melanocyte inducing transcription factor multiple interactions ISO SB 203580 inhibits the reaction [Cannabidiol results in increased expression of MITF mRNA] CTD PMID:28601556 NCBI chr 4:131,965,676...132,177,790
Ensembl chr 4:131,965,714...132,177,790 		JBrowse link
G Mknk1 MAPK interacting serine/threonine kinase 1 multiple interactions ISO 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MKNK1 protein]]; [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one co-treated with SB 203580] inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MKNK1 protein]; SB 203580 inhibits the reaction [Anisomycin results in increased activity of MKNK1 protein]; SB 203580 inhibits the reaction [arsenite results in increased activity of MKNK1 protein]; SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MKNK1 protein]; SB 203580 promotes the reaction [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MKNK1 protein]]
[SB 203580 co-treated with U 0126] inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MKNK1 protein] 		CTD PMID:9545260 PMID:12781867 PMID:16431125 NCBI chr 5:134,554,881...134,594,392
Ensembl chr 5:134,554,943...134,594,393 		JBrowse link
G Mmp1 matrix metallopeptidase 1 multiple interactions ISO SB 203580 inhibits the reaction [2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester results in increased expression of and results in increased activity of MMP1 protein]; SB 203580 inhibits the reaction [benzo(k)fluoranthene results in increased expression of MMP1 mRNA]; SB 203580 inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of and results in increased activity of MMP1 protein]; SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP1 protein] CTD PMID:20004183 PMID:21635667 PMID:24469321 NCBI chr 8:12,943,453...12,963,966
Ensembl chr 8:12,943,453...12,963,964 		JBrowse link
G Mmp13 matrix metallopeptidase 13 multiple interactions ISO
EXP 		SB 203580 analog inhibits the reaction [IL1B results in increased expression of MMP13 mRNA]; SB 203580 inhibits the reaction [S100A4 protein results in increased expression of MMP13 protein]; SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP13 protein]
SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of MMP13 mRNA]
SB 203580 inhibits the reaction [gadolinium chloride results in increased expression of MMP13 mRNA]; SB 203580 inhibits the reaction [halofuginone results in increased expression of MMP13 mRNA] 		CTD PMID:12493575 PMID:16489207 PMID:16948116 PMID:19656660 PMID:20004183 More... NCBI chr 8:12,782,829...12,793,108
Ensembl chr 8:12,782,813...12,793,105 		JBrowse link
G Mmp2 matrix metallopeptidase 2 multiple interactions
affects expression
decreases expression 		ISO
EXP 		brazilein promotes the reaction [SB 203580 results in decreased expression of and results in decreased activity of MMP2 protein]; SB 203580 affects the reaction [U 0126 promotes the reaction [Plant Extracts results in decreased expression of MMP2 protein]]; SB 203580 inhibits the reaction [benz(a)anthracene results in increased expression of MMP2 mRNA]; SB 203580 inhibits the reaction [Glucose promotes the reaction [Air Pollutants results in increased activity of MMP2 protein]]; SB 203580 inhibits the reaction [Glucose promotes the reaction [Particulate Matter results in increased activity of MMP2 protein]]; SB 203580 inhibits the reaction [indeno(1,2,3-cd)pyrene results in increased expression of MMP2 mRNA]; SB 203580 inhibits the reaction [Norepinephrine results in increased expression of MMP2 mRNA]; SB 203580 inhibits the reaction [taiwanin E results in decreased expression of MMP2 protein]; SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MMP2 protein]; SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP2 mRNA]; SB 203580 promotes the reaction [brazilein results in decreased expression of and results in decreased activity of MMP2 protein]; SB 203580 promotes the reaction [resveratrol results in decreased expression of and results in decreased activity of MMP2 protein]; SB 203580 promotes the reaction [resveratrol results in decreased expression of MMP2]; SB 203580 results in decreased expression of and results in decreased activity of MMP2 protein
SB 203580 affects the expression of MMP2 mRNA; SB 203580 affects the expression of MMP2 protein
SB 203580 results in decreased expression of MMP2 		CTD PMID:16575906 PMID:20599481 PMID:21635667 PMID:23707804 PMID:24841706 More... NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856 		JBrowse link
G Mmp25 matrix metallopeptidase 25 multiple interactions ISO SB 203580 inhibits the reaction [benzo(k)fluoranthene results in increased expression of MMP25 mRNA] CTD PMID:21635667 NCBI chr10:13,164,974...13,180,503
Ensembl chr10:13,164,977...13,180,503 		JBrowse link
G Mmp3 matrix metallopeptidase 3 multiple interactions ISO SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP3 protein] CTD PMID:20004183 NCBI chr 8:12,925,267...12,938,828
Ensembl chr 8:12,925,280...12,938,826 		JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions
decreases expression
decreases activity 		ISO
EXP 		[kahweol acetate co-treated with SB 203580] inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of and results in increased activity of MMP9 protein]; SB 203580 inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]; SB 203580 inhibits the reaction [Arsenic Trioxide results in increased expression of MMP9 mRNA]; SB 203580 inhibits the reaction [Arsenic Trioxide results in increased expression of MMP9 protein]; SB 203580 inhibits the reaction [FSL-1 lipoprotein, synthetic results in increased expression of MMP9 mRNA]; SB 203580 inhibits the reaction [FSL-1 lipoprotein, synthetic results in increased secretion of MMP9 protein]; SB 203580 inhibits the reaction [Glucose promotes the reaction [Air Pollutants results in increased activity of MMP9 protein]]; SB 203580 inhibits the reaction [Glucose promotes the reaction [Particulate Matter results in increased activity of MMP9 protein]]; SB 203580 inhibits the reaction [hydroquinone results in increased secretion of MMP9 protein]; SB 203580 inhibits the reaction [Oxidopamine results in increased expression of MMP9 mRNA]; SB 203580 inhibits the reaction [taiwanin E results in decreased expression of MMP9 protein]; SB 203580 inhibits the reaction [tetrabromobisphenol A results in increased expression of MMP9 mRNA]; SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of and results in increased activity of MMP9 protein]; SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of MMP9 protein]; SB 203580 inhibits the reaction [thymoquinone results in decreased expression of MMP9 protein]; SB 203580 inhibits the reaction [TNF protein results in increased expression of and results in increased activity of MMP9 protein]; SB 203580 promotes the reaction [3,5-bis(2-fluorobenzylidene)piperidin-4-one inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MMP9 protein]]; SB 203580 promotes the reaction [ovatodiolide results in decreased activity of MMP9 protein]; SB 203580 promotes the reaction [Resveratrol results in decreased expression of MMP9]; SB 203580 promotes the reaction [Resveratrol results in increased expression of and results in increased activity of MMP9 protein]
SB 203580 results in decreased expression of MMP9 mRNA; SB 203580 results in decreased expression of MMP9 protein
SB 203580 results in decreased activity of MMP9 protein
SB 203580 inhibits the reaction [Coal Ash results in decreased expression of MMP9 mRNA]; SB 203580 inhibits the reaction [Doxorubicin results in increased activity of MMP9 protein]; SB 203580 inhibits the reaction [Doxorubicin results in increased expression of MMP9 mRNA]; SB 203580 inhibits the reaction [gadolinium chloride results in increased expression of MMP9 mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased activity of MMP9 protein]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased activity of MMP9 protein]; SB 203580 inhibits the reaction [T-2 Toxin results in increased expression of MMP9 mRNA]; SB 203580 promotes the reaction [U 0126 inhibits the reaction [Lipopolysaccharides results in increased activity of MMP9 protein]]; U 0126 promotes the reaction [SB 203580 inhibits the reaction [Lipopolysaccharides results in increased activity of MMP9 protein]]
SB 203580 inhibits the reaction [Leukotriene B4 results in increased expression of MMP9 protein]; SB 203580 inhibits the reaction [Leukotriene C4 results in increased expression of MMP9 protein]; SB 203580 inhibits the reaction [Leukotriene D4 results in increased expression of MMP9 protein]; SB 203580 inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of MMP9 protein] 		CTD PMID:12493575 PMID:15657063 PMID:15728660 PMID:16213474 PMID:16683234 More... NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442 		JBrowse link
G Mpo myeloperoxidase multiple interactions
decreases activity 		EXP
ISO 		SB 203580 inhibits the reaction [Resveratrol results in decreased activity of MPO protein]; SB 203580 inhibits the reaction [Tropisetron results in decreased activity of MPO protein]
SB 203580 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of MPO protein]; SB 203580 inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]
SB 203580 results in decreased activity of MPO protein 		CTD PMID:17368305 PMID:21192278 PMID:23285267 PMID:27920472 PMID:32033504 NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056 		JBrowse link
G Mt1a metallothionein 1A multiple interactions ISO SB 203580 promotes the reaction [Copper results in increased activity of MT1 promoter] CTD PMID:14576086 NCBI chr19:10,831,959...10,832,975
Ensembl chr17:79,695,809...79,696,200
Ensembl chr  X:79,695,809...79,696,200
Ensembl chr19:79,695,809...79,696,200 		JBrowse link
G Mt3 metallothionein 3 multiple interactions ISO SB 203580 inhibits the reaction [Cadmium results in increased expression of MT3] CTD PMID:21783819 NCBI chr19:10,854,676...10,856,080
Ensembl chr19:10,854,677...10,856,080 		JBrowse link
G Mtmr10 myotubularin related protein 10 multiple interactions ISO SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of MTMR10 mRNA] CTD PMID:28329830 NCBI chr 1:127,271,139...127,322,621
Ensembl chr 1:127,270,870...127,322,621 		JBrowse link
G Mtor mechanistic target of rapamycin kinase multiple interactions EXP SB 203580 inhibits the reaction [fenvalerate results in decreased phosphorylation of MTOR protein]; SB 203580 inhibits the reaction [osthol inhibits the reaction [Antineoplastic Agents, Immunological results in increased phosphorylation of MTOR protein]] CTD PMID:31734597 PMID:37769856 NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435 		JBrowse link
G Muc4 mucin 4, cell surface associated multiple interactions ISO SB 203580 inhibits the reaction [Particulate Matter results in increased expression of MUC4 mRNA]; SB 203580 inhibits the reaction [Particulate Matter results in increased expression of MUC4 protein]; SB 203580 inhibits the reaction [Vehicle Emissions results in increased expression of MUC4 mRNA]; SB 203580 inhibits the reaction [Vehicle Emissions results in increased expression of MUC4 protein] CTD PMID:28049186 NCBI chr11:81,513,321...81,575,200 JBrowse link
G Muc5ac mucin 5AC, oligomeric mucus/gel-forming multiple interactions ISO SB 203580 inhibits the reaction [EGF protein results in increased secretion of MUC5AC protein]; SB 203580 inhibits the reaction [o,p'-DDT results in increased expression of MUC5AC mRNA]; SB 203580 inhibits the reaction [polyhexamethyleneguanidine results in increased expression of MUC5AC mRNA]; SB 203580 inhibits the reaction [polyhexamethyleneguanidine results in increased expression of MUC5AC protein]; SB 203580 inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of MUC5AC mRNA] CTD PMID:20971882 PMID:22766066 PMID:30935901 PMID:34167450 NCBI chr 1:206,293,717...206,326,006
Ensembl chr 1:206,293,869...206,326,006 		JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor multiple interactions ISO SB 203580 inhibits the reaction [Cadmium results in increased expression of MYC protein] CTD PMID:29993192 NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028 		JBrowse link
G Myh7 myosin heavy chain 7 affects expression EXP SB 203580 affects the expression of MYH7 mRNA CTD PMID:21084678 NCBI chr15:32,416,525...32,439,851
Ensembl chr15:32,416,527...32,438,194 		JBrowse link
G Myocd myocardin multiple interactions ISO SB 203580 inhibits the reaction [TGFB1 protein results in increased expression of MYOCD mRNA] CTD PMID:21712382 NCBI chr10:50,332,356...50,426,819
Ensembl chr10:50,332,356...50,426,819 		JBrowse link
G Myod1 myogenic differentiation 1 multiple interactions ISO SB 203580 inhibits the reaction [bakuchiol results in increased expression of MYOD1 protein] CTD PMID:26902638 NCBI chr 1:106,021,161...106,023,871
Ensembl chr 1:106,021,161...106,023,871 		JBrowse link
G Myog myogenin multiple interactions ISO SB 203580 inhibits the reaction [bakuchiol results in increased expression of MYOG protein] CTD PMID:26902638 NCBI chr13:48,297,476...48,300,065
Ensembl chr13:48,297,235...48,300,065 		JBrowse link
G Ncf1 neutrophil cytosolic factor 1 multiple interactions ISO SB 203580 inhibits the reaction [arsenic trioxide results in increased phosphorylation of and affects the localization of NCF1 protein] CTD PMID:18424721 NCBI chr12:28,121,816...28,131,080
Ensembl chr12:28,121,366...28,131,079 		JBrowse link
G Nedd4 NEDD4 E3 ubiquitin protein ligase multiple interactions ISO SB 203580 inhibits the reaction [fulvestrant promotes the reaction [NEDD4 protein binds to and results in increased ubiquitination of GJA1 protein]] CTD PMID:29180066 NCBI chr 8:82,264,751...82,349,642
Ensembl chr 8:82,264,649...82,349,633 		JBrowse link
G Nfatc1 nuclear factor of activated T-cells 1 multiple interactions ISO SB 203580 affects the reaction [NFE2L2 protein affects the reaction [sodium arsenite affects the expression of NFATC1 protein]]; SB 203580 affects the reaction [sodium arsenite affects the expression of NFATC1 protein] CTD PMID:30742845 NCBI chr18:76,321,386...76,430,997
Ensembl chr18:76,321,386...76,430,990 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 multiple interactions ISO
EXP 		2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [SB 203580 inhibits the reaction [Quercetin affects the localization of NFE2L2 protein]]; [SB 203580 co-treated with Cycloheximide] inhibits the reaction [Quercetin results in decreased expression of NFE2L2 protein]; [SB 203580 co-treated with Quercetin] results in increased expression of NFE2L2 protein; Cycloheximide inhibits the reaction [[SB 203580 co-treated with Quercetin] results in increased expression of NFE2L2 protein]; Cycloheximide inhibits the reaction [SB 203580 affects the reaction [Quercetin affects the localization of NFE2L2 protein]]; SB 203580 affects the reaction [Quercetin affects the localization of NFE2L2 protein]; SB 203580 inhibits the reaction [gallium nitrate results in increased activity of NFE2L2 protein]; SB 203580 inhibits the reaction [Quercetin affects the localization of and results in increased activity of NFE2L2 protein]; SB 203580 inhibits the reaction [Quercetin affects the localization of NFE2L2 protein]; SB 203580 inhibits the reaction [Quercetin results in decreased expression of NFE2L2 protein]; SB 203580 promotes the reaction [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Quercetin affects the localization of NFE2L2 protein]]
SB 203580 inhibits the reaction [aureusidin affects the localization of NFE2L2 protein]; SB 203580 inhibits the reaction [Chitosan analog inhibits the reaction [Doxorubicin affects the localization of NFE2L2 protein]]; SB 203580 inhibits the reaction [Curcumin affects the localization of NFE2L2 protein]
SB 203580 affects the reaction [[NFE2L2 protein affects the susceptibility to sodium arsenite] affects the reaction [[CSF1R protein co-treated with TNFSF11 protein] affects the expression of ATP6V0D2 mRNA]]; SB 203580 affects the reaction [[NFE2L2 protein affects the susceptibility to sodium arsenite] affects the reaction [[CSF1R protein co-treated with TNFSF11 protein] affects the expression of CTSK mRNA]]; SB 203580 affects the reaction [NFE2L2 protein affects the reaction [sodium arsenite affects the expression of NFATC1 protein]]; SB 203580 inhibits the reaction [2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone affects the localization of NFE2L2 protein]; SB 203580 inhibits the reaction [Arsenic Trioxide results in increased expression of NFE2L2 mRNA]; SB 203580 inhibits the reaction [farrerol affects the localization of NFE2L2 protein]; SB 203580 promotes the reaction [[Plant Extracts co-treated with Ethanol] results in increased expression of and affects the localization of NFE2L2 protein] 		CTD PMID:17433488 PMID:17640564 PMID:18586083 PMID:22197970 PMID:22488045 More... NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090 		JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions ISO SB 203580 inhibits the reaction [Paraquat affects the localization of [NFKB1 protein binds to RELA protein]]; SB 203580 inhibits the reaction [Paraquat promotes the reaction [endotoxin, Escherichia coli affects the localization of [NFKB1 protein binds to RELA protein]]]
SB 203580 inhibits the reaction [indoleacetic acid affects the localization of NFKB1 protein] 		CTD PMID:16919916 PMID:30324315 NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088 		JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions
decreases expression 		ISO
EXP 		SB 203580 inhibits the reaction [icariin results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; SB 203580 inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]
SB 203580 results in decreased expression of NFKBIA protein
SB 203580 promotes the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein]; SB 203580 promotes the reaction [Iron results in increased phosphorylation of NFKBIA protein]
SB 203580 inhibits the reaction [1,2,5,8-tetrahydroxy anthraquinone results in increased expression of NFKBIA protein]; SB 203580 inhibits the reaction [Glucose results in increased phosphorylation of NFKBIA protein] 		CTD PMID:17172471 PMID:18423597 PMID:19132243 PMID:23707484 PMID:33030807 NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072 		JBrowse link
G Ngf nerve growth factor multiple interactions
decreases activity 		EXP SB 203580 inhibits the reaction [pentaacetyl geniposide results in increased expression of NGF mRNA]; SB 203580 inhibits the reaction [pentaacetyl geniposide results in increased expression of NGF protein]
SB 203580 results in decreased activity of NGF protein 		CTD PMID:9733710 PMID:17651887 NCBI chr 2:192,589,580...192,642,971
Ensembl chr 2:192,589,582...192,643,834 		JBrowse link
G Ngfr nerve growth factor receptor multiple interactions EXP SB 203580 inhibits the reaction [pentaacetyl geniposide results in increased expression of NGFR mRNA]; SB 203580 inhibits the reaction [pentaacetyl geniposide results in increased expression of NGFR protein] CTD PMID:17651887 NCBI chr10:81,012,077...81,030,305
Ensembl chr10:81,012,089...81,030,305 		JBrowse link
G Nlrp3 NLR family, pyrin domain containing 3 multiple interactions ISO
EXP 		SB 203580 inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of NLRP3 protein]; SB 203580 inhibits the reaction [APP protein results in increased expression of NLRP3 protein]
SB 203580 inhibits the reaction [Acrolein results in increased expression of NLRP3 protein] 		CTD PMID:28004443 PMID:31639409 PMID:34510229 NCBI chr10:44,826,299...44,853,373
Ensembl chr10:44,828,014...44,853,394 		JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions
decreases expression
increases degradation 		ISO
EXP 		SB 203580 inhibits the reaction [[IFNG protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of NOS2 mRNA]; SB 203580 inhibits the reaction [deoxynivalenol inhibits the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased expression of NOS2 protein]]; SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of NOS2 protein]
SB 203580 results in decreased expression of NOS2 mRNA; SB 203580 results in decreased expression of NOS2 protein
SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of NOS2 mRNA]; SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of NOS2 protein]; SB 203580 inhibits the reaction [[IFNG protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of NOS2 protein]; SB 203580 inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of NOS2 protein]; SB 203580 inhibits the reaction [cobaltous chloride results in increased expression of NOS2 protein]; SB 203580 inhibits the reaction [Manganese promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA]]; SB 203580 inhibits the reaction [Particulate Matter results in increased expression of NOS2 mRNA]
SB 203580 results in increased degradation of NOS2 mRNA
1-dodecylsulfonyl-5N,6O-oxomethylidenenojirimycin promotes the reaction [SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; SB 203580 inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide]; SB 203580 inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; SB 203580 inhibits the reaction [[trimethyltin chloride results in increased abundance of trimethyltin] which results in increased expression of NOS2 mRNA]; SB 203580 inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; SB 203580 inhibits the reaction [lipoteichoic acid results in increased expression of NOS2 protein]; SB 203580 inhibits the reaction [Methoxychlor results in increased expression of NOS2 mRNA]; SB 203580 inhibits the reaction [S100B protein results in increased expression of NOS2 mRNA]; SB 203580 inhibits the reaction [S100B protein results in increased expression of NOS2 protein]; SB 203580 inhibits the reaction [TGFB1 protein inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of NOS2 protein]] 		CTD PMID:11518563 PMID:12911628 PMID:14734799 PMID:15979571 PMID:16307444 More... NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880 		JBrowse link
G Nos3 nitric oxide synthase 3 multiple interactions ISO SB 203580 inhibits the reaction [arsenite results in increased phosphorylation of and results in increased activity of NOS3 protein] CTD PMID:11788791 NCBI chr 4:11,686,088...11,706,604
Ensembl chr 4:11,686,268...11,706,664 		JBrowse link
G Notch1 notch receptor 1 multiple interactions ISO SB 203580 inhibits the reaction [o,p'-DDT results in increased activity of NOTCH1 protein] CTD PMID:18791200 NCBI chr 3:29,676,040...29,721,613
Ensembl chr 3:29,676,171...29,721,613 		JBrowse link
G Nox1 NADPH oxidase 1 multiple interactions EXP SB 203580 inhibits the reaction [Lead results in increased expression of NOX1 mRNA]; SB 203580 inhibits the reaction [Mercuric Chloride results in increased expression of NOX1 mRNA] CTD PMID:23415682 PMID:25596430 NCBI chr  X:101,572,338...101,625,571
Ensembl chr  X:101,572,340...101,595,520 		JBrowse link
G Nox4 NADPH oxidase 4 multiple interactions EXP SB 203580 inhibits the reaction [Lead results in increased expression of NOX4 mRNA] CTD PMID:25596430 NCBI chr 1:150,313,736...150,491,480
Ensembl chr 1:150,313,728...150,491,483 		JBrowse link
G Nppa natriuretic peptide A affects secretion
multiple interactions 		EXP SB 203580 affects the secretion of NPPA protein
SB203580 increases expression of mRNA and potentiates the reaction [sunitinib increases expression of mRNA] in rat cardiomyocytes
SB 203580 inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]; SB 203580 promotes the reaction [Sunitinib results in increased expression of NPPA mRNA] 		CTD
RGD		 PMID:10727428 PMID:21084678 PMID:24247421 PMID:24247421 RGD:401793741 NCBI chr 5:163,712,184...163,713,493
Ensembl chr 5:163,712,184...163,713,493 		JBrowse link
G Nppb natriuretic peptide B affects expression
decreases expression
multiple interactions 		EXP SB 203580 affects the expression of NPPB protein
SB 203580 results in decreased expression of NPPB mRNA
SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of NPPB protein] 		CTD PMID:21084678 PMID:22224641 NCBI chr 5:163,699,955...163,701,314
Ensembl chr 5:163,699,839...163,701,310 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions
decreases expression 		ISO SB 203580 inhibits the reaction [Particulate Matter analog results in increased expression of NQO1 mRNA]; SB 203580 inhibits the reaction [Particulate Matter analog results in increased expression of NQO1 protein]; SB 203580 inhibits the reaction [Plant Extracts results in increased expression of NQO1 protein]; SB 203580 inhibits the reaction [Quercetin results in increased expression of NQO1 mRNA]; SB 203580 inhibits the reaction [Vehicle Emissions analog results in increased expression of NQO1 mRNA]; SB 203580 inhibits the reaction [Vehicle Emissions analog results in increased expression of NQO1 protein]
SB 203580 inhibits the reaction [2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone results in increased expression of NQO1 mRNA]; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of NQO1 mRNA]; SB 203580 promotes the reaction [Copper results in increased expression of NQO1 mRNA]; SB 203580 promotes the reaction [Lead results in increased expression of NQO1 mRNA]
SB 203580 results in decreased expression of NQO1 mRNA 		CTD PMID:16920990 PMID:18752316 PMID:27454768 PMID:28329830 PMID:30626086 More... NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260 		JBrowse link
G Nr1h3 nuclear receptor subfamily 1, group H, member 3 increases expression ISO SB 203580 results in increased expression of NR1H3 mRNA CTD PMID:19883121 NCBI chr 3:97,614,616...97,632,053
Ensembl chr 3:97,614,616...97,624,532 		JBrowse link
G Nr3c1 nuclear receptor subfamily 3, group C, member 1 multiple interactions ISO SB 203580 inhibits the reaction [deacylcortivazol results in increased phosphorylation of NR3C1 protein]; SB 203580 inhibits the reaction [Dexamethasone results in increased phosphorylation of NR3C1 protein] CTD PMID:15817653 NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,522,783...31,643,843 		JBrowse link
G Nr4a1 nuclear receptor subfamily 4, group A, member 1 multiple interactions ISO SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of NR4A1 mRNA] CTD PMID:28329830 NCBI chr 7:134,247,153...134,268,044
Ensembl chr 7:134,247,192...134,268,041 		JBrowse link
G Ocln occludin multiple interactions ISO SB 203580 inhibits the reaction [Arsenic Trioxide results in decreased expression of OCLN protein]; SB 203580 inhibits the reaction [Clopidogrel results in decreased expression of OCLN protein]
SB 203580 inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of OCLN protein] 		CTD PMID:23220562 PMID:23761298 PMID:27818224 PMID:32683294 NCBI chr 2:33,391,303...33,442,207
Ensembl chr 2:33,391,303...33,430,411 		JBrowse link
G Olr1 oxidized low density lipoprotein receptor 1 multiple interactions ISO SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of OLR1 mRNA] CTD PMID:28329830 NCBI chr 4:164,612,460...164,635,082
Ensembl chr 4:164,612,463...164,634,598 		JBrowse link
G Osgin1 oxidative stress induced growth inhibitor 1 multiple interactions ISO SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of OSGIN1 mRNA] CTD PMID:28329830 NCBI chr19:64,380,336...64,409,165
Ensembl chr19:64,401,173...64,409,162 		JBrowse link
G Osm oncostatin M multiple interactions ISO SB 203580 inhibits the reaction [OSM protein results in increased expression of and results in increased secretion of IL6 protein]; SB 203580 inhibits the reaction [OSM protein results in increased expression of IL6 mRNA] CTD PMID:21548952 NCBI chr14:83,327,202...83,332,073
Ensembl chr14:83,327,554...83,331,827 		JBrowse link
G Park7 Parkinsonism associated deglycase multiple interactions ISO SB 203580 promotes the reaction [PARK7 gene mutant form inhibits the reaction [Lipopolysaccharides results in increased secretion of Dinoprostone]]; SB 203580 promotes the reaction [PARK7 gene mutant form inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]] CTD PMID:26691871 NCBI chr 5:166,636,551...166,659,825
Ensembl chr 5:166,636,552...166,659,825 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO SB 203580 inhibits the reaction [1,4-naphthoquinone analog results in increased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [3-oxo-29-noroleana-1,9(11),12-trien-2,20-dicarbonitrile results in increased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [[ESR1 protein results in increased susceptibility to Quercetin] which results in increased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [[ESR2 protein results in increased susceptibility to Estradiol] which results in increased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [[ESR2 protein results in increased susceptibility to Quercetin] which results in increased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [Arsenic Trioxide results in increased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [CSC-3436 promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]]; SB 203580 inhibits the reaction [Doxorubicin results in increased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [Emodin results in increased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [isoliensinine results in increased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in decreased cleavage of PARP1 protein]]; SB 203580 inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [Rotenone results in increased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [scutebarbatine A results in increased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [Tamoxifen results in increased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [TNFSF10 protein promotes the reaction [CSC-3436 results in increased cleavage of PARP1 protein]]; SB 203580 promotes the reaction [[sodium arsenite co-treated with TNF protein] results in increased cleavage of PARP1 protein]; SB 203580 promotes the reaction [luteolin-7-glucoside results in increased cleavage of PARP1 protein] CTD PMID:14645110 PMID:16328441 PMID:16843435 PMID:19194971 PMID:19777565 More... NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567 		JBrowse link
G Pck1 phosphoenolpyruvate carboxykinase 1 multiple interactions EXP SB 203580 inhibits the reaction [Buthionine Sulfoximine results in increased expression of PCK1 mRNA] CTD PMID:16960379 NCBI chr 3:182,348,572...182,354,521
Ensembl chr 3:182,348,572...182,354,561 		JBrowse link
G Pcna proliferating cell nuclear antigen multiple interactions ISO SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PCNA protein]] CTD PMID:32890875 NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901 		JBrowse link
G Pdgfb platelet derived growth factor subunit B multiple interactions ISO SB 203580 inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]; SB 203580 results in decreased susceptibility to [PDGFB protein binds to PDGFB protein]
SB 203580 promotes the reaction [PDGFB protein results in increased phosphorylation of MAPK1 protein] 		CTD PMID:9671412 PMID:15728660 PMID:23457620 NCBI chr 7:113,419,882...113,438,343
Ensembl chr 7:113,420,710...113,438,343 		JBrowse link
G Pdx1 pancreatic and duodenal homeobox 1 multiple interactions ISO [SB 203580 co-treated with INS protein] inhibits the reaction [Glucose affects the localization of PDX1 protein]; SB 203580 inhibits the reaction [[Glucose co-treated with sodium arsenite] affects the localization of PDX1 protein]; SB 203580 inhibits the reaction [Glucose affects the localization of PDX1 protein]; SB 203580 inhibits the reaction [Glucose results in increased phosphorylation of and results in increased activity of PDX1 protein]; SB 203580 inhibits the reaction [sodium arsenite affects the localization of PDX1 protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of PDX1 protein] CTD PMID:9873045 PMID:11574405 NCBI chr12:12,793,957...12,799,156
Ensembl chr12:12,793,957...12,799,156 		JBrowse link
G Phlda1 pleckstrin homology-like domain, family A, member 1 multiple interactions ISO SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of PHLDA1 mRNA] CTD PMID:28329830 NCBI chr 7:48,853,690...48,855,894
Ensembl chr 7:48,853,260...48,857,542 		JBrowse link
G Pla2g4a phospholipase A2 group 4A multiple interactions ISO
EXP 		SB 203580 inhibits the reaction [Capsaicin results in increased phosphorylation of PLA2G4A protein]
SB 203580 inhibits the reaction [Hydrogen Peroxide results in decreased expression of PLA2G4A mRNA] 		CTD PMID:15683734 PMID:19959817 NCBI chr13:64,427,921...64,572,352
Ensembl chr13:64,427,916...64,589,641 		JBrowse link
G Pla2g7 phospholipase A2 group VII multiple interactions ISO SB 203580 inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PLA2G7 mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of PLA2G7 protein] CTD PMID:21176638 PMID:21432021 NCBI chr 9:24,859,491...24,901,747
Ensembl chr 9:24,859,502...24,901,747 		JBrowse link
G Plaur plasminogen activator, urokinase receptor multiple interactions ISO SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of PLAUR mRNA] CTD PMID:28329830 NCBI chr 1:89,181,363...89,196,308
Ensembl chr 1:89,178,453...89,198,130 		JBrowse link
G Pld1 phospholipase D1 multiple interactions ISO SB 203580 inhibits the reaction [Tobacco Smoke Pollution analog results in increased expression of PLD1 mRNA]; SB 203580 inhibits the reaction [Tobacco Smoke Pollution analog results in increased phosphorylation of PLD1 protein] CTD PMID:26763395 NCBI chr 2:112,777,820...112,975,857
Ensembl chr 2:112,777,951...112,976,245 		JBrowse link
G Pld2 phospholipase D2 multiple interactions ISO SB 203580 inhibits the reaction [PLD2 protein promotes the reaction [epigallocatechin gallate results in increased expression of PTGS2 protein]] CTD PMID:15210717 NCBI chr10:55,754,957...55,772,819
Ensembl chr10:55,754,988...55,771,435 		JBrowse link
G Pomc proopiomelanocortin multiple interactions EXP SB 203580 inhibits the reaction [POMC protein modified form results in increased secretion of Corticosterone] CTD PMID:20837582 NCBI chr 6:32,659,137...32,665,175
Ensembl chr 6:32,659,346...32,665,173 		JBrowse link
G Postn periostin multiple interactions EXP SB 203580 inhibits the reaction [AGT protein results in increased expression of POSTN mRNA]; SB 203580 inhibits the reaction [FGF1 protein results in increased expression of POSTN mRNA] CTD PMID:15121739 PMID:17485602 NCBI chr 2:140,677,774...140,709,304
Ensembl chr 2:140,677,754...140,709,300 		JBrowse link
G Pou5f1 POU class 5 homeobox 1 multiple interactions ISO SB 203580 inhibits the reaction [(1R,3S,3aR,8bS)-3a-(4-Bromophenyl)-6,8-dimethoxy-3-phenyl-2,3,3a,8b-tetrahydro-1H-cyclopenta(b)benzofuran-1,8b-diol results in decreased expression of POU5F1 protein] CTD PMID:24607276 NCBI chr20:3,227,836...3,232,598
Ensembl chr20:3,227,837...3,232,598 		JBrowse link
G Ppard peroxisome proliferator-activated receptor delta multiple interactions ISO SB 203580 inhibits the reaction [Indomethacin results in increased expression of PPARD protein] CTD PMID:17341418 NCBI chr20:6,300,527...6,365,707
Ensembl chr20:6,352,183...6,365,707 		JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions
increases expression
decreases expression 		ISO
EXP 		[SB 203580 results in decreased activity of MAPK14 protein] inhibits the reaction [[octanoic acid co-treated with Dexamethasone] results in increased expression of PPARG protein alternative form]
SB 203580 inhibits the reaction [Ethanol results in decreased expression of PPARG protein]
SB 203580 results in increased expression of PPARG mRNA; SB 203580 results in increased expression of PPARG protein
SB 203580 results in decreased expression of PPARG mRNA; SB 203580 results in decreased expression of PPARG protein 		CTD PMID:14984747 PMID:23603106 PMID:24412557 NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104 		JBrowse link
G Pram1 PML-RARA regulated adaptor molecule 1 multiple interactions ISO SB 203580 inhibits the reaction [Cadmium Chloride affects the localization of PRAM1 protein] CTD PMID:12508112 NCBI chr 7:15,125,813...15,142,494 JBrowse link
G Prdx1 peroxiredoxin 1 multiple interactions ISO SB 203580 inhibits the reaction [sodium arsenate results in increased expression of PRDX1 protein] CTD PMID:11796722 NCBI chr 5:135,383,906...135,399,504
Ensembl chr 5:135,383,906...135,399,504 		JBrowse link
G Prdx2 peroxiredoxin 2 multiple interactions ISO SB 203580 inhibits the reaction [Formaldehyde results in decreased expression of PRDX2 protein] CTD PMID:20347000 NCBI chr19:40,085,788...40,091,083
Ensembl chr19:40,084,430...40,091,006 		JBrowse link
G Prkaa1 protein kinase AMP-activated catalytic subunit alpha 1 multiple interactions ISO [SB 203580 co-treated with Quercetin] results in increased phosphorylation of PRKAA1 protein CTD PMID:24535669 NCBI chr 2:55,967,766...56,003,450
Ensembl chr 2:55,967,351...56,003,450 		JBrowse link
G Procr protein C receptor multiple interactions ISO SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased cleavage of PROCR protein] CTD PMID:24632454 NCBI chr 3:164,714,727...164,718,994
Ensembl chr 3:164,711,636...164,718,989 		JBrowse link
G Psen1 presenilin 1 multiple interactions ISO [PSEN1 protein affects the susceptibility to SB 203580] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein] CTD PMID:22302987 NCBI chr 6:109,054,160...109,106,191
Ensembl chr 6:109,060,352...109,106,189 		JBrowse link
G Pten phosphatase and tensin homolog multiple interactions ISO SB 203580 inhibits the reaction [IL18 protein results in increased expression of PTEN mRNA] CTD PMID:18215737 NCBI chr 1:240,043,707...240,110,330
Ensembl chr 1:240,043,707...240,110,330 		JBrowse link
G Ptgds prostaglandin D2 synthase multiple interactions ISO SB 203580 inhibits the reaction [2-chloroethyl ethyl sulfide results in increased expression of PTGDS mRNA] CTD PMID:20382172 NCBI chr 3:28,680,044...28,682,978
Ensembl chr 3:28,680,044...28,682,978 		JBrowse link
G Ptges2 prostaglandin E synthase 2 multiple interactions ISO SB 203580 inhibits the reaction [2-chloroethyl ethyl sulfide results in increased expression of PTGES2 mRNA] CTD PMID:20382172 NCBI chr 3:36,088,246...36,095,430
Ensembl chr 3:36,088,246...36,097,694 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions
decreases expression 		ISO
EXP 		SB 203580 analog inhibits the reaction [IL1B results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased activity of PTGS2 protein]; SB 203580 inhibits the reaction [[methanandamide results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Dinoprostone]; SB 203580 inhibits the reaction [[nickel sulfate co-treated with macrophage stimulatory lipopeptide 2] results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [Aflatoxin B1 results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [Aspirin results in decreased degradation of PTGS2 mRNA]; SB 203580 inhibits the reaction [Aspirin results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [Aspirin results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [Benzene results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [Ceramides results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [Chlorpyrifos results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [EDN1 protein results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [epigallocatechin gallate results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [IL1A results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [IL1A results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [IL1B results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PTGS2 protein]]; SB 203580 inhibits the reaction [manganese chloride results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [Melitten results in decreased expression of PTGS2 protein]; SB 203580 inhibits the reaction [methanandamide results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [methylmercuric chloride results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [PLD2 protein promotes the reaction [epigallocatechin gallate results in increased expression of PTGS2 protein]]; SB 203580 inhibits the reaction [sodium arsenite results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [sodium arsenite results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [Sodium Fluoride results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [Styrene results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [Toluene results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [VEGFA protein results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [VEGFA protein results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [Zinc results in increased expression of PTGS2 protein]
SB 203580 inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [AGT protein results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [AGT protein results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [cadmium sulfate results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [cadmium sulfate results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [epigallocatechin gallate results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [lead acetate results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [Lead results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [manganese chloride results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [Mercuric Chloride results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [Serotonin results in increased expression of PTGS2 mRNA]
SB 203580 results in decreased expression of PTGS2 mRNA; SB 203580 results in decreased expression of PTGS2 protein
SB 203580 inhibits the reaction [1-bromopropane results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [2-chloroethyl ethyl sulfide results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [[Cadmium Chloride results in increased expression of PTGS2 mRNA] which results in increased abundance of Dinoprostone]; SB 203580 inhibits the reaction [[Cadmium Chloride results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone]; SB 203580 inhibits the reaction [Cadmium Chloride results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [Cadmium Chloride results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [deoxynivalenol results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [deoxynivalenol results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [deoxynivalenol results in increased stability of PTGS2 mRNA]; SB 203580 inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [lipoteichoic acid results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [Nickel results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [nonylphenol results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [o,p'-DDT results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [o,p'-DDT results in increased expression of PTGS2 protein] 		CTD PMID:11527419 PMID:11854442 PMID:12377986 PMID:12911628 PMID:14742690 More... NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320 		JBrowse link
G Ptx3 pentraxin 3 multiple interactions ISO SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of PTX3 mRNA] CTD PMID:28329830 NCBI chr 2:152,797,563...152,803,372
Ensembl chr 2:152,781,955...152,803,372 		JBrowse link
G Rad51 RAD51 recombinase multiple interactions ISO SB 203580 inhibits the reaction [ochratoxin A results in decreased expression of RAD51]; SB 203580 inhibits the reaction [Prodigiosin results in decreased expression of RAD51 mRNA] CTD PMID:22579953 PMID:24525463 NCBI chr 3:126,554,210...126,578,888
Ensembl chr 3:126,554,190...126,579,469 		JBrowse link
G Rb1 RB transcriptional corepressor 1 multiple interactions ISO SB 203580 inhibits the reaction [FGF2 protein results in increased phosphorylation of RB1 protein] CTD PMID:15249425 NCBI chr15:54,780,858...54,911,989
Ensembl chr15:54,780,858...54,911,857 		JBrowse link
G Rbm4 RNA binding motif protein 4 multiple interactions ISO SB 203580 inhibits the reaction [sodium arsenite affects the localization of RBM4 protein] CTD PMID:17284590 NCBI chr 1:211,507,845...211,516,907
Ensembl chr 1:211,506,343...211,516,891 		JBrowse link
G Rbpj recombination signal binding protein for immunoglobulin kappa J region multiple interactions ISO [PSEN1 protein affects the susceptibility to SB 203580] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein] CTD PMID:22302987 NCBI chr14:61,551,366...61,736,220
Ensembl chr14:61,551,366...61,736,307 		JBrowse link
G Reg3g regenerating family member 3 gamma multiple interactions EXP SB 203580 inhibits the reaction [AGT protein results in increased expression of REG3G mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of REG3G mRNA] CTD PMID:27798352 NCBI chr 4:112,482,183...112,484,738
Ensembl chr 4:112,482,183...112,484,738 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO
EXP 		SB 203580 affects the reaction [sodium arsenite affects the expression of RELA protein]; SB 203580 inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein]; SB 203580 inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased activity of RELA protein]; SB 203580 inhibits the reaction [chrysin results in increased activity of RELA protein]; SB 203580 inhibits the reaction [deoxynivalenol results in increased activity of RELA protein]; SB 203580 inhibits the reaction [ferruginol results in increased expression of RELA protein]; SB 203580 inhibits the reaction [Galactose affects the localization of RELA protein]; SB 203580 inhibits the reaction [IL18 protein results in increased phosphorylation of and results in increased activity of RELA protein]; SB 203580 inhibits the reaction [Mustard Gas results in increased phosphorylation of RELA protein]; SB 203580 inhibits the reaction [Paraquat results in increased phosphorylation of RELA protein]; SB 203580 inhibits the reaction [vanadyl sulfate results in increased activity of RELA protein]
SB 203580 inhibits the reaction [Acrolein results in increased phosphorylation of RELA protein]; SB 203580 inhibits the reaction [Cyclosporine affects the localization of RELA protein]; SB 203580 inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased phosphorylation of RELA protein]
SB 203580 inhibits the reaction [endotoxin, Escherichia coli results in increased activity of RELA protein]; SB 203580 inhibits the reaction [icariin results in increased expression of and affects the localization of RELA protein]; SB 203580 inhibits the reaction [Paraquat affects the localization of [NFKB1 protein binds to RELA protein]]; SB 203580 inhibits the reaction [Paraquat promotes the reaction [endotoxin, Escherichia coli affects the localization of [NFKB1 protein binds to RELA protein]]] 		CTD PMID:10873158 PMID:16919916 PMID:18215737 PMID:18423597 PMID:18457675 More... NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817 		JBrowse link
G Rest RE1-silencing transcription factor multiple interactions ISO SB 203580 inhibits the reaction [Sodium Glutamate results in increased expression of REST mRNA] CTD PMID:16782274 NCBI chr14:31,213,415...31,233,451
Ensembl chr14:31,213,415...31,248,662 		JBrowse link
G Retn resistin multiple interactions
decreases expression 		ISO SB 203580 inhibits the reaction [octylphenol results in increased expression of RETN protein]
SB 203580 results in decreased expression of RETN protein 		CTD PMID:18417718 NCBI chr12:6,508,653...6,511,115
Ensembl chr12:6,508,801...6,511,116 		JBrowse link
G Rnd3 Rho family GTPase 3 multiple interactions ISO SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of RND3 mRNA] CTD PMID:28329830 NCBI chr 3:55,981,142...55,998,494
Ensembl chr 3:55,980,355...55,998,536 		JBrowse link
G Rps6ka5 ribosomal protein S6 kinase A5 multiple interactions ISO
EXP 		[U 0126 co-treated with SB 203580] inhibits the reaction [sodium arsenite results in increased activity of RPS6KA5 protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased activity of RPS6KA5 protein]
SB 203580 inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of RPS6KA5 protein] 		CTD PMID:12547826 PMID:15522277 NCBI chr 6:125,558,434...125,736,576
Ensembl chr 6:125,558,434...125,735,856 		JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 multiple interactions ISO SB 203580 promotes the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]; Sodium Salicylate inhibits the reaction [SB 203580 promotes the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]] CTD PMID:10993886 NCBI chr10:71,817,794...71,865,211
Ensembl chr10:71,815,614...71,865,238 		JBrowse link
G Runx2 RUNX family transcription factor 2 multiple interactions EXP [pyrazolanthrone co-treated with SB 203580 co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] inhibits the reaction [Quercetin results in increased expression of RUNX2 mRNA]; SB 203580 inhibits the reaction [cobaltous chloride results in increased expression of RUNX2 mRNA] CTD PMID:26136938 PMID:31472278 NCBI chr 9:23,661,278...23,990,248
Ensembl chr 9:23,664,952...23,990,027 		JBrowse link
G S100a4 S100 calcium-binding protein A4 multiple interactions ISO SB 203580 inhibits the reaction [S100A4 protein results in increased expression of MMP13 protein] CTD PMID:16948116 NCBI chr 2:178,388,529...178,390,838
Ensembl chr 2:178,388,526...178,390,837 		JBrowse link
G S100b S100 calcium binding protein B multiple interactions ISO SB 203580 inhibits the reaction [S100B protein results in increased expression of NOS2 mRNA]; SB 203580 inhibits the reaction [S100B protein results in increased expression of NOS2 protein] CTD PMID:16376947 NCBI chr20:12,372,345...12,381,159
Ensembl chr20:12,372,348...12,381,081 		JBrowse link
G Sele selectin E multiple interactions ISO SB 203580 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SELE mRNA] CTD PMID:16582018 NCBI chr13:78,935,997...78,945,905
Ensembl chr13:78,936,036...78,945,903 		JBrowse link
G Serpinb2 serpin family B member 2 multiple interactions ISO SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of SERPINB2 mRNA] CTD PMID:28329830 NCBI chr13:24,051,933...24,065,032
Ensembl chr13:24,056,021...24,065,031 		JBrowse link
G Serpine1 serpin family E member 1 multiple interactions ISO SB 203580 inhibits the reaction [cupric oxide results in increased expression of SERPINE1 mRNA] CTD PMID:20171267 NCBI chr12:25,237,977...25,248,356
Ensembl chr12:25,237,952...25,248,357 		JBrowse link
G Serpinh1 serpin family H member 1 decreases expression
multiple interactions 		ISO SB 203580 results in decreased expression of SERPINH1 mRNA
SB 203580 inhibits the reaction [Oxygen deficiency results in increased expression of SERPINH1 mRNA] 		CTD PMID:13679210 NCBI chr 1:163,055,630...163,063,177
Ensembl chr 1:163,055,630...163,062,976 		JBrowse link
G Sesn2 sestrin 2 multiple interactions ISO [SB 203580 co-treated with Quercetin] results in increased expression of SESN2 protein CTD PMID:24535669 NCBI chr 5:149,986,304...150,005,255
Ensembl chr 5:149,986,317...150,005,255 		JBrowse link
G Sirt1 sirtuin 1 multiple interactions ISO SB 203580 inhibits the reaction [Hydrogen Peroxide affects the localization of SIRT1 protein]
SB 203580 inhibits the reaction [icariin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of SIRT1 mRNA]]; SB 203580 inhibits the reaction [icariin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of SIRT1 protein]] 		CTD PMID:19303870 PMID:25512378 NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,305,476...25,328,000 		JBrowse link
G Slc10a2 solute carrier family 10 member 2 multiple interactions ISO SB 203580 inhibits the reaction [deoxynivalenol results in decreased expression of SLC10A2 mRNA] CTD PMID:37315771 NCBI chr16:91,088,089...91,111,025
Ensembl chr16:91,076,423...91,111,025 		JBrowse link
G Slc20a1 solute carrier family 20 member 1 multiple interactions ISO SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of SLC20A1 mRNA] CTD PMID:28329830 NCBI chr 3:136,880,360...136,894,255
Ensembl chr 3:136,880,290...136,894,249 		JBrowse link
G Slc6a2 solute carrier family 6 member 2 multiple interactions ISO SB 203580 inhibits the reaction [Cocaine results in increased expression of SLC6A2 protein] CTD PMID:25724654 NCBI chr19:30,183,289...30,228,292
Ensembl chr19:30,183,383...30,223,348 		JBrowse link
G Slc7a1 solute carrier family 7 member 1 multiple interactions ISO SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of SLC7A1 mRNA] CTD PMID:28329830 NCBI chr12:11,664,488...11,740,030
Ensembl chr12:11,664,399...11,740,030 		JBrowse link
G Slc7a11 solute carrier family 7 member 11 multiple interactions ISO SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of SLC7A11 mRNA] CTD PMID:28329830 NCBI chr 2:136,532,912...136,668,560
Ensembl chr 2:136,532,246...136,695,695 		JBrowse link
G Smad2 SMAD family member 2 multiple interactions EXP [SB 203580 co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] inhibits the reaction [Paraquat results in increased phosphorylation of SMAD2 protein]; SB 203580 inhibits the reaction [Paraquat results in increased phosphorylation of SMAD2 protein] CTD PMID:25873302 NCBI chr18:72,124,792...72,193,345
Ensembl chr18:72,124,863...72,187,388 		JBrowse link
G Smad3 SMAD family member 3 multiple interactions ISO SB 203580 inhibits the reaction [TGFB2 protein results in increased phosphorylation of SMAD3 protein] CTD PMID:18253093 NCBI chr 8:73,022,204...73,132,324
Ensembl chr 8:73,024,760...73,132,324 		JBrowse link
G Snai1 snail family transcriptional repressor 1 multiple interactions ISO SB 203580 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 mRNA]; SB 203580 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 protein]; SB 203580 inhibits the reaction [benz(a)anthracene results in increased expression of SNAI1 mRNA]; SB 203580 inhibits the reaction [benzo(k)fluoranthene results in increased expression of SNAI1 mRNA]; SB 203580 inhibits the reaction [indeno(1,2,3-cd)pyrene results in increased expression of SNAI1 mRNA]; SB 203580 inhibits the reaction [thymoquinone results in decreased expression of SNAI1 protein] CTD PMID:21635667 PMID:27060453 PMID:33396024 NCBI chr 3:176,667,476...176,671,965 JBrowse link
G Snai2 snail family transcriptional repressor 2 multiple interactions ISO SB 203580 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 protein] CTD PMID:33396024 NCBI chr11:99,686,934...99,690,349
Ensembl chr11:99,686,934...99,690,349 		JBrowse link
G Snora23 small nucleolar RNA, H/ACA box 23 multiple interactions ISO SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of SNORA23 mRNA] CTD PMID:28329830 NCBI chr 1:173,525,793...173,525,975
Ensembl chr 1:173,525,793...173,525,975 		JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions ISO
EXP 		SB 203580 inhibits the reaction [MAPK11 protein results in increased phosphorylation of SOD2 protein]
SB 203580 inhibits the reaction [[Paraquat results in increased abundance of Reactive Oxygen Species] which results in increased expression of SOD2 mRNA] 		CTD PMID:24376630 PMID:24465521 NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168 		JBrowse link
G Sox9 SRY-box transcription factor 9 multiple interactions ISO SB 203580 inhibits the reaction [resveratrol results in increased expression of SOX9] CTD PMID:24841706 NCBI chr10:98,305,744...98,311,250
Ensembl chr10:98,305,744...98,311,250 		JBrowse link
G Sp1 Sp1 transcription factor multiple interactions ISO SB 203580 inhibits the reaction [Hydrogen Peroxide promotes the reaction [SP1 protein results in increased expression of CAV1 protein]] CTD PMID:17108117 NCBI chr 7:135,419,864...135,450,513
Ensembl chr 7:135,420,050...135,450,513 		JBrowse link
G Sp7 Sp7 transcription factor multiple interactions EXP SB 203580 inhibits the reaction [cobaltous chloride results in increased expression of SP7 mRNA]; SB 203580 inhibits the reaction [cobaltous chloride results in increased expression of SP7 protein] CTD PMID:31472278 NCBI chr 7:135,363,193...135,373,376
Ensembl chr 7:135,363,199...135,373,559 		JBrowse link
G Spp1 secreted phosphoprotein 1 multiple interactions EXP SB 203580 inhibits the reaction [cobaltous chloride results in increased expression of SPP1 protein] CTD PMID:19356721 NCBI chr14:5,613,569...5,620,695
Ensembl chr14:5,613,576...5,619,820 		JBrowse link
G Sqstm1 sequestosome 1 multiple interactions EXP
ISO 		SB 203580 inhibits the reaction [fenvalerate results in decreased expression of SQSTM1 protein]; SB 203580 inhibits the reaction [osthol inhibits the reaction [Antineoplastic Agents, Immunological results in increased expression of SQSTM1 protein]]
SB 203580 inhibits the reaction [sodium arsenite affects the expression of SQSTM1 protein] 		CTD PMID:31734597 PMID:34861471 PMID:37769856 NCBI chr10:35,026,598...35,037,750
Ensembl chr10:35,026,598...35,037,750 		JBrowse link
G Srf serum response factor multiple interactions ISO SB 203580 inhibits the reaction [Anisomycin results in increased phosphorylation of SRF protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased phosphorylation of SRF protein]; SB 203580 inhibits the reaction [TGFB1 protein results in increased expression of SRF protein] CTD PMID:12660819 PMID:21712382 NCBI chr 9:21,924,050...21,933,338
Ensembl chr 9:21,924,076...21,933,337 		JBrowse link
G Srrt serrate, RNA effector molecule multiple interactions ISO SB 203580 inhibits the reaction [sodium arsenite results in increased expression of SRRT protein] CTD PMID:26404762 NCBI chr12:25,027,883...25,042,847
Ensembl chr12:25,029,334...25,042,845 		JBrowse link
G Ssb small RNA binding exonuclease protection factor La multiple interactions ISO SB 203580 inhibits the reaction [SSB protein results in increased secretion of CXCL8 protein] CTD PMID:25915936 NCBI chr 3:75,024,385...75,034,016
Ensembl chr 3:75,024,474...75,034,031 		JBrowse link
G Star steroidogenic acute regulatory protein multiple interactions
increases expression 		ISO
EXP 		SB 203580 inhibits the reaction [LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]]
SB 203580 inhibits the reaction [nickel sulfate results in decreased expression of STAR mRNA]; SB 203580 inhibits the reaction [nickel sulfate results in decreased expression of STAR protein]
SB 203580 results in increased expression of STAR mRNA; SB 203580 results in increased expression of STAR protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [SB 203580 promotes the reaction [sodium arsenite results in increased expression of STAR mRNA]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [SB 203580 results in increased expression of STAR mRNA]; [N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with SB 203580] inhibits the reaction [perfluorooctane sulfonic acid inhibits the reaction [[CRTC2 protein binds to CREB1 protein modified form] which binds to STAR promoter]]; [N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with SB 203580] inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of STAR protein]; SB 203580 inhibits the reaction [perfluorooctane sulfonic acid inhibits the reaction [[CRTC2 protein binds to CREB1 protein modified form] which binds to STAR promoter]]; SB 203580 inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of STAR protein]; SB 203580 promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; SB 203580 promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]; SB 203580 promotes the reaction [sodium arsenite results in increased expression of STAR mRNA]; SB 203580 promotes the reaction [sodium arsenite results in increased expression of STAR protein] 		CTD PMID:15713539 PMID:19849856 PMID:29567110 PMID:33359577 NCBI chr16:72,969,824...72,974,447
Ensembl chr16:72,961,518...72,974,447 		JBrowse link
G Stat1 signal transducer and activator of transcription 1 multiple interactions ISO SB 203580 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]; SB 203580 inhibits the reaction [nickel sulfate results in increased phosphorylation of STAT1 protein] CTD PMID:16355272 PMID:20525893 NCBI chr 9:56,911,522...56,951,926
Ensembl chr 9:56,911,523...57,077,346 		JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions
increases phosphorylation 		ISO SB 203580 inhibits the reaction [1,2,5,8-tetrahydroxy anthraquinone results in decreased phosphorylation of STAT3 protein]; SB 203580 inhibits the reaction [1,4-naphthoquinone analog results in decreased phosphorylation of STAT3 protein]
SB 203580 results in increased phosphorylation of STAT3 protein 		CTD PMID:30871965 PMID:33030807 NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359 		JBrowse link
G Stat5a signal transducer and activator of transcription 5A multiple interactions ISO SB 203580 affects the reaction [JTE 907 affects the phosphorylation of STAT5A protein] CTD PMID:30552973 NCBI chr10:86,285,859...86,310,187
Ensembl chr10:86,285,547...86,310,184 		JBrowse link
G Sts steroid sulfatase multiple interactions ISO SB 203580 inhibits the reaction [IGF2 protein results in increased expression of STS mRNA] CTD PMID:24055520 NCBI chr  X:46,102,524...46,110,868
Ensembl chr  X:46,102,548...46,111,104 		JBrowse link
G Sult1a1 sulfotransferase family 1A member 1 multiple interactions ISO SB 203580 inhibits the reaction [Gallic Acid results in increased expression of SULT1A1 protein] CTD PMID:16308312 NCBI chr 1:190,702,592...190,706,112
Ensembl chr 1:190,702,592...190,706,131 		JBrowse link
G Sumo1 small ubiquitin-like modifier 1 multiple interactions ISO SB 203580 inhibits the reaction [Cadmium Chloride affects the localization of SUMO1 protein] CTD PMID:12508112 NCBI chr 9:68,572,901...68,602,803
Ensembl chr 9:68,572,911...68,602,890 		JBrowse link
G Tac1 tachykinin, precursor 1 multiple interactions EXP SB 203580 inhibits the reaction [GR 73632 promotes the reaction [Capsaicin results in increased secretion of TAC1 protein]] CTD PMID:18809416 NCBI chr 4:36,645,344...36,653,548
Ensembl chr 4:36,645,571...36,653,546 		JBrowse link
G Tac4 tachykinin precursor 4 multiple interactions EXP SB 203580 inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TAC4 mRNA] CTD PMID:22384199 NCBI chr10:80,704,640...80,712,972
Ensembl chr10:80,701,987...80,712,972 		JBrowse link
G Taf4b TATA-box binding protein associated factor 4b multiple interactions ISO SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of TAF4B mRNA] CTD PMID:28329830 NCBI chr18:6,227,299...6,360,970
Ensembl chr18:6,227,345...6,356,275 		JBrowse link
G Tert telomerase reverse transcriptase multiple interactions ISO [pyrazolanthrone co-treated with SB 203580 co-treated with U 0126] inhibits the reaction [Isothiocyanates results in increased expression of TERT mRNA] CTD PMID:23382840 NCBI chr 1:31,465,766...31,488,650
Ensembl chr 1:31,466,056...31,488,111 		JBrowse link
G Tff1 trefoil factor 1 multiple interactions ISO SB 203580 affects the reaction [deoxynivalenol affects the expression of TFF1 mRNA] CTD PMID:30854615 NCBI chr20:9,237,095...9,240,956
Ensembl chr20:9,237,095...9,240,956 		JBrowse link
G Tff2 trefoil factor 2 multiple interactions ISO SB 203580 affects the reaction [deoxynivalenol affects the expression of TFF2 mRNA] CTD PMID:30854615 NCBI chr20:9,217,110...9,220,979
Ensembl chr20:9,217,121...9,220,979 		JBrowse link
G Tff3 trefoil factor 3 multiple interactions ISO SB 203580 affects the reaction [deoxynivalenol affects the expression of TFF3 mRNA] CTD PMID:30854615 NCBI chr20:9,194,623...9,199,333
Ensembl chr20:9,194,626...9,199,333 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO
EXP 		SB 203580 analog inhibits the reaction [TGFB1 protein results in increased expression of CCN2 protein]; SB 203580 inhibits the reaction [Asbestos, Serpentine results in increased secretion of TGFB1 protein]; SB 203580 inhibits the reaction [nickel monoxide results in increased expression of TGFB1 protein]; SB 203580 inhibits the reaction [TGFB1 protein affects the localization of JUNB protein]; SB 203580 inhibits the reaction [TGFB1 protein results in decreased expression of CCND1 protein]; SB 203580 inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 protein]; SB 203580 inhibits the reaction [TGFB1 protein results in decreased expression of KLF5 mRNA]; SB 203580 inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; SB 203580 inhibits the reaction [TGFB1 protein results in increased expression of CNN1 protein]; SB 203580 inhibits the reaction [TGFB1 protein results in increased expression of ITGB6 mRNA]; SB 203580 inhibits the reaction [TGFB1 protein results in increased expression of JUNB mRNA]; SB 203580 inhibits the reaction [TGFB1 protein results in increased expression of MIR143]; SB 203580 inhibits the reaction [TGFB1 protein results in increased expression of MIR145]; SB 203580 inhibits the reaction [TGFB1 protein results in increased expression of MYOCD mRNA]; SB 203580 inhibits the reaction [TGFB1 protein results in increased expression of SRF protein]; SB 203580 inhibits the reaction [TGFB1 protein results in increased phosphorylation of ATF2 protein]
SB 203580 inhibits the reaction [Silicon Dioxide results in increased expression of TGFB1 protein]; SB 203580 inhibits the reaction [TGFB1 protein inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of and results in decreased secretion of IGF1 protein]]; SB 203580 inhibits the reaction [TGFB1 protein inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of and results in increased secretion of IL1B protein]]; SB 203580 inhibits the reaction [TGFB1 protein inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of and results in increased secretion of TNF protein]]; SB 203580 inhibits the reaction [TGFB1 protein inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of ITGAM protein]]; SB 203580 inhibits the reaction [TGFB1 protein inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of NOS2 protein]]
SB 203580 inhibits the reaction [[Calcitriol co-treated with TGFB1 protein] results in increased secretion of VEGFA protein]; SB 203580 inhibits the reaction [TGFB1 protein results in increased secretion of VEGFA protein]; SB 203580 inhibits the reaction [Vehicle Emissions results in increased expression of TGFB1 mRNA] 		CTD PMID:11591817 PMID:12649123 PMID:16598785 PMID:19778233 PMID:21303922 More... NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899 		JBrowse link
G Tgfb2 transforming growth factor, beta 2 multiple interactions ISO SB 203580 inhibits the reaction [TGFB2 protein results in increased expression of COL1A1 mRNA]; SB 203580 inhibits the reaction [TGFB2 protein results in increased phosphorylation of SMAD3 protein] CTD PMID:18253093 NCBI chr13:100,691,540...100,793,227
Ensembl chr13:100,692,953...100,792,856 		JBrowse link
G Th tyrosine hydroxylase multiple interactions EXP SB 203580 inhibits the reaction [fenvalerate results in decreased expression of TH protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of TH protein] CTD PMID:9288946 PMID:31734597 NCBI chr 1:207,500,959...207,508,276
Ensembl chr 1:207,500,962...207,557,227 		JBrowse link
G Thbs1 thrombospondin 1 multiple interactions ISO SB 203580 inhibits the reaction [Fluorouracil results in increased expression of THBS1 mRNA] CTD PMID:18757417 NCBI chr 3:125,510,250...125,525,402
Ensembl chr 3:125,510,250...125,525,402 		JBrowse link
G Timp1 TIMP metallopeptidase inhibitor 1 multiple interactions ISO SB 203580 inhibits the reaction [Dronabinol results in increased expression of TIMP1 protein]; SB 203580 inhibits the reaction [methanandamide results in increased expression of TIMP1 protein]; SB 203580 inhibits the reaction [thymoquinone results in increased expression of TIMP1 protein] CTD PMID:18159069 PMID:27060453 NCBI chr  X:3,766,509...3,772,578
Ensembl chr  X:3,766,510...3,771,135 		JBrowse link
G Timp2 TIMP metallopeptidase inhibitor 2 multiple interactions ISO SB 203580 inhibits the reaction [thymoquinone results in increased expression of TIMP2 protein] CTD PMID:27060453 NCBI chr10:104,041,604...104,089,214
Ensembl chr10:104,041,604...104,089,214 		JBrowse link
G Tjp1 tight junction protein 1 multiple interactions ISO SB 203580 inhibits the reaction [clopidogrel results in decreased expression of TJP1 protein]
SB 203580 inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of TJP1 protein] 		CTD PMID:23220562 PMID:23761298 NCBI chr 1:128,260,330...128,505,018
Ensembl chr 1:128,260,330...128,505,158 		JBrowse link
G Tlr2 toll-like receptor 2 multiple interactions ISO SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of TLR2 mRNA] CTD PMID:12888452 NCBI chr 2:171,499,189...171,504,831
Ensembl chr 2:171,497,060...171,520,194 		JBrowse link
G Tnf tumor necrosis factor multiple interactions
decreases expression
increases expression
decreases response to substance 		ISO
EXP 		2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [SB 203580 inhibits the reaction [Lead results in increased expression of and results in increased stability of TNF mRNA]]; [nickel monoxide co-treated with SB 203580] results in decreased expression of TNF protein; [pirinixic acid co-treated with SB 203580] inhibits the reaction [TNF protein results in decreased expression of APOA1 mRNA]; SB 203580 inhibits the reaction [2,2-dichloroacetyl chloride results in increased expression of TNF mRNA]; SB 203580 inhibits the reaction [[IFNG protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of NOS2 mRNA]; SB 203580 inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of TNF mRNA]; SB 203580 inhibits the reaction [Asbestos, Crocidolite results in increased expression of TNF mRNA]; SB 203580 inhibits the reaction [Buthionine Sulfoximine promotes the reaction [TNF protein results in increased expression of CCL5 protein]]; SB 203580 inhibits the reaction [DDT results in increased expression of TNF mRNA]; SB 203580 inhibits the reaction [deoxynivalenol inhibits the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased expression of NOS2 protein]]; SB 203580 inhibits the reaction [IL17A protein promotes the reaction [TNF protein results in increased expression of IL6 mRNA]]; SB 203580 inhibits the reaction [Lead results in increased expression of and results in increased stability of TNF mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; SB 203580 inhibits the reaction [Methotrexate results in decreased expression of TNF protein]; SB 203580 inhibits the reaction [Mustard Gas results in increased expression of TNF protein]; SB 203580 inhibits the reaction [Mustard Gas results in increased secretion of TNF protein]; SB 203580 inhibits the reaction [nickel monoxide results in increased expression of TNF protein]; SB 203580 inhibits the reaction [nickel sulfate results in increased expression of TNF protein]; SB 203580 inhibits the reaction [nonylphenol results in increased expression of and results in increased secretion of TNF protein]; SB 203580 inhibits the reaction [nonylphenol results in increased expression of TNF]; SB 203580 inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; SB 203580 inhibits the reaction [Shiga Toxin results in increased expression of TNF protein]; SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNF mRNA]; SB 203580 inhibits the reaction [TNF protein results in increased expression of and results in increased activity of MMP9 protein]; SB 203580 inhibits the reaction [TNF protein results in increased expression of CCL5 protein]; SB 203580 inhibits the reaction [TNF protein results in increased expression of F3 mRNA]; SB 203580 inhibits the reaction [TNF protein results in increased expression of FOS mRNA]; SB 203580 inhibits the reaction [TNF protein results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased activity of ALOX5 protein]; SB 203580 inhibits the reaction [TNF protein results in increased phosphorylation of EIF4E protein]; SB 203580 inhibits the reaction [TNF results in increased expression of CCL2 protein]; SB 203580 inhibits the reaction [TNF results in increased expression of ICAM1 protein]; SB 203580 promotes the reaction [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lead results in increased expression of and results in increased stability of TNF mRNA]]; SB 203580 promotes the reaction [[sodium arsenite co-treated with TNF protein] results in increased cleavage of PARP1 protein]; SB 203580 promotes the reaction [bufalin results in increased expression of TNF mRNA]; SB 203580 promotes the reaction [TNF protein results in increased phosphorylation of MAPK1 protein]; SB 203580 promotes the reaction [TNF protein results in increased phosphorylation of MAPK3 protein]; SB 203580 promotes the reaction [Zymosan results in increased secretion of TNF protein]
[SB 203580 inhibits the reaction [Lipopolysaccharides co-treated with TNF protein]] which results in increased phosphorylation of HSPB1 protein; [SB 203580 inhibits the reaction [Lipopolysaccharides co-treated with TNF protein]] which results in increased phosphorylation of MAPK14 protein; SB 203580 inhibits the reaction [2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [ACE2 protein inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]]; SB 203580 inhibits the reaction [7-Ala-angiotensin (1-7) inhibits the reaction [ACE2 protein inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]]; SB 203580 inhibits the reaction [lead acetate results in increased expression of TNF protein]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; SB 203580 inhibits the reaction [Manganese promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TNF protein]]; SB 203580 inhibits the reaction [Particulate Matter results in increased expression of TNF mRNA]; SB 203580 inhibits the reaction [Resveratrol results in decreased expression of TNF protein]
SB 203580 results in decreased expression of TNF protein
[SB 203580 co-treated with U 0126] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; SB 203580 inhibits the reaction [[Polysaccharides co-treated with IFNG protein] results in increased expression of TNF protein]; SB 203580 inhibits the reaction [Cisplatin results in increased expression of TNF mRNA]; SB 203580 inhibits the reaction [Cisplatin results in increased expression of TNF protein]; SB 203580 inhibits the reaction [cobaltous chloride results in increased expression of TNF protein]; SB 203580 inhibits the reaction [CPG-oligonucleotide results in increased secretion of TNF protein]; SB 203580 inhibits the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; SB 203580 inhibits the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; SB 203580 inhibits the reaction [deoxynivalenol results in increased expression of TNF mRNA]; SB 203580 inhibits the reaction [deoxynivalenol results in increased secretion of TNF protein]; SB 203580 inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; SB 203580 inhibits the reaction [endotoxin, Escherichia coli results in increased expression of TNF protein]; SB 203580 inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; SB 203580 inhibits the reaction [Mercuric Chloride results in increased expression of TNF mRNA]; SB 203580 inhibits the reaction [nivalenol results in increased secretion of TNF protein]; SB 203580 inhibits the reaction [Paraquat promotes the reaction [endotoxin, Escherichia coli results in increased expression of TNF protein]]; SB 203580 inhibits the reaction [Paraquat results in increased expression of TNF protein]; SB 203580 inhibits the reaction [TGFB1 protein inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of and results in increased secretion of TNF protein]]; SB 203580 inhibits the reaction [TNF protein results in increased expression of CCL11 protein]; SB 203580 inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; SB 203580 inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]; SB 203580 promotes the reaction [PARK7 gene mutant form inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]
SB 203580 results in increased expression of TNF mRNA
SB 203580 results in decreased susceptibility to TNF protein 		CTD PMID:1970628 PMID:9545260 PMID:9799232 PMID:10712238 PMID:10779545 More... NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303 		JBrowse link
G Tnfaip6 TNF alpha induced protein 6 decreases expression ISO SB 203580 results in decreased expression of TNFAIP6 mRNA CTD PMID:20660070 NCBI chr 3:56,911,398...56,930,797
Ensembl chr 3:56,911,252...56,930,796 		JBrowse link
G Tnfrsf11b TNF receptor superfamily member 11B multiple interactions
decreases expression 		ISO SB 203580 inhibits the reaction [IL1B protein results in decreased expression of TNFRSF11B protein]; SB 203580 promotes the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of TNFRSF11B mRNA]
SB 203580 inhibits the reaction [Alprostadil results in increased secretion of TNFRSF11B protein]; SB 203580 inhibits the reaction [Dinoprost results in increased expression of and results in increased secretion of TNFRSF11B protein]; SB 203580 inhibits the reaction [Dinoprostone results in increased secretion of TNFRSF11B protein]; SB 203580 inhibits the reaction [FGF2 protein results in increased secretion of TNFRSF11B protein]; SB 203580 inhibits the reaction [Prostaglandin D2 results in increased secretion of TNFRSF11B protein]
SB 203580 results in decreased expression of TNFRSF11B mRNA 		CTD PMID:20660070 PMID:22727857 PMID:24333336 PMID:24813642 PMID:25234201 More... NCBI chr 7:87,456,318...87,484,324
Ensembl chr 7:87,456,319...87,485,075 		JBrowse link
G Tnfrsf1a TNF receptor superfamily member 1A multiple interactions ISO SB 203580 inhibits the reaction [Cisplatin results in increased expression of TNFRSF1A protein] CTD PMID:15701814 NCBI chr 4:159,837,119...159,849,817
Ensembl chr 4:159,837,032...159,849,816 		JBrowse link
G Tnfrsf1b TNF receptor superfamily member 1B multiple interactions ISO SB 203580 inhibits the reaction [Cisplatin results in increased expression of TNFRSF1B protein] CTD PMID:15701814 NCBI chr 5:162,356,250...162,387,411
Ensembl chr 5:162,353,848...162,387,411 		JBrowse link
G Tnfsf10 TNF superfamily member 10 increases response to substance
multiple interactions 		ISO SB 203580 results in increased susceptibility to TNFSF10 protein
SB 203580 inhibits the reaction [CSC-3436 promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]]; SB 203580 inhibits the reaction [TNFSF10 protein promotes the reaction [CSC-3436 results in increased cleavage of PARP1 protein]] 		CTD PMID:19497411 PMID:34599545 NCBI chr 2:112,136,550...112,155,903 JBrowse link
G Tnfsf11 TNF superfamily member 11 multiple interactions ISO [SB 203580 co-treated with CSF1R protein co-treated with TNFSF11 protein] results in decreased expression of ATP6V0D2 mRNA; [SB 203580 co-treated with CSF1R protein co-treated with TNFSF11 protein] results in decreased expression of CTSK mRNA; [SB 203580 co-treated with sodium arsenite co-treated with CSF1R protein co-treated with TNFSF11 protein] results in decreased expression of ATP6V0D2 mRNA; [SB 203580 co-treated with sodium arsenite co-treated with CSF1R protein co-treated with TNFSF11 protein] results in decreased expression of CTSK mRNA; SB 203580 affects the reaction [[NFE2L2 protein affects the susceptibility to sodium arsenite] affects the reaction [[CSF1R protein co-treated with TNFSF11 protein] affects the expression of ATP6V0D2 mRNA]]; SB 203580 affects the reaction [[NFE2L2 protein affects the susceptibility to sodium arsenite] affects the reaction [[CSF1R protein co-treated with TNFSF11 protein] affects the expression of CTSK mRNA]]; SB 203580 inhibits the reaction [[sodium arsenite co-treated with CSF1R protein co-treated with TNFSF11 protein] results in increased expression of ATP6V0D2 mRNA]; SB 203580 inhibits the reaction [[sodium arsenite co-treated with CSF1R protein co-treated with TNFSF11 protein] results in increased expression of CTSK mRNA] CTD PMID:30742845 NCBI chr15:60,083,008...60,114,479
Ensembl chr15:60,083,008...60,114,479 		JBrowse link
G Tp53 tumor protein p53 multiple interactions EXP
ISO 		SB 203580 inhibits the reaction [dibenzo(a,l)pyrene results in increased phosphorylation of TP53 protein]
SB 203580 inhibits the reaction [deoxynivalenol results in increased phosphorylation of and results in increased activity of TRP53 protein]; SB 203580 inhibits the reaction [Ethanol results in increased expression of and results in increased phosphorylation of TP53 protein]
SB 203580 inhibits the reaction [[Cisplatin co-treated with fisetin] results in increased phosphorylation of TP53 protein]; SB 203580 inhibits the reaction [[sodium arsenite co-treated with Vitamin K 3] results in increased phosphorylation of TP53 protein]; SB 203580 inhibits the reaction [Curcumin results in increased phosphorylation of TP53 protein]; SB 203580 inhibits the reaction [icaritin results in increased phosphorylation of TP53 protein]; SB 203580 inhibits the reaction [Pyrogallol results in increased expression of TP53 protein]; SB 203580 inhibits the reaction [S-allylcysteine results in increased phosphorylation of TP53 protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased expression of TP53 protein]; SB 203580 inhibits the reaction [Sulindac affects the localization of TP53 protein] 		CTD PMID:15734884 PMID:15976193 PMID:16005925 PMID:17136320 PMID:19020741 More... NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299 		JBrowse link
G Tpp2 tripeptidyl peptidase 2 multiple interactions ISO SB 203580 inhibits the reaction [Etoposide affects the localization of TPP2 protein] CTD PMID:20643100 NCBI chr 9:53,538,788...53,620,253
Ensembl chr 9:53,538,313...53,620,251 		JBrowse link
G Trpv1 transient receptor potential cation channel, subfamily V, member 1 multiple interactions EXP SB 203580 inhibits the reaction [GR 73632 results in increased phosphorylation of TRPV1 protein] CTD PMID:18809416 NCBI chr10:58,349,936...58,375,021
Ensembl chr10:58,340,223...58,375,021 		JBrowse link
G Tsc22d1 TSC22 domain family, member 1 increases expression EXP SB 203580 results in increased expression of TSC22D1 mRNA CTD PMID:26464165 NCBI chr15:58,159,612...58,260,244
Ensembl chr15:58,159,952...58,183,322 		JBrowse link
G Twist1 twist family bHLH transcription factor 1 multiple interactions ISO SB 203580 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of TWIST1 mRNA]; SB 203580 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of TWIST1 protein]; SB 203580 inhibits the reaction [thymoquinone results in decreased expression of TWIST1 protein] CTD PMID:27060453 PMID:33396024 NCBI chr 6:56,402,309...56,404,303
Ensembl chr 6:56,398,061...56,404,965 		JBrowse link
G Txnrd1 thioredoxin reductase 1 multiple interactions ISO SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of TXNRD1 mRNA] CTD PMID:28329830 NCBI chr 7:22,717,620...22,802,553
Ensembl chr 7:22,719,317...22,739,817 		JBrowse link
G Tymp thymidine phosphorylase decreases expression
multiple interactions 		ISO SB 203580 results in decreased expression of TYMP mRNA
SB 203580 inhibits the reaction [salinomycin results in increased expression of TYMP mRNA]; SB 203580 promotes the reaction [[tanespimycin co-treated with salinomycin] results in decreased expression of TYMP mRNA] 		CTD PMID:30796972 NCBI chr 7:122,318,396...122,323,716
Ensembl chr 7:122,316,520...122,324,003 		JBrowse link
G Tyr tyrosinase multiple interactions ISO SB 203580 inhibits the reaction [Cannabidiol results in increased activity of TYR protein]; SB 203580 inhibits the reaction [Cannabidiol results in increased expression of TYR mRNA]
SB 203580 inhibits the reaction [[resorcinol co-treated with Cycloheximide] results in increased expression of TYR protein]; SB 203580 inhibits the reaction [resorcinol results in decreased activity of TYR protein] 		CTD PMID:28601556 PMID:29621941 NCBI chr 1:150,527,687...150,622,857
Ensembl chr 1:150,527,687...150,622,857 		JBrowse link
G Tyrp1 tyrosinase-related protein 1 multiple interactions ISO SB 203580 inhibits the reaction [Cannabidiol results in increased expression of TYRP1 mRNA] CTD PMID:28601556 NCBI chr 5:100,327,111...100,345,657
Ensembl chr 5:100,327,125...100,345,657 		JBrowse link
G Ucp3 uncoupling protein 3 multiple interactions ISO SB 203580 inhibits the reaction [Oxygen deficiency results in increased expression of UCP3 protein] CTD PMID:18579531 NCBI chr 1:164,227,910...164,240,893
Ensembl chr 1:164,227,882...164,241,210 		JBrowse link
G Ugt1a1 UDP glucuronosyltransferase family 1 member A1 multiple interactions ISO SB 203580 inhibits the reaction [chrysin results in increased expression of UGT1A1 mRNA] CTD PMID:17256720 NCBI chr 9:96,249,143...96,256,264
Ensembl chr 9:96,144,786...96,256,264 		JBrowse link
G Vasp vasodilator-stimulated phosphoprotein multiple interactions ISO SB 203580 inhibits the reaction [cyanoginosin LR results in increased phosphorylation of VASP protein] CTD PMID:24677693 NCBI chr 1:88,038,026...88,053,783
Ensembl chr 1:88,038,037...88,058,650 		JBrowse link
G Vcam1 vascular cell adhesion molecule 1 multiple interactions ISO SB 203580 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of VCAM1 mRNA]; SB 203580 inhibits the reaction [EDN1 protein results in increased expression of VCAM1 mRNA]; SB 203580 inhibits the reaction [melamine results in increased expression of VCAM1 mRNA]
SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of VCAM1 mRNA]; SB 203580 inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] 		CTD PMID:16582018 PMID:18457675 PMID:22915474 PMID:28329830 PMID:28483571 NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:206,723,044...206,742,801 		JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions
decreases secretion
decreases expression 		ISO
EXP 		SB 203580 inhibits the reaction [4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid results in increased expression of VEGFA mRNA]; SB 203580 inhibits the reaction [4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid results in increased expression of VEGFA protein]; SB 203580 inhibits the reaction [4-tert-octylphenol results in increased secretion of VEGFA protein]; SB 203580 inhibits the reaction [butylbenzyl phthalate results in increased secretion of VEGFA protein]; SB 203580 inhibits the reaction [Dieldrin results in increased secretion of VEGFA protein]; SB 203580 inhibits the reaction [Estradiol results in increased secretion of VEGFA protein]; SB 203580 inhibits the reaction [Genistein results in increased secretion of VEGFA protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of VEGFA protein]]; SB 203580 inhibits the reaction [Melitten results in decreased expression of VEGFA protein]; SB 203580 inhibits the reaction [Oxygen deficiency results in increased expression of VEGFA mRNA]; SB 203580 inhibits the reaction [sodium arsenite results in increased expression of VEGFA mRNA]; SB 203580 inhibits the reaction [sodium arsenite results in increased expression of VEGFA protein]; SB 203580 inhibits the reaction [Troglitazone results in increased expression of VEGFA mRNA]; SB 203580 inhibits the reaction [Troglitazone results in increased expression of VEGFA protein]; SB 203580 inhibits the reaction [VEGFA protein results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [VEGFA protein results in increased expression of PTGS2 protein]
SB 203580 results in decreased secretion of VEGFA protein
SB 203580 inhibits the reaction [[Calcitriol co-treated with TGFB1 protein] results in increased secretion of VEGFA protein]; SB 203580 inhibits the reaction [Calcitriol results in increased secretion of VEGFA protein]; SB 203580 inhibits the reaction [TGFB1 protein results in increased secretion of VEGFA protein]
SB 203580 results in decreased expression of VEGFA mRNA; SB 203580 results in decreased expression of VEGFA protein
SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of VEGFA mRNA]; SB 203580 inhibits the reaction [arsenic trioxide results in increased expression of VEGFA mRNA] 		CTD PMID:12482858 PMID:13679210 PMID:16598785 PMID:18252963 PMID:18596194 More... NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194 		JBrowse link
G Vegfc vascular endothelial growth factor C decreases secretion ISO SB 203580 results in decreased secretion of VEGFC protein CTD PMID:19779139 NCBI chr16:44,445,293...44,560,887
Ensembl chr16:44,445,293...44,560,887 		JBrowse link
G Vim vimentin multiple interactions ISO SB 203580 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM mRNA]; SB 203580 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM protein]; SB 203580 inhibits the reaction [Amiodarone results in increased expression of VIM mRNA]; SB 203580 inhibits the reaction [Amiodarone results in increased expression of VIM protein]; SB 203580 inhibits the reaction [cyanoginosin LR results in increased phosphorylation of VIM protein]; SB 203580 inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of VIM protein] CTD PMID:22960429 PMID:26971374 PMID:31071512 PMID:33396024 NCBI chr17:81,577,261...81,585,746
Ensembl chr17:81,568,272...81,585,746 		JBrowse link
G Xdh xanthine dehydrogenase multiple interactions EXP SB 203580 inhibits the reaction [Oxygen deficiency results in increased phosphorylation of and results in increased activity of XDH protein] CTD PMID:11278616 NCBI chr 6:27,282,319...27,344,022
Ensembl chr 6:27,282,057...27,344,350 		JBrowse link
G Xiap X-linked inhibitor of apoptosis decreases expression ISO SB 203580 results in decreased expression of XIAP protein CTD PMID:30801954 NCBI chr  X:125,756,107...125,803,979
Ensembl chr  X:125,737,971...125,803,978 		JBrowse link
G Zc3h12a zinc finger CCCH type containing 12A multiple interactions EXP SB 203580 inhibits the reaction [Silicon Dioxide results in increased expression of ZC3H12A protein] CTD PMID:26865670 NCBI chr 5:142,661,193...142,670,051
Ensembl chr 5:142,661,199...142,669,985 		JBrowse link
G Zfp36 zinc finger protein 36 multiple interactions ISO SB 203580 inhibits the reaction [isoeugenol results in increased expression of ZFP36 protein] CTD PMID:21969073 NCBI chr 1:92,796,628...92,799,108
Ensembl chr 1:92,796,628...92,799,108 		JBrowse link
SB-202190 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions ISO SB-202190 inhibits the reaction [benzo[a]pyrene and polycyclic arene increases expression of CYP1A1 mRNA in lung epithelial cell] RGD PMID:20464547 RGD:152975620 NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012 		JBrowse link
G Fgf9 fibroblast growth factor 9 multiple interactions ISO SB-202190 inhibits the reaction [ benzo[a]pyrene and polycyclic arene increases expression of FGF9 mRNA in lung epithelial cell] RGD PMID:20464547 RGD:152975620 NCBI chr15:36,325,552...36,369,995
Ensembl chr15:36,325,599...36,367,926 		JBrowse link
G Il1a interleukin 1 alpha multiple interactions ISO SB-202190 inhibits the reaction [benzo[a]pyrene and polycyclic arene increases expression of IL1A mRNA in lung epithelial cell] RGD PMID:20464547 RGD:152975620 NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013 		JBrowse link
SB-239063 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Aqp4 aquaporin 4 multiple interactions EXP SB 239063 inhibits the reaction [manganese(III) acetate dihydrate results in increased expression of AQP4 protein] CTD PMID:20648640 NCBI chr18:6,782,389...6,799,034
Ensembl chr18:6,782,389...6,799,098 		JBrowse link
G Atf4 activating transcription factor 4 multiple interactions ISO SB 239063 inhibits the reaction [perhexiline maleate results in increased expression of ATF4 protein] CTD PMID:33309543 NCBI chr 7:113,684,681...113,686,739
Ensembl chr 7:113,684,681...113,686,739 		JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions EXP SB 239063 inhibits the reaction [Particulate Matter results in decreased expression of BCL2 protein] CTD PMID:26472149 NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900 		JBrowse link
G Casp3 caspase 3 multiple interactions ISO SB 239063 inhibits the reaction [prostaglandin E2 glyceryl ester results in increased cleavage of and results in increased activity of CASP3 protein] CTD PMID:17539917 NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732 		JBrowse link
G Cxcl3 C-X-C motif chemokine ligand 3 multiple interactions ISO [alpha-Tocopherol co-treated with SB 239063] inhibits the reaction [Ozone promotes the reaction [Ovalbumin results in increased expression of CXCL1 mRNA]] CTD PMID:29284473 NCBI chr14:17,571,900...17,573,624
Ensembl chr14:17,571,900...17,573,624 		JBrowse link
G Cyp19a1 cytochrome P450, family 19, subfamily a, polypeptide 1 multiple interactions EXP SB 239063 inhibits the reaction [bisphenol A results in increased expression of and results in increased activity of CYP19A1 protein] CTD PMID:20096755 NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:63,449,148...63,476,917 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions ISO SB 239063 inhibits the reaction [perhexiline maleate results in increased expression of DDIT3 protein] CTD PMID:33309543 NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509 		JBrowse link
G Dnm1l dynamin 1-like multiple interactions EXP [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased susceptibility to SB 239063] which results in decreased expression of DNM1L protein CTD PMID:26116440 NCBI chr11:98,084,049...98,135,663
Ensembl chr11:98,085,397...98,137,420 		JBrowse link
G Dusp1 dual specificity phosphatase 1 multiple interactions ISO SB 239063 inhibits the reaction [[Air Pollutants results in increased abundance of Ozone] promotes the reaction [Ovalbumin results in decreased expression of DUSP1 protein]] CTD PMID:24188200 NCBI chr10:17,184,853...17,187,646
Ensembl chr10:17,184,823...17,187,644 		JBrowse link
G Ednrb endothelin receptor type B multiple interactions EXP SB 239063 inhibits the reaction [Smoke results in increased expression of EDNRB mRNA]; SB 239063 inhibits the reaction [Smoke results in increased expression of EDNRB protein] CTD PMID:18718921 NCBI chr15:87,055,490...87,086,765
Ensembl chr15:87,057,691...87,086,765 		JBrowse link
G Gpx1 glutathione peroxidase 1 multiple interactions ISO [alpha-Tocopherol co-treated with SB 239063] inhibits the reaction [Ovalbumin promotes the reaction [Ozone results in increased activity of GPX1 protein]] CTD PMID:29284473 NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:117,905,280...117,906,581 		JBrowse link
G Gsk3b glycogen synthase kinase 3 beta multiple interactions EXP [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased susceptibility to SB 239063] which results in increased phosphorylation of GSK3B protein CTD PMID:26116440 NCBI chr11:76,004,502...76,154,665
Ensembl chr11:76,009,507...76,153,249 		JBrowse link
G Hspb1 heat shock protein family B (small) member 1 multiple interactions ISO SB 239063 inhibits the reaction [[[Air Pollutants results in increased abundance of Ozone] which co-treated with Ovalbumin] results in increased phosphorylation of HSPB1 protein] CTD PMID:24188200 NCBI chr12:26,430,640...26,432,301
Ensembl chr12:26,430,640...26,432,301 		JBrowse link
G Ifng interferon gamma multiple interactions ISO SB 239063 inhibits the reaction [Ozone promotes the reaction [Ovalbumin results in increased expression of IFNG protein]] CTD PMID:29284473 NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216 		JBrowse link
G Il13 interleukin 13 multiple interactions ISO [alpha-Tocopherol co-treated with SB 239063] inhibits the reaction [Ozone promotes the reaction [Ovalbumin results in increased expression of IL13 protein]]; SB 239063 inhibits the reaction [Ovalbumin results in increased expression of IL13 protein]; SB 239063 inhibits the reaction [Ozone promotes the reaction [Ovalbumin results in increased expression of IL13 protein]] CTD PMID:25287866 PMID:29284473 NCBI chr10:38,290,926...38,293,483
Ensembl chr10:38,290,926...38,293,483 		JBrowse link
G Il17a interleukin 17A multiple interactions ISO SB 239063 inhibits the reaction [Ozone promotes the reaction [Ovalbumin results in increased expression of IL17A mRNA]] CTD PMID:29284473 NCBI chr 9:30,640,844...30,644,331
Ensembl chr 9:30,640,844...30,644,331 		JBrowse link
G Il6 interleukin 6 multiple interactions ISO SB 239063 inhibits the reaction [Ovalbumin results in increased expression of IL6 protein]; SB 239063 inhibits the reaction [Ozone promotes the reaction [Ovalbumin results in increased expression of IL6 protein]] CTD PMID:25287866 PMID:29284473 NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions EXP [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased susceptibility to SB 239063] which results in increased phosphorylation of MAPK1 protein CTD PMID:26116440 NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825 		JBrowse link
G Mapk14 mitogen activated protein kinase 14 multiple interactions ISO SB 239063 inhibits the reaction [[[Air Pollutants results in increased abundance of Ozone] which co-treated with Ovalbumin] results in increased phosphorylation of MAPK14 protein]; SB 239063 inhibits the reaction [[Air Pollutants results in increased abundance of Ozone] promotes the reaction [Ovalbumin results in increased phosphorylation of MAPK14 protein]]; SB 239063 inhibits the reaction [[Ovalbumin co-treated with Ozone] results in increased phosphorylation of MAPK14 protein]; SB 239063 inhibits the reaction [Ozone promotes the reaction [Ovalbumin results in increased phosphorylation of MAPK14 protein]] CTD PMID:24188200 PMID:25287866 PMID:29284473 NCBI chr20:6,751,288...6,812,294
Ensembl chr20:6,751,357...6,812,294 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions EXP [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased susceptibility to SB 239063] which results in increased phosphorylation of MAPK3 protein CTD PMID:26116440 NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411 		JBrowse link
G Mff mitochondrial fission factor multiple interactions EXP [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased susceptibility to SB 239063] which results in decreased expression of MFF protein CTD PMID:26116440 NCBI chr 9:91,455,931...91,484,171
Ensembl chr 9:91,455,871...91,484,171 		JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions EXP SB 239063 inhibits the reaction [25-hydroxyprotopanaxadiol results in increased phosphorylation of PPARG protein] CTD PMID:33676887 NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104 		JBrowse link
G Ppargc1a PPARG coactivator 1 alpha multiple interactions EXP SB 239063 inhibits the reaction [25-hydroxyprotopanaxadiol results in increased phosphorylation of PPARGC1A protein] CTD PMID:33676887 NCBI chr14:63,073,505...63,729,215
Ensembl chr14:63,273,189...63,729,213 		JBrowse link
G Sqstm1 sequestosome 1 multiple interactions EXP [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased susceptibility to SB 239063] which results in increased expression of SQSTM1 protein CTD PMID:26116440 NCBI chr10:35,026,598...35,037,750
Ensembl chr10:35,026,598...35,037,750 		JBrowse link
SCH772984 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acta2 actin alpha 2, smooth muscle multiple interactions ISO SCH772984 inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] CTD PMID:31706003 NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503 		JBrowse link
G Adm adrenomedullin decreases secretion
multiple interactions 		EXP SCH772984 results in decreased secretion of ADM protein
SCH772984 inhibits the reaction [diphenylarsinic acid results in increased secretion of ADM protein] 		CTD PMID:28087833 NCBI chr 1:174,164,178...174,182,372
Ensembl chr 1:174,178,773...174,182,371 		JBrowse link
G App amyloid beta precursor protein multiple interactions EXP SCH772984 inhibits the reaction [APP protein modified form results in increased expression of GRK2 protein] CTD PMID:30399361 NCBI chr11:37,506,207...37,724,351
Ensembl chr11:37,506,408...37,722,971 		JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO SCH772984 inhibits the reaction [pachastrissamine analog inhibits the reaction [BCL2 protein binds to BECN1 protein]] CTD PMID:35123989 NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900 		JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions ISO SCH772984 inhibits the reaction [pachastrissamine analog inhibits the reaction [BCL2L1 protein binds to BECN1 protein]] CTD PMID:35123989 NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907
Ensembl chr 1:161,745,540...161,764,907 		JBrowse link
G Becn1 beclin 1 multiple interactions ISO SCH772984 inhibits the reaction [pachastrissamine analog inhibits the reaction [BCL2 protein binds to BECN1 protein]]; SCH772984 inhibits the reaction [pachastrissamine analog inhibits the reaction [BCL2L1 protein binds to BECN1 protein]] CTD PMID:35123989 NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,731,650...86,747,002 		JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions EXP SCH772984 inhibits the reaction [diphenylarsinic acid results in increased secretion of CCL2 protein] CTD PMID:28087833 NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875 		JBrowse link
G Creb1 cAMP responsive element binding protein 1 multiple interactions EXP SCH772984 inhibits the reaction [diphenylarsinic acid results in increased phosphorylation of and results in increased expression of CREB1 protein]; SCH772984 results in decreased phosphorylation of and results in decreased expression of CREB1 protein CTD PMID:28087833 NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:73,397,306...73,466,339 		JBrowse link
G Cxcl1 C-X-C motif chemokine ligand 1 multiple interactions EXP SCH772984 inhibits the reaction [diphenylarsinic acid results in increased secretion of CXCL1 protein] CTD PMID:28087833 NCBI chr14:17,477,542...17,479,321
Ensembl chr14:17,477,549...17,479,811 		JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 multiple interactions EXP SCH772984 inhibits the reaction [Ethylene Chlorohydrin results in increased expression of CYP2E1 mRNA]; SCH772984 inhibits the reaction [Ethylene Chlorohydrin results in increased expression of CYP2E1 protein] CTD PMID:31585129 NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495 		JBrowse link
G Fgf2 fibroblast growth factor 2 multiple interactions
increases secretion 		EXP SCH772984 promotes the reaction [diphenylarsinic acid results in increased secretion of FGF2 protein]
SCH772984 results in increased secretion of FGF2 protein 		CTD PMID:28087833 NCBI chr 2:122,164,454...122,218,796
Ensembl chr 2:122,164,454...122,224,493 		JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP [SCH772984 co-treated with bilobalide] inhibits the reaction [Oxaliplatin promotes the reaction [Morphine results in increased expression of FOS protein]]; SCH772984 inhibits the reaction [diphenylarsinic acid results in increased expression of and results in increased phosphorylation of FOS protein]; SCH772984 inhibits the reaction [Oxaliplatin promotes the reaction [Morphine results in increased expression of FOS protein]] CTD PMID:28087833 PMID:32319158 NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598 		JBrowse link
G Gpr4 G protein-coupled receptor 4 multiple interactions ISO SCH772984 inhibits the reaction [GPR4 protein affects the phosphorylation of MAPK1 protein]; SCH772984 inhibits the reaction [GPR4 protein affects the phosphorylation of MAPK3 protein] CTD PMID:33161135 NCBI chr 1:87,993,398...88,004,568
Ensembl chr 1:87,993,430...88,006,254 		JBrowse link
G Grk2 G protein-coupled receptor kinase 2 multiple interactions EXP SCH772984 inhibits the reaction [APP protein modified form results in increased expression of GRK2 protein] CTD PMID:30399361 NCBI chr 1:211,010,259...211,031,013
Ensembl chr 1:211,009,978...211,031,015 		JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions ISO SCH772984 inhibits the reaction [pachastrissamine analog results in increased expression of HMOX1 protein] CTD PMID:35123989 NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818 		JBrowse link
G Hspa1a heat shock protein family A (Hsp70) member 1A multiple interactions EXP SCH772984 inhibits the reaction [diphenylarsinic acid results in increased expression of HSPA1A protein] CTD PMID:28087833 NCBI chr20:3,875,411...3,877,866
Ensembl chr20:3,855,780...3,877,979 		JBrowse link
G Il6 interleukin 6 multiple interactions EXP SCH772984 promotes the reaction [diphenylarsinic acid results in increased secretion of IL6 protein] CTD PMID:28087833 NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP SCH772984 inhibits the reaction [diphenylarsinic acid results in increased expression of and results in increased phosphorylation of JUN protein] CTD PMID:28087833 NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285 		JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 multiple interactions ISO SCH772984 inhibits the reaction [pachastrissamine analog promotes the reaction [KEAP1 protein binds to SQSTM1 protein]] CTD PMID:35123989 NCBI chr 8:28,044,555...28,054,042
Ensembl chr 8:28,044,555...28,054,042 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO SCH772984 inhibits the reaction [pachastrissamine analog results in increased lipidation of MAP1LC3B protein] CTD PMID:35123989 NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358
Ensembl chr16:66,574,407...66,584,358 		JBrowse link
G Map2k1 mitogen activated protein kinase kinase 1 increases phosphorylation EXP SCH772984 results in increased phosphorylation of MAP2K1 protein CTD PMID:28087833 NCBI chr 8:73,578,747...73,650,184
Ensembl chr 8:73,578,752...73,650,184 		JBrowse link
G Map2k2 mitogen activated protein kinase kinase 2 increases phosphorylation EXP SCH772984 results in increased phosphorylation of MAP2K2 protein CTD PMID:28087833 NCBI chr 7:9,241,449...9,264,216
Ensembl chr 7:9,241,310...9,260,940 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 increases phosphorylation
decreases phosphorylation
multiple interactions
decreases expression
decreases activity 		EXP
ISO 		SCH772984 results in increased phosphorylation of MAPK1 protein
SCH772984 results in decreased phosphorylation of MAPK1 protein
SCH772984 inhibits the reaction [3,4,5-tri-O-(E)-caffeoylquinic acid analog results in increased phosphorylation of MAPK1 protein]; SCH772984 inhibits the reaction [GPR4 protein affects the phosphorylation of MAPK1 protein]; SCH772984 inhibits the reaction [Ozone results in increased phosphorylation of MAPK1 protein]; SCH772984 inhibits the reaction [pachastrissamine analog results in increased phosphorylation of MAPK1 protein]; SCH772984 inhibits the reaction [saikosaponin D results in increased phosphorylation of and results in increased activity of MAPK1 protein]
SCH772984 inhibits the reaction [diphenylarsinic acid results in increased phosphorylation of MAPK1 protein]
SCH772984 results in decreased expression of MAPK1 protein
SCH772984 results in decreased activity of MAPK1 protein 		CTD PMID:28087833 PMID:29925859 PMID:32156566 PMID:32822868 PMID:33161135 More... NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 decreases activity
decreases phosphorylation
decreases expression
multiple interactions
increases phosphorylation 		EXP
ISO 		SCH772984 results in decreased activity of MAPK3 protein
SCH772984 results in decreased phosphorylation of MAPK3 protein
SCH772984 results in decreased expression of MAPK3 protein
SCH772984 inhibits the reaction [3,4,5-tri-O-(E)-caffeoylquinic acid analog results in increased phosphorylation of MAPK3 protein]; SCH772984 inhibits the reaction [GPR4 protein affects the phosphorylation of MAPK3 protein]; SCH772984 inhibits the reaction [Ozone results in increased phosphorylation of MAPK3 protein]; SCH772984 inhibits the reaction [pachastrissamine analog results in increased phosphorylation of MAPK3 protein]; SCH772984 inhibits the reaction [saikosaponin D results in increased phosphorylation of and results in increased activity of MAPK3 protein]
SCH772984 results in increased phosphorylation of MAPK3 protein
SCH772984 inhibits the reaction [diphenylarsinic acid results in increased phosphorylation of MAPK3 protein] 		CTD PMID:28087833 PMID:29925859 PMID:32156566 PMID:32822868 PMID:33161135 More... NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411 		JBrowse link
G Mapk8 mitogen-activated protein kinase 8 decreases expression
multiple interactions 		EXP SCH772984 results in decreased expression of MAPK8 protein
SCH772984 inhibits the reaction [diphenylarsinic acid results in increased phosphorylation of MAPK8 protein] 		CTD PMID:28087833 NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 multiple interactions EXP SCH772984 inhibits the reaction [diphenylarsinic acid results in increased expression of NFE2L2 protein] CTD PMID:28087833 NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions ISO SCH772984 inhibits the reaction [pachastrissamine analog results in increased expression of NQO1 protein] CTD PMID:35123989 NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO SCH772984 inhibits the reaction [3,4,5-tri-O-(E)-caffeoylquinic acid analog results in increased phosphorylation of RELA protein] CTD PMID:32156566 NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817 		JBrowse link
G Sp1 Sp1 transcription factor multiple interactions EXP SCH772984 inhibits the reaction [Ethylene Chlorohydrin results in increased expression of and results in increased phosphorylation of SP1 protein]; SCH772984 inhibits the reaction [Ethylene Chlorohydrin results in increased expression of SP1 mRNA] CTD PMID:31585129 NCBI chr 7:135,419,864...135,450,513
Ensembl chr 7:135,420,050...135,450,513 		JBrowse link
G Spi1 Spi-1 proto-oncogene multiple interactions ISO SCH772984 inhibits the reaction [saikosaponin D results in increased expression of SPI1 protein] CTD PMID:32822868 NCBI chr 3:97,529,509...97,548,204
Ensembl chr 3:97,527,572...97,549,540 		JBrowse link
G Sqstm1 sequestosome 1 multiple interactions ISO SCH772984 inhibits the reaction [pachastrissamine analog promotes the reaction [KEAP1 protein binds to SQSTM1 protein]]; SCH772984 inhibits the reaction [pachastrissamine analog results in increased expression of SQSTM1 protein] CTD PMID:35123989 NCBI chr10:35,026,598...35,037,750
Ensembl chr10:35,026,598...35,037,750 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO SCH772984 inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; SCH772984 inhibits the reaction [TGFB1 protein results in increased expression of VIM protein] CTD PMID:31706003 NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899 		JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO SCH772984 inhibits the reaction [nivalenol results in increased secretion of TNF protein] CTD PMID:38616237 NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303 		JBrowse link
G Vim vimentin multiple interactions ISO SCH772984 inhibits the reaction [TGFB1 protein results in increased expression of VIM protein] CTD PMID:31706003 NCBI chr17:81,577,261...81,585,746
Ensembl chr17:81,568,272...81,585,746 		JBrowse link
selumetinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bcl2l11 Bcl2-like 11 increases expression ISO AZD 6244 results in increased expression of BCL2L11 protein CTD PMID:22729845 NCBI chr 3:135,820,042...135,857,330
Ensembl chr 3:135,817,562...135,960,695 		JBrowse link
G Camp cathelicidin antimicrobial peptide multiple interactions ISO AZD 6244 promotes the reaction [Calcitriol promotes the reaction [resveratrol results in increased expression of CAMP mRNA]]; AZD 6244 promotes the reaction [resveratrol promotes the reaction [Calcitriol results in increased expression of CAMP mRNA]] CTD PMID:24039193 NCBI chr 8:118,720,184...118,721,998
Ensembl chr 8:118,720,184...118,721,998 		JBrowse link
G Casp3 caspase 3 multiple interactions
increases cleavage 		ISO AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]]
Doxorubicin promotes the reaction [AZD 6244 results in increased cleavage of CASP3 protein] 		CTD PMID:17876044 PMID:27222248 NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732 		JBrowse link
G Casp7 caspase 7 increases cleavage
multiple interactions 		ISO AZD 6244 results in increased cleavage of CASP7 protein
Doxorubicin promotes the reaction [AZD 6244 results in increased cleavage of CASP7 protein] 		CTD PMID:17876044 NCBI chr 1:265,442,647...265,481,938
Ensembl chr 1:265,442,676...265,482,512 		JBrowse link
G Casp8 caspase 8 multiple interactions ISO AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]] CTD PMID:27222248 NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699 		JBrowse link
G Ccnb1 cyclin B1 decreases expression
multiple interactions 		ISO AZD 6244 results in decreased expression of CCNB1 protein
Doxorubicin promotes the reaction [AZD 6244 results in decreased expression of CCNB1 protein] 		CTD PMID:17876044 NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:33,646,252...33,655,225 		JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO AZD 6244 results in decreased expression of and results in decreased phosphorylation of CCND1 protein; Doxorubicin promotes the reaction [AZD 6244 results in decreased expression of and results in decreased phosphorylation of CCND1 protein] CTD PMID:17876044 NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810 		JBrowse link
G Cdk2 cyclin dependent kinase 2 multiple interactions
decreases expression 		ISO Doxorubicin promotes the reaction [AZD 6244 results in decreased expression of CDK2 protein] CTD PMID:17876044 NCBI chr 7:1,714,392...1,721,964
Ensembl chr 7:1,714,392...1,721,878 		JBrowse link
G Cdk4 cyclin-dependent kinase 4 decreases expression
multiple interactions 		ISO AZD 6244 results in decreased expression of CDK4 protein
Doxorubicin promotes the reaction [AZD 6244 results in decreased expression of CDK4 protein] 		CTD PMID:17876044 NCBI chr 7:64,771,453...64,774,891
Ensembl chr 7:64,771,147...64,775,163 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions ISO AZD 6244 promotes the reaction [decitabine results in increased expression of CDKN1A] CTD PMID:19422044 NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969 		JBrowse link
G Chd4 chromodomain helicase DNA binding protein 4 multiple interactions ISO AZD 6244 inhibits the reaction [Harmine results in increased phosphorylation of CHD4 protein] CTD PMID:27805061 NCBI chr 4:159,584,623...159,617,867
Ensembl chr 4:159,584,654...159,617,866 		JBrowse link
G Creb1 cAMP responsive element binding protein 1 decreases phosphorylation ISO AZD 6244 results in decreased phosphorylation of CREB1 protein CTD PMID:31790661 NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:73,397,306...73,466,339 		JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 multiple interactions ISO [Ku 0063794 co-treated with AZD 6244] results in decreased phosphorylation of EIF4EBP1 protein CTD PMID:22415236 NCBI chr16:71,495,457...71,508,845
Ensembl chr16:71,487,930...71,508,874 		JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit decreases phosphorylation ISO AZD 6244 results in decreased phosphorylation of FOS protein CTD PMID:31790661 NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598 		JBrowse link
G Jak2 Janus kinase 2 increases phosphorylation ISO selumetinib increases phosphorylation of JAK2 protein in colonic epithelium RGD PMID:30706361 RGD:127285668 NCBI chr 1:236,408,905...236,468,769
Ensembl chr 1:236,408,662...236,468,762 		JBrowse link
G Kras KRAS proto-oncogene, GTPase multiple interactions ISO AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK1 protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK3 protein]; AZD 6244 inhibits the reaction [KRAS protein mutant form affects the susceptibility to vemurafenib] CTD PMID:27222248 NCBI chr 4:179,916,255...179,949,613
Ensembl chr 4:179,919,802...179,949,320 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
decreases phosphorylation 		ISO AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK1 protein]
AZD 6244 results in decreased phosphorylation of and results in decreased activity of MAPK1 protein; Doxorubicin promotes the reaction [AZD 6244 results in decreased phosphorylation of and results in decreased activity of MAPK1 protein]
AZD 6244 results in decreased phosphorylation of MAPK1 protein 		CTD PMID:17876044 PMID:22415236 PMID:27222248 PMID:31790661 NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
decreases phosphorylation 		ISO AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK3 protein]
AZD 6244 results in decreased phosphorylation of and results in decreased activity of MAPK3 protein; Doxorubicin promotes the reaction [AZD 6244 results in decreased phosphorylation of and results in decreased activity of MAPK3 protein]
AZD 6244 results in decreased phosphorylation of MAPK3 protein 		CTD PMID:17876044 PMID:22415236 PMID:27222248 PMID:31790661 NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411 		JBrowse link
G Mmp1 matrix metallopeptidase 1 decreases activity ISO AZD 6244 results in decreased activity of MMP1 protein CTD PMID:31790661 NCBI chr 8:12,943,453...12,963,966
Ensembl chr 8:12,943,453...12,963,964 		JBrowse link
G Mmp2 matrix metallopeptidase 2 decreases activity ISO AZD 6244 results in decreased activity of MMP2 protein CTD PMID:31790661 NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856 		JBrowse link
G Mmp9 matrix metallopeptidase 9 decreases activity ISO AZD 6244 results in decreased activity of MMP9 protein CTD PMID:31790661 NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442 		JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor multiple interactions
decreases expression 		ISO Doxorubicin promotes the reaction [AZD 6244 results in decreased expression of MYC protein] CTD PMID:17876044 NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 increases cleavage
multiple interactions 		ISO AZD 6244 results in increased cleavage of PARP1 protein
Doxorubicin promotes the reaction [AZD 6244 results in increased cleavage of PARP1 protein]
AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]] 		CTD PMID:17876044 PMID:27222248 NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567 		JBrowse link
G Rps6ka1 ribosomal protein S6 kinase A1 multiple interactions
decreases phosphorylation 		ISO Doxorubicin promotes the reaction [AZD 6244 results in decreased phosphorylation of RPS6KA1 protein] CTD PMID:17876044 NCBI chr 5:151,362,819...151,402,064
Ensembl chr 5:151,362,819...151,476,044 		JBrowse link
G Socs3 suppressor of cytokine signaling 3 multiple interactions ISO AZD 6244 inhibits the reaction [flavone results in increased expression of SOCS3 mRNA]; AZD 6244 inhibits the reaction [flavone results in increased expression of SOCS3 protein] CTD PMID:23782265 NCBI chr10:103,692,579...103,695,975
Ensembl chr10:103,690,976...103,704,825 		JBrowse link
G Ucp1 uncoupling protein 1 multiple interactions ISO AZD 6244 inhibits the reaction [Harmine results in increased expression of UCP1 mRNA] CTD PMID:27805061 NCBI chr19:41,713,350...41,721,421
Ensembl chr19:41,713,351...41,721,420 		JBrowse link
G Ugt1a1 UDP glucuronosyltransferase family 1 member A1 decreases activity ISO AZD 6244 results in decreased activity of UGT1A1 protein CTD PMID:38823552 NCBI chr 9:96,249,143...96,256,264
Ensembl chr 9:96,144,786...96,256,264 		JBrowse link
G Ugt1a5 UDP glucuronosyltransferase family 1 member A5 decreases activity ISO AZD 6244 results in decreased activity of UGT1A4 protein CTD PMID:38823552 NCBI chr 9:96,210,053...96,256,264
Ensembl chr 9:96,144,786...96,256,264 		JBrowse link
G Ugt2b7 UDP glucuronosyltransferase family 2 member B7 decreases activity ISO AZD 6244 results in decreased activity of UGT2B7 protein CTD PMID:38823552 NCBI chr14:21,251,535...21,274,451
Ensembl chr14:21,251,535...21,274,451 		JBrowse link
trametinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Aadat aminoadipate aminotransferase multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of AADAT mRNA CTD PMID:36139627 NCBI chr16:34,520,236...34,566,388
Ensembl chr16:34,520,238...34,566,540 		JBrowse link
G Abhd11 abhydrolase domain containing 11 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ABHD11 mRNA CTD PMID:36139627 NCBI chr12:27,318,739...27,322,016
Ensembl chr12:27,318,749...27,321,970 		JBrowse link
G Acaca acetyl-CoA carboxylase alpha multiple interactions ISO trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACACA mRNA] CTD PMID:29950559 NCBI chr10:69,511,627...69,773,888
Ensembl chr10:69,511,857...69,773,888 		JBrowse link
G Ache acetylcholinesterase multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ACHE mRNA CTD PMID:36139627 NCBI chr12:25,042,882...25,050,608
Ensembl chr12:25,043,461...25,050,410 		JBrowse link
G Acly ATP citrate lyase multiple interactions ISO trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACLY mRNA] CTD PMID:29950559 NCBI chr10:85,912,402...85,964,605
Ensembl chr10:85,912,402...85,963,631 		JBrowse link
G Acp7 acid phosphatase 7, tartrate resistant multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ACP7 mRNA CTD PMID:36139627 NCBI chr 1:93,022,801...93,048,484
Ensembl chr 1:93,024,991...93,048,873 		JBrowse link
G Acsl5 acyl-CoA synthetase long-chain family member 5 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ACSL5 mRNA CTD PMID:36139627 NCBI chr 1:264,294,851...264,341,943
Ensembl chr 1:264,294,864...264,341,943 		JBrowse link
G Acsm3 acyl-CoA synthetase medium-chain family member 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ACSM3 mRNA CTD PMID:36139627 NCBI chr 1:183,564,652...183,591,328
Ensembl chr 1:183,564,635...183,591,437 		JBrowse link
G Acta2 actin alpha 2, smooth muscle multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ACTA2 mRNA CTD PMID:36139627 NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503 		JBrowse link
G Actbl2 actin, beta-like 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ACTBL2 mRNA CTD PMID:36139627 NCBI chr 2:44,591,391...44,594,138
Ensembl chr 2:44,591,391...44,594,138 		JBrowse link
G Acy3 aminoacylase 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ACY3 mRNA CTD PMID:36139627 NCBI chr 1:210,709,238...210,715,258
Ensembl chr 1:210,709,294...210,715,633 		JBrowse link
G Adamts1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ADAMTS1 mRNA CTD PMID:36139627 NCBI chr11:38,418,565...38,427,384
Ensembl chr11:38,418,101...38,427,390 		JBrowse link
G Adamts16 ADAM metallopeptidase with thrombospondin type 1 motif, 16 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ADAMTS16 mRNA CTD PMID:36139627 NCBI chr 1:34,258,899...34,388,952
Ensembl chr 1:34,258,899...34,388,952 		JBrowse link
G Adamts4 ADAM metallopeptidase with thrombospondin type 1 motif, 4 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ADAMTS4 mRNA CTD PMID:36139627 NCBI chr13:86,203,011...86,212,500
Ensembl chr13:86,202,642...86,212,514 		JBrowse link
G Adamts6 ADAM metallopeptidase with thrombospondin type 1 motif, 6 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ADAMTS6 mRNA CTD PMID:36139627 NCBI chr 2:37,155,260...37,367,077
Ensembl chr 2:37,155,288...37,367,070 		JBrowse link
G Adgrg1 adhesion G protein-coupled receptor G1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ADGRG1 mRNA CTD PMID:36139627 NCBI chr19:10,009,983...10,047,138
Ensembl chr19:10,010,031...10,047,124 		JBrowse link
G Adgrl3 adhesion G protein-coupled receptor L3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ADGRL3 mRNA CTD PMID:36139627 NCBI chr14:26,690,891...27,458,132
Ensembl chr14:26,722,194...27,280,418 		JBrowse link
G Adrb2 adrenoceptor beta 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ADRB2 mRNA CTD PMID:36139627 NCBI chr18:57,912,760...57,914,802
Ensembl chr18:57,911,348...57,914,803 		JBrowse link
G Afap1l1 actin filament associated protein 1-like 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of AFAP1L1 mRNA CTD PMID:36139627 NCBI chr18:57,454,120...57,514,584
Ensembl chr18:57,454,121...57,514,480 		JBrowse link
G Agr2 anterior gradient 2, protein disulphide isomerase family member multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of AGR2 mRNA CTD PMID:36139627 NCBI chr 6:58,435,908...58,456,678
Ensembl chr 6:58,435,908...58,456,677 		JBrowse link
G Akap5 A-kinase anchoring protein 5 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of AKAP5 mRNA CTD PMID:36139627 NCBI chr 6:100,787,169...100,796,712
Ensembl chr 6:100,790,148...100,796,620 		JBrowse link
G Akna AT-hook transcription factor multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of AKNA mRNA CTD PMID:36139627 NCBI chr 5:81,792,928...81,839,936
Ensembl chr 5:81,792,929...81,831,528 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 increases phosphorylation
multiple interactions 		ISO trametinib results in increased phosphorylation of AKT1 protein
[omipalisib co-treated with trametinib] results in decreased phosphorylation of AKT1 protein 		CTD PMID:22733540 NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610 		JBrowse link
G Akt3 AKT serine/threonine kinase 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of AKT3 mRNA CTD PMID:36139627 NCBI chr13:91,475,839...91,758,060
Ensembl chr13:91,475,839...91,748,020 		JBrowse link
G Aldh1a1 aldehyde dehydrogenase 1 family, member A1 multiple interactions ISO [trametinib co-treated with 6-bromoindirubin-3'-oxime] results in increased expression of ALDH1 protein; XAV939 inhibits the reaction [[trametinib co-treated with 6-bromoindirubin-3'-oxime] results in increased expression of ALDH1 protein] CTD PMID:37116855 NCBI chr 1:227,426,939...227,579,497
Ensembl chr 1:227,427,070...227,579,500 		JBrowse link
G Aldh1a2 aldehyde dehydrogenase 1 family, member A2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ALDH1A2 mRNA CTD PMID:36139627 NCBI chr 8:80,758,641...80,837,891
Ensembl chr 8:80,758,142...80,837,883 		JBrowse link
G Aldoc aldolase, fructose-bisphosphate C multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ALDOC mRNA CTD PMID:36139627 NCBI chr10:63,715,544...63,719,133
Ensembl chr10:63,715,489...63,719,133 		JBrowse link
G Aloxe3 arachidonate epidermal lipoxygenase 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ALOXE3 mRNA CTD PMID:36139627 NCBI chr10:54,329,224...54,353,167
Ensembl chr10:54,329,043...54,353,166 		JBrowse link
G Alpg alkaline phosphatase, germ cell multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ALPG mRNA CTD PMID:36139627 NCBI chr 9:95,187,995...95,205,127
Ensembl chr 9:95,198,334...95,205,742 		JBrowse link
G Amn1 antagonist of mitotic exit network 1 homolog multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of AMN1 mRNA CTD PMID:36139627 NCBI chr 4:183,886,469...183,913,411
Ensembl chr 4:183,886,474...183,913,411 		JBrowse link
G Ampd3 adenosine monophosphate deaminase 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of AMPD3 mRNA CTD PMID:36139627 NCBI chr 1:174,319,526...174,364,605
Ensembl chr 1:174,294,867...174,364,608 		JBrowse link
G Ang angiogenin multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ANG mRNA CTD PMID:36139627 NCBI chr15:26,786,233...26,796,883
Ensembl chr15:26,786,065...26,801,106 		JBrowse link
G Angptl4 angiopoietin-like 4 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ANGPTL4 mRNA CTD PMID:36139627 NCBI chr 7:15,252,450...15,259,971
Ensembl chr 7:15,252,473...15,258,681 		JBrowse link
G Ank3 ankyrin 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ANK3 mRNA CTD PMID:36139627 NCBI chr20:18,601,307...19,224,790
Ensembl chr20:18,601,826...19,084,879 		JBrowse link
G Ankef1 ankyrin repeat and EF-hand domain containing 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ANKEF1 mRNA CTD PMID:36139627 NCBI chr 3:144,300,500...144,335,759
Ensembl chr 3:144,300,529...144,335,753 		JBrowse link
G Ankrd2 ankyrin repeat domain 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ANKRD2 mRNA CTD PMID:36139627 NCBI chr 1:250,796,419...250,805,867
Ensembl chr 1:250,796,409...250,805,870 		JBrowse link
G Ankrd24 ankyrin repeat domain 24 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ANKRD24 mRNA CTD PMID:36139627 NCBI chr 7:8,712,720...8,731,910
Ensembl chr 7:8,712,722...8,731,910 		JBrowse link
G Ankrd37 ankyrin repeat domain 37 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ANKRD37 mRNA CTD PMID:36139627 NCBI chr16:53,001,487...53,004,545
Ensembl chr16:52,994,740...53,004,545 		JBrowse link
G Ankrd65 ankyrin repeat domain 65 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ANKRD65 mRNA CTD PMID:36139627 NCBI chr 5:171,680,597...171,682,854
Ensembl chr 5:171,680,597...171,683,431 		JBrowse link
G Ano7 anoctamin 7 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ANO7 mRNA CTD PMID:36139627 NCBI chr 9:101,364,915...101,392,711
Ensembl chr 9:101,364,842...101,394,173 		JBrowse link
G Anpep alanyl aminopeptidase, membrane multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ANPEP mRNA CTD PMID:36139627 NCBI chr 1:143,176,645...143,219,447
Ensembl chr 1:143,176,645...143,195,101 		JBrowse link
G Aoc3 amine oxidase, copper containing 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of AOC3 mRNA CTD PMID:36139627 NCBI chr10:86,773,018...86,780,961 JBrowse link
G Apln apelin multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of APLN mRNA CTD PMID:36139627 NCBI chr  X:132,058,739...132,091,518
Ensembl chr  X:132,081,759...132,091,246 		JBrowse link
G Apobr apolipoprotein B receptor multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of APOBR mRNA CTD PMID:36139627 NCBI chr 1:190,599,595...190,603,782
Ensembl chr 1:190,597,638...190,616,809 		JBrowse link
G Appl1 adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1 multiple interactions ISO trametinib inhibits the reaction [Poly I-C results in increased degradation of APPL1 protein] CTD PMID:25780039 NCBI chr16:2,125,234...2,173,457
Ensembl chr16:2,125,234...2,173,421 		JBrowse link
G Arfgef3 ARFGEF family member 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ARFGEF3 mRNA CTD PMID:36139627 NCBI chr 1:15,058,574...15,223,742
Ensembl chr 1:15,058,579...15,223,742 		JBrowse link
G Arhgap31 Rho GTPase activating protein 31 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ARHGAP31 mRNA CTD PMID:36139627 NCBI chr11:75,544,176...75,657,087
Ensembl chr11:75,544,040...75,661,076 		JBrowse link
G Arhgap8 Rho GTPase activating protein 8 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ARHGAP8 mRNA CTD PMID:36139627 NCBI chr 7:117,723,512...117,782,031
Ensembl chr 7:117,730,578...117,782,030 		JBrowse link
G Armh1 armadillo-like helical domain containing 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ARMH1 mRNA CTD PMID:36139627 NCBI chr 5:135,919,057...135,958,653
Ensembl chr 5:135,919,057...135,958,626 		JBrowse link
G Atg9b autophagy related 9B multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ATG9B mRNA CTD PMID:36139627 NCBI chr 4:11,678,548...11,686,097
Ensembl chr 4:11,678,299...11,686,079 		JBrowse link
G Atp10d ATPase phospholipid transporting 10D (putative) multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ATP10D mRNA CTD PMID:36139627 NCBI chr14:36,265,696...36,366,460
Ensembl chr14:36,265,696...36,366,460 		JBrowse link
G Atp13a3 ATPase 13A3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ATP13A3 mRNA CTD PMID:36139627 NCBI chr11:83,860,725...83,946,899
Ensembl chr11:83,870,218...83,944,662 		JBrowse link
G Atp2a3 ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ATP2A3 mRNA CTD PMID:36139627 NCBI chr10:58,079,710...58,111,279
Ensembl chr10:58,079,852...58,111,278 		JBrowse link
G Atp6v0d2 ATPase H+ transporting V0 subunit D2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ATP6V0D2 mRNA CTD PMID:36139627 NCBI chr 5:38,133,151...38,182,245
Ensembl chr 5:38,133,158...38,182,245 		JBrowse link
G Avil advillin multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of AVIL mRNA CTD PMID:36139627 NCBI chr 7:64,711,294...64,729,436
Ensembl chr 7:64,711,403...64,729,436 		JBrowse link
G Bach2 BTB domain and CNC homolog 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of BACH2 mRNA CTD PMID:36139627 NCBI chr 5:51,428,802...51,779,030
Ensembl chr 5:51,434,870...51,774,234 		JBrowse link
G Bambi BMP and activin membrane-bound inhibitor multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of BAMBI mRNA CTD PMID:36139627 NCBI chr17:58,816,438...58,821,003
Ensembl chr17:58,816,442...58,821,247 		JBrowse link
G Barx2 BARX homeobox 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of BARX2 mRNA CTD PMID:36139627 NCBI chr 8:38,509,277...38,576,978
Ensembl chr 8:38,509,277...38,576,978 		JBrowse link
G Batf3 basic leucine zipper ATF-like transcription factor 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of BATF3 mRNA CTD PMID:36139627 NCBI chr13:105,220,782...105,232,365
Ensembl chr13:105,220,390...105,232,369 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO [trametinib co-treated with 6-bromoindirubin-3'-oxime] results in decreased expression of BAX protein CTD PMID:37116855 NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429 		JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO [trametinib co-treated with 6-bromoindirubin-3'-oxime] results in increased expression of BCL2 protein CTD PMID:37116855 NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900 		JBrowse link
G Bcl2l11 Bcl2-like 11 multiple interactions
increases expression 		ISO [trametinib co-treated with omipalisib] results in increased expression of BCL2L11 protein
trametinib results in increased expression of BCL2L11 protein 		CTD PMID:22733540 NCBI chr 3:135,820,042...135,857,330
Ensembl chr 3:135,817,562...135,960,695 		JBrowse link
G Bcl2l14 Bcl2-like 14 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of BCL2L14 mRNA CTD PMID:36139627 NCBI chr 4:168,948,919...168,989,450
Ensembl chr 4:168,948,946...168,990,079 		JBrowse link
G Bco2 beta-carotene oxygenase 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of BCO2 mRNA CTD PMID:36139627 NCBI chr 8:59,778,571...59,803,597
Ensembl chr 8:59,778,575...59,799,168 		JBrowse link
G Bex1 brain expressed X-linked 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of BEX2 mRNA CTD PMID:36139627 NCBI chr  X:104,010,639...104,012,143
Ensembl chr  X:104,010,371...104,011,236 		JBrowse link
G Bicdl2 BICD family like cargo adaptor 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of BICDL2 mRNA CTD PMID:36139627 NCBI chr10:13,196,205...13,204,642
Ensembl chr10:13,195,913...13,204,642 		JBrowse link
G Bin2 bridging integrator 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of BIN2 mRNA CTD PMID:36139627 NCBI chr 7:133,620,782...133,647,019
Ensembl chr 7:133,620,140...133,647,218 		JBrowse link
G Blacat1 BLACAT1 overlapping LEMD1 locus multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of BLACAT1 mRNA CTD PMID:36139627 NCBI chr13:46,189,091...46,202,506
Ensembl chr13:46,197,208...46,197,306 		JBrowse link
G Blnk B-cell linker multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of BLNK mRNA CTD PMID:36139627 NCBI chr 1:249,703,064...249,770,533
Ensembl chr 1:249,703,072...249,770,533 		JBrowse link
G Bmp6 bone morphogenetic protein 6 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of BMP6 mRNA CTD PMID:36139627 NCBI chr17:26,523,704...26,785,558
Ensembl chr17:26,523,704...26,675,261 		JBrowse link
G Borcs8 BLOC-1 related complex subunit 8 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of BORCS8 mRNA CTD PMID:36139627 NCBI chr16:19,308,247...19,314,910
Ensembl chr16:19,308,247...19,314,963 		JBrowse link
G Braf B-Raf proto-oncogene, serine/threonine kinase multiple interactions ISO betulin affects the reaction [BRAF protein affects the susceptibility to [dabrafenib co-treated with trametinib]]; BRAF protein affects the reaction [[APS-2-79 results in increased susceptibility to trametinib] which results in increased phosphorylation of MAPK1 protein]; BRAF protein affects the reaction [[APS-2-79 results in increased susceptibility to trametinib] which results in increased phosphorylation of MAPK3 protein]; BRAF protein affects the susceptibility to [dabrafenib co-treated with trametinib]; fatostatin affects the reaction [BRAF protein affects the susceptibility to [dabrafenib co-treated with trametinib]]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the cleavage of SREBF1 protein]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACACA mRNA]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACLY mRNA]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of FASN mRNA]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the phosphorylation of MAPK1 protein]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the phosphorylation of MAPK3 protein] CTD PMID:27556948 PMID:29950559 NCBI chr 4:69,329,772...69,476,931
Ensembl chr 4:69,342,813...69,476,931 		JBrowse link
G Btc betacellulin multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of BTC mRNA CTD PMID:36139627 NCBI chr14:16,992,668...17,031,178
Ensembl chr14:16,992,193...17,033,078 		JBrowse link
G Btg2 BTG anti-proliferation factor 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of BTG2 mRNA CTD PMID:36139627 NCBI chr13:48,083,931...48,087,690
Ensembl chr13:48,083,931...48,087,690 		JBrowse link
G C13h1orf116 similar to human chromosome 1 open reading frame 116 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of C1ORF116 mRNA CTD PMID:36139627 NCBI chr13:44,739,716...44,753,695
Ensembl chr13:44,727,092...44,754,009 		JBrowse link
G C14h7orf57 similar to human chromosome 7 open reading frame 57 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of C7ORF57 mRNA CTD PMID:36139627 NCBI chr14:87,962,231...87,982,043
Ensembl chr14:87,959,540...87,982,040 		JBrowse link
G C1h6orf118 similar to human chromosome 6 open reading frame 118 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of C6ORF118 mRNA CTD PMID:36139627 NCBI chr 1:54,287,934...54,311,640
Ensembl chr 1:54,287,936...54,311,847 		JBrowse link
G C1r complement C1r multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of C1R mRNA CTD PMID:36139627 NCBI chr 4:159,099,013...159,109,770
Ensembl chr 4:159,098,918...159,109,714 		JBrowse link
G C1s complement C1s multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of C1S mRNA CTD PMID:36139627 NCBI chr 4:159,116,549...159,128,736
Ensembl chr 4:159,116,549...159,128,736 		JBrowse link
G C3h15orf48 similar to human chromosome 15 open reading frame 48 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of COXFA4L3 mRNA CTD PMID:36139627 NCBI chr 3:130,173,535...130,177,088
Ensembl chr 3:130,173,416...130,177,089 		JBrowse link
G C7 complement C7 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of C7 mRNA CTD PMID:36139627 NCBI chr 2:55,815,687...55,892,605
Ensembl chr 2:55,816,807...55,892,672 		JBrowse link
G Ca9 carbonic anhydrase 9 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CA9 mRNA CTD PMID:36139627 NCBI chr 5:62,559,024...62,565,626
Ensembl chr 5:62,558,823...62,565,626 		JBrowse link
G Cacna1d calcium voltage-gated channel subunit alpha1 D multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CACNA1D mRNA CTD PMID:36139627 NCBI chr16:5,233,682...5,527,549
Ensembl chr16:5,233,690...5,674,692 		JBrowse link
G Cacna1f calcium voltage-gated channel subunit alpha1 F multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CACNA1F mRNA CTD PMID:36139627 NCBI chr  X:17,539,992...17,568,308
Ensembl chr  X:17,539,920...17,568,308 		JBrowse link
G Cacnb4 calcium voltage-gated channel auxiliary subunit beta 4 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CACNB4 mRNA CTD PMID:36139627 NCBI chr 3:57,315,900...57,578,271
Ensembl chr 3:57,315,900...57,578,220 		JBrowse link
G Calb2 calbindin 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CALB2 mRNA CTD PMID:36139627 NCBI chr19:55,023,849...55,050,858
Ensembl chr19:55,023,838...55,057,952 		JBrowse link
G Capn12 calpain 12 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CAPN12 mRNA CTD PMID:36139627 NCBI chr 1:93,298,571...93,311,220
Ensembl chr 1:93,298,571...93,310,630 		JBrowse link
G Capn8 calpain 8 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CAPN8 mRNA CTD PMID:36139627 NCBI chr13:96,783,640...96,847,825
Ensembl chr13:96,783,667...96,847,820 		JBrowse link
G Casp1 caspase 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CASP1 mRNA CTD PMID:36139627 NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:10,746,333...10,882,275 		JBrowse link
G Casp3 caspase 3 multiple interactions ISO [GNAQ gene mutant form results in increased susceptibility to [trametinib co-treated with omipalisib]] which results in increased cleavage of CASP3 protein; trametinib promotes the reaction [physapubescin B results in increased expression of CASP3 protein modified form]
[trametinib co-treated with 6-bromoindirubin-3'-oxime] results in decreased cleavage of CASP3 protein 		CTD PMID:22733540 PMID:33035574 PMID:37116855 NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732 		JBrowse link
G Casp7 caspase 7 multiple interactions ISO [GNAQ gene mutant form results in increased susceptibility to [trametinib co-treated with omipalisib]] which results in increased cleavage of CASP7 protein CTD PMID:22733540 NCBI chr 1:265,442,647...265,481,938
Ensembl chr 1:265,442,676...265,482,512 		JBrowse link
G Casp9 caspase 9 multiple interactions ISO trametinib promotes the reaction [physapubescin B results in increased expression of CASP9 protein modified form] CTD PMID:33035574 Ensembl chr 5:159,391,188...159,409,648 JBrowse link
G Catspere catsper channel auxiliary subunit epsilon multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CATSPERE mRNA CTD PMID:36139627 NCBI chr13:92,331,826...92,487,215
Ensembl chr13:92,351,281...92,483,149 		JBrowse link
G Ccdc110 coiled-coil domain containing 110 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CCDC110 mRNA CTD PMID:36139627 NCBI chr16:53,048,305...53,069,606
Ensembl chr16:53,047,965...53,069,777 		JBrowse link
G Ccdc87 coiled-coil domain containing 87 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CCDC87 mRNA CTD PMID:36139627 NCBI chr 1:211,564,419...211,567,115
Ensembl chr 1:211,475,789...211,568,008 		JBrowse link
G Ccdc89 coiled-coil domain containing 89 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CCDC89 mRNA CTD PMID:36139627 NCBI chr 1:153,798,786...153,800,048
Ensembl chr 1:153,797,440...153,803,002 		JBrowse link
G Ccl22 C-C motif chemokine ligand 22 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CCL22 mRNA CTD PMID:36139627 NCBI chr19:10,263,589...10,270,359
Ensembl chr19:10,263,589...10,270,359 		JBrowse link
G Ccl5 C-C motif chemokine ligand 5 multiple interactions ISO trametinib promotes the reaction [Lipopolysaccharides results in increased expression of CCL5 mRNA]; trametinib promotes the reaction [Poly I-C results in increased expression of CCL5 mRNA] CTD PMID:25780039 NCBI chr10:68,820,330...68,824,906
Ensembl chr10:68,738,651...68,824,884 		JBrowse link
G Ccm2l CCM2 like scaffold protein multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CCM2L mRNA CTD PMID:36139627 NCBI chr 3:161,993,717...162,009,372
Ensembl chr 3:161,859,312...162,009,371 		JBrowse link
G Ccne2 cyclin E2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CCNE2 mRNA CTD PMID:36139627 NCBI chr 5:29,082,169...29,094,879
Ensembl chr 5:29,082,703...29,094,882 		JBrowse link
G Ccr1 C-C motif chemokine receptor 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CCR1 mRNA CTD PMID:36139627 NCBI chr 8:132,433,711...132,439,266
Ensembl chr 8:132,431,592...132,439,374 		JBrowse link
G Cd22 CD22 molecule multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CD22 mRNA CTD PMID:36139627 NCBI chr 1:95,243,785...95,270,430
Ensembl chr 1:95,244,868...95,259,730 		JBrowse link
G Cd274 CD274 molecule multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CD274 mRNA CTD PMID:36139627 NCBI chr 1:236,526,215...236,549,956
Ensembl chr 1:236,496,463...236,549,951 		JBrowse link
G Cd72 Cd72 molecule multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CD72 mRNA CTD PMID:36139627 NCBI chr 5:62,493,155...62,500,779
Ensembl chr 5:62,493,161...62,500,519 		JBrowse link
G Cd74 CD74 molecule multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CD74 mRNA CTD PMID:36139627 NCBI chr18:56,527,071...56,536,406
Ensembl chr18:56,527,132...56,536,410 		JBrowse link
G Cd82 Cd82 molecule multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CD82 mRNA CTD PMID:36139627 NCBI chr 3:99,842,748...99,887,298
Ensembl chr 3:99,842,757...99,886,744 		JBrowse link
G Cdcp1 CUB domain containing protein 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CDCP1 mRNA CTD PMID:36139627 NCBI chr 8:131,706,140...131,742,799
Ensembl chr 8:131,706,140...131,742,877 		JBrowse link
G Cdh15 cadherin 15 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CDH15 mRNA CTD PMID:36139627 NCBI chr19:67,812,169...67,834,986
Ensembl chr19:67,812,164...67,834,985 		JBrowse link
G Cdh3 cadherin 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CDH3 mRNA CTD PMID:36139627 NCBI chr19:51,303,414...51,353,900
Ensembl chr19:51,300,083...51,354,257 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CDKN1A mRNA CTD PMID:36139627 NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969 		JBrowse link
G Cdkn1c cyclin-dependent kinase inhibitor 1C multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CDKN1C mRNA CTD PMID:36139627 NCBI chr 1:208,084,801...208,087,680
Ensembl chr 1:208,084,787...208,087,498 		JBrowse link
G Cenps centromere protein S multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CENPS mRNA CTD PMID:36139627 NCBI chr 5:164,847,009...164,856,705 JBrowse link
G Cfap184 cilia and flagella associated protein 184 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CFAP184 mRNA CTD PMID:36139627 NCBI chr14:78,501,256...78,503,715
Ensembl chr14:78,486,414...78,507,808 		JBrowse link
G Cfap45 cilia and flagella associated protein 45 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CFAP45 mRNA CTD PMID:36139627 NCBI chr13:87,521,831...87,545,236
Ensembl chr13:87,521,518...87,545,234 		JBrowse link
G Cfap92 cilia and flagella associated protein 92 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CFAP92 mRNA CTD PMID:36139627 NCBI chr 4:121,683,889...121,738,920
Ensembl chr 4:121,683,889...121,737,802 		JBrowse link
G Cfap96 cilia and flagella associated protein 96 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CFAP96 mRNA CTD PMID:36139627 NCBI chr16:53,023,623...53,048,176
Ensembl chr16:53,023,878...53,048,965 		JBrowse link
G Cfh complement factor H multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CFH mRNA CTD PMID:36139627 NCBI chr13:54,063,079...54,164,523
Ensembl chr13:54,062,531...54,164,532 		JBrowse link
G Chd7 chromodomain helicase DNA binding protein 7 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CHD7 mRNA CTD PMID:36139627 NCBI chr 5:26,609,245...26,792,736
Ensembl chr 5:26,609,407...26,792,734 		JBrowse link
G Chd9nb CHD9 neighbor multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CHD9NB mRNA CTD PMID:36139627 NCBI chr19:32,348,739...32,350,224 JBrowse link
G Chgb chromogranin B multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CHGB mRNA CTD PMID:36139627 NCBI chr 3:140,496,712...140,510,057
Ensembl chr 3:140,495,951...140,510,054 		JBrowse link
G Chrm4 cholinergic receptor, muscarinic 4 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CHRM4 mRNA CTD PMID:36139627 NCBI chr 3:98,349,080...98,356,821
Ensembl chr 3:98,348,650...98,358,771 		JBrowse link
G Chrna10 cholinergic receptor nicotinic alpha 10 subunit multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CHRNA10 mRNA CTD PMID:36139627 NCBI chr 1:165,898,932...165,905,348
Ensembl chr 1:165,899,261...165,903,458 		JBrowse link
G Ciart circadian associated repressor of transcription multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CIART mRNA CTD PMID:36139627 NCBI chr 2:186,108,744...186,113,778
Ensembl chr 2:186,108,752...186,112,246 		JBrowse link
G Cimip2a ciliary microtubule inner protein 2A multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CIMIP2A mRNA CTD PMID:36139627 NCBI chr 3:28,429,413...28,437,210
Ensembl chr 3:28,431,410...28,436,125 		JBrowse link
G Cldn9 claudin 9 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CLDN9 mRNA CTD PMID:36139627 NCBI chr10:13,218,728...13,220,159
Ensembl chr10:13,218,729...13,220,178 		JBrowse link
G Cnih2 cornichon family AMPA receptor auxiliary protein 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CNIH2 mRNA CTD PMID:36139627 NCBI chr 1:211,828,791...211,834,474
Ensembl chr 1:211,828,794...211,834,437 		JBrowse link
G Col13a1 collagen type XIII alpha 1 chain multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of COL13A1 mRNA CTD PMID:36139627 NCBI chr20:30,326,744...30,466,800
Ensembl chr20:30,326,744...30,466,800 		JBrowse link
G Col1a2 collagen type I alpha 2 chain multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of COL1A2 mRNA CTD PMID:36139627 NCBI chr 4:33,518,557...33,553,484
Ensembl chr 4:33,518,420...33,553,995 		JBrowse link
G Col5a3 collagen type V alpha 3 chain multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of COL5A3 mRNA CTD PMID:36139627 NCBI chr 8:27,580,768...27,626,002
Ensembl chr 8:27,580,768...27,626,122 		JBrowse link
G Col6a3 collagen type VI alpha 3 chain multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of COL6A3 mRNA CTD PMID:36139627 NCBI chr 9:98,809,171...98,887,060
Ensembl chr 9:98,809,171...98,886,990 		JBrowse link
G Col9a2 collagen type IX alpha 2 chain multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of COL9A2 mRNA CTD PMID:36139627 NCBI chr 5:139,892,798...139,910,131
Ensembl chr 5:139,892,798...139,909,855 		JBrowse link
G Colq collagen like tail subunit of asymmetric acetylcholinesterase multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of COLQ mRNA CTD PMID:36139627 NCBI chr16:6,738,251...6,830,492
Ensembl chr16:6,738,251...6,793,501 		JBrowse link
G Cpe carboxypeptidase E multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CPE mRNA CTD PMID:36139627 NCBI chr16:29,796,707...29,908,647
Ensembl chr16:29,796,689...29,909,524 		JBrowse link
G Cracr2b calcium release activated channel regulator 2B multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CRACR2B mRNA CTD PMID:36139627 NCBI chr 1:205,987,957...205,993,515
Ensembl chr 1:205,990,507...205,993,516 		JBrowse link
G Creb3l1 cAMP responsive element binding protein 3-like 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CREB3L1 mRNA CTD PMID:36139627 NCBI chr 3:98,408,240...98,449,104
Ensembl chr 3:98,408,058...98,449,104 		JBrowse link
G Creb3l3 cAMP responsive element binding protein 3-like 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CREB3L3 mRNA CTD PMID:36139627 NCBI chr 7:9,273,320...9,281,755
Ensembl chr 7:9,273,338...9,281,778 		JBrowse link
G Creg2 cellular repressor of E1A-stimulated genes 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CREG2 mRNA CTD PMID:36139627 NCBI chr 9:49,367,693...49,441,133
Ensembl chr 9:49,399,114...49,440,985 		JBrowse link
G Crybg1 crystallin beta-gamma domain containing 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CRYBG1 mRNA CTD PMID:36139627 NCBI chr20:49,007,673...49,204,040
Ensembl chr20:49,007,929...49,204,047 		JBrowse link
G Crym crystallin, mu multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CRYM mRNA CTD PMID:36139627 NCBI chr 1:183,991,752...184,006,923
Ensembl chr 1:183,991,745...184,006,962 		JBrowse link
G Csad cysteine sulfinic acid decarboxylase multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CSAD mRNA CTD PMID:36139627 NCBI chr 7:135,187,175...135,216,495
Ensembl chr 7:135,187,175...135,215,581 		JBrowse link
G Csf3 colony stimulating factor 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CSF3 mRNA CTD PMID:36139627 NCBI chr10:84,157,485...84,159,860
Ensembl chr10:84,157,211...84,159,860 		JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions ISO [trametinib co-treated with 6-bromoindirubin-3'-oxime] results in decreased expression of CTNNB1 protein CTD PMID:37116855 NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:129,517,545...129,544,662 		JBrowse link
G Ctsc cathepsin C multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CTSC mRNA CTD PMID:36139627 NCBI chr 1:151,440,860...151,472,430
Ensembl chr 1:151,441,032...151,474,082 		JBrowse link
G Ctsl cathepsin L multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CTSL mRNA CTD PMID:36139627 NCBI chr17:770,104...776,266
Ensembl chr17:770,093...777,113 		JBrowse link
G Ctso cathepsin O multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CTSO mRNA CTD PMID:36139627 NCBI chr 2:169,528,468...169,551,975
Ensembl chr 2:169,528,511...169,554,995 		JBrowse link
G Cx3cl1 C-X3-C motif chemokine ligand 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CX3CL1 mRNA CTD PMID:36139627 NCBI chr19:10,233,326...10,244,856
Ensembl chr19:10,233,329...10,242,999 		JBrowse link
G Cxcl10 C-X-C motif chemokine ligand 10 multiple interactions ISO trametinib promotes the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; trametinib promotes the reaction [Poly I-C results in increased expression of CXCL10 mRNA] CTD PMID:25780039 NCBI chr14:15,989,066...15,991,263
Ensembl chr14:15,989,018...15,991,261 		JBrowse link
G Cyp26b1 cytochrome P450, family 26, subfamily b, polypeptide 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CYP26B1 mRNA CTD PMID:36139627 NCBI chr 4:118,599,356...118,616,176
Ensembl chr 4:118,599,356...118,616,176 		JBrowse link
G Ddit4l DNA-damage-inducible transcript 4-like multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DDIT4L mRNA CTD PMID:36139627 NCBI chr 2:228,800,831...228,804,478
Ensembl chr 2:228,801,705...228,806,225 		JBrowse link
G Ddx60 DEXD/H-box helicase 60 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of DDX60 mRNA CTD PMID:36139627 NCBI chr16:33,087,940...33,208,843
Ensembl chr16:33,087,988...33,208,839 		JBrowse link
G Dennd3 DENN domain containing 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DENND3 mRNA CTD PMID:36139627 NCBI chr 7:107,304,860...107,362,573
Ensembl chr 7:107,220,192...107,362,573 		JBrowse link
G Depp1 DEPP autophagy regulator 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DEPP1 mRNA CTD PMID:36139627 NCBI chr 4:151,583,105...151,585,455
Ensembl chr 4:151,581,502...151,586,233 		JBrowse link
G Deptor DEP domain containing MTOR-interacting protein multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DEPTOR mRNA CTD PMID:36139627 NCBI chr 7:88,404,745...88,574,065
Ensembl chr 7:88,404,620...88,574,041 		JBrowse link
G Dhrs2 dehydrogenase/reductase 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of DHRS2 mRNA CTD PMID:36139627 NCBI chr15:32,658,855...32,673,591
Ensembl chr15:32,659,223...32,673,588 		JBrowse link
G Dio2 iodothyronine deiodinase 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of DIO2 mRNA CTD PMID:36139627 NCBI chr 6:115,396,308...115,410,594
Ensembl chr 6:115,396,308...115,410,594 		JBrowse link
G Dkk3 dickkopf WNT signaling pathway inhibitor 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DKK3 mRNA CTD PMID:36139627 NCBI chr 1:175,672,834...175,715,867
Ensembl chr 1:175,672,834...175,715,186 		JBrowse link
G Dlc1 DLC1 Rho GTPase activating protein multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DLC1 mRNA CTD PMID:36139627 NCBI chr16:61,954,177...62,374,819
Ensembl chr16:61,995,001...62,374,819 		JBrowse link
G Dmkn dermokine multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DMKN mRNA CTD PMID:36139627 NCBI chr 1:95,140,737...95,158,676
Ensembl chr 1:95,141,620...95,157,439 		JBrowse link
G Dnaaf8 dynein axonemal assembly factor 8 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of DNAAF8 mRNA CTD PMID:36139627 NCBI chr10:11,107,988...11,121,475
Ensembl chr10:11,107,404...11,121,345 		JBrowse link
G Dnah11 dynein, axonemal, heavy chain 11 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DNAH11 mRNA CTD PMID:36139627 NCBI chr 6:144,982,130...145,298,523
Ensembl chr 6:144,973,797...145,298,692 		JBrowse link
G Doc2b double C2 domain beta multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DOC2B mRNA CTD PMID:36139627 NCBI chr10:61,126,295...61,151,533
Ensembl chr10:61,126,295...61,151,533 		JBrowse link
G Dok3 docking protein 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DOK3 mRNA CTD PMID:36139627 NCBI chr17:9,114,763...9,121,781
Ensembl chr17:9,114,762...9,120,335 		JBrowse link
G Drc3 dynein regulatory complex subunit 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of DRC3 mRNA CTD PMID:36139627 NCBI chr10:45,620,045...45,698,902
Ensembl chr10:45,648,410...45,698,900 		JBrowse link
G Duox1 dual oxidase 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of DUOX1 mRNA CTD PMID:36139627 NCBI chr 3:129,714,125...129,749,186
Ensembl chr 3:129,714,149...129,749,187 		JBrowse link
G Duox2 dual oxidase 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DUOX2 mRNA CTD PMID:36139627 NCBI chr 3:129,680,543...129,698,886
Ensembl chr 3:129,680,546...129,699,203 		JBrowse link
G Duoxa1 dual oxidase maturation factor 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DUOXA1 mRNA CTD PMID:36139627 NCBI chr 3:129,703,416...129,714,110
Ensembl chr 3:129,703,416...129,706,829 		JBrowse link
G Dusp4 dual specificity phosphatase 4 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DUSP4 mRNA CTD PMID:36139627 NCBI chr16:64,079,893...64,101,396
Ensembl chr16:64,079,893...64,093,700 		JBrowse link
G Dusp5 dual specificity phosphatase 5 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DUSP5 mRNA CTD PMID:36139627 NCBI chr 1:262,543,774...262,557,201
Ensembl chr 1:262,543,738...262,562,417 		JBrowse link
G Dusp6 dual specificity phosphatase 6 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DUSP6 mRNA CTD PMID:36139627 NCBI chr 7:35,979,502...35,983,834
Ensembl chr 7:35,977,921...35,983,833 		JBrowse link
G E2f2 E2F transcription factor 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of E2F2 mRNA CTD PMID:36139627 NCBI chr 5:153,682,789...153,706,087
Ensembl chr 5:153,682,789...153,706,087 		JBrowse link
G E2f7 E2F transcription factor 7 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of E2F7 mRNA CTD PMID:36139627 NCBI chr 7:48,036,881...48,079,055
Ensembl chr 7:48,037,749...48,079,055 		JBrowse link
G Efemp2 EGF containing fibulin extracellular matrix protein 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of EFEMP2 mRNA CTD PMID:36139627 NCBI chr 1:212,211,057...212,218,739
Ensembl chr 1:212,210,972...212,218,739 		JBrowse link
G Efna3 ephrin A3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of EFNA3 mRNA CTD PMID:36139627 NCBI chr 2:177,026,928...177,035,838
Ensembl chr 2:177,026,933...177,044,843 		JBrowse link
G Egf epidermal growth factor multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of EGF mRNA CTD PMID:36139627 NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:220,893,660...220,976,297 		JBrowse link
G Eif4e3 eukaryotic translation initiation factor 4E family member 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of EIF4E3 mRNA CTD PMID:36139627 NCBI chr 4:133,709,802...133,858,398
Ensembl chr 4:133,625,768...133,885,647 		JBrowse link
G Elf5 E74 like ETS transcription factor 5 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ELF5 mRNA CTD PMID:36139627 NCBI chr 3:110,264,460...110,291,926
Ensembl chr 3:110,252,797...110,291,926 		JBrowse link
G Elmod1 ELMO domain containing 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ELMOD1 mRNA CTD PMID:36139627 NCBI chr 8:63,194,539...63,251,526
Ensembl chr 8:63,137,295...63,251,322 		JBrowse link
G Eno2 enolase 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ENO2 mRNA CTD PMID:36139627 NCBI chr 4:159,258,371...159,267,220
Ensembl chr 4:159,258,371...159,267,220 		JBrowse link
G Eno4 enolase 4 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ENO4 mRNA CTD PMID:36139627 NCBI chr 1:268,073,318...268,113,494
Ensembl chr 1:268,082,522...268,106,300 		JBrowse link
G Enpp1 ectonucleotide pyrophosphatase/phosphodiesterase 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ENPP1 mRNA CTD PMID:36139627 NCBI chr 1:22,518,051...22,583,044
Ensembl chr 1:22,518,069...22,583,044 		JBrowse link
G Entpd2 ectonucleoside triphosphate diphosphohydrolase 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ENTPD2 mRNA CTD PMID:36139627 NCBI chr 3:28,611,722...28,617,237
Ensembl chr 3:28,611,772...28,618,184 		JBrowse link
G Epas1 endothelial PAS domain protein 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of EPAS1 mRNA CTD PMID:36139627 NCBI chr 6:13,543,252...13,626,147
Ensembl chr 6:13,544,389...13,624,729 		JBrowse link
G Epha3 Eph receptor A3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of EPHA3 mRNA CTD PMID:36139627 NCBI chr11:14,585,041...14,920,721
Ensembl chr11:14,586,727...14,920,425 		JBrowse link
G Epha8 Eph receptor A8 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of EPHA8 mRNA CTD PMID:36139627 NCBI chr 5:154,449,566...154,476,966
Ensembl chr 5:154,449,566...154,476,966 		JBrowse link
G Eppk1 epiplakin 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of EPPK1 mRNA CTD PMID:36139627 NCBI chr 7:109,697,607...109,718,468
Ensembl chr 7:109,697,607...109,718,468 		JBrowse link
G Erap1 endoplasmic reticulum aminopeptidase 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ERAP1 mRNA CTD PMID:36139627 NCBI chr 2:5,666,337...5,705,256
Ensembl chr 2:5,666,436...5,740,056 		JBrowse link
G Erfl ETS repressor factor like multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ERFL mRNA CTD PMID:36139627 NCBI chr 1:89,649,244...89,654,379
Ensembl chr 1:89,649,303...89,665,872 		JBrowse link
G Ero1a endoplasmic reticulum oxidoreductase 1 alpha multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ERO1A mRNA CTD PMID:36139627 NCBI chr15:20,974,771...21,010,170
Ensembl chr15:20,972,679...21,018,039 		JBrowse link
G Esrp1 epithelial splicing regulatory protein 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ESRP1 mRNA CTD PMID:36139627 NCBI chr 5:29,224,831...29,279,381
Ensembl chr 5:29,225,360...29,279,278 		JBrowse link
G Etv2 ETS variant transcription factor 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ETV2 mRNA CTD PMID:36139627 NCBI chr 1:95,017,980...95,021,582
Ensembl chr 1:95,017,687...95,021,457 		JBrowse link
G Etv4 ETS variant transcription factor 4 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ETV4 mRNA CTD PMID:36139627 NCBI chr10:87,206,977...87,222,202
Ensembl chr10:87,206,977...87,222,318 		JBrowse link
G Evi2a ecotropic viral integration site 2A multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of EVI2A mRNA CTD PMID:36139627 NCBI chr10:64,983,727...64,987,627
Ensembl chr10:64,983,705...64,999,516 		JBrowse link
G Exoc3l1 exocyst complex component 3-like 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of EXOC3L1 mRNA CTD PMID:36139627 NCBI chr19:50,076,761...50,084,278
Ensembl chr19:50,076,266...50,082,422 		JBrowse link
G Exoc3l4 exocyst complex component 3-like 4 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of EXOC3L4 mRNA CTD PMID:36139627 NCBI chr 6:136,273,857...136,287,877
Ensembl chr 6:136,273,854...136,287,881 		JBrowse link
G Exph5 exophilin 5 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of EXPH5 mRNA CTD PMID:36139627 NCBI chr 8:62,595,116...62,671,575
Ensembl chr 8:62,595,116...62,671,575 		JBrowse link
G F2rl1 F2R like trypsin receptor 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of F2RL1 mRNA CTD PMID:36139627 NCBI chr 2:28,507,003...28,519,954
Ensembl chr 2:28,507,003...28,519,954 		JBrowse link
G Fam107b family with sequence similarity 107, member B multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of FAM107B mRNA CTD PMID:36139627 NCBI chr17:79,387,795...79,594,165
Ensembl chr17:79,387,795...79,594,288 		JBrowse link
G Fam186b family with sequence similarity 186, member B multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of FAM186B mRNA CTD PMID:36139627 NCBI chr 7:132,287,686...132,303,188
Ensembl chr 7:132,287,692...132,303,123 		JBrowse link
G Fam241a family with sequence similarity 241 member A multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of FAM241A mRNA CTD PMID:36139627 NCBI chr 2:219,019,025...219,049,648
Ensembl chr 2:219,018,241...219,049,770 		JBrowse link
G Fasn fatty acid synthase multiple interactions ISO trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of FASN mRNA] CTD PMID:29950559 NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,570,413...106,588,583 		JBrowse link
G Fat2 FAT atypical cadherin 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of FAT2 mRNA CTD PMID:36139627 NCBI chr10:39,864,765...39,957,027
Ensembl chr10:39,864,766...39,956,902 		JBrowse link
G Fbxo36 F-box protein 36 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of FBXO36 mRNA CTD PMID:36139627 NCBI chr 9:93,490,618...93,555,298
Ensembl chr 9:93,489,865...93,555,305 		JBrowse link
G Fdxr ferredoxin reductase multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of FDXR mRNA CTD PMID:36139627 NCBI chr10:101,006,845...101,015,582
Ensembl chr10:101,006,849...101,015,542 		JBrowse link
G Fgf19 fibroblast growth factor 19 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of FGF19 mRNA CTD PMID:36139627 NCBI chr 1:209,485,813...209,490,267
Ensembl chr 1:209,485,813...209,490,267 		JBrowse link
G Fhip1a FHF complex subunit HOOK interacting protein 1A multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of FHIP1A mRNA CTD PMID:36139627 NCBI chr 2:173,319,252...173,489,514
Ensembl chr 2:173,319,257...173,453,902 		JBrowse link
G Flacc1 flagellum associated containing coiled-coil domains 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of FLACC1 mRNA CTD PMID:36139627 NCBI chr 9:67,809,731...67,837,793
Ensembl chr 9:67,809,739...67,837,793 		JBrowse link
G Flnc filamin C multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of FLNC mRNA CTD PMID:36139627 NCBI chr 4:58,999,445...59,027,240
Ensembl chr 4:58,999,547...59,027,240 		JBrowse link
G Fmn1 formin 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of FMN1 mRNA CTD PMID:36139627 NCBI chr 3:120,555,445...120,939,978
Ensembl chr 3:120,555,431...120,933,124 		JBrowse link
G Fndc11 fibronectin type III domain containing 11 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of FNDC11 mRNA CTD PMID:36139627 NCBI chr 3:188,708,045...188,710,670
Ensembl chr 3:188,707,334...188,714,164 		JBrowse link
G Foxd4 forkhead box D4 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of FOXD4 mRNA CTD PMID:36139627 NCBI chr 1:231,983,872...231,985,565 JBrowse link
G Foxq1 forkhead box Q1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of FOXQ1 mRNA CTD PMID:36139627 NCBI chr17:33,121,454...33,124,087
Ensembl chr17:33,121,545...33,123,720 		JBrowse link
G Frmd4b FERM domain containing 4B multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of FRMD4B mRNA CTD PMID:36139627 NCBI chr 4:131,452,361...131,778,734
Ensembl chr 4:131,452,365...131,640,287 		JBrowse link
G Fscn1 fascin actin-bundling protein 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of FSCN1 mRNA CTD PMID:36139627 NCBI chr12:16,710,601...16,723,734
Ensembl chr12:16,710,601...16,723,734 		JBrowse link
G Fut11 fucosyltransferase 11 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of POFUT4 mRNA CTD PMID:36139627 NCBI chr15:3,648,022...3,651,582
Ensembl chr15:3,643,009...3,651,610 		JBrowse link
G Fyb2 FYN binding protein 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of FYB2 mRNA CTD PMID:36139627 NCBI chr 5:124,906,005...125,029,867
Ensembl chr 5:124,905,982...125,029,865 		JBrowse link
G Gab2 GRB2-associated binding protein 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GAB2 mRNA CTD PMID:36139627 NCBI chr 1:160,841,066...161,036,940
Ensembl chr 1:160,841,066...161,036,940 		JBrowse link
G Gad1 glutamate decarboxylase 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GAD1 mRNA CTD PMID:36139627 NCBI chr 3:75,777,260...75,818,099
Ensembl chr 3:75,777,534...75,818,759 		JBrowse link
G Gal3st1 galactose-3-O-sulfotransferase 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GAL3ST1 mRNA CTD PMID:36139627 NCBI chr14:83,094,265...83,109,992
Ensembl chr14:83,094,385...83,109,978 		JBrowse link
G Galnt7 polypeptide N-acetylgalactosaminyltransferase 7 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of GALNT7 mRNA CTD PMID:36139627 NCBI chr16:37,589,368...37,713,911
Ensembl chr16:37,589,425...37,713,909 		JBrowse link
G Gas6 growth arrest specific 6 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of GAS6 mRNA CTD PMID:36139627 NCBI chr16:82,747,676...82,778,090
Ensembl chr16:82,747,345...82,778,088 		JBrowse link
G Gask1b golgi associated kinase 1B multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GASK1B mRNA CTD PMID:36139627 NCBI chr 2:167,345,738...167,410,606
Ensembl chr 2:167,345,809...167,410,603 		JBrowse link
G Gbp2 guanylate binding protein 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GBP2 mRNA CTD PMID:36139627 NCBI chr 2:234,005,727...234,021,812
Ensembl chr 2:234,008,590...234,021,810 		JBrowse link
G Gckr glucokinase regulator multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GCKR mRNA CTD PMID:36139627 NCBI chr 6:30,765,071...30,795,627
Ensembl chr 6:30,765,075...30,795,627 		JBrowse link
G Gcnt3 glucosaminyl (N-acetyl) transferase 3, mucin type multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GCNT3 mRNA CTD PMID:36139627 NCBI chr 8:79,570,081...79,577,389
Ensembl chr 8:79,566,753...79,581,595 		JBrowse link
G Gdap1 ganglioside-induced differentiation-associated-protein 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of GDAP1 mRNA CTD PMID:36139627 NCBI chr 5:6,715,935...6,735,013
Ensembl chr 5:6,715,935...6,735,313 		JBrowse link
G Ghr growth hormone receptor multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of GHR mRNA CTD PMID:36139627 NCBI chr 2:54,269,066...54,532,595
Ensembl chr 2:54,270,206...54,532,331 		JBrowse link
G Gipc3 GIPC PDZ domain containing family, member 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GIPC3 mRNA CTD PMID:36139627 NCBI chr 7:9,026,905...9,034,005
Ensembl chr 7:9,026,905...9,034,795 		JBrowse link
G Gipr gastric inhibitory polypeptide receptor multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GIPR mRNA CTD PMID:36139627 NCBI chr 1:87,932,316...87,956,084
Ensembl chr 1:87,932,623...87,942,492 		JBrowse link
G Gjb3 gap junction protein, beta 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GJB3 mRNA CTD PMID:36139627 NCBI chr 5:144,933,692...144,939,435
Ensembl chr 5:144,933,696...144,940,280 		JBrowse link
G Gjb4 gap junction protein, beta 4 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GJB4 mRNA CTD PMID:36139627 NCBI chr 5:144,948,231...144,964,014
Ensembl chr 5:144,951,184...144,964,097 		JBrowse link
G Gldc glycine decarboxylase multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GLDC mRNA CTD PMID:36139627 NCBI chr 1:237,296,753...237,375,620
Ensembl chr 1:237,296,753...237,375,604 		JBrowse link
G Glul glutamate-ammonia ligase multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GLUL mRNA CTD PMID:36139627 NCBI chr13:68,519,500...68,585,554
Ensembl chr13:68,576,067...68,585,520 		JBrowse link
G Gna11 G protein subunit alpha 11 increases response to substance ISO GNA11 protein mutant form results in increased susceptibility to trametinib CTD PMID:22733540 NCBI chr 7:8,814,285...8,828,628
Ensembl chr 7:8,814,327...8,830,558 		JBrowse link
G Gnaq G protein subunit alpha q multiple interactions
increases response to substance 		ISO [GNAQ gene mutant form results in increased susceptibility to [trametinib co-treated with omipalisib]] which results in increased cleavage of CASP3 protein; [GNAQ gene mutant form results in increased susceptibility to [trametinib co-treated with omipalisib]] which results in increased cleavage of CASP7 protein; GNAQ gene mutant form results in increased susceptibility to [trametinib co-treated with omipalisib]
GNAQ protein mutant form results in increased susceptibility to trametinib 		CTD PMID:22733540 NCBI chr 1:222,852,453...223,098,754
Ensembl chr 1:222,852,097...223,126,742 		JBrowse link
G Gpnmb glycoprotein nmb multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GPNMB mRNA CTD PMID:36139627 NCBI chr 4:79,341,128...79,362,366
Ensembl chr 4:79,341,021...79,380,240 		JBrowse link
G Gpr146 G protein-coupled receptor 146 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GPR146 mRNA CTD PMID:36139627 NCBI chr12:20,365,790...20,381,122
Ensembl chr12:20,364,269...20,381,345 		JBrowse link
G Gpr37l1 G protein-coupled receptor 37-like 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of GPR37L1 mRNA CTD PMID:36139627 NCBI chr13:49,150,355...49,157,204
Ensembl chr13:49,150,359...49,157,204 		JBrowse link
G Gpr39 G protein-coupled receptor 39 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of GPR39 mRNA CTD PMID:36139627 NCBI chr13:39,667,908...39,879,944
Ensembl chr13:39,667,909...39,880,902 		JBrowse link
G Gpr87 G protein-coupled receptor 87 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GPR87 mRNA CTD PMID:36139627 NCBI chr 2:145,589,630...145,608,094
Ensembl chr 2:145,589,569...145,604,442 		JBrowse link
G Gramd1b GRAM domain containing 1B multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GRAMD1B mRNA CTD PMID:36139627 NCBI chr 8:49,551,642...49,790,965
Ensembl chr 8:49,556,332...49,791,052 		JBrowse link
G Grb7 growth factor receptor bound protein 7 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GRB7 mRNA CTD PMID:36139627 NCBI chr10:83,936,538...83,949,344
Ensembl chr10:83,939,299...83,949,382 		JBrowse link
G Grin2d glutamate ionotropic receptor NMDA type subunit 2D multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GRIN2D mRNA CTD PMID:36139627 NCBI chr 1:105,443,317...105,483,400
Ensembl chr 1:105,444,813...105,481,236 		JBrowse link
G Gsdmc gasdermin C multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of GSDMC mRNA CTD PMID:36139627 NCBI chr 7:97,482,713...97,509,985
Ensembl chr 7:97,483,257...97,499,587 		JBrowse link
G Gsk3b glycogen synthase kinase 3 beta multiple interactions ISO [trametinib co-treated with 6-bromoindirubin-3'-oxime] affects the phosphorylation of GSK3B protein CTD PMID:37116855 NCBI chr11:76,004,502...76,154,665
Ensembl chr11:76,009,507...76,153,249 		JBrowse link
G Gtf2ird2 GTF2I repeat domain containing 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of GTF2IRD2 mRNA CTD PMID:36139627 NCBI chr12:28,134,199...28,179,089
Ensembl chr12:28,133,792...28,172,876 		JBrowse link
G Guca1b guanylate cyclase activator 1B multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GUCA1B mRNA CTD PMID:36139627 NCBI chr 9:21,097,274...21,105,107
Ensembl chr 9:21,097,274...21,105,107 		JBrowse link
G H1f2 H1.2 linker histone, cluster member multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of H1-2 mRNA CTD PMID:36139627 NCBI chr17:41,818,962...41,820,453
Ensembl chr17:41,779,051...41,822,317 		JBrowse link
G H2ac22 H2A clustered histone 22 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of H2AC11 mRNA CTD PMID:36139627 NCBI chr17:41,812,378...41,812,875
Ensembl chr17:41,797,862...41,812,946 		JBrowse link
G H2ac6 H2A clustered histone 6 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of H2AC6 mRNA CTD PMID:36139627 NCBI chr17:47,403,701...47,404,167 JBrowse link
G Hal histidine ammonia lyase multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of HAL mRNA CTD PMID:36139627 NCBI chr 7:29,894,495...29,924,744
Ensembl chr 7:29,893,855...29,924,744 		JBrowse link
G Hapln2 hyaluronan and proteoglycan link protein 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of HAPLN2 mRNA CTD PMID:36139627 NCBI chr 2:175,786,767...175,794,515
Ensembl chr 2:175,789,009...175,794,438 		JBrowse link
G Has3 hyaluronan synthase 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of HAS3 mRNA CTD PMID:36139627 NCBI chr19:51,668,276...51,691,042 JBrowse link
G Hbegf heparin-binding EGF-like growth factor multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of HBEGF mRNA CTD PMID:36139627 NCBI chr18:28,380,337...28,390,220
Ensembl chr18:28,380,337...28,390,220 		JBrowse link
G Hecw2 HECT, C2 and WW domain containing E3 ubiquitin protein ligase 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of HECW2 mRNA CTD PMID:36139627 NCBI chr 9:62,853,904...63,247,472
Ensembl chr 9:62,859,645...63,074,758 		JBrowse link
G Herc6 HECT and RLD domain containing E3 ubiquitin protein ligase family member 6 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of HERC6 mRNA CTD PMID:36139627 NCBI chr 4:88,854,612...88,897,043
Ensembl chr 4:88,854,640...88,896,993 		JBrowse link
G Hey1 hes-related family bHLH transcription factor with YRPW motif 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of HEY1 mRNA CTD PMID:36139627 NCBI chr 2:95,003,935...95,006,457
Ensembl chr 2:95,002,943...95,007,624 		JBrowse link
G Heyl hes-related family bHLH transcription factor with YRPW motif-like multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of HEYL mRNA CTD PMID:36139627 NCBI chr 5:140,793,271...140,810,262
Ensembl chr 5:140,793,271...140,810,262 		JBrowse link
G Hic1 HIC ZBTB transcriptional repressor 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of HIC1 mRNA CTD PMID:36139627 NCBI chr10:60,512,855...60,517,812
Ensembl chr10:60,500,565...60,523,448 		JBrowse link
G Hilpda hypoxia inducible lipid droplet-associated multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of HILPDA mRNA CTD PMID:36139627 NCBI chr 4:58,836,463...58,839,423
Ensembl chr 4:58,836,463...58,839,423 		JBrowse link
G Hivep2 HIVEP zinc finger 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of HIVEP2 mRNA CTD PMID:36139627 NCBI chr 1:10,176,880...10,376,089
Ensembl chr 1:10,179,402...10,376,089 		JBrowse link
G Hk2 hexokinase 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of HK2 mRNA CTD PMID:36139627 NCBI chr 4:116,792,258...116,841,275
Ensembl chr 4:116,792,258...116,841,275 		JBrowse link
G Hkdc1 hexokinase domain containing 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of HKDC1 mRNA CTD PMID:36139627 NCBI chr20:30,878,037...30,917,044
Ensembl chr20:30,878,319...30,916,704 		JBrowse link
G Hoga1 4-hydroxy-2-oxoglutarate aldolase 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of HOGA1 mRNA CTD PMID:36139627 NCBI chr 1:250,806,430...250,833,544
Ensembl chr 1:250,806,255...250,833,869 		JBrowse link
G Hoxa13 homeo box A13 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of HOXA13 mRNA CTD PMID:36139627 NCBI chr 4:82,689,566...82,691,701
Ensembl chr 4:82,689,566...82,691,701 		JBrowse link
G Hoxb9 homeo box B9 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of HOXB9 mRNA CTD PMID:36139627 NCBI chr10:81,733,857...81,737,363
Ensembl chr10:81,733,658...81,738,872 		JBrowse link
G Hoxc4 homeo box C4 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of HOXC4 mRNA CTD PMID:36139627 NCBI chr 7:136,049,059...136,051,601
Ensembl chr 7:136,049,059...136,051,601 		JBrowse link
G Hpcal4 hippocalcin-like 4 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of HPCAL4 mRNA CTD PMID:36139627 NCBI chr 5:140,739,577...140,751,529
Ensembl chr 5:140,739,635...140,751,530 		JBrowse link
G Hs3st3b1 heparan sulfate-glucosamine 3-sulfotransferase 3B1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of HS3ST3B1 mRNA CTD PMID:36139627 NCBI chr10:49,060,693...49,093,185
Ensembl chr10:49,060,693...49,093,185 		JBrowse link
G Hsd17b14 hydroxysteroid (17-beta) dehydrogenase 14 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of HSD17B14 mRNA CTD PMID:36139627 NCBI chr 1:105,165,695...105,176,045
Ensembl chr 1:105,165,695...105,176,510 		JBrowse link
G Hspa1a heat shock protein family A (Hsp70) member 1A multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of HSPA1A mRNA CTD PMID:36139627 NCBI chr20:3,875,411...3,877,866
Ensembl chr20:3,855,780...3,877,979 		JBrowse link
G Htra1 HtrA serine peptidase 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of HTRA1 mRNA CTD PMID:36139627 NCBI chr 1:194,928,069...194,977,619
Ensembl chr 1:194,927,687...194,977,620 		JBrowse link
G Hunk hormonally upregulated Neu-associated kinase multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of HUNK mRNA CTD PMID:36139627 NCBI chr11:43,127,244...43,244,502
Ensembl chr11:43,127,244...43,244,502 		JBrowse link
G Hyal1 hyaluronidase 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of HYAL1 mRNA CTD PMID:36139627 NCBI chr 8:117,129,311...117,133,162
Ensembl chr 8:117,129,277...117,133,146 		JBrowse link
G Ifi35 interferon-induced protein 35 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of IFI35 mRNA CTD PMID:36139627 NCBI chr10:86,881,270...86,889,523
Ensembl chr10:86,887,122...86,889,750 		JBrowse link
G Ifnb1 interferon beta 1 multiple interactions ISO trametinib promotes the reaction [Lipopolysaccharides results in increased expression of IFNB1 mRNA]; trametinib promotes the reaction [Poly I-C results in increased expression of IFNB1 mRNA] CTD PMID:25780039 NCBI chr 5:108,066,650...108,067,487
Ensembl chr 5:108,066,650...108,067,487 		JBrowse link
G Ifnlr1 interferon, lambda receptor 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of IFNLR1 mRNA CTD PMID:36139627 NCBI chr 5:153,203,597...153,225,911
Ensembl chr 5:153,203,597...153,225,911 		JBrowse link
G Igf2bp3 insulin-like growth factor 2 mRNA binding protein 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of IGF2BP3 mRNA CTD PMID:36139627 NCBI chr 4:79,391,367...79,525,923
Ensembl chr 4:79,393,067...79,525,730 		JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of IGFBP1 mRNA CTD PMID:36139627 NCBI chr14:86,261,277...86,266,344
Ensembl chr14:86,261,277...86,266,344 		JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of IL1B mRNA CTD PMID:36139627 NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601 		JBrowse link
G Il1rapl1 interleukin 1 receptor accessory protein-like 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of IL1RAPL1 mRNA CTD PMID:36139627 NCBI chr  X:55,322,779...56,827,486
Ensembl chr  X:55,328,964...56,826,613 		JBrowse link
G Il6r interleukin 6 receptor multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of IL6R mRNA CTD PMID:36139627 NCBI chr 2:177,582,020...177,646,705
Ensembl chr 2:177,582,164...177,645,221 		JBrowse link
G Inka1 inka box actin regulator 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of INKA1 mRNA CTD PMID:36139627 NCBI chr 8:117,552,875...117,554,565
Ensembl chr 8:117,552,875...117,554,565 		JBrowse link
G Inpp5d inositol polyphosphate-5-phosphatase D multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of INPP5D mRNA CTD PMID:36139627 NCBI chr 9:95,735,533...95,840,584
Ensembl chr 9:95,735,530...95,840,589 		JBrowse link
G Insyn1 inhibitory synaptic factor 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of INSYN1 mRNA CTD PMID:36139627 NCBI chr 8:67,799,989...67,810,685
Ensembl chr 8:67,799,304...67,814,536 		JBrowse link
G Iqank1 IQ motif and ankyrin repeat containing 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of IQANK1 mRNA CTD PMID:36139627 NCBI chr 7:109,605,642...109,639,854
Ensembl chr 7:109,605,703...109,639,853 		JBrowse link
G Iqcn IQ motif containing N multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of IQCN mRNA CTD PMID:36139627 NCBI chr16:18,750,492...18,766,184
Ensembl chr16:18,750,353...18,767,534 		JBrowse link
G Irak2 interleukin-1 receptor-associated kinase 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of IRAK2 mRNA CTD PMID:36139627 NCBI chr 4:148,341,704...148,398,211
Ensembl chr 4:148,341,719...148,398,210 		JBrowse link
G Irf1 interferon regulatory factor 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of IRF1 mRNA CTD PMID:36139627 NCBI chr10:38,417,935...38,424,946
Ensembl chr10:38,417,148...38,424,947 		JBrowse link
G Irf3 interferon regulatory factor 3 multiple interactions ISO trametinib promotes the reaction [Lipopolysaccharides results in increased phosphorylation of IRF3 protein] CTD PMID:25780039 NCBI chr 1:104,616,608...104,621,402
Ensembl chr 1:104,616,469...104,621,401 		JBrowse link
G Ism2 isthmin 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ISM2 mRNA CTD PMID:36139627 NCBI chr 6:112,652,772...112,675,098
Ensembl chr 6:112,657,122...112,675,295 		JBrowse link
G Itga10 integrin subunit alpha 10 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ITGA10 mRNA CTD PMID:36139627 NCBI chr 2:186,871,711...186,891,012
Ensembl chr 2:186,871,711...186,891,012 		JBrowse link
G Itga2 integrin subunit alpha 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ITGA2 mRNA CTD PMID:36139627 NCBI chr 2:48,253,412...48,354,509
Ensembl chr 2:48,253,412...48,354,509 		JBrowse link
G Itga6 integrin subunit alpha 6 multiple interactions ISO [trametinib co-treated with 6-bromoindirubin-3'-oxime] results in increased expression of ITGA6 protein; XAV939 inhibits the reaction [[trametinib co-treated with 6-bromoindirubin-3'-oxime] results in increased expression of ITGA6 protein] CTD PMID:37116855 NCBI chr 3:77,012,168...77,097,076
Ensembl chr 3:77,017,766...77,097,076 		JBrowse link
G Itgax integrin subunit alpha X multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ITGAX mRNA CTD PMID:36139627 NCBI chr 1:192,140,089...192,171,151
Ensembl chr 1:192,149,905...192,171,151 		JBrowse link
G Itgb3 integrin subunit beta 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ITGB3 mRNA CTD PMID:36139627 NCBI chr10:90,009,927...90,067,787
Ensembl chr10:90,009,900...90,067,800 		JBrowse link
G Itgb4 integrin subunit beta 4 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ITGB4 mRNA CTD PMID:36139627 NCBI chr10:101,705,592...101,741,933
Ensembl chr10:101,705,587...101,741,932 		JBrowse link
G Jak3 Janus kinase 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of JAK3 mRNA CTD PMID:36139627 NCBI chr16:18,418,807...18,432,515
Ensembl chr16:18,420,415...18,433,222 		JBrowse link
G Jam2 junctional adhesion molecule 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of JAM2 mRNA CTD PMID:36139627 NCBI chr11:37,316,287...37,366,517
Ensembl chr11:37,317,511...37,367,510 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [omipalisib co-treated with trametinib] results in increased phosphorylation of JUN protein; JUN results in decreased susceptibility to [omipalisib co-treated with trametinib] CTD PMID:22733540 NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285 		JBrowse link
G Kcnj4 potassium inwardly-rectifying channel, subfamily J, member 4 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of KCNJ4 mRNA CTD PMID:36139627 NCBI chr 7:112,927,494...112,954,547
Ensembl chr 7:112,922,532...112,954,826 		JBrowse link
G Kcnk5 potassium two pore domain channel subfamily K member 5 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of KCNK5 mRNA CTD PMID:36139627 NCBI chr15:4,171,625...4,213,896
Ensembl chr15:4,171,610...4,213,897 		JBrowse link
G Kdm7a lysine demethylase 7A multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of KDM7A mRNA CTD PMID:36139627 NCBI chr 4:68,866,263...68,992,979
Ensembl chr 4:68,871,677...68,931,506 		JBrowse link
G Kiaa1755 KIAA1755 ortholog multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of KIAA1755 mRNA CTD PMID:36139627 NCBI chr 3:167,270,476...167,305,337
Ensembl chr 3:167,192,612...167,304,240 		JBrowse link
G Kif17 kinesin family member 17 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of KIF17 mRNA CTD PMID:36139627 NCBI chr 5:155,765,592...155,802,941
Ensembl chr 5:155,765,592...155,803,247 		JBrowse link
G Klf7 KLF transcription factor 7 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of KLF7 mRNA CTD PMID:36139627 NCBI chr 9:72,927,485...73,020,167
Ensembl chr 9:72,933,136...73,020,056 		JBrowse link
G Klhdc7a kelch domain containing 7A multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of KLHDC7A mRNA CTD PMID:36139627 NCBI chr 5:157,501,740...157,507,843
Ensembl chr 5:157,485,191...157,507,954 		JBrowse link
G Klhdc7b kelch domain containing 7B multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of KLHDC7B mRNA CTD PMID:36139627 NCBI chr 7:122,331,708...122,335,364
Ensembl chr 7:122,331,708...122,335,364 		JBrowse link
G Krt15 keratin 15 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of KRT15 mRNA CTD PMID:36139627 NCBI chr10:85,567,197...85,571,014
Ensembl chr10:85,567,202...85,571,142 		JBrowse link
G Krt17 keratin 17 multiple interactions ISO [trametinib co-treated with 6-bromoindirubin-3'-oxime] results in increased expression of KRT17 protein; XAV939 inhibits the reaction [[trametinib co-treated with 6-bromoindirubin-3'-oxime] results in increased expression of KRT17 protein] CTD PMID:37116855 NCBI chr10:85,679,068...85,683,792
Ensembl chr10:85,679,070...85,683,787 		JBrowse link
G Krt7 keratin 7 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of KRT7 mRNA CTD PMID:36139627 NCBI chr 7:134,407,626...134,423,787
Ensembl chr 7:134,407,584...134,423,786 		JBrowse link
G Krt86 keratin 86 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of KRT86 mRNA CTD PMID:36139627 NCBI chr 7:134,470,224...134,476,873
Ensembl chr 7:134,470,224...134,476,873 		JBrowse link
G Lad1 ladinin 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LAD1 mRNA CTD PMID:36139627 NCBI chr13:49,801,347...49,815,709
Ensembl chr13:49,800,472...49,815,709 		JBrowse link
G Lama2 laminin subunit alpha 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LAMA2 mRNA CTD PMID:36139627 NCBI chr 1:19,492,126...20,140,056
Ensembl chr 1:19,244,599...20,140,056 		JBrowse link
G Lama4 laminin subunit alpha 4 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LAMA4 mRNA CTD PMID:36139627 NCBI chr20:43,946,898...44,087,972
Ensembl chr20:43,946,898...44,087,972 		JBrowse link
G Lamc2 laminin subunit gamma 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LAMC2 mRNA CTD PMID:36139627 NCBI chr13:67,835,199...67,894,694
Ensembl chr13:67,835,199...67,895,102 		JBrowse link
G Laptm5 lysosomal protein transmembrane 5 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of LAPTM5 mRNA CTD PMID:36139627 NCBI chr 5:148,371,880...148,393,927
Ensembl chr 5:148,339,435...148,393,927 		JBrowse link
G Lat2 linker for activation of T cells family, member 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of LAT2 mRNA CTD PMID:36139627 NCBI chr12:27,740,647...27,754,760
Ensembl chr12:27,740,654...27,755,843 		JBrowse link
G Lcp1 lymphocyte cytosolic protein 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LCP1 mRNA CTD PMID:36139627 NCBI chr15:56,846,375...56,954,090
Ensembl chr15:56,847,433...56,954,092 		JBrowse link
G Ldlr low density lipoprotein receptor multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LDLR mRNA CTD PMID:36139627 NCBI chr 8:28,546,191...28,569,075
Ensembl chr 8:28,546,146...28,570,675 		JBrowse link
G Ldlrad1 low density lipoprotein receptor class A domain containing 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LDLRAD1 mRNA CTD PMID:36139627 NCBI chr 5:127,212,581...127,229,753
Ensembl chr 5:127,220,764...127,229,725 		JBrowse link
G Ldlrad4 low density lipoprotein receptor class A domain containing 4 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of LDLRAD4 mRNA CTD PMID:36139627 NCBI chr18:63,789,089...64,118,166
Ensembl chr18:63,790,440...64,113,064 		JBrowse link
G Lemd1 LEM domain containing 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LEMD1 mRNA CTD PMID:36139627 NCBI chr13:46,183,860...46,250,105
Ensembl chr13:46,218,085...46,250,562 		JBrowse link
G Lgals9 galectin 9 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LGALS9 mRNA CTD PMID:36139627 NCBI chr10:64,405,044...64,428,249
Ensembl chr10:64,405,044...64,428,070 		JBrowse link
G Lgi3 leucine-rich repeat LGI family, member 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LGI3 mRNA CTD PMID:36139627 NCBI chr15:52,015,317...52,022,445
Ensembl chr15:52,015,230...52,022,443 		JBrowse link
G Lhx1 LIM homeobox 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LHX1 mRNA CTD PMID:36139627 NCBI chr10:69,894,288...69,901,076
Ensembl chr10:69,894,288...69,901,076 		JBrowse link
G Lhx6 LIM homeobox 6 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LHX6 mRNA CTD PMID:36139627 NCBI chr 3:39,829,846...39,853,681
Ensembl chr 3:39,830,990...39,853,559 		JBrowse link
G Lipg lipase G, endothelial type multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LIPG mRNA CTD PMID:36139627 NCBI chr18:70,790,077...70,811,259
Ensembl chr18:70,790,077...70,812,260 		JBrowse link
G Liph lipase H multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LIPH mRNA CTD PMID:36139627 NCBI chr11:92,536,724...92,586,117
Ensembl chr11:92,537,860...92,586,120 		JBrowse link
G Lonrf3 LON peptidase N-terminal domain and ring finger 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LONRF3 mRNA CTD PMID:36139627 NCBI chr  X:120,430,975...120,469,648
Ensembl chr  X:120,430,996...120,464,572 		JBrowse link
G Lox lysyl oxidase multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LOX mRNA CTD PMID:36139627 NCBI chr18:48,162,889...48,175,640
Ensembl chr18:48,165,688...48,239,810 		JBrowse link
G Lratd2 LRAT domain containing 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LRATD2 mRNA CTD PMID:36139627 NCBI chr 7:94,270,753...94,276,445
Ensembl chr 7:94,073,513...94,277,046 		JBrowse link
G Lrrc37a leucine rich repeat containing 37A multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of LRRC37A3 mRNA CTD PMID:36139627 NCBI chr10:88,896,517...88,933,472
Ensembl chr10:88,896,703...88,933,361 		JBrowse link
G Lsr lipolysis stimulated lipoprotein receptor multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of LSR mRNA CTD PMID:36139627 NCBI chr 1:95,313,830...95,329,471
Ensembl chr 1:95,313,033...95,329,354 		JBrowse link
G Ltbp1 latent transforming growth factor beta binding protein 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of LTBP1 mRNA CTD PMID:36139627 NCBI chr 6:25,781,625...26,177,346
Ensembl chr 6:25,781,638...26,454,036 		JBrowse link
G Ltbp2 latent transforming growth factor beta binding protein 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LTBP2 mRNA CTD PMID:36139627 NCBI chr 6:110,161,029...110,261,586
Ensembl chr 6:110,161,029...110,257,298 		JBrowse link
G Lyst lysosomal trafficking regulator multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LYST mRNA CTD PMID:36139627 NCBI chr17:93,225,509...93,427,650
Ensembl chr17:93,225,540...93,427,650 		JBrowse link
G Lzts1 leucine zipper tumor suppressor 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of LZTS1 mRNA CTD PMID:36139627 NCBI chr16:25,309,502...25,364,942
Ensembl chr16:25,309,507...25,364,940 		JBrowse link
G Mad1l1 mitotic arrest deficient 1 like 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MAD1L1 mRNA CTD PMID:36139627 NCBI chr12:19,434,782...19,744,574
Ensembl chr12:19,434,746...19,744,567 		JBrowse link
G Maff MAF bZIP transcription factor F multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MAFF mRNA CTD PMID:36139627 NCBI chr 7:112,792,787...112,804,139
Ensembl chr 7:112,791,416...112,804,147 		JBrowse link
G Map1a microtubule-associated protein 1A multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of MAP1A mRNA CTD PMID:36139627 NCBI chr 3:128,716,907...128,736,638
Ensembl chr 3:128,716,940...128,740,159 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO trametinib affects the expression of and affects the lipidation of MAP1LC3B protein CTD PMID:30339727 NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358
Ensembl chr16:66,574,407...66,584,358 		JBrowse link
G Map2k1 mitogen activated protein kinase kinase 1 decreases response to substance
decreases phosphorylation
multiple interactions 		ISO MAP2K1 protein mutant form results in decreased susceptibility to trametinib
trametinib results in decreased phosphorylation of MAP2K1 protein
[MAP2K1 protein mutant form results in decreased susceptibility to trametinib] inhibits the reaction [trametinib results in decreased phosphorylation of MAPK1 protein]; [MAP2K1 protein mutant form results in decreased susceptibility to trametinib] inhibits the reaction [trametinib results in decreased phosphorylation of MAPK3 protein] 		CTD PMID:29768711 PMID:37116855 NCBI chr 8:73,578,747...73,650,184
Ensembl chr 8:73,578,752...73,650,184 		JBrowse link
G Map4k1 mitogen activated protein kinase kinase kinase kinase 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of MAP4K1 mRNA CTD PMID:36139627 NCBI chr 1:93,398,460...93,419,996
Ensembl chr 1:93,398,454...93,419,993 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
decreases phosphorylation 		ISO [APS-2-79 results in increased susceptibility to trametinib] which results in increased phosphorylation of MAPK1 protein; [MAP2K1 protein mutant form results in decreased susceptibility to trametinib] inhibits the reaction [trametinib results in decreased phosphorylation of MAPK1 protein]; [omipalisib co-treated with trametinib] results in decreased phosphorylation of MAPK1 protein; BRAF protein affects the reaction [[APS-2-79 results in increased susceptibility to trametinib] which results in increased phosphorylation of MAPK1 protein]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the phosphorylation of MAPK1 protein]; trametinib inhibits the reaction [AZD5991 results in increased phosphorylation of MAPK1 protein]; trametinib inhibits the reaction [physapubescin B results in increased phosphorylation of MAPK1 protein]; trametinib inhibits the reaction [tapotoclax results in increased phosphorylation of MAPK1 protein]
trametinib inhibits the reaction [camostat results in increased phosphorylation of MAPK1 protein]; trametinib inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]; trametinib inhibits the reaction [Poly I-C results in increased phosphorylation of MAPK1 protein] 		CTD PMID:22733540 PMID:25104499 PMID:25780039 PMID:27556948 PMID:29768711 More... NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
decreases phosphorylation 		ISO [APS-2-79 results in increased susceptibility to trametinib] which results in increased phosphorylation of MAPK3 protein; [MAP2K1 protein mutant form results in decreased susceptibility to trametinib] inhibits the reaction [trametinib results in decreased phosphorylation of MAPK3 protein]; [omipalisib co-treated with trametinib] results in decreased phosphorylation of MAPK3 protein; BRAF protein affects the reaction [[APS-2-79 results in increased susceptibility to trametinib] which results in increased phosphorylation of MAPK3 protein]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the phosphorylation of MAPK3 protein]; trametinib inhibits the reaction [AZD5991 results in increased phosphorylation of MAPK3 protein]; trametinib inhibits the reaction [physapubescin B results in increased phosphorylation of MAPK3 protein]; trametinib inhibits the reaction [tapotoclax results in increased phosphorylation of MAPK3 protein]
trametinib inhibits the reaction [camostat results in increased phosphorylation of MAPK3 protein]; trametinib inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]; trametinib inhibits the reaction [Poly I-C results in increased phosphorylation of MAPK3 protein] 		CTD PMID:22733540 PMID:25104499 PMID:25780039 PMID:27556948 PMID:29768711 More... NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411 		JBrowse link
G Marchf4 membrane associated ring-CH-type finger 4 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MARCHF4 mRNA CTD PMID:36139627 NCBI chr 9:81,527,703...81,647,448
Ensembl chr 9:81,527,703...81,647,448 		JBrowse link
G Mast4 microtubule associated serine/threonine kinase family member 4 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MAST4 mRNA CTD PMID:36139627 NCBI chr 2:35,627,190...36,219,090
Ensembl chr 2:35,627,190...36,218,832 		JBrowse link
G Matn2 matrilin 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of MATN2 mRNA CTD PMID:36139627 NCBI chr 7:67,380,140...67,529,767
Ensembl chr 7:67,380,168...67,530,153 		JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member multiple interactions ISO trametinib inhibits the reaction [AZD5991 results in increased phosphorylation of MCL1 protein]; trametinib inhibits the reaction [tapotoclax results in increased phosphorylation of MCL1 protein] CTD PMID:36346691 NCBI chr 2:185,884,840...185,912,532
Ensembl chr 2:185,908,168...185,938,782 		JBrowse link
G Mctp1 multiple C2 and transmembrane domain containing 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MCTP1 mRNA CTD PMID:36139627 NCBI chr 2:7,798,968...8,493,596
Ensembl chr 2:7,803,382...8,493,596 		JBrowse link
G Mdga1 MAM domain containing glycosylphosphatidylinositol anchor 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of MDGA1 mRNA CTD PMID:36139627 NCBI chr20:7,901,856...7,965,834
Ensembl chr20:7,901,856...7,965,834 		JBrowse link
G Meis1 Meis homeobox 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of MEIS1 mRNA CTD PMID:36139627 NCBI chr14:97,356,949...97,499,646
Ensembl chr14:97,322,748...97,495,083 		JBrowse link
G Mest mesoderm specific transcript multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of MEST mRNA CTD PMID:36139627 NCBI chr 4:60,321,814...60,332,288
Ensembl chr 4:60,316,102...60,333,509 		JBrowse link
G Mid1 midline 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MID1 mRNA CTD PMID:36139627 NCBI chr  X:27,678,248...28,053,049
Ensembl chr  X:27,681,867...27,906,105 		JBrowse link
G Milr1 mast cell immunoglobulin-like receptor 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MILR1 mRNA CTD PMID:36139627 NCBI chr10:92,184,002...92,205,001
Ensembl chr10:92,187,479...92,205,003 		JBrowse link
G Mki67 marker of proliferation Ki-67 multiple interactions ISO [trametinib co-treated with 6-bromoindirubin-3'-oxime] results in increased expression of MKI67 protein CTD PMID:37116855 NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:199,926,150...199,952,593 		JBrowse link
G Mlph melanophilin multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MLPH mRNA CTD PMID:36139627 NCBI chr 9:98,955,036...98,990,566
Ensembl chr 9:98,955,141...98,990,556 		JBrowse link
G Mmp1 matrix metallopeptidase 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MMP1 mRNA CTD PMID:36139627 NCBI chr 8:12,943,453...12,963,966
Ensembl chr 8:12,943,453...12,963,964 		JBrowse link
G Mmp12 matrix metallopeptidase 12 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MMP12 mRNA CTD PMID:36139627 NCBI chr 8:12,866,652...12,876,554
Ensembl chr 8:12,866,641...12,884,478 		JBrowse link
G Mmp13 matrix metallopeptidase 13 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MMP13 mRNA CTD PMID:36139627 NCBI chr 8:12,782,829...12,793,108
Ensembl chr 8:12,782,813...12,793,105 		JBrowse link
G Mmp14 matrix metallopeptidase 14 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MMP14 mRNA CTD PMID:36139627 NCBI chr15:31,857,824...31,867,049
Ensembl chr15:31,857,546...31,869,893 		JBrowse link
G Mmp19 matrix metallopeptidase 19 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of MMP19 mRNA CTD PMID:36139627 NCBI chr 7:1,805,732...1,814,054
Ensembl chr 7:1,805,860...1,814,863 		JBrowse link
G Mmp3 matrix metallopeptidase 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MMP3 mRNA CTD PMID:36139627 NCBI chr 8:12,925,267...12,938,828
Ensembl chr 8:12,925,280...12,938,826 		JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MMP9 mRNA CTD PMID:36139627 NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442 		JBrowse link
G Morn3 MORN repeat containing 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MORN3 mRNA CTD PMID:36139627 NCBI chr12:39,166,463...39,190,737
Ensembl chr12:39,168,112...39,189,367 		JBrowse link
G Mpzl2 myelin protein zero-like 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of MPZL2 mRNA CTD PMID:36139627 NCBI chr 8:54,244,920...54,256,064
Ensembl chr 8:54,243,556...54,256,074 		JBrowse link
G Mrap2 melanocortin 2 receptor accessory protein 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of MRAP2 mRNA CTD PMID:36139627 NCBI chr 8:96,968,239...97,024,581
Ensembl chr 8:96,988,079...97,024,579 		JBrowse link
G Muc3a mucin 3A, cell surface associated multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MUC3A mRNA CTD PMID:36139627 NCBI chr12:25,082,728...25,091,494
Ensembl chr12:25,082,837...25,097,265 		JBrowse link
G Muc5b mucin 5B, oligomeric mucus/gel-forming multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MUC5B mRNA CTD PMID:36139627 NCBI chr 1:206,346,400...206,378,367
Ensembl chr 1:206,346,400...206,378,367 		JBrowse link
G Mybph myosin binding protein H multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MYBPH mRNA CTD PMID:36139627 NCBI chr13:48,205,162...48,212,928
Ensembl chr13:48,205,269...48,212,928 		JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor decreases expression ISO trametinib results in decreased expression of MYC protein CTD PMID:22733540 NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028 		JBrowse link
G Myh15 myosin, heavy chain 15 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MYH15 mRNA CTD PMID:36139627 NCBI chr11:65,084,666...65,226,010
Ensembl chr11:65,084,467...65,245,716 		JBrowse link
G Myo10 myosin X multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MYO10 mRNA CTD PMID:36139627 NCBI chr 2:77,831,532...78,036,137
Ensembl chr 2:77,831,532...78,036,137 		JBrowse link
G Myo15a myosin XVA multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MYO15A mRNA CTD PMID:36139627 NCBI chr10:45,776,907...45,835,473
Ensembl chr10:45,776,907...45,835,473 		JBrowse link
G Myo15b myosin XVB multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MYO15B mRNA CTD PMID:36139627 NCBI chr10:101,587,672...101,625,092
Ensembl chr10:101,587,672...101,625,092 		JBrowse link
G Myo5c myosin VC multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of MYO5C mRNA CTD PMID:36139627 NCBI chr 8:84,870,031...84,946,996
Ensembl chr 8:84,870,043...84,946,996 		JBrowse link
G Myo7b myosin VIIb multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MYO7B mRNA CTD PMID:36139627 NCBI chr18:23,862,533...23,944,081
Ensembl chr18:23,862,533...23,944,049 		JBrowse link
G N4bp3 Nedd4 binding protein 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of N4BP3 mRNA CTD PMID:36139627 NCBI chr10:36,400,053...36,407,609
Ensembl chr10:36,400,057...36,407,637 		JBrowse link
G Nanog Nanog homeobox multiple interactions ISO [trametinib co-treated with 6-bromoindirubin-3'-oxime] results in increased expression of NANOG protein; XAV939 inhibits the reaction [[trametinib co-treated with 6-bromoindirubin-3'-oxime] results in increased expression of NANOG protein] CTD PMID:37116855 NCBI chr 4:157,615,687...157,623,061
Ensembl chr 4:157,615,687...157,623,061 		JBrowse link
G Nav3 neuron navigator 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NAV3 mRNA CTD PMID:36139627 NCBI chr 7:46,938,577...47,726,839
Ensembl chr 7:46,940,670...47,504,893 		JBrowse link
G Ndrg1 N-myc downstream regulated 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NDRG1 mRNA CTD PMID:36139627 NCBI chr 7:100,573,526...100,614,902
Ensembl chr 7:100,573,523...100,614,913 		JBrowse link
G Ndrg4 NDRG family member 4 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NDRG4 mRNA CTD PMID:36139627 NCBI chr19:9,357,470...9,393,465
Ensembl chr19:9,357,470...9,392,972 		JBrowse link
G Ndufv2 NADH:ubiquinone oxidoreductase core subunit V2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NDUFV2 mRNA CTD PMID:36139627 NCBI chr 9:113,137,305...113,157,571
Ensembl chr 9:113,137,306...113,157,520 		JBrowse link
G Nedd9 neural precursor cell expressed, developmentally down-regulated 9 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of NEDD9 mRNA CTD PMID:36139627 NCBI chr17:23,495,531...23,673,780
Ensembl chr17:23,495,492...23,675,668 		JBrowse link
G Nes nestin multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NES mRNA CTD PMID:36139627 NCBI chr 2:175,735,715...175,745,631
Ensembl chr 2:175,736,551...175,746,228 		JBrowse link
G Neurl3 neuralized E3 ubiquitin protein ligase 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NEURL3 mRNA CTD PMID:36139627 NCBI chr 9:45,990,373...45,998,470
Ensembl chr 9:45,990,375...45,998,535 		JBrowse link
G Ngef neuronal guanine nucleotide exchange factor multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NGEF mRNA CTD PMID:36139627 NCBI chr 9:95,594,823...95,692,381
Ensembl chr 9:95,594,823...95,692,251 		JBrowse link
G Ngfr nerve growth factor receptor increases expression
affects response to substance 		ISO trametinib results in increased expression of NGFR protein
NGFR protein affects the susceptibility to trametinib 		CTD PMID:30339727 NCBI chr10:81,012,077...81,030,305
Ensembl chr10:81,012,089...81,030,305 		JBrowse link
G Nhsl1 NHS-like 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NHSL1 mRNA CTD PMID:36139627 NCBI chr 1:14,775,874...15,008,327
Ensembl chr 1:14,705,839...15,008,327 		JBrowse link
G Nhsl2 NHS-like 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NHSL2 mRNA CTD PMID:36139627 NCBI chr  X:71,009,940...71,249,427
Ensembl chr  X:71,009,949...71,241,289 		JBrowse link
G Nim1k NIM1 serine/threonine protein kinase multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NIM1K mRNA CTD PMID:36139627 NCBI chr 2:53,403,467...53,451,248
Ensembl chr 2:53,403,473...53,419,656 		JBrowse link
G Nipal4 NIPA-like domain containing 4 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NIPAL4 mRNA CTD PMID:36139627 NCBI chr10:31,085,267...31,101,979
Ensembl chr10:31,085,267...31,101,979 		JBrowse link
G Nkx2-1 NK2 homeobox 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NKX2-1 mRNA CTD PMID:36139627 NCBI chr 6:79,731,677...79,735,952
Ensembl chr 6:79,731,677...79,736,441 		JBrowse link
G Nlgn1 neuroligin 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NLGN1 mRNA CTD PMID:36139627 NCBI chr 2:110,184,987...111,110,316
Ensembl chr 2:110,186,573...110,909,984 		JBrowse link
G Nlrp1a NLR family, pyrin domain containing 1A multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NLRP1 mRNA CTD PMID:36139627 NCBI chr10:56,277,134...56,332,229
Ensembl chr10:56,277,134...56,323,880 		JBrowse link
G Nmnat2 nicotinamide nucleotide adenylyltransferase 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of NMNAT2 mRNA CTD PMID:36139627 NCBI chr13:67,655,794...67,831,609
Ensembl chr13:67,655,807...67,831,608 		JBrowse link
G Nog noggin multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NOG mRNA CTD PMID:36139627 NCBI chr10:74,625,874...74,627,501
Ensembl chr10:74,625,875...74,628,103 		JBrowse link
G Notch4 notch receptor 4 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NOTCH4 mRNA CTD PMID:36139627 NCBI chr20:4,164,969...4,189,072
Ensembl chr20:4,161,730...4,189,072 		JBrowse link
G Npas1 neuronal PAS domain protein 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NPAS1 mRNA CTD PMID:36139627 NCBI chr 1:86,295,509...86,316,018
Ensembl chr 1:86,295,515...86,314,893 		JBrowse link
G Npb neuropeptide B multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of NPB mRNA CTD PMID:36139627 NCBI chr10:106,382,307...106,385,566
Ensembl chr10:106,384,779...106,385,878 		JBrowse link
G Npr3 natriuretic peptide receptor 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NPR3 mRNA CTD PMID:36139627 NCBI chr 2:62,592,557...62,660,497
Ensembl chr 2:62,597,668...62,660,066 		JBrowse link
G Nptx1 neuronal pentraxin 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NPTX1 mRNA CTD PMID:36139627 NCBI chr10:105,309,578...105,318,829
Ensembl chr10:105,309,578...105,318,863 		JBrowse link
G Nr1d1 nuclear receptor subfamily 1, group D, member 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NR1D1 mRNA CTD PMID:36139627 NCBI chr10:84,224,599...84,231,812
Ensembl chr10:84,224,540...84,231,812 		JBrowse link
G Nr3c2 nuclear receptor subfamily 3, group C, member 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NR3C2 mRNA CTD PMID:36139627 NCBI chr19:47,619,853...47,964,089
Ensembl chr19:47,619,853...47,964,078 		JBrowse link
G Nrep neuronal regeneration related protein multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NREP mRNA CTD PMID:36139627 NCBI chr18:25,291,219...25,320,742
Ensembl chr18:25,291,219...25,320,742 		JBrowse link
G Nrp1 neuropilin 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of NRP1 mRNA CTD PMID:36139627 NCBI chr19:73,256,557...73,411,705
Ensembl chr19:73,256,557...73,411,702 		JBrowse link
G Nrp2 neuropilin 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NRP2 mRNA CTD PMID:36139627 NCBI chr 9:71,616,602...71,731,869
Ensembl chr 9:71,616,657...71,731,871 		JBrowse link
G Nt5e 5' nucleotidase, ecto multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NT5E mRNA CTD PMID:36139627 NCBI chr 8:98,150,925...98,195,646
Ensembl chr 8:98,150,900...98,195,645 		JBrowse link
G Ntsr1 neurotensin receptor 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NTSR1 mRNA CTD PMID:36139627 NCBI chr 3:187,983,778...188,033,934
Ensembl chr 3:187,983,778...188,033,934 		JBrowse link
G Nyap1 neuronal tyrosine-phosphorylated phosphoinositide-3-kinase adaptor 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NYAP1 mRNA CTD PMID:36139627 NCBI chr12:24,591,574...24,604,417
Ensembl chr12:24,593,064...24,604,336 		JBrowse link
G Oas1a 2'-5' oligoadenylate synthetase 1A multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of OAS1 mRNA CTD PMID:36139627 NCBI chr12:41,330,423...41,341,130
Ensembl chr12:41,285,211...41,341,128 		JBrowse link
G Oas3 2'-5'-oligoadenylate synthetase 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of OAS3 mRNA CTD PMID:36139627 NCBI chr12:41,439,645...41,463,392
Ensembl chr12:41,439,643...41,464,420 		JBrowse link
G Oasl 2'-5'-oligoadenylate synthetase-like multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of OASL mRNA CTD PMID:36139627 NCBI chr12:47,343,551...47,356,509
Ensembl chr12:47,343,551...47,356,483 		JBrowse link
G Obscn obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of OBSCN mRNA CTD PMID:36139627 NCBI chr10:44,273,686...44,419,275
Ensembl chr10:44,288,866...44,419,297 		JBrowse link
G Onecut3 one cut homeobox 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ONECUT3 mRNA CTD PMID:36139627 NCBI chr 7:9,850,685...9,869,988
Ensembl chr 7:9,850,685...9,869,988 		JBrowse link
G Osgin1 oxidative stress induced growth inhibitor 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of OSGIN1 mRNA CTD PMID:36139627 NCBI chr19:64,380,336...64,409,165
Ensembl chr19:64,401,173...64,409,162 		JBrowse link
G P2rx6 purinergic receptor P2X 6 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of P2RX6 mRNA CTD PMID:36139627 NCBI chr11:96,944,167...96,956,424
Ensembl chr11:96,944,169...96,954,646 		JBrowse link
G P3h2 prolyl 3-hydroxylase 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of P3H2 mRNA CTD PMID:36139627 NCBI chr11:88,139,086...88,280,221
Ensembl chr11:88,139,078...88,281,203 		JBrowse link
G Pag1 phosphoprotein membrane anchor with glycosphingolipid microdomains 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of PAG1 mRNA CTD PMID:36139627 NCBI chr 2:93,842,747...93,984,314
Ensembl chr 2:93,964,594...93,977,227 		JBrowse link
G Paqr5 progestin and adipoQ receptor family member 5 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of PAQR5 mRNA CTD PMID:36139627 NCBI chr 8:71,327,397...71,409,201
Ensembl chr 8:71,327,397...71,409,201 		JBrowse link
G Paqr9 progestin and adipoQ receptor family member 9 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of PAQR9 mRNA CTD PMID:36139627 NCBI chr 8:104,993,884...104,996,180
Ensembl chr 8:104,993,827...104,998,285 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO trametinib promotes the reaction [physapubescin B results in increased cleavage of PARP1 protein] CTD PMID:33035574 NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567 		JBrowse link
G Pbld1 phenazine biosynthesis-like protein domain containing 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of PBLD mRNA CTD PMID:36139627 NCBI chr20:25,549,974...25,565,390
Ensembl chr20:25,549,974...25,565,226 		JBrowse link
G Pcdhb19 protocadherin beta 19 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of PCDHB12 mRNA CTD PMID:36139627 NCBI chr18:29,478,848...29,481,656 JBrowse link
G Pde2a phosphodiesterase 2A multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of PDE2A mRNA CTD PMID:36139627 NCBI chr 1:165,235,623...165,327,466
Ensembl chr 1:165,235,623...165,327,466 		JBrowse link
G Pdp2 pyruvate dehydrogenase phosphatase catalytic subunit 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of PDP2 mRNA CTD PMID:36139627 NCBI chr19:392,858...400,529
Ensembl chr19:392,183...400,902 		JBrowse link
G Per1 period circadian regulator 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of PER1 mRNA CTD PMID:36139627 NCBI chr10:54,299,002...54,313,804
Ensembl chr10:54,302,641...54,314,211 		JBrowse link
G Pfkfb4 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of PFKFB4 mRNA CTD PMID:36139627 NCBI chr 8:118,522,371...118,565,478
Ensembl chr 8:118,522,365...118,565,468 		JBrowse link
G Pfn4 profilin family, member 4 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of PFN4 mRNA CTD PMID:36139627 NCBI chr 6:33,506,077...33,516,163
Ensembl chr 6:33,506,077...33,516,163 		JBrowse link
G Pgbd5 piggyBac transposable element derived 5 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of PGBD5 mRNA CTD PMID:36139627 NCBI chr19:69,234,171...69,299,315
Ensembl chr19:69,234,171...69,299,560 		JBrowse link
G Phlda2 pleckstrin homology-like domain, family A, member 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of PHLDA2 mRNA CTD PMID:36139627 NCBI chr 1:208,126,302...208,127,241
Ensembl chr 1:208,126,302...208,127,920 		JBrowse link
G Phospho1 phosphoethanolamine/phosphocholine phosphatase 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of PHOSPHO1 mRNA CTD PMID:36139627 NCBI chr10:81,258,810...81,266,345
Ensembl chr10:81,257,427...81,268,481 		JBrowse link
G Phtf1 putative homeodomain transcription factor 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of PHTF1 mRNA CTD PMID:36139627 NCBI chr 2:194,161,343...194,249,925
Ensembl chr 2:194,161,000...194,219,530 		JBrowse link
G Phyhip phytanoyl-CoA 2-hydroxylase interacting protein multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of PHYHIP mRNA CTD PMID:36139627 NCBI chr15:51,943,670...51,954,921
Ensembl chr15:51,943,378...51,954,920 		JBrowse link
G Piezo2 piezo-type mechanosensitive ion channel component 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of PIEZO2 mRNA CTD PMID:36139627 NCBI chr18:58,738,734...59,115,252
Ensembl chr18:58,738,740...59,115,215 		JBrowse link
G Pik3ip1 phosphoinositide-3-kinase interacting protein 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of PIK3IP1 mRNA CTD PMID:36139627 NCBI chr14:82,428,315...82,440,261
Ensembl chr14:82,428,248...82,440,260 		JBrowse link
G Pik3r3 phosphoinositide-3-kinase regulatory subunit 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of PIK3R3 mRNA CTD PMID:36139627 NCBI chr 5:134,936,790...135,009,303
Ensembl chr 5:134,934,857...135,007,762 		JBrowse link
G Piwil2 piwi-like RNA-mediated gene silencing 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of PIWIL2 mRNA CTD PMID:36139627 NCBI chr15:51,841,104...51,907,729
Ensembl chr15:51,841,405...51,907,819 		JBrowse link
G Pkd1l2 polycystin 1 like 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of PKD1L2 mRNA CTD PMID:36139627 NCBI chr19:61,958,351...62,045,324
Ensembl chr19:61,958,415...62,044,358 		JBrowse link
G Plac1 placenta enriched 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of PLAC1 mRNA CTD PMID:36139627 NCBI chr  X:137,740,896...137,874,688
Ensembl chr  X:137,740,890...137,905,210 		JBrowse link
G Plag1 PLAG1 zinc finger multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of PLAG1 mRNA CTD PMID:36139627 NCBI chr 5:21,699,650...21,754,325
Ensembl chr 5:21,702,987...21,711,240 		JBrowse link
G Plat plasminogen activator, tissue type multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of PLAT mRNA CTD PMID:36139627 NCBI chr16:75,943,061...76,022,037
Ensembl chr16:75,943,064...75,967,696 		JBrowse link
G Plaur plasminogen activator, urokinase receptor multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of PLAUR mRNA CTD PMID:36139627 NCBI chr 1:89,181,363...89,196,308
Ensembl chr 1:89,178,453...89,198,130 		JBrowse link
G Plcxd3 phosphatidylinositol-specific phospholipase C, X domain containing 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of PLCXD3 mRNA CTD PMID:36139627 NCBI chr 2:55,294,597...55,473,968
Ensembl chr 2:55,294,613...55,474,220 		JBrowse link
G Pld1 phospholipase D1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of PLD1 mRNA CTD PMID:36139627 NCBI chr 2:112,777,820...112,975,857
Ensembl chr 2:112,777,951...112,976,245 		JBrowse link
G Plek2 pleckstrin 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of PLEK2 mRNA CTD PMID:36139627 NCBI chr 6:103,434,156...103,452,457
Ensembl chr 6:103,434,156...103,452,371 		JBrowse link
G Plin1 perilipin 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of PLIN1 mRNA CTD PMID:36139627 NCBI chr 1:143,073,612...143,086,199
Ensembl chr 1:143,074,214...143,086,206 		JBrowse link
G Plin4 perilipin 4 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of PLIN4 mRNA CTD PMID:36139627 NCBI chr 9:1,016,334...1,025,249
Ensembl chr 9:1,016,302...1,025,368 		JBrowse link
G Plxna2 plexin A2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of PLXNA2 mRNA CTD PMID:36139627 NCBI chr13:108,683,155...108,888,336
Ensembl chr13:108,691,530...108,887,453 		JBrowse link
G Podxl podocalyxin-like multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of PODXL mRNA CTD PMID:36139627 NCBI chr 4:61,102,434...61,149,131
Ensembl chr 4:61,102,419...61,149,789 		JBrowse link
G Pou2f2 POU class 2 homeobox 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of POU2F2 mRNA CTD PMID:36139627 NCBI chr 1:89,810,153...89,897,560
Ensembl chr 1:89,812,093...89,897,564 		JBrowse link
G Pou2f3 POU class 2 homeobox 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of POU2F3 mRNA CTD PMID:36139627 NCBI chr 8:52,392,363...52,474,756
Ensembl chr 8:52,392,497...52,474,756 		JBrowse link
G Pou5f1 POU class 5 homeobox 1 multiple interactions ISO [trametinib co-treated with 6-bromoindirubin-3'-oxime] results in increased expression of POU5F1 protein; XAV939 inhibits the reaction [[trametinib co-treated with 6-bromoindirubin-3'-oxime] results in increased expression of POU5F1 protein] CTD PMID:37116855 NCBI chr20:3,227,836...3,232,598
Ensembl chr20:3,227,837...3,232,598 		JBrowse link
G Pou6f1 POU class 6 homeobox 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of POU6F1 mRNA CTD PMID:36139627 NCBI chr 7:133,556,506...133,580,004
Ensembl chr 7:133,558,928...133,579,671 		JBrowse link
G Ppfia3 PTPRF interacting protein alpha 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of PPFIA3 mRNA CTD PMID:36139627 NCBI chr 1:104,953,598...104,982,373
Ensembl chr 1:104,953,598...104,982,278 		JBrowse link
G Ppm1n protein phosphatase, Mg2+/Mn2+ dependent 1N multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of PPM1N mRNA CTD PMID:36139627 NCBI chr 1:88,057,365...88,062,912
Ensembl chr 1:88,058,624...88,060,700 		JBrowse link
G Ppp1r16b protein phosphatase 1, regulatory subunit 16B multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of PPP1R16B mRNA CTD PMID:36139627 NCBI chr 3:167,743,518...167,839,511
Ensembl chr 3:167,743,952...167,839,242 		JBrowse link
G Prag1 PEAK1 related kinase activating pseudokinase 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of PRAG1 mRNA CTD PMID:36139627 NCBI chr16:62,791,249...62,844,532
Ensembl chr16:62,786,329...62,844,532 		JBrowse link
G Prex1 phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of PREX1 mRNA CTD PMID:36139627 NCBI chr 3:175,724,939...175,875,764
Ensembl chr 3:175,726,012...175,875,764 		JBrowse link
G Prickle1 prickle planar cell polarity protein 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of PRICKLE1 mRNA CTD PMID:36139627 NCBI chr 7:126,518,587...126,614,581
Ensembl chr 7:126,518,587...126,614,581 		JBrowse link
G Prkg2 protein kinase cGMP-dependent 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of PRKG2 mRNA CTD PMID:36139627 NCBI chr14:10,864,020...10,972,617
Ensembl chr14:10,864,186...10,972,614 		JBrowse link
G Prnd prion like protein doppel multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of PRND mRNA CTD PMID:36139627 NCBI chr 3:139,666,383...139,671,647
Ensembl chr 3:139,666,068...139,671,890 		JBrowse link
G Prodh1 proline dehydrogenase 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of PRODH mRNA CTD PMID:36139627 NCBI chr11:96,414,275...96,431,604
Ensembl chr11:96,414,224...96,433,418 		JBrowse link
G Prodh2 proline dehydrogenase 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of PRODH2 mRNA CTD PMID:36139627 NCBI chr 1:94,881,000...94,894,609
Ensembl chr 1:94,881,061...94,894,609 		JBrowse link
G Prr5l proline rich 5 like multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of PRR5L mRNA CTD PMID:36139627 NCBI chr 3:108,458,107...108,628,552
Ensembl chr 3:108,458,633...108,537,763 		JBrowse link
G Prss22 serine protease 22 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of PRSS22 mRNA CTD PMID:36139627 NCBI chr10:13,533,725...13,538,435
Ensembl chr10:13,533,725...13,538,435 		JBrowse link
G Prss53 serine protease 53 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of PRSS53 mRNA CTD PMID:36139627 NCBI chr 1:191,923,398...191,931,292
Ensembl chr 1:191,925,434...191,955,449 		JBrowse link
G Prtn3 proteinase 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of PRTN3 mRNA CTD PMID:36139627 NCBI chr 7:10,472,750...10,482,037
Ensembl chr 7:10,472,755...10,482,474 		JBrowse link
G Psd3 pleckstrin and Sec7 domain containing 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of PSD3 mRNA CTD PMID:36139627 NCBI chr16:26,238,595...26,802,535
Ensembl chr16:26,340,028...26,802,535 		JBrowse link
G Psmb10 proteasome 20S subunit beta 10 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of PSMB10 mRNA CTD PMID:36139627 NCBI chr19:50,740,808...50,743,292
Ensembl chr19:50,740,811...50,743,210 		JBrowse link
G Psmb9 proteasome 20S subunit beta 9 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of PSMB9 mRNA CTD PMID:36139627 NCBI chr20:4,668,952...4,674,421
Ensembl chr20:4,668,739...4,674,421 		JBrowse link
G Ptgir prostaglandin I2 receptor multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of PTGIR mRNA CTD PMID:36139627 NCBI chr 1:86,707,690...86,710,073
Ensembl chr 1:86,707,503...86,711,874 		JBrowse link
G Ptk6 protein tyrosine kinase 6 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of PTK6 mRNA CTD PMID:36139627 NCBI chr 3:188,684,633...188,693,224
Ensembl chr 3:188,684,633...188,693,224 		JBrowse link
G Pxmp2 peroxisomal membrane protein 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of PXMP2 mRNA CTD PMID:36139627 NCBI chr12:52,053,951...52,064,283
Ensembl chr12:52,053,788...52,064,283 		JBrowse link
G Pygb glycogen phosphorylase B multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of PYGB mRNA CTD PMID:36139627 NCBI chr 3:160,072,141...160,118,930
Ensembl chr 3:160,072,115...160,123,961 		JBrowse link
G Rab11fip4 RAB11 family interacting protein 4 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of RAB11FIP4 mRNA CTD PMID:36139627 NCBI chr10:65,048,070...65,156,086
Ensembl chr10:65,048,140...65,152,722 		JBrowse link
G Rab38 RAB38, member RAS oncogene family multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of RAB38 mRNA CTD PMID:36139627 NCBI chr 1:151,595,153...151,675,492
Ensembl chr 1:151,595,078...151,675,493 		JBrowse link
G Rab39a RAB39A, member RAS oncogene family multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of RAB39A mRNA CTD PMID:36139627 NCBI chr 8:62,984,434...63,002,053
Ensembl chr 8:62,984,434...63,002,053 		JBrowse link
G Rab7b Rab7b, member RAS oncogene family multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of RAB7B mRNA CTD PMID:36139627 NCBI chr13:45,673,396...45,699,798
Ensembl chr13:45,673,416...45,709,933 		JBrowse link
G Rac2 Rac family small GTPase 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of RAC2 mRNA CTD PMID:36139627 NCBI chr 7:111,981,825...112,009,201
Ensembl chr 7:111,996,742...112,009,267 		JBrowse link
G Rapgef5 Rap guanine nucleotide exchange factor 5 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of RAPGEF5 mRNA CTD PMID:36139627 NCBI chr 6:144,588,162...144,822,908
Ensembl chr 6:144,580,976...144,822,908 		JBrowse link
G Rasa4 RAS p21 protein activator 4 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of RASA4B mRNA CTD PMID:36139627 NCBI chr12:26,189,416...26,216,801
Ensembl chr12:26,189,339...26,216,860 		JBrowse link
G Rasl11a RAS-like family 11 member A multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of RASL11A mRNA CTD PMID:36139627 NCBI chr12:13,372,023...13,374,784
Ensembl chr12:13,372,023...13,376,451 		JBrowse link
G Rassf9 Ras association domain family member 9 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of RASSF9 mRNA CTD PMID:36139627 NCBI chr 7:39,486,257...39,518,090
Ensembl chr 7:39,409,870...39,519,675 		JBrowse link
G Rb1 RB transcriptional corepressor 1 decreases phosphorylation ISO trametinib results in decreased phosphorylation of RB1 protein CTD PMID:22733540 NCBI chr15:54,780,858...54,911,989
Ensembl chr15:54,780,858...54,911,857 		JBrowse link
G Reep1 receptor accessory protein 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of REEP1 mRNA CTD PMID:36139627 NCBI chr 4:105,303,974...105,420,611
Ensembl chr 4:105,303,969...105,420,602 		JBrowse link
G Rem2 RRAD and GEM like GTPase 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of REM2 mRNA CTD PMID:36139627 NCBI chr15:31,903,972...31,908,451
Ensembl chr15:31,903,965...31,908,445 		JBrowse link
G Rgmb repulsive guidance molecule BMP co-receptor b multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of RGMB mRNA CTD PMID:36139627 NCBI chr 1:65,439,748...65,465,149
Ensembl chr 1:65,441,410...65,465,098 		JBrowse link
G Ribc2 RIB43A domain with coiled-coils 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of RIBC2 mRNA CTD PMID:36139627 NCBI chr 7:118,122,722...118,137,772
Ensembl chr 7:118,122,408...118,137,767 		JBrowse link
G Rimkla ribosomal modification protein rimK-like family member A multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of RIMKLA mRNA CTD PMID:36139627 NCBI chr 5:138,357,463...138,384,132
Ensembl chr 5:138,359,743...138,384,060 		JBrowse link
G Rnf182 ring finger protein 182 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of RNF182 mRNA CTD PMID:36139627 NCBI chr17:21,232,084...21,287,329
Ensembl chr17:21,232,084...21,299,723 		JBrowse link
G Rnf223 ring finger protein 223 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of RNF223 mRNA CTD PMID:36139627 NCBI chr 5:172,005,566...172,008,456
Ensembl chr 5:172,005,566...172,008,458 		JBrowse link
G Robo4 roundabout guidance receptor 4 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ROBO4 mRNA CTD PMID:36139627 NCBI chr 8:45,308,739...45,322,522
Ensembl chr 8:45,308,739...45,322,531 		JBrowse link
G Ror2 receptor tyrosine kinase-like orphan receptor 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ROR2 mRNA CTD PMID:36139627 NCBI chr17:12,124,749...12,300,044
Ensembl chr17:12,124,749...12,300,044 		JBrowse link
G Rora RAR-related orphan receptor A multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of RORA mRNA CTD PMID:36139627 NCBI chr 8:78,182,710...78,915,730
Ensembl chr 8:78,182,620...78,915,730 		JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 decreases phosphorylation ISO trametinib results in decreased phosphorylation of RPS6KB1 protein CTD PMID:22733540 NCBI chr10:71,817,794...71,865,211
Ensembl chr10:71,815,614...71,865,238 		JBrowse link
G Rragd Ras-related GTP binding D multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of RRAGD mRNA CTD PMID:36139627 NCBI chr 5:52,170,234...52,205,700
Ensembl chr 5:52,169,783...52,209,000 		JBrowse link
G Rspo1 R-spondin 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of RSPO1 mRNA CTD PMID:36139627 NCBI chr 5:142,536,162...142,557,611
Ensembl chr 5:142,536,344...142,557,776 		JBrowse link
G RT1-Ha RT1 class II, locus Ha multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of HLA-DPA1 mRNA CTD PMID:36139627 NCBI chr20:4,762,425...4,772,439
Ensembl chr20:4,763,033...4,772,141 		JBrowse link
G Rtn2 reticulon 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of RTN2 mRNA CTD PMID:36139627 NCBI chr 1:88,063,124...88,076,082
Ensembl chr 1:88,063,119...88,076,043 		JBrowse link
G Rtp4 receptor (chemosensory) transporter protein 4 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of RTP4 mRNA CTD PMID:36139627 NCBI chr11:90,741,992...90,840,061
Ensembl chr11:90,741,992...90,753,851 		JBrowse link
G Runx2 RUNX family transcription factor 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of RUNX2 mRNA CTD PMID:36139627 NCBI chr 9:23,661,278...23,990,248
Ensembl chr 9:23,664,952...23,990,027 		JBrowse link
G Rxfp4 relaxin family peptide/INSL5 receptor 4 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of RXFP4 mRNA CTD PMID:36139627 NCBI chr 2:176,421,332...176,422,486 JBrowse link
G Ryr1 ryanodine receptor 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of RYR1 mRNA CTD PMID:36139627 NCBI chr 1:93,420,078...93,551,305
Ensembl chr 1:93,420,078...93,551,305 		JBrowse link
G S100a2 S100 calcium binding protein A2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of S100A2 mRNA CTD PMID:36139627 NCBI chr 2:178,374,659...178,375,903 JBrowse link
G Sall4 spalt-like transcription factor 4 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of SALL4 mRNA CTD PMID:36139627 NCBI chr 3:177,891,705...177,909,743
Ensembl chr 3:177,891,705...177,909,743 		JBrowse link
G Samd15 sterile alpha motif domain containing 15 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of SAMD15 mRNA CTD PMID:36139627 NCBI chr 6:112,572,352...112,587,142
Ensembl chr 6:112,572,501...112,576,796 		JBrowse link
G Samd9l sterile alpha motif domain containing 9 like multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of SAMD9L mRNA CTD PMID:36139627 NCBI chr 4:32,316,748...32,331,112
Ensembl chr 4:32,222,623...32,331,067 		JBrowse link
G Saxo5 stabilizer of axonemal microtubules 5 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of SAXO5 mRNA CTD PMID:36139627 NCBI chr12:6,318,845...6,336,018
Ensembl chr12:6,318,903...6,336,009 		JBrowse link
G Scarf1 scavenger receptor class F, member 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of SCARF1 mRNA CTD PMID:36139627 NCBI chr10:60,857,494...60,869,795
Ensembl chr10:60,857,478...60,869,810 		JBrowse link
G Scnn1b sodium channel epithelial 1 subunit beta multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of SCNN1B mRNA CTD PMID:36139627 NCBI chr 1:185,861,326...185,915,717
Ensembl chr 1:185,854,733...185,916,049 		JBrowse link
G Sdcbp2 syndecan binding protein 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of SDCBP2 mRNA CTD PMID:36139627 NCBI chr 3:160,521,309...160,558,452
Ensembl chr 3:160,530,927...160,558,446 		JBrowse link
G Sec14l2 SEC14-like lipid binding 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of SEC14L2 mRNA CTD PMID:36139627 NCBI chr14:83,197,384...83,222,059
Ensembl chr14:83,197,387...83,217,317 		JBrowse link
G Sema3c semaphorin 3C multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of SEMA3C mRNA CTD PMID:36139627 NCBI chr 4:18,538,452...18,702,453
Ensembl chr 4:18,538,454...18,701,740 		JBrowse link
G Sema7a semaphorin 7A (John Milton Hagen blood group) multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of SEMA7A mRNA CTD PMID:36139627 NCBI chr 8:67,244,318...67,267,060
Ensembl chr 8:67,243,824...67,267,058 		JBrowse link
G Serpina3n serpin family A member 3N multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of SERPINA3 mRNA CTD PMID:36139627 NCBI chr 6:129,088,392...129,095,950
Ensembl chr 6:129,088,398...129,097,415 		JBrowse link
G Serpina5 serpin family A member 5 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of SERPINA5 mRNA CTD PMID:36139627 NCBI chr 6:128,774,006...128,793,187
Ensembl chr 6:128,784,991...128,793,186 		JBrowse link
G Serpinb8 serpin family B member 8 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of SERPINB8 mRNA CTD PMID:36139627 NCBI chr13:24,141,557...24,164,894
Ensembl chr13:24,129,855...24,166,076 		JBrowse link
G Serpine1 serpin family E member 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of SERPINE1 mRNA CTD PMID:36139627 NCBI chr12:25,237,977...25,248,356
Ensembl chr12:25,237,952...25,248,357 		JBrowse link
G Serpine2 serpin family E member 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of SERPINE2 mRNA CTD PMID:36139627 NCBI chr 9:88,573,138...88,637,252
Ensembl chr 9:88,573,149...88,637,202 		JBrowse link
G Serpini1 serpin family I member 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of SERPINI1 mRNA CTD PMID:36139627 NCBI chr 2:162,645,209...162,731,737
Ensembl chr 2:162,645,350...162,731,740 		JBrowse link
G Sfn stratifin multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of SFN mRNA CTD PMID:36139627 NCBI chr 5:151,110,582...151,111,854
Ensembl chr 5:151,110,530...151,111,995 		JBrowse link
G Sfxn2 sideroflexin 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of SFXN2 mRNA CTD PMID:36139627 NCBI chr 1:255,388,428...255,400,724
Ensembl chr 1:255,388,429...255,409,780 		JBrowse link
G Sfxn3 sideroflexin 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of SFXN3 mRNA CTD PMID:36139627 NCBI chr 1:253,856,935...253,866,219
Ensembl chr 1:253,856,882...253,887,542 		JBrowse link
G Sh2d5 SH2 domain containing 5 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of SH2D5 mRNA CTD PMID:36139627 NCBI chr 5:155,753,087...155,763,936
Ensembl chr 5:155,750,803...155,763,936 		JBrowse link
G Sh3d21 SH3 domain containing 21 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of SH3D21 mRNA CTD PMID:36139627 NCBI chr 5:143,713,718...143,729,073
Ensembl chr 5:143,713,718...143,729,257 		JBrowse link
G Sh3tc2 SH3 domain and tetratricopeptide repeats 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of SH3TC2 mRNA CTD PMID:36139627 NCBI chr18:57,686,701...57,747,735
Ensembl chr18:57,686,735...57,800,541 		JBrowse link
G Shf Src homology 2 domain containing F multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of SHF mRNA CTD PMID:36139627 NCBI chr 3:129,749,903...129,769,912
Ensembl chr 3:129,749,584...129,769,929 		JBrowse link
G Siglec15 sialic acid binding Ig-like lectin 15 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of SIGLEC15 mRNA CTD PMID:36139627 NCBI chr18:73,781,536...73,797,014
Ensembl chr18:73,781,536...73,797,014 		JBrowse link
G Slc10a5 solute carrier family 10, member 5 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of SLC10A5 mRNA CTD PMID:36139627 NCBI chr 2:93,364,959...93,366,263
Ensembl chr 2:93,360,766...93,368,978 		JBrowse link
G Slc17a7 solute carrier family 17 member 7 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of SLC17A7 mRNA CTD PMID:36139627 NCBI chr 1:104,786,172...104,798,049
Ensembl chr 1:104,785,955...104,798,049 		JBrowse link
G Slc2a3 solute carrier family 2 member 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of SLC2A3 mRNA CTD PMID:36139627 NCBI chr 4:157,632,887...157,698,034
Ensembl chr 4:157,632,887...157,646,186 		JBrowse link
G Slc47a2 solute carrier family 47 member 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of SLC47A2 mRNA CTD PMID:36139627 NCBI chr10:46,490,262...46,532,954
Ensembl chr10:46,489,831...46,533,425 		JBrowse link
G Slc4a11 solute carrier family 4 member 11 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of SLC4A11 mRNA CTD PMID:36139627 NCBI chr 3:138,353,305...138,365,983
Ensembl chr 3:138,353,305...138,365,754 		JBrowse link
G Slc4a7 solute carrier family 4 member 7 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of SLC4A7 mRNA CTD PMID:36139627 NCBI chr15:13,015,854...13,095,485
Ensembl chr15:13,015,854...13,095,292 		JBrowse link
G Slc5a1 solute carrier family 5 member 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of SLC5A1 mRNA CTD PMID:36139627 NCBI chr14:81,778,495...81,843,084
Ensembl chr14:81,778,348...81,846,624 		JBrowse link
G Slc6a9 solute carrier family 6 member 9 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of SLC6A9 mRNA CTD PMID:36139627 NCBI chr 5:136,660,022...136,694,173
Ensembl chr 5:136,659,948...136,694,172 		JBrowse link
G Slc9a3 solute carrier family 9 member A3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of SLC9A3 mRNA CTD PMID:36139627 NCBI chr 1:30,953,215...30,996,209
Ensembl chr 1:30,953,216...30,996,002 		JBrowse link
G Slitrk3 SLIT and NTRK-like family, member 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of SLITRK3 mRNA CTD PMID:36139627 NCBI chr 2:159,983,650...159,996,194
Ensembl chr 2:159,973,029...159,996,342 		JBrowse link
G Smim5 small integral membrane protein 5 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of SMIM5 mRNA CTD PMID:36139627 NCBI chr10:101,632,966...101,642,089
Ensembl chr10:101,632,966...101,638,746 		JBrowse link
G Smoc2 SPARC related modular calcium binding 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of SMOC2 mRNA CTD PMID:36139627 NCBI chr 1:63,935,627...64,064,952
Ensembl chr 1:63,935,647...64,064,955 		JBrowse link
G Smpd3 sphingomyelin phosphodiesterase 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of SMPD3 mRNA CTD PMID:36139627 NCBI chr19:51,072,209...51,155,639
Ensembl chr19:51,072,209...51,085,936 		JBrowse link
G Snai2 snail family transcriptional repressor 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of SNAI2 mRNA CTD PMID:36139627 NCBI chr11:99,686,934...99,690,349
Ensembl chr11:99,686,934...99,690,349 		JBrowse link
G Snai3 snail family transcriptional repressor 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of SNAI3 mRNA CTD PMID:36139627 NCBI chr19:67,425,311...67,437,830
Ensembl chr19:67,425,157...67,434,268 		JBrowse link
G Socs2 suppressor of cytokine signaling 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of SOCS2 mRNA CTD PMID:36139627 NCBI chr 7:31,890,564...31,932,092
Ensembl chr 7:31,874,463...31,930,423 		JBrowse link
G Sox2 SRY-box transcription factor 2 multiple interactions ISO [trametinib co-treated with 6-bromoindirubin-3'-oxime] results in increased expression of SOX2 protein; XAV939 inhibits the reaction [[trametinib co-treated with 6-bromoindirubin-3'-oxime] results in increased expression of SOX2 protein] CTD PMID:37116855 NCBI chr 2:119,465,131...119,467,542
Ensembl chr 2:119,454,541...119,496,350 		JBrowse link
G Spata18 spermatogenesis associated 18 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of SPATA18 mRNA CTD PMID:36139627 NCBI chr14:34,885,995...34,912,704
Ensembl chr14:34,885,995...34,912,736 		JBrowse link
G Spats2l spermatogenesis associated, serine-rich 2-like multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of SPATS2L mRNA CTD PMID:36139627 NCBI chr 9:66,814,217...66,988,084
Ensembl chr 9:66,814,228...66,988,578 		JBrowse link
G Spns3 SPNS lysolipid transporter 3, sphingosine-1-phosphate multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of SPNS3 mRNA CTD PMID:36139627 NCBI chr10:57,612,796...57,667,601
Ensembl chr10:57,612,819...57,667,414 		JBrowse link
G Spocd1 SPOC domain containing 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of SPOCD1 mRNA CTD PMID:36139627 NCBI chr 5:147,573,460...147,581,165 JBrowse link
G Spon1 spondin 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of SPON1 mRNA CTD PMID:36139627 NCBI chr 1:177,363,526...177,662,689
Ensembl chr 1:177,363,197...177,662,676 		JBrowse link
G Spsb1 splA/ryanodine receptor domain and SOCS box containing 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of SPSB1 mRNA CTD PMID:36139627 NCBI chr 5:165,641,255...165,701,482
Ensembl chr 5:165,642,851...165,654,225 		JBrowse link
G Sptb spectrin, beta, erythrocytic multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of SPTB mRNA CTD PMID:36139627 NCBI chr 6:101,043,512...101,170,389
Ensembl chr 6:101,045,216...101,170,278 		JBrowse link
G Sptbn4 spectrin, beta, non-erythrocytic 4 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of SPTBN4 mRNA CTD PMID:36139627 NCBI chr 1:91,778,379...91,865,970
Ensembl chr 1:91,778,380...91,865,049 		JBrowse link
G Sqstm1 sequestosome 1 decreases expression ISO trametinib results in decreased expression of SQSTM1 protein CTD PMID:30339727 NCBI chr10:35,026,598...35,037,750
Ensembl chr10:35,026,598...35,037,750 		JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions ISO trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the cleavage of SREBF1 protein] CTD PMID:29950559 NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,507,152...45,529,164 		JBrowse link
G Srxn1 sulfiredoxin 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of SRXN1 mRNA CTD PMID:36139627 NCBI chr 3:161,064,812...161,070,372
Ensembl chr 3:161,059,931...161,088,765 		JBrowse link
G St3gal1 ST3 beta-galactoside alpha-2,3-sialyltransferase 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ST3GAL1 mRNA CTD PMID:36139627 NCBI chr 7:100,734,300...100,802,443
Ensembl chr 7:100,734,300...100,745,242 		JBrowse link
G Stambpl1 STAM binding protein-like 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of STAMBPL1 mRNA CTD PMID:36139627 NCBI chr 1:241,095,695...241,158,225
Ensembl chr 1:241,113,239...241,158,225 		JBrowse link
G Stat3 signal transducer and activator of transcription 3 increases phosphorylation
multiple interactions 		ISO trametinib results in increased phosphorylation of STAT3 protein
physapubescin B inhibits the reaction [trametinib results in increased phosphorylation of STAT3 protein] 		CTD PMID:33035574 NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359 		JBrowse link
G Stc1 stanniocalcin 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of STC1 mRNA CTD PMID:36139627 NCBI chr15:50,709,439...50,720,093
Ensembl chr15:50,709,415...50,720,082 		JBrowse link
G Stn1 STN1 subunit of CST complex multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of STN1 mRNA CTD PMID:36139627 NCBI chr 1:256,336,916...256,371,143
Ensembl chr 1:256,315,367...256,370,736 		JBrowse link
G Stom stomatin multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of STOM mRNA CTD PMID:36139627 NCBI chr 3:39,042,503...39,064,818
Ensembl chr 3:39,042,503...39,064,818 		JBrowse link
G Sulf2 sulfatase 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of SULF2 mRNA CTD PMID:36139627 NCBI chr 3:175,241,322...175,323,808
Ensembl chr 3:175,241,322...175,323,651 		JBrowse link
G Sult2b1 sulfotransferase family 2B member 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of SULT2B1 mRNA CTD PMID:36139627 NCBI chr 1:105,336,614...105,397,744
Ensembl chr 1:105,336,614...105,397,744 		JBrowse link
G Sycp2 synaptonemal complex protein 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of SYCP2 mRNA CTD PMID:36139627 NCBI chr 3:185,814,033...185,876,516
Ensembl chr 3:185,814,035...185,876,492 		JBrowse link
G Sync syncoilin, intermediate filament protein multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of SYNC mRNA CTD PMID:36139627 NCBI chr 5:146,915,715...146,940,547
Ensembl chr 5:146,916,361...146,943,191 		JBrowse link
G Syne3 spectrin repeat containing, nuclear envelope family member 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of SYNE3 mRNA CTD PMID:36139627 NCBI chr 6:129,637,644...129,729,542
Ensembl chr 6:129,641,123...129,729,509 		JBrowse link
G Syt12 synaptotagmin 12 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of SYT12 mRNA CTD PMID:36139627 NCBI chr 1:211,158,745...211,189,780
Ensembl chr 1:211,159,800...211,189,037 		JBrowse link
G Syt5 synaptotagmin 5 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of SYT5 mRNA CTD PMID:36139627 NCBI chr 1:78,320,034...78,327,750
Ensembl chr 1:78,320,034...78,327,746 		JBrowse link
G Sytl2 synaptotagmin-like 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of SYTL2 mRNA CTD PMID:36139627 NCBI chr 1:153,685,403...153,791,758
Ensembl chr 1:153,665,327...153,791,756 		JBrowse link
G Tac3 tachykinin precursor 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of TAC3 mRNA CTD PMID:36139627 NCBI chr 7:65,447,817...65,454,427
Ensembl chr 7:65,447,817...65,454,427 		JBrowse link
G Tafa2 TAFA chemokine like family member 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of TAFA2 mRNA CTD PMID:36139627 NCBI chr 7:60,827,985...61,303,873
Ensembl chr 7:60,891,958...61,303,869 		JBrowse link
G Tapbpl TAP binding protein-like multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of TAPBPL mRNA CTD PMID:36139627 NCBI chr 4:159,707,686...159,715,137
Ensembl chr 4:159,708,511...159,715,137 		JBrowse link
G Tbx4 T-box transcription factor 4 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of TBX4 mRNA CTD PMID:36139627 NCBI chr10:71,228,145...71,258,222
Ensembl chr10:71,197,727...71,258,218 		JBrowse link
G Tcaf2 TRPM8 channel-associated factor 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of TCAF2 mRNA CTD PMID:36139627
G Tchh trichohyalin multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of TCHH mRNA CTD PMID:36139627 NCBI chr 2:181,787,109...181,795,463
Ensembl chr 2:181,787,109...181,795,463 		JBrowse link
G Tex9 testis expressed 9 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of TEX9 mRNA CTD PMID:36139627 NCBI chr 8:82,049,194...82,094,613
Ensembl chr 8:82,058,514...82,094,801 		JBrowse link
G Tfpi2 tissue factor pathway inhibitor 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of TFPI2 mRNA CTD PMID:36139627 NCBI chr 4:32,936,462...32,941,385
Ensembl chr 4:32,936,854...32,941,426 		JBrowse link
G Tfr2 transferrin receptor 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of TFR2 mRNA CTD PMID:36139627 NCBI chr12:24,744,450...24,761,413
Ensembl chr12:24,744,450...24,761,413 		JBrowse link
G Tjp3 tight junction protein 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of TJP3 mRNA CTD PMID:36139627 NCBI chr 7:9,078,757...9,097,003
Ensembl chr 7:9,084,315...9,096,984 		JBrowse link
G Tlcd1 TLC domain containing 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of TLCD1 mRNA CTD PMID:36139627 NCBI chr10:63,572,541...63,574,574
Ensembl chr10:63,572,518...63,574,567 		JBrowse link
G Tle6 TLE family member 6, subcortical maternal complex member multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of TLE6 mRNA CTD PMID:36139627 NCBI chr 7:8,757,846...8,769,405
Ensembl chr 7:8,759,925...8,769,404 		JBrowse link
G Tlr1 toll-like receptor 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of TLR1 mRNA CTD PMID:36139627 NCBI chr14:43,737,761...43,750,389
Ensembl chr14:43,740,379...43,756,243 		JBrowse link
G Tlr3 toll-like receptor 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of TLR3 mRNA CTD PMID:36139627 NCBI chr16:53,554,916...53,572,321
Ensembl chr16:53,555,131...53,568,385 		JBrowse link
G Tlr6 toll-like receptor 6 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of TLR6 mRNA CTD PMID:36139627 NCBI chr14:43,715,809...43,727,019
Ensembl chr14:43,698,751...43,740,462 		JBrowse link
G Tm4sf19 transmembrane 4 L six family member 19 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of TM4SF19 mRNA CTD PMID:36139627 NCBI chr11:81,876,714...81,899,603
Ensembl chr11:81,877,435...81,888,484 		JBrowse link
G Tmc8 transmembrane channel-like 8 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of TMC8 mRNA CTD PMID:36139627 NCBI chr10:103,498,505...103,509,496
Ensembl chr10:103,499,041...103,509,294 		JBrowse link
G Tmem117 transmembrane protein 117 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of TMEM117 mRNA CTD PMID:36139627 NCBI chr 7:127,636,862...128,098,944
Ensembl chr 7:127,636,825...128,098,941 		JBrowse link
G Tmem144 transmembrane protein 144 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of TMEM144 mRNA CTD PMID:36139627 NCBI chr 2:167,258,788...167,291,701
Ensembl chr 2:167,258,789...167,290,902 		JBrowse link
G Tmem156 transmembrane protein 156 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of TMEM156 mRNA CTD PMID:36139627 NCBI chr14:43,568,131...43,606,109
Ensembl chr14:43,577,023...43,606,109 		JBrowse link
G Tmem158 transmembrane protein 158 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of TMEM158 mRNA CTD PMID:36139627 NCBI chr 8:131,791,137...131,792,135
Ensembl chr 8:131,787,277...131,796,882 		JBrowse link
G Tmem236 transmembrane protein 236 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of TMEM236 mRNA CTD PMID:36139627 NCBI chr17:82,075,020...82,149,796
Ensembl chr17:82,096,528...82,148,211 		JBrowse link
G Tmem25 transmembrane protein 25 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of TMEM25 mRNA CTD PMID:36139627 NCBI chr 8:54,003,907...54,009,469
Ensembl chr 8:54,003,907...54,009,325 		JBrowse link
G Tmem255b transmembrane protein 255B multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of TMEM255B mRNA CTD PMID:36139627 NCBI chr16:82,759,236...82,810,450
Ensembl chr16:82,774,136...82,808,929 		JBrowse link
G Tmem269 transmembrane protein 269 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of TMEM269 mRNA CTD PMID:36139627 NCBI chr 5:138,102,637...138,121,078
Ensembl chr 5:138,102,637...138,115,353 		JBrowse link
G Tmem270 transmembrane protein 270 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of TMEM270 mRNA CTD PMID:36139627 NCBI chr12:27,430,092...27,435,243
Ensembl chr12:27,429,985...27,435,242 		JBrowse link
G Tmem45a transmembrane protein 45A multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of TMEM45A mRNA CTD PMID:36139627 NCBI chr11:57,181,686...57,268,630
Ensembl chr11:57,182,785...57,282,722 		JBrowse link
G Tmem92 transmembrane protein 92 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of TMEM92 mRNA CTD PMID:36139627 NCBI chr10:80,246,205...80,257,650 JBrowse link
G Tnfsf15 TNF superfamily member 15 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of TNFSF15 mRNA CTD PMID:36139627 NCBI chr 5:82,150,376...82,171,743
Ensembl chr 5:82,150,376...82,171,882 		JBrowse link
G Tnxb tenascin XB multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of TNXB mRNA CTD PMID:36139627 Ensembl chr20:4,031,082...4,090,128 JBrowse link
G Tp53i3 tumor protein p53 inducible protein 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of TP53I3 mRNA CTD PMID:36139627 NCBI chr 6:33,537,779...33,545,204 JBrowse link
G Tph1 tryptophan hydroxylase 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of TPH1 mRNA CTD PMID:36139627 NCBI chr 1:106,293,695...106,314,628
Ensembl chr 1:106,085,953...106,312,484 		JBrowse link
G Trank1 tetratricopeptide repeat and ankyrin repeat containing 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of TRANK1 mRNA CTD PMID:36139627 NCBI chr 8:120,153,381...120,233,879
Ensembl chr 8:120,154,362...120,234,087 		JBrowse link
G Trib1 tribbles pseudokinase 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of TRIB1 mRNA CTD PMID:36139627 NCBI chr 7:93,096,001...93,102,547
Ensembl chr 7:93,095,973...93,117,480 		JBrowse link
G Trib2 tribbles pseudokinase 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of TRIB2 mRNA CTD PMID:36139627 NCBI chr 6:44,274,762...44,299,139
Ensembl chr 6:44,274,762...44,299,094 		JBrowse link
G Trim29 tripartite motif-containing 29 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of TRIM29 mRNA CTD PMID:36139627 NCBI chr 8:52,579,175...52,603,919
Ensembl chr 8:52,579,175...52,603,919 		JBrowse link
G Trim63 tripartite motif containing 63 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of TRIM63 mRNA CTD PMID:36139627 NCBI chr 5:151,817,209...151,831,026
Ensembl chr 5:151,817,225...151,831,058 		JBrowse link
G Trim9 tripartite motif-containing 9 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of TRIM9 mRNA CTD PMID:36139627 NCBI chr 6:94,492,789...94,592,597
Ensembl chr 6:94,493,268...94,592,551 		JBrowse link
G Trmt9b tRNA methyltransferase 9B (putative) multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of TRMT9B mRNA CTD PMID:36139627 NCBI chr16:62,439,625...62,495,526
Ensembl chr16:62,446,393...62,495,518 		JBrowse link
G Trpv2 transient receptor potential cation channel, subfamily V, member 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of TRPV2 mRNA CTD PMID:36139627 NCBI chr10:47,772,223...47,797,956
Ensembl chr10:47,764,839...47,793,533 		JBrowse link
G Tsc22d3 TSC22 domain family, member 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of TSC22D3 mRNA CTD PMID:36139627 NCBI chr  X:109,006,410...109,066,389
Ensembl chr  X:109,006,420...109,015,519 		JBrowse link
G Tsnaxip1 translin-associated factor X interacting protein 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of TSNAXIP1 mRNA CTD PMID:36139627 NCBI chr19:50,626,846...50,647,848
Ensembl chr19:50,626,920...50,644,688 		JBrowse link
G Ttc39a tetratricopeptide repeat domain 39A multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of TTC39A mRNA CTD PMID:36139627 NCBI chr 5:129,379,560...129,441,779
Ensembl chr 5:129,380,753...129,433,372 		JBrowse link
G Ttpa alpha tocopherol transfer protein multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of TTPA mRNA CTD PMID:36139627 NCBI chr 5:38,294,415...38,315,471
Ensembl chr 5:38,292,665...38,315,804 		JBrowse link
G Tuba1a tubulin, alpha 1A multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of TUBA1A mRNA CTD PMID:36139627 NCBI chr 7:131,992,151...131,996,850
Ensembl chr 7:131,968,770...131,996,035 		JBrowse link
G Txk TXK tyrosine kinase multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of TXK mRNA CTD PMID:36139627 NCBI chr14:35,817,270...35,873,454
Ensembl chr14:35,817,893...35,873,460 		JBrowse link
G Uap1l1 UDP-N-acetylglucosamine pyrophosphorylase 1 like 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of UAP1L1 mRNA CTD PMID:36139627 NCBI chr 3:28,570,854...28,579,766
Ensembl chr 3:28,573,358...28,578,630 		JBrowse link
G Uba7 ubiquitin-like modifier activating enzyme 7 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of UBA7 mRNA CTD PMID:36139627 NCBI chr 8:117,543,902...117,552,709
Ensembl chr 8:117,543,957...117,556,142 		JBrowse link
G Ufsp1 UFM1-specific peptidase 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of UFSP1 mRNA CTD PMID:36139627 NCBI chr12:25,042,882...25,043,896
Ensembl chr12:25,042,116...25,044,087 		JBrowse link
G Uhrf2 ubiquitin like with PHD and ring finger domains 2 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of UHRF2 mRNA CTD PMID:36139627 NCBI chr 1:237,224,050...237,291,406
Ensembl chr 1:237,228,456...237,292,353 		JBrowse link
G Upk1a uroplakin 1A multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of UPK1A mRNA CTD PMID:36139627 NCBI chr 1:94,987,110...94,998,083
Ensembl chr 1:94,987,108...94,997,787 		JBrowse link
G Upk3b uroplakin 3B multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of UPK3B mRNA CTD PMID:36139627 NCBI chr12:26,266,838...26,274,240
Ensembl chr12:26,266,838...26,274,240 		JBrowse link
G Ush1g USH1 protein network component sans multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of USH1G mRNA CTD PMID:36139627 NCBI chr10:101,055,923...101,062,753
Ensembl chr10:101,057,208...101,062,564 		JBrowse link
G Vdr vitamin D receptor multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of VDR mRNA CTD PMID:36139627 NCBI chr 7:130,864,764...130,916,757
Ensembl chr 7:130,866,745...130,916,757 		JBrowse link
G Veph1 ventricular zone expressed PH domain-containing 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of VEPH1 mRNA CTD PMID:36139627 NCBI chr 2:152,592,648...152,847,566
Ensembl chr 2:152,601,680...152,847,318 		JBrowse link
G Vgf VGF nerve growth factor inducible multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of VGF mRNA CTD PMID:36139627 NCBI chr12:25,274,004...25,281,803
Ensembl chr12:25,273,333...25,282,703 		JBrowse link
G Vtn vitronectin multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of VTN mRNA CTD PMID:36139627 NCBI chr10:63,892,782...63,895,862
Ensembl chr10:63,892,766...63,895,860 		JBrowse link
G Wasf3 WASP family member 3 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of WASF3 mRNA CTD PMID:36139627 NCBI chr12:13,675,642...13,774,648
Ensembl chr12:13,675,645...13,774,559 		JBrowse link
G Wfdc21 WAP four-disulfide core domain 21 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of WFDC21P mRNA CTD PMID:36139627 NCBI chr10:69,125,336...69,131,205
Ensembl chr10:69,125,320...69,131,201 		JBrowse link
G Wnt10b Wnt family member 10B multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of WNT10B mRNA CTD PMID:36139627 NCBI chr 7:131,801,046...131,806,850
Ensembl chr 7:131,801,046...131,806,850 		JBrowse link
G Wnt11 Wnt family member 11 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of WNT11 mRNA CTD PMID:36139627 NCBI chr 1:162,545,660...162,565,456
Ensembl chr 1:162,545,680...162,564,660 		JBrowse link
G Wnt2b Wnt family member 2B multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of WNT2B mRNA CTD PMID:36139627 NCBI chr 2:195,142,573...195,156,945
Ensembl chr 2:195,135,176...195,157,144 		JBrowse link
G Wnt4 Wnt family member 4 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of WNT4 mRNA CTD PMID:36139627 NCBI chr 5:154,797,245...154,818,565
Ensembl chr 5:154,797,311...154,817,128 		JBrowse link
G Wnt7b Wnt family member 7B multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of WNT7B mRNA CTD PMID:36139627 NCBI chr 7:118,514,684...118,559,316
Ensembl chr 7:118,514,684...118,559,316 		JBrowse link
G Wnt8b Wnt family member 8B multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of WNT8B mRNA CTD PMID:36139627 NCBI chr 1:253,303,369...253,325,224
Ensembl chr 1:253,295,557...253,325,224 		JBrowse link
G Xaf1 XIAP associated factor 1 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of XAF1 mRNA CTD PMID:36139627 NCBI chr10:57,415,935...57,428,348
Ensembl chr10:57,415,658...57,428,349 		JBrowse link
G Zc3h6 zinc finger CCCH type containing 6 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ZC3H6 mRNA CTD PMID:36139627 NCBI chr 3:136,656,116...136,717,560
Ensembl chr 3:136,657,414...136,706,504 		JBrowse link
G Zfp608 zinc finger protein 608 multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ZNF608 mRNA CTD PMID:36139627 NCBI chr18:50,503,043...50,611,019
Ensembl chr18:50,503,045...50,608,622 		JBrowse link
G Zwint ZW10 interacting kinetochore protein multiple interactions ISO [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ZWINT mRNA CTD PMID:36139627 NCBI chr20:15,502,559...15,953,701
Ensembl chr20:15,937,396...15,953,203 		JBrowse link
U0126 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Eef2 eukaryotic translation elongation factor 2 multiple interactions ISO U0126 inhibits the reaction [carbachol decreases phosphorylation of EEF2 protein in colon cancer cells] RGD PMID:31227218 RGD:153298919 NCBI chr 7:9,183,836...9,196,255
Ensembl chr 7:9,183,961...9,189,544 		JBrowse link
G Gria1 glutamate ionotropic receptor AMPA type subunit 1 multiple interactions EXP U0126 inhibits the reaction [BDNF increases expression of Gria1 protein on nucleus accumbens medium spiny neurons]
U0126 inhibits the reaction [Morphine increases localization of Gria1 protein on shell of nucleus accumbens cell surface] 		RGD PMID:24712995 PMID:25746394 RGD:405650624, RGD:11087075 NCBI chr10:41,710,540...42,030,105
Ensembl chr10:41,711,080...42,030,309 		JBrowse link
G Gria2 glutamate ionotropic receptor AMPA type subunit 2 multiple interactions EXP U0126 inhibits the reaction [BDNF increases expression of Gria2 protein on nucleus accumbens medium spiny neurons] RGD PMID:24712995 RGD:405650624 NCBI chr 2:168,247,490...168,367,616
Ensembl chr 2:168,247,496...168,367,616 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 decreases reaction EXP U0126 inhibits the reaction [estrogen increases phosphorylation of Mapk1/3 protein] in rat uterus RGD PMID:17272396 RGD:152177689 NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 decreases reaction EXP U0126 inhibits the reaction [estrogen increases phosphorylation of Mapk1/3 protein] in rat uterus RGD PMID:17272396 RGD:152177689 NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411 		JBrowse link
G Prkaa1 protein kinase AMP-activated catalytic subunit alpha 1 multiple interactions EXP U0126 inhibits the reaction [17alpha-ethynylestradiol increases phosphorylation of Prkaa1 in primary hepatocytes] RGD PMID:27090119 RGD:15090804 NCBI chr 2:55,967,766...56,003,450
Ensembl chr 2:55,967,351...56,003,450 		JBrowse link
VX-745 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Il1b interleukin 1 beta multiple interactions ISO VX-745 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein] CTD PMID:28629242 NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601 		JBrowse link
G Il6 interleukin 6 decreases secretion
multiple interactions 		ISO VX-745 results in decreased secretion of IL6 protein
VX-745 inhibits the reaction [TNF protein results in increased secretion of IL6 protein] 		CTD PMID:12393542 NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610 		JBrowse link
G Mapk14 mitogen activated protein kinase 14 decreases activity ISO VX-745 results in decreased activity of MAPK14 protein CTD PMID:28629242 NCBI chr20:6,751,288...6,812,294
Ensembl chr20:6,751,357...6,812,294 		JBrowse link
G Slc22a2 solute carrier family 22 member 2 multiple interactions ISO VX-745 inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] CTD PMID:21599003 NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:50,668,817...50,711,019 		JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO VX-745 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; VX-745 inhibits the reaction [TNF protein results in increased secretion of IL6 protein] CTD PMID:12393542 PMID:28629242 NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303 		JBrowse link
G Vegfa vascular endothelial growth factor A decreases secretion ISO VX-745 results in decreased secretion of VEGFA protein CTD PMID:12393542 NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 20874
    role 20844
      biological role 20831
        inhibitor 19071
          enzyme inhibitor 18710
            EC 2.* (transferase) inhibitor 14864
              EC 2.7.* (P-containing group transferase) inhibitor 14367
                EC 2.7.11.* (protein-serine/threonine kinase) inhibitor 10070
                  EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor 1314
                    1-(3-tert-butyl-1-methylpyrazol-5-yl)-3-(4-chlorophenyl)urea 0
                    2-(2-amino-3-methoxyphenyl)chromen-4-one 0
                    3-fluoro-5-morpholin-4-yl-N-[1-(2-pyridin-4-ylethyl)-1H-indol-6-yl]benzamide 0
                    4-methyl-N-[3-(morpholin-4-yl)phenyl]-3-[3-(piperidin-4-yl)-1,2-benzoxazol-6-yl]benzamide 0
                    4-phenoxy-N-(pyridin-2-ylmethyl)benzamide 0
                    9-(4-hydroxyphenyl)-2,7-phenanthroline 0
                    CH5126766 0
                    G-573 0
                    MK-8353 0
                    N-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)-2-fluorobenzamide 0
                    N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide 0
                    N-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide 0
                    N-cyclopropyl-3-\{4-[(cyclopropylmethyl)carbamoyl]phenyl\}-4-methylbenzamide 0
                    N-cyclopropyl-3-\{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydropyrazolo[3,4-b]pyridin-4-yl]amino\}-4-methylbenzamide 0
                    PD169316 0
                    PH 797804 0
                    R-1487 hydrochloride 0
                    RO4927350 0
                    SB 203580 439
                    SB-202190 3
                    SB-239063 24
                    SB-245391 0
                    SB-284851-BT 0
                    SB220025 0
                    SCH772984 34
                    TAK-733 0
                    U0126 + 6
                    U0126.EtOH 0
                    VX-745 6
                    auraptene 24
                    binimetinib 1
                    c-Jun N-terminal kinase inhibitor + 475
                    cercosporamide 0
                    cobimetinib 10
                    cobimetinib fumarate 0
                    doramapimod 63
                    hypothemycin 0
                    losmapimod 0
                    pamapimod 0
                    pluripotin 0
                    selumetinib 29
                    talmapimod 0
                    trametinib + 640
                    trametinib dimethyl sulfoxide 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 20874
    role 20844
      biological role 20831
        inhibitor 19071
          enzyme inhibitor 18710
            EC 2.* (transferase) inhibitor 14864
              EC 2.7.* (P-containing group transferase) inhibitor 14367
                protein kinase inhibitor 13969
                  EC 2.7.11.* (protein-serine/threonine kinase) inhibitor 10070
                    EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor 1314
                      1-(3-tert-butyl-1-methylpyrazol-5-yl)-3-(4-chlorophenyl)urea 0
                      2-(2-amino-3-methoxyphenyl)chromen-4-one 0
                      3-fluoro-5-morpholin-4-yl-N-[1-(2-pyridin-4-ylethyl)-1H-indol-6-yl]benzamide 0
                      4-methyl-N-[3-(morpholin-4-yl)phenyl]-3-[3-(piperidin-4-yl)-1,2-benzoxazol-6-yl]benzamide 0
                      4-phenoxy-N-(pyridin-2-ylmethyl)benzamide 0
                      9-(4-hydroxyphenyl)-2,7-phenanthroline 0
                      CH5126766 0
                      G-573 0
                      MK-8353 0
                      N-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)-2-fluorobenzamide 0
                      N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide 0
                      N-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide 0
                      N-cyclopropyl-3-\{4-[(cyclopropylmethyl)carbamoyl]phenyl\}-4-methylbenzamide 0
                      N-cyclopropyl-3-\{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydropyrazolo[3,4-b]pyridin-4-yl]amino\}-4-methylbenzamide 0
                      PD169316 0
                      PH 797804 0
                      R-1487 hydrochloride 0
                      RO4927350 0
                      SB 203580 439
                      SB-202190 3
                      SB-239063 24
                      SB-245391 0
                      SB-284851-BT 0
                      SB220025 0
                      SCH772984 34
                      TAK-733 0
                      U0126 + 6
                      U0126.EtOH 0
                      VX-745 6
                      auraptene 24
                      binimetinib 1
                      c-Jun N-terminal kinase inhibitor + 475
                      cercosporamide 0
                      cobimetinib 10
                      cobimetinib fumarate 0
                      doramapimod 63
                      hypothemycin 0
                      losmapimod 0
                      pamapimod 0
                      pluripotin 0
                      selumetinib 29
                      talmapimod 0
                      trametinib + 640
                      trametinib dimethyl sulfoxide 0
paths to the root